National Cancer Institute

Division of Extramural Activities

Annual Report 2013















U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Precision Cancer Medicine: To Integrate a Taxonomic Classification of Cancer and Translate It Into the Clinic

In March 2011, at the request of the Director of the National Institutes of Health, an *ad hoc* Committee of the National Research Council met to discuss the feasibility, need, scope, impact, and consequences of defining a "New Taxonomy" of human diseases based on molecular biology. The concept that developed, that of **Precision Medicine**, includes four basic premises. First, the **Information Commons** for each disease type has to be populated with a variety of -omic, phenotypic, clinical, and epidemiological data. Second, these data are integrated into a **Knowledge Network** that examines the interconnectivity of each layer of data from the **Information Commons**. Third, the **Knowledge Network** is used to develop new **Taxonomic Classifiers** with the goal of improving patient diagnosis, decisions on therapeutic strategies and health outcomes. Finally, the knowledge is used to guide biomedical, prevention, and Clinical research in mechanistic and observational studies. If realized, the benefits of **Precision Medicine** can be leveraged for most, if not all, disease types including human cancer.

Extramural and Intramural laboratories, including the Laboratory of Human Carcinogenesis (LHC), NCI, are currently building a **Knowledge Network** of these multiple types of cancer to support our ongoing efforts to enhance disease subtyping and contribute to a more detailed taxonomy that will lead to more precise clinical management of these complex diseases.

The strategy in LHC is to begin by analyzing national and international cohorts and then validate those findings in multiple levels of genomic data from patients and controls using different types of biospecimens. After results are validated in multiple cohorts, they are integrated as part of our **Information Commons**. When possible, the same patients are included for different studies as this allows for a full integration of the different levels of data to determine if it improves cancer taxonomy. The multiple layers of information gathered in an ongoing **lung cancer** study provide a view of each component of the **Information Commons** (see figure below).

Examples of Contributions of the LHC to the Lung Cancer Information Commons



External Exposome: Childhood exposure to secondhand smoke increases lung cancer risk in never smokers [1].

Internal Exposome: Inflammatory cytokines are associated with lung cancer risk, diagnosis and survival [2, 3].

Genome: EGFR mutations increase miR-21 and inhibit apoptosis [4].

Epigenome: miR-21 expression predicts survival in stage I lung cancer [5].

Microbiome: The tumor microbiota is being identified and analyzed as potential biomarkers.

Metabolome: Urinary metabolites are associated with risk, diagnosis, and prognosis [6].

Transcriptome: 4 coding-gene signature has been validated in multiple cohorts as a prognostic classifier for stage I lung cancer [7].

References Cited:

1. Olivo-Marston, S.E., et al., Childhood exposure to secondhand smoke and functional mannose binding lectin polymorphisms are associated with increased lung cancer risk. *Cancer Epidemiol Biomarkers Prev*, 2009;18(12):3375-83.
2. Pine, S.R., et al., Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. *J Natl Cancer Inst*, 2011;103(14):1112-22.
3. Seike, M., et al., Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. *J Natl Cancer Inst*, 2007;99(16):1257-69.
4. Seike, M., et al., Mir-21 is an EGFR-regulated anti apoptic factor in lung cancer in never-smokers. *Proc Natl Acad Sci U S A*, 2009;106(29): 12085-90.
5. Saito, M., et al., The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. *Clin Cancer Res*, 2011;17(7):1875-82.
6. Mathe, E.A., et al., Non-invasive urinary metabolic profiling identifies diagnostic and prognostic markers in lung cancer. *Cancer Res*, 2014; 74(12):3259-70.
7. Akagi, I., et al., Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. *Cancer Res*, 2013;73(13):3821-32.

National Cancer Institute

Division of Extramural Activities
Annual Report 2013



Images and narrative are courtesy of Dr. Curtis C. Harris, Chief, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health. The Precision Medicine Research Strategy illustration is modified from "Toward Precision Medicine," National Research Council, National Academy of Sciences, 2011. The Genome illustration is taken from The Cancer Genome Atlas Network, *Nature*, 2014.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Contents

Introduction 1
Overview of the Division of Extramural Activities 3
Special Activities in the Office of the Director, DEA 4
Program Coordination: A Resource for New Funding Initiatives 6
Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications 7
Peer Review — The Next Step 9
NCI Grant and RFA Funding 17
Supporting Peer Review Consultants 19
DEA's Role in Advisory Activities 21
Committee Management Activities 23
Portfolio Tracking and Analysis 25
Information Resources Management 29
Organizational Structure of the Division of Extramural Activities 31

Figures

Figure 1. Receipt and Referral of NCI Grant Applications, FY2009 - 2013 7
Figure 2. DEA Review Workload, FY2009 - 2013 10
Figure 3. Program Project (P01), SPORE, and Other Multi-Project Research Applications Reviewed, FY2009 - 2013 12
Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed, FY2009 - 2013 14
Figure 5. Technology Initiatives Applications Reviewed, FY2009 - 2013 15
Figure 6. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area, FY2012 17
Figure 7. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area, FY2013 18
Figure 8. BSA Approved RFA/Cooperative Agreement Funding Concept Set-Asides by Division/Office/Center 18
Figure 9. FY2013 Success Rates for Applications in High Incidence Cancers 27
Figure 10. FY2013 Success Rates for Applications in Selected Special Interest Categories 28

Tables

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2013, Sorted by Date of Publication 42
Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2013, Sorted by Division, Office, and Center 43
Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2013, Sorted by Date of Publication 44
Table 3a. Program Announcements (PAs) Published by the NCI in FY2013, Sorted by Date of Publication 46
Table 3b. Program Announcements (PAs) Published by the NCI in FY2013, Sorted by Division, Office, and Center 48
Table 4. NCI Participation in Trans-NIH Program Announcements (PAs/PARs) in FY2013, Sorted by Date of Publication 50

Table 5. Applications Received for Referral by the NCI/DEA in FY2013, Sorted by Mechanism . . . 52
Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2013, Sorted by Mechanism . . . 54
Table 7. Applications Reviewed by NCI Initial Review Group (IRG) Subcommittees and Special Emphasis Panels (SEPs) in FY2013 . . . 55
Table 8. Summary of Investigator-Initiated Program Project (P01) Applications Reviewed in FY2013 . . . 55
Table 9. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2013 . . . 55
Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2013 . . . 56
Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2013 . . . 58
Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2013 . . . 60
Table 13. Summary of NCI Grant Awards by Mechanism in FY2013 . . . 62
Table 14. Average Total Cost and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2009 - FY2013 . . . 64
Table 15. NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change . . . 67
Table 16. NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change . . . 75
Table 17. NCI Funding of Foreign Research Grants in FY2013 . . . 95
Table 18. Foreign Components of U.S. Domestic Research Grants in FY2013 . . . 98

Appendixes

Appendix A: Activities of the National Cancer Advisory Board . . . 100
Appendix B: Activities of the Board of Scientific Advisors . . . 101
Appendix C: List of Chartered Committees . . . 102
Appendix D: NCI Initial Review Group Consultants . . . 114
Appendix E: NCI Grant Mechanisms and Descriptions . . . 167
Appendix F: Glossary of Acronyms . . . 177
Appendix G: Cancer Information Sources on the Internet . . . 180

Introduction

The Division of Extramural Activities (DEA) is the organizational component of the National Cancer Institute (NCI) responsible for coordinating the scientific review of extramural research and for conducting systematic surveillance of that research after funding. DEA solicits advice from individuals and/or committees of experts on the technical and scientific merit of grants, cooperative agreements, and contracts. The peer review process is critically important to science in that it allows good ideas to surface and to be judged on their merit and promise. The peer review system is the keystone for ensuring that the best science is supported.

DEA coordinates the activities of: (1) the National Cancer Advisory Board (NCAB), which consists of members appointed by the President, and conducts the second-level review of grants and cooperative agreements and advises the Director, NCI, on policy for the conduct of the National Cancer Program; (2) the Board of Scientific Advisors (BSA) with distinguished scientists from outside the NCI and representatives from the advocacy community advises the NCI leadership on the progress and future direction of the NCI extramural program, evaluates NCI extramural programs, and reviews NCI-initiated research concepts; (3) the NCI-Frederick Advisory Committee (NFAC) composed of eminent scientists from outside of the NCI provides advice to the Director, NCI, and the Associate Director, Frederick National Laboratory for Cancer Research (FNLCR) on the state of research at the FNLCR and makes recommendations for the best use of the Laboratory's capabilities and infrastructure to meet the most urgent needs of the Institute; and (4) extramural training opportunities for NCI program and review staff.

DEA evaluates the content of all extramural research funded by the NCI and annually track the NCI research portfolio of approximately 8,000 research and training awards by using consistent budget-linked scientific information to provide a basis for budget projections; maintain extensive records of this research and provide specialized analyses of the costs, goals, and accomplishments of the research; and serve as an NCI resource to others for reporting and dissemination of the NCI's research portfolio. The DEA monitors budgetary limitations for grant applications; participates in establishing policies to expedite funding; and initiates and implements changes to applications, guidelines, and award processes. The Division coordinates, for the NCI, the review and response to appeals from applicants regarding the peer review process or the subsequent disposition and management of grants, cooperative agreements, and contracts; and responds and coordinates requests from the NIH Office of Extramural Research's Agency Extramural Research Integrity Officer for information and assistance regarding scientists (or institutions) supported by NCI research funds who were the subject of allegations, inquiries, and/or investigations of possible research misconduct.

The intent of this annual report is to provide insight and useful information about the research funding process and the role of the DEA in support of NCI's mission. A comprehensive look at each of the major areas of responsibility within the Division is provided. The data presented cover Fiscal Year (FY) 2013 (1 October 2012 - 30 September 2013) and provide data comparison with previous years.

To implement a biomedical research program of the highest quality, the NCI draws on the national pool of scientists actually engaged in research for assistance in selecting the best research and training projects. A sincere thanks to the more than 2,300 researchers, clinicians, and advocates who gave unselfishly of their time in FY2013. Their contribution to the continuing success of NCI's peer review and advisory activities is most appreciated.

Paulette S. Gray, Ph.D.
Director
Division of Extramural Activities

Division of Extramural Activities



Overview of the Division of Extramural Activities

The paramount goal of the National Cancer Institute (NCI) is to develop the knowledge base that will ultimately lessen the impact of cancer. Among the most important contributors to this base are the outstanding extramurally funded scientists supported by the NCI through grants, contracts, and cooperative agreements. The DEA was established within the NCI to provide the Institute and the scientific community with expert scientific review of the merits of extramural research. An important part of DEA's mission is to manage and coordinate the second level of grants review by the National Cancer Advisory Board (NCAB) and the concept review of all new and reissued Requests for Applications (RFAs) and research and development (R&D) Requests for Proposals (RFPs) with the Board of Scientific Advisors (BSA).

The **Committee Management Office** (CMO) provides oversight of all NCI-chartered advisory boards and committees, working groups, task forces, and chartered review groups, and it serves as an NIH service center for the National Center for Complementary and Alternative Medicine, the NIH Council of Councils, and a Department of Health and Human Services (HHS) chartered advisory committee. The CMO provides policy guidance and assistance to ensure that the NCI and client HHS/NIH Institutes, Centers, and Offices operate within the appropriate Federal Advisory Committee Act (FACA), the Government in Sunshine Act, and various other policies, procedures, and guidelines.

The DEA also provides effective and timely coordination of program initiatives from the initial concept stage through publication of RFAs, PAs, Notices, and RFPs, and, finally, through the peer review of grant and cooperative agreement applications and contract proposals. The **Office of Referral, Review, and Program Coordination** (ORRPC), with four branches, was established for: (1) coordination of the development and issuance of NCI program initiatives; (2) execution of grant referral; and (3) management of NCI review activities. Review activities include the organization and management of peer review for all applications and proposals received in response to RFAs, R&D RFPs, Program Announcements with Special Receipt (PARs), and multi-component grant initiatives. The program coordination responsibilities of the DEA, in cooperation with NCI extramural program divisions, offices, and centers, extend to the development of all new extramural program guidelines and funding opportunity announcements (FOAs).

Another program coordination activity is the development and maintenance of referral guidelines for assignment of grant applications to the NCI. These guidelines, included in the *Referral Guidelines for Funding Components of PHS*, are critical to the development of program initiatives across the NIH, as well as to the prompt referral of unsolicited grant applications to the NCI. These guidelines differ from the NCI Internal Referral Guidelines, which are vital to the prompt referral of grant applications to the appropriate NCI program areas.

The **Research Analysis and Evaluation Branch** (RAEB) works closely with the NCI Office of Budget and Finance to provide budget-linked portfolio data for NCI grants and contracts. In doing so, the Institute has the capability of responding expeditiously to congressional and other inquiries. This Branch has historical budget-linked portfolio data that go back to the 1930s.

The DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as possible to staff, advisory groups, and applicants. To facilitate this evaluation, the **Office of Extramural Applications** (OEA), through the **Applied Information Systems Branch** (AISB), maintains a Web-based information system to provide key information on new initiatives. This Web-based information system includes early notice of approved concepts, listings of active PAs and recently published RFAs, and policies related to the clearance of new program initiatives. This information is provided in both public Internet (**http://deainfo.nci.nih.gov/funding.htm**) and NCI limited-access Intranet versions. Both RAEB and AISB were actively involved in elevating the DEA Funded Research Portfolio website to become the NCI Funded Research Portfolio (NFRP) website (**http://fundedresearch.cancer.gov**).

Special Activities in the Office of the Director, DEA

In addition to managing and coordinating the extramural operations described in this report, the DEA Office of the Director (OD) is a focal point and repository of information and policies related to various funding mechanisms for NIH grants, staff and awardee responsibilities, eligibility requirements, receipt dates for all granting mechanisms, and special programs. The DEA OD ensures that the NCI meets the congressional mandate to promote increased participation of women, children, and members of minority and medically underserved populations in the research areas of cancer cause, prevention, control, diagnosis, and treatment. The NIH Revitalization Act of 1993 mandates that women and members of minority groups be included as subjects in each research project, unless there are clear scientific or ethical reasons that inclusion is inappropriate with respect to the health of the subject or the purpose of the research. Administrative procedures allow NCI staff to resolve inclusion problems after initial review of grant applications that are otherwise highly meritorious. In the event that a grantee believes the proposed study does not warrant or require inclusion of women or persons from minority groups, he or she can apply for a waiver of this requirement. The DEA Director is the Appeals Officer for the NCI and has the authority to grant waivers. In FY2013, 21 applications with preliminary bars to award were received by the DEA. Through corrective action, working with the applicants and program directors, all bars to award were brought into compliance before awards were made.

Additionally, the DEA Director serves as the locus for implementation and oversight of NCI policies concerning extramural research integrity and serves as a resource to all NCI staff with questions in this area. In this role, the DEA Director and designees work to address concerns about extramural research misconduct, misuse of human and animal research subjects, financial mismanagement, and financial conflict of interest involving NCI-supported research. The DEA Director functions as the NCI Research Integrity Officer (RIO) and receives from the appropriate sources all documents related to research misconduct for transmittal and reporting to relevant sources. In FY2013, 10 cases of alleged research misconduct involving NCI funding were opened and under investigation by the Office of Research Integrity, HHS, and referred to the Director, DEA. Twelve cases were closed, and two cases were found to involve research misconduct.*

*Cases found to involve research misconduct are published in the *Federal Register* and *NIH Guide for Grants and Contracts*.

Extramural Staff Training

Program and Review Extramural Staff Training Office (PRESTO)

The Program and Review Extramural Staff Training Office (PRESTO), which resides in the DEA OD, develops and coordinates the training of Program, Review, and other extramural staff. The mission of PRESTO is to increase the knowledge base of new and experienced staff members and optimize their effectiveness in supporting the goals of the NCI. To accomplish this mission, PRESTO: (1) designs and implements a broad-based curriculum for Program and Review staff; (2) provides training on specialized topics related to understanding of and compliance with NIH policies; and (3) identifies and develops resources to facilitate individual learning and performance. Finally, PRESTO tracks the participation of extramural staff in NIH- and NCI-sponsored training activities

*Cases found to involve research misconduct are published in the *Federal Register* and *NIH Guide for Grants and Contracts*.

as well as continuously evaluates the efficacy of these activities.

During FY2013, PRESTO activities included:

- Revision of the NCI-Specific Curriculum for Extramural Staff, implementing a series of online presentations covering the grants and contracts process and face-to-face panel discussions that addressed special topics and case studies relevant to extramural grant activities).
- Development of the NCI Scientific Review Officer Handbook.
- Production of online screencasts for training extramural staff in the use of electronic resources (e.g., Real-Time Meeting Status System).
- Organization of forums on core administrative responsibilities, including those related to Portfolio Analysis, Research Misconduct, Research Advocacy, and Workbench Tools for Program Officers.
- Coordination of State-of-the-Science forums on RNA Metabolism, NCI-International Collaborations in GI Cancer, and Cancer Prevention, with emphasis on NCI-supported research.
- Enhancement of the PRESTO website (**http://deaintranet.nci.nih.gov/presto/index.htm**) on the DEA intranet.
- Updating of the NCI Extramural Glossary.

PRESTO continues to collaborate with NCI Divisions, Offices, Centers, and groups both internal and external to the NCI, to provide customized job-related training and career development opportunities.

During FY2014, PRESTO will continue to provide a variety of training opportunities for NCI extramural staff, including new Staff Assistants, and will implement additional training formats (e.g., hands-on workshops, webinars, and roundtable discussion groups).

Program Coordination: A Resource for New Funding Initiatives

The DEA performs critical functions in the development of new strategic funding initiatives at the NCI and in the coordination of their publication as Funding Opportunity Announcements, which comprise both RFAs and Program Announcements (PAs). Specifically, members of the **Program Coordination and Referral Branch** (PCRB) provide expert assistance to NCI program staff members as they work to develop and publish new (and reissue) FOAs. PCRB staff members disseminate various operating policies and procedures pertaining to extramural funding programs. To maintain consistency and completeness, all new and reissued NCI FOAs, Notices, and various associated guidelines are reviewed, edited as needed, and cleared through the DEA, under PCRB coordination, before being forwarded to the NIH Office of Extramural Research for approval and publication in the *NIH Guide for Grants and Contracts* and on Grants.gov. In these steps, PCRB staff members help to streamline and clarify FOA technical parameters and requirements as well as optimize accuracy, precision, and clarity of their presentation in the proper format. PCRB verifies consistency with NIH-wide requirements, provides quality control, and coordinates timelines throughout the development and publication processes. Overall, these services ensure the high quality and timely availability of NCI's funding opportunities for cancer researchers as prospective applicants.

Tables 1a and **1b** show the variety of RFAs issued by the NCI in FY2013, and **Table 2** lists RFAs issued by other NIH institutes or centers (ICs) that the NCI has joined as a participating partner. **Tables 3a** and **3b** show the variety of PAs issued by the NCI in FY2013, and **Table 4** lists PAs issued by other NIH ICs that the NCI has joined as a participating partner.

PCRB staff members continue to provide relevant information and timely updates to all NCI extramural staff members on activities and results related to the requirements for and uses of electronic grant applications. The Branch also serves as a direct source of guidance on this topic for program directors at the NCI and applicants in the extramural scientific community. The Referral Office (RO) staff persons in PCRB collaborated with NCI information technology staff members and their contractors to successfully develop and deploy an improved Web-based Awaiting Receipt of Application (ARA) management system (permission for special application receipts), which contributes to an improved efficiency of use by NCI staff members and quality of service for the NCI's grant applicants and awardees. In addition to performing their program coordination and referral responsibilities, PCRB Health Scientist Administrators also served as Scientific Review Officers (SROs) in managing the reviews of 368 student loan repayment program (LRP) contract proposals in FY2013.

Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications

In FY2013, a total of 13,852 grant applications were submitted to the NCI for funding with appropriated funds (see Figure 1 and Table 5). Applications for 51 different types of funding award mechanisms (Appendix E), including the Investigator-Initiated Research Project (R01), Career Development Awards (K series), Research Program Project (P01), Cancer Center Support Grant (CCSG, P30), Specialized Program of Research Excellence (SPORE, P50), Small Research Project (R03), Exploratory/Developmental Project (R21), Exploratory/Developmental Phase II Project (R33), Small Business Technology Transfer (STTR) Grant (R41/R42), Small Business Innovation Research (SBIR) Grant (R43/R44), and U-series (Cooperative Agreement) mechanisms, were received.

All applications submitted to the National Institutes of Health (NIH) are assigned to an Institute or Center (IC). The IC in turn has a structure in place to address internal assignments. DEA's **Program Coordination and Referral Branch** is responsible for receipt, referral, and assignment of applications as well as for program (i.e., scientific initiative and funding opportunity) development functions. Upon receipt of primary and secondary assignments of applications to the NCI by the NIH Center for Scientific Review (CSR), the DEA Referral Officers (ROs): (1) assign all incoming applications to one of the 50 NCI extramural research program areas; (2) track program acceptance; and (3) whenever necessary, negotiate transfers of grant applications to and from

Figure 1. Receipt and Referral of NCI Grant Applications*
FY2009 - 2013



*Includes NCI Primary and Secondary applications received and referred.

other NIH ICs and even other HHS research funding agencies, such as the Agency for Healthcare Research and Quality (AHRQ), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).

The ROs distribute all of the applications that are to be directly reviewed by NCI DEA-managed peer review groups. These applications include those for Program Projects (P01), Planning Grants (P20), Cancer Centers (P30), Specialized Centers (P50), Conference Grants (R13), Small Grants, certain Phased Innovation Grants (R21/R33), Training Grants (T32 and R25), K-series Career Development Grants, certain R01 Research Project Grants (such as large multi-site clinical trials), and Cooperative Agreement applications.

The first point of contact for applicants is often the RO. The RO is the receipt point for Letters of Intent (LOIs) from potential applicants for multi-component P01 and R13 grants and inquiries about applications for Academic Research Enhancement Award (AREA, R15) grants for research at institutions and organizations that have little or no current NIH grant award support. Additionally, applicants contact the Referral Office for information about NCI programs, their eligibility to apply the relevance of their proposed research to the missions of various NCI programs, and the names and contact information of NCI program staff members to guide them through the application process.

DEA's RO serves as the primary NCI contact locus for the extramural scientific community in need of information related to funding opportunities, mechanisms, policies, processes, procedures, new initiatives announced as RFAs or PAs, and the peer review process. In addition, the ROs assist members of the extramural community in navigating NIH and NCI Web pages to obtain current grants-related information, forms, and guidelines.

Peer Review—The Next Step

Once applications are referred to the NCI and the appropriate program, they must be reviewed. The high caliber of NCI-sponsored research is maintained through a peer review process in which experts in the appropriate fields review and score the merit of research grant applications and contract proposals. The peer review mechanism helps to ensure that the NCI uses its resources wisely and funds research that has the potential to make a significant contribution to science and medicine. The NCI's extramural programs and activities are funded primarily through peer reviewed grants and cooperative agreements. Programs that are funded through research and development contracts also are subject to peer review, including contract-supported projects conducted within the intramural research program.

The peer review system of the NIH consists of two sequential levels of review mandated by statute. The first level is of grant applications assigned to the NCI. This review is performed by either an NIH CSR study section, a chartered NCI Initial Review Group (IRG) subcommittee, or an NCI Special Emphasis Panel (SEP), whose primary purpose is to review and evaluate the scientific merit/impact of research grant and cooperative agreement applications. The second level of review, which is for program relevance, is conducted by the National Cancer Advisory Board (NCAB).

Most investigators are familiar with the NIH CSR study sections, which have primary responsibility for managing the peer review of R01 grant and Fellowship (F) applications. It is less widely known, however, that grant applications representing requests for more than 50 percent of the NCI's extramural budget are reviewed by chartered IRGs and SEPs that are directly formed and managed within the NCI by the DEA. Peer review managed by either the CSR or the DEA is usually determined by the choice of grant mechanism.

The NCI has no direct input into the selection of peer reviewers who serve on CSR study sections. In contrast, members of the NCI IRGs and SEPs are selected by DEA review staff, with suggestions from NCI program staff. All chartered DEA IRG subcommittee members are approved by the Director, DEA, based on their knowledge of the various disciplines and fields related to cancer. The NCI has four active IRG specialized review subcommittees; for example, Subcommittee A reviews Cancer Center grant applications, Subcommittee F reviews Institutional Training and Education applications, Subcommittee I reviews Transition to Independence applications, and Subcommittee J reviews Career Development applications. (The membership of NCI-chartered subcommittees may be found in **Appendix C** and at **http://deainfo.nci.nih.gov/advisory/irg/irg.htm**.) IRG members are appointed for varying terms of service, which may be up to 6 years. DEA SEPs may be formed to review grant applications received in response to RFAs and PARs, other specialized applications, or R&D contract proposals received in response to RFPs. Members of such panels are selected on a one-time, as-needed basis to review specific grant and cooperative agreement applications, or contract proposals. Additional information about NCI SEPs can be accessed at **http://deainfo.nci.nih.gov/advisory/sep/sep.htm**.

Both the SEPs and IRGs provide advice on the scientific and technical merit of applications for research and research training grants, cooperative agreements, and contract proposals relating to scientific areas relevant to cancer. DEA SROs manage the scientific reviews of grant applications and R&D contract proposals, including the selection of peer reviewers and the overall administration of the peer review process.

The peer review of grant applications generally occurs in the fall, winter, and spring prior to the February, June, and September NCAB meetings, respectively.

Review Workload

In FY2013, the DEA organized, managed, and reported the review of a total of 4,094 grant and

cooperative agreement applications (Table 6) and 644 contract proposals (Table 12) assigned to the NCI for funding with appropriated dollars. The total number of grant, cooperative agreement applications, and contract proposals reviewed in FY2013 was 5,094 (Figure 2). Table 7 provides a summary of the applications reviewed by NCI IRG subcommittees and SEPs. Twelve meetings of the NCI IRG subcommittees and 105 SEPs were convened to review grant applications and contract proposals of various types. In addition, there were 14 site visits and 53 other review-associated meetings, such as orientation teleconferences and applicant interviews. Approximately 2,396 peer reviewers and expert consultants served on the NCI DEA-managed IRG subcommittees, SEPs, and workgroups in FY2013 (see Appendixes C and D). Members were selected because they are authorities in relevant fields of biomedical research or because they represent informed consumer perspectives.

Peer Review Functions

The **Office of Referral, Review, and Program Coordination** (ORRPC) is responsible for the coordination and management of the review of grant applications, cooperative agreement applications, and contract proposals for the Institute, and it includes three review branches, a referral branch, and the Office of the Associate Director. The review branches are responsible for organizing, managing, and reporting the scientific peer review of applications for a wide variety of grant mechanisms and topics. Reviews of grant applications are conducted by one of the four NCI IRG subcommittees or by specially convened SEPs as shown in Table 7.

Figure 2. DEA Review Workload*
FY2009 - 2013



*Withdrawn applications are not included.

The **Research Programs Review Branch** (RPRB) and the **Resources and Training Review Branch** (RTRB) are primarily responsible for the peer review of a variety of unsolicited multi-component, cancer training, and career development grant applications (see **Table 6**). The RPRB has primary responsibility for review of unsolicited P01 and SPORE applications involving translational research focused on various disease sites. The RTRB has primary responsibility for review of applications for cancer centers, cancer training, and career development, as well as for managing the four NCI IRG subcommittees (see **Appendix D**).

Reviews conducted by the RTRB, including those of the Cancer Center Support Grant (CCSG) applications, involve a two-tier initial peer review process. Normally, the first tier of the review involves a site visit to the applicant's institution by an expert review panel. This review format provides an opportunity for the reviewers to question the applicants directly to clarify issues in the application, thereby enhancing the review process. The review panel members prepare a draft review report, which is then considered, along with the written application, by the relevant NCI IRG for final impact scoring of the CCSG application. Subcommittee A is the "parent IRG subcommittee" for the P30 CCSG applications. The other three subcommittees of the NCI IRG (Subcommittees F, I, and J) review all of the career development, training, and education grant applications submitted to the NCI.

The **Special Review and Logistics Branch** (SRLB) organizes and manages peer review primarily for grant applications submitted in response to most of NCI's RFAs, specialized PARs, and R&D contract proposals submitted in response to RFPs. All of these reviews are conducted by SEPs. In addition, the **Program Coordination and Referral Branch** (PCRB) often collaborates with the review branches to assist in the review of special initiatives and also has responsibility for the review of conference grant and loan repayment program applications.

SROs in these review units prepare the summary statements, which present the peer reviewers' written evaluations of and recommendations for the applications considered at each review committee meeting. Each principal investigator (applicant) for an application also receives the summary statement as do the NCAB members for second-level review.

Research Programs Review Branch

Program Project (P01) Applications

A significant proportion of the effort of the RPRB during FY2013 was associated with the review of unsolicited P01 applications. During FY2013, the SROs in the RPRB organized and managed the review of 74 new, renewal (competing), resubmitted (amended), and revised (competitive supplement) P01 applications (see **Table 8**). Forty-one (55%) of the applications were proposing new multidisciplinary research programs, and 27 (36%) of the applications were amended (**Table 8**). Thirty two (43%) of the 74 applications were referred to NCI's Division of Cancer Treatment and Diagnosis (DCTD) (see **Table 9**). The 74 applications requested $172,561,561 in total costs for the first year (see **Table 9**) and $886,261,871 in total costs for all years. Of the 74 P01 applications reviewed in FY2013, 14 (19%) included multiple PIs.

P01 applications are reviewed in groups of up to 10 applications by a one-tier, "paper only" review process. All review panels are constituted as SEPs, with reviewers recruited based on the expertise needed for the applications being reviewed. The applications are grouped based on science, typically into three to four SEPs. The groupings vary depending on the number of applications that are received and the science proposed. A SEP may include applications representing a continuum of research from basic through translational to preclinical and clinical studies. The SEP reviewers evaluate and score projects, cores, and integration, and then assign the overall impact score to each application.

Specialized Programs of Research Excellence (SPORE, P50)

The other major responsibility for RPRB during FY2013 was the peer review of applications

received for the NCI SPORE. These large, complex, multidisciplinary P50 research center applications focus on translational research directly applicable to human disease in various organ sites. During FY2013, the RPRB organized and managed six SEPs for the review of a total of 46 SPORE applications (see **Figure 3**). These 46 applications addressed multiple organ sites, with the following distribution of applications: Brain (6); Breast (4); Ovarian (2); Gastrointestinal (GI)(2); Pancreas (4); Head and Neck (HN)(3); Leukemia (3); Lymphoma (1); Myeloma (2); Lung (5); Mesothelioma (1); Prostate (7); Skin (5); Thyroid (1); and Neuroendocrine Tumors (1). Overall, 24 (51%) of the 46 applications were for new SPOREs, and 23 (50%) were renewal applications. The applications requested $114,722,315 in total costs for the first year of support and $524,816,257 in total costs for all years.

The disease sites addressed in SPORE applications for each review round continued to be very varied. Fifteen applications addressing 10 different disease sites were reviewed for the February 2013 NCAB meeting, 25 applications addressing 12 disease sites were reviewed for the June 2013 NCAB meeting, and seven applications addressing six disease sites were reviewed for the September 2013 NCAB meeting.

Potential applicants for both P01 and SPORE grants are strongly encouraged to have pre-submission conferences with the appropriate NCI program (and review) staff members so that they fully understand the guidelines, requirements, and goals of these complex applications. SROs from RPRB routinely participate in these pre-submission conferences to ensure that applicants also understand the formatting requirements, the review process, the special review criteria, and the special scoring paradigms for these applications.

Figure 3. P01, SPORE, and Other Multi-Project Research Applications Reviewed* FY2009 - 2013



*Withdrawn applications are not included.

Resources and Training Review Branch

In FY2013, the RTRB administered four NCI IRG subcommittees (A, F, I, and J). The RTRB has the responsibility for the reviews of applications for Cancer Centers, Institutional Training and Education Programs, and Career Development awards. Its staff members also participate in the reviews of applications for other funding mechanisms managed by the DEA.

The reviews conducted by the RTRB subcommittees are of two types: (1) the complex, multidisciplinary applications, such as Cancer Center Support Grants (CCSG) and (2) single component training and Career Development applications. The review formats for the CCSG applications generally involve a two-step initial review. The first step of the review involves a site visit to the applicant institution. Each group of experts serves as a fact-finding body to clarify any information or issues related to the application through discussion with the applicants. This site visit committee prepares a draft report that is presented, along with the full application, for discussion, evaluation, and final scoring by parent subcommittee, NCI IRG Subcommittee A. Scoring by a parent subcommittee provides a more uniform evaluation of applications than scoring by individual site visit review teams. During FY2013, Subcommittee A reviewed 14 CCSG applications. The single component Career Development, Training, and Education grant applications submitted to the NCI are reviewed by Subcommittees F, I, and J.

Training and Career Development

The number of career development applications increased significantly from 2009 (385 applications) to 474 in 2010, stabilized in 2011 and 2012, and increased to 513 in 2013. The number of training grant applications remained fairly constant from 2009 to 2013 with 141 applications in 2013 (see **Figure 4**).

Cancer Centers

NCI Subcommittee A implemented new cancer center guidelines. Under the new guidelines, Cancer Centers have the option to request peer review of their renewal applications by NCI Subcommittee A without a site visit.

National Clinical Trials Network (NCTN)

Late in FY2010, the NCI initiated an effort to upgrade the Clinical Trials Cooperative Group Program into a new consolidated and integrated Program referred to as the NCI National Clinical Trials Network (NCTN). The overall goal of the NCTN Program is to conduct definitive, randomized, late phase clinical treatment trials and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials, as part of the NCI's overall clinical research program for adults and children with cancer.

In July 2012, six FOAs were posted soliciting U10 and U24 applications for Network Group Operations Centers, Network Group Statistics and Data Management Centers, Network Group Integrated Translational Science Centers, Canadian Collaborating Clinical Trials Network, Network Lead Academic Participating Sites and Network Radiotherapy and Imaging Core Services Centers. In the summer of FY2013, the DEA received and reviewed 82 U10 applications for 5 Network Group Operations Centers; 5 Network Group Statistics and Data Management Centers; 12 Network Group Integrated Translational Science Centers; one Canadian Collaborating Clinical Trials Network; and 59 Network Lead Academic Participating Site applications along with one U24 Network Radiotherapy and Imaging Core Services Center application.

Other RTRB Activities

To assist reviewers in preparing for their participation in peer review, Reviewer Guides are maintained for all of the application types reviewed by the RTRB. These Reviewer Guides were updated for the newly reissued FOAs and for electronic receipt. This resource was especially helpful for the subcommittee members who evaluate Training and Career Development grant applications because most reviewers on each subcommittee review multiple activity codes. The

**Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed*
FY2009 - 2013**



CD Mechanisms: K01, K05, K07, K08, K18, K22, K23, K24, K25, K99. T&E Mechanisms: K12, R25, T32.
*Withdrawn applications are not included.

Reviewer Guides contain general information on peer review and NIH rules regarding the use of human subjects in research, as well as specific instructions for each of the mechanisms to be reviewed by that subcommittee. These mechanism-specific guides have been completed for all education, training, and career development types of applications that are reviewed in the RTRB, and for the Cancer Centers applications that are evaluated by Subcommittee A.

Special Review and Logistics Branch

The SRLB organizes and manages peer reviews for grant applications submitted in response to NCI RFAs and specialized PARs as well as for contract proposals submitted in response to specific RFPs. The reviews are conducted in SEPs and involve recruiting scientists with the appropriate expertise for each review meeting. During FY2013, the DEA reviewed 4,450 applications received in response to 29 RFAs (Table 10) and 42 PAs/PARs (Table 11).

Following approval of RFA concepts by the NCI Scientific Program Leaders (SPL) and the BSA, program staff members prepare RFAs for publication in the *NIH Guide for Grants and Contracts*. DEA staff members, including members of the SRLB, assist in critically reading the draft documents and in providing recommendations for clarity relative to application requirements and review criteria. In an RFA, a specific, published dollar amount is set aside by the Institute and approved by the BSA, whereas for a PAR, there is no dollar set-aside and no requirement for BSA review. Table 10 lists the RFAs and number of related applications that were reviewed by the DEA in FY2013. Table 11 presents the number of applications submitted in response to PAs or PARs, the review of which is shared by the SRLB, the RPRB, and the RTRB. The Institute also issues RFP solicitations seeking offers for contracts to support activities targeted to highly specific institute goals.

Technology Research Applications

The majority of technology research initiatives use the R21 Exploratory/Developmental award mechanism and the R33 Exploratory/Developmental Phase II award mechanism. The R21 mechanism is intended to encourage exploratory/developmental research by providing support for exploratory pilot projects in the early stages of project development. The R33 mechanism is suitable for projects where "proof-of-principle" of the proposed technology or methodology already has been established and supportive preliminary data are available. Both of these mechanisms are well suited for technology development. In 2013, 288 technology applications for Exploratory/Developmental grants (R21) and Exploratory/Developmental Phase II grants (R33) were reviewed under 8 RFAs (Figure 5, Table 10).

The Small Business Innovation Research (SBIR) program supports Phase I feasibility applications (R43), Phase II applications (R44), and Fast-Track applications (R43/R44). In 2009, there was the first issuance of the SBIR Phase II Bridge Award RFA designed to "bridge the gap" between the end of the Phase II award and commercial development. That program continued in 2013. Eleven R44 applications were reviewed for SBIR Phase II B Bridge Awards. In 2013, a PAR entitled "Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology," invited applications for cooperative agreement SBIR (U43/U44) awards. Thirty-seven U43 and four U44 applications were reviewed by the DEA for this initiative.

Small Grant Programs

Several small grant (R03) PAR program initiatives in the areas of cancer prevention (PAR11-079), cancer epidemiology (PAR12-039), and behavioral research in cancer control (PAR12-035) stimulated increased interest in the applicant community. In FY2013, there were 314 applications submitted in response to the three initiatives.

Figure 5. Technology Initiatives Applications Reviewed* FY2009 - 2013



*Withdrawn applications are not included.

Research and Development Contract Proposals

The DEA SRLB, RPRB, RTRB, and PCRB reviewed 644 R&D contract proposals (including 368 Loan Repayment Program applications) received in response to 36 RFPs. Of those 36 RFPs, 33 were part of the Omnibus Solicitation for Small Business Innovation Research (SBIR) published each fall (Phase I and II topics) or letter solicitations sent to a Phase I awardee (Table 12). During review, several elements of each proposal are individually evaluated and scored, with the combined score indicating the overall merit. After negotiations, contract awards result from the RFP solicitation. Phase II SBIR proposals are submitted by Phase I awardees at the request of the Institute. To facilitate the contract review process, the SRLB has been working with the staff of DEA's Applied Information Systems Branch to develop a series of Web-based documents to be used for contract peer review.

Research Answers to NCI's Provocative Questions (PQ)

Following input from the scientific community through focus groups, forums, and online postings, 24 perplexing scientific questions were identified. Six questions grouped in four thematic cancer areas in need of research answers were identified: Cancer Prevention and Risk (Group A); Mechanisms of Tumor Development or Recurrence (Group B); Tumor Detection, Diagnosis, and Prognosis (Group C); and Cancer Therapy and Outcomes (Group D). One hundred and seventeen (117) R01 Research Project and 79 R21 Exploratory/Developmental applications in four thematic areas were submitted in response to eight RFAs (CA12-015, CA12-016, CA12-017, CA12-018, CA12-019, CA12-020, CA12-021, and CA12-022). Applications were peer reviewed to assess the technical merit of four in-person review meetings to assign a final impact score.

NCI Grant and RFA Funding

The Board of Scientific Advisors (BSA) is responsible for advising the NCI Director on the extramural program and the future direction and funding of each Division's extramural research. As such, it provides concept review for NCI-sponsored RFAs. Figures 6 and 7 show total NCI Grant and RFA funding according to scientific concept area in FY2012 and FY2013. Figure 8 shows RFA concepts that the BSA approved from FY2010 through FY2013 according to the sponsoring NCI Division, Office, and Center.

Table 13 presents a summary of total funding of NCI grant awards by mechanism for FY2013. In Table 14, a comparison is made of the average cost and number of NCI R01, P01, R03, R13, R21, P30, P50, U01, U10, and U19 grants and cooperative agreements awarded in FY2009 through FY2013 according to the extramural divisions, offices, and centers.

Trends in grant funding according to scientific discipline and organ site are provided in Tables 15 and 16. Table 17 reports NCI's funding of Foreign research grants in FY2013, and Table 18 reports Foreign components of U.S. Domestic research grants in FY2013. **Note:** Some grant awards made during a fiscal year may have been for grant applications reviewed in a prior fiscal year.

Figure 6. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area FY2012



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants.
Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 7. NCI Grant and RFA/Cooperative Agreement Funding Percentages by Concept Area FY2013



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants.
Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 8. BSA Approved RFA/Cooperative Agreement Funding Concept Set-Asides by Division/Office/Center



Legend:

DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCP	Division of Cancer Prevention
DCTD	Division of Cancer Treatment and Diagnosis
OD	Office of the Director
OD-OCG	Office of the Director - Office of Cancer Genomics
OD-OCTR	Office of the Director - Office of Centers, Training, and Resources
OD-CRCHD	Office of the Director - Center to Reduce Cancer Heath Disparities
OD-OHAM	Office of the Director - Office of HIV and AIDS Malignancy
OD-CSSI	Office of the Director - Center for Strategic Scientific Initiatives
OD-OBBR	Office of the Director - Office of Biorepositories and Biospecimen Research
OD-SBIRDC	Office of the Director - Small Business Innovation Research Development Center
TRANS-1	NCI (DCCPS), Trans-NIH
TRANS-2	NCI (DCTD), Trans-NIH

* Indicates co-funding among NCI Divisions/Offices/Centers.

Supporting Peer Review Consultants

Ensuring that highly qualified individuals are available for expert review of grant applications and contract proposals requires an efficient administrative support system. The DEA's **Scientific Review and Evaluation Activities** (SREA) unit, residing within the NCI **Committee Management Office (CMO)**, supports the NCI peer review process by compensating consultants for their services on the NCI IRG subcommittees or SEPs and by reimbursing for their travel and other expenses (see **Appendices C** and **D**). The SREA staff also approves and processes payments for other activities related to review, including hotel contracts, teleconferencing services, and contract-supported ticketing services.

The NCI SREA program is a multi-million dollar program. The staff members of CMO continue to oversee the successful reconciliation of peer review costs charged against the SREA account, identify erroneous charges, and keep an extensive tracking sheet on all costs related to approximately 128 peer review-associated meetings, which all contribute to successfully managing the budget. The CMO is able to provide the DEA Director with a clear picture of funds spent against the SREA budget throughout the year to ensure there are enough funds to cover all NCI peer review activities.

During FY2013, approximately 2,396 consultants were paid honoraria and a flat-rate reimbursement for meals and incidental expenses for serving at more than 164 peer review meetings (**Appendix D**). There were 3,493 instances of honoraria and flat rate payments to NCI's peer review consultants. The SREA staff works diligently to ensure reviewers are reimbursed in a timely manner and, when appropriate, contacts every reviewer with an unpaid or returned reimbursement status. The SROs have expressed their gratitude to the members of the SREA team for tracking the reviewers' payments and, when necessary, helping reviewers complete their Secure Payee Registration System (SPRS) registration. Due to these proactive efforts by the SREA staff, only 13 of 3,493 instances of honoraria and flat-rate payments owed to NCI peer review consultants were not paid in FY2013.

On May 26, 2013 HHS revised the "Policy on Promoting Efficient Spending: Use of Appropriated Funds for Conferences and Meetings, Food, Promotional Items, and Printing and Publications." This revision superseded the October 23, 2012 waiver that exempted peer review meetings from January 3, 2012, HHS policies review and reporting requirements. This policy once again included NIH peer review meetings in the approval and reporting requirements. The Committee Management Officer and SREA Team Lead met with the Division Director, Associate Director, Office of Referral, Review and Program Coordination, DEA Branch Program Analysts/Specialists and Administrative Officers to discuss the revisions to the policy and how these changes would impact NCI DEA peer review meetings. To minimalize the effect that this policy change would have on DEA review staff's workload, SREA created templates for completing the required approval forms and total meeting cost calculation tools to ensure that all face-to-face meetings did not exceed the $75K threshold. The NCI DEA was able to achieve significant cost savings in regards to peer review meeting spending because of the teamwork between SREA and the review staff. On July 15, 2013, Dr. Lawrence Tabak approved a Class Approval for scientific review meetings and Advisory committees for all meetings being held through the 2013 calendar year with total costs below the $75K threshold. These meetings are now exempt from the approval and reporting process.

The SREA is also responsible for ensuring all meeting logistic invoices (i.e., hotels, WTS and teleconference services charges) are accurate and valid before all invoices are processed for payment. All discrepancies are immediately addressed with the appropriate vendor, and a revised invoice is requested. SREA staff ensured the timely review and approval of 97 hotel contracts and 106 hotel invoices.

The SREA staff collaborates with the Associate Director, ORRPC, NCI DEA Branch Chiefs, CMO, and Scientific Review Officers on the development of NCI SREA policies and procedures. On an ongoing basis, they monitor and evaluate current SREA activities and initiate changes and improvements when warranted. In addition, CMO and SREA collaborate with Program and Review Extramural Staff Training Office (PRESTO) staff to ensure the training needs of DEA review staff are met for all aspects of CMO and SREA activities. CMO and SREA documents related to peer review meeting activities are sent to PRESTO to be posted on the "NCI/DEA Peer Review Reference Guide for Staff Assistants" page on the PRESTO website. The documents are then utilized by NCI DEA SROs and SAs. These training tools are imperative to the peer review process and the integrity of the NCI's mission.

DEA's Role in Advisory Activities

Beyond its central role in coordinating the referral of grants and peer review, perhaps the most far-reaching role the DEA plays across the NCI is the coordination and administration of NCI's nine chartered Federal advisory committees (see Appendix C). The memberships and activities of these advisory bodies are coordinated by the Office of the Director, DEA, and the Committee Management Office, DEA, in consultation with the NCI Director. A primary responsibility of the DEA is coordination of the activities of the NCAB, whose members are appointed by the President and whose responsibilities include conducting the second-level review of grant and cooperative agreement applications, as well as advising the NCI Director on policy for the conduct of the National Cancer Program. The DEA also coordinates administration of the Board of Scientific Advisors (BSA), the body responsible for the oversight and concept review of the extramural programs and initiatives of the NCI. Under the various chartered committees, working groups are formed to address and make recommendations on several important areas of cancer research related to basic research, clinical trials, diverse populations, cancer advocacy, treatment, cancer control, drug development, prevention, communication, education, and so on. As such, the DEA plays a major role in the development and issuance of PAs, PARs, and RFAs, the major extramural program initiatives used by the NCI to fund extramural research. The DEA Director serves as Executive Secretary to the NCAB and the BSA. (See Appendices A and B for highlights of the activities of these Boards in FY2013 and Appendix C for a list of current chartered committee members.)

Major NCI Advisory Bodies Administered by the DEA

National Cancer Advisory Board (NCAB). NCI's principal advisory body is the Presidentially appointed NCAB. The Board advises the Department of Health and Human Services (HHS) Secretary and the NCI Director on issues related to the entire National Cancer Program and provides a second level of review for grant applications referred to the NCI and for the Food and Drug Administration (FDA) (see Appendix A).

President's Cancer Panel (PCP). The PCP consists of three members appointed by the President, who by virtue of their training, experience, and background, are exceptionally qualified to appraise the National Cancer Program. At least two members of the Panel are distinguished scientists or physicians, and the third member is a nationally recognized cancer research advocate. The Panel monitors the development and execution of the activities of the National Cancer Program, and reports directly to the President. Any delays or hindrances in the rapid execution of the Program are immediately brought to the attention of the President.

Board of Scientific Advisors (BSA). The BSA represents the scientific community's voice in NCI-supported extramural science. The Board, composed of distinguished scientists from outside the NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs and policies, and it reviews concepts for new research opportunities and solicitations to ensure that those concepts are meritorious and consistent with the Institute's mission (see Appendix B).

Boards of Scientific Counselors (BSCs) for Basic Sciences, and for Clinical Sciences and Epidemiology. The two BSCs, managed through the Office of the Director (OD), NCI, advise the Institute leadership on the progress and future direction of NCI's Intramural Research Program residing in the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics (DCEG). These groups of scientific experts from outside the NCI evaluate the performance and productivity of NCI staff scientists through periodic site visits to intramural laboratories and provide

evaluation and advice on the course of research for each Laboratory and Branch.

Director's Consumer Liaison Group (DCLG). The DCLG advises the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. To this end, the DCLG will conduct these activities with the intent to identify new approaches, promote innovation, recognize unforeseen risks or barriers, and identify unintended consequences that could result from NCI decisions or actions. Additionally, the DCLG will provide insight into enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders.

Clinical Trials and Translational Research Advisory Committee (CTAC). The CTAC advises and makes recommendations to the NCI Director, NCI Deputy Directors, and the NCI Division/Office/Center (DOC) Directors on the NCI-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process. In addition, the Committee makes recommendations regarding the effectiveness of NCI's translational research management and administration program, including needs and opportunities across disease sites, patient populations, translational developmental pathways, and the range of molecular mechanisms responsible for cancer development. The CTAC also will advise on the appropriate magnitude for dedicated translational research priorities and recommend allocation of translational research operations across organizational units, programs, disease sites, populations, developmental pathways, and molecular mechanisms. This responsibility encompasses oversight of all clinical trials, both extramural and intramural. The Committee provides broad scientific and programmatic advice on the investment of taxpayer dollars in clinical trials and related science.

NCI Frederick Advisory Committee (NFAC). The NFAC provides advice and makes recommendations to the Director, NCI, and the Associate Director, NCI-Frederick, on the optimal use of the NCI-Frederick facility to rapidly meet the most urgent needs of the Institute. The NCI facility in Frederick, Maryland, was established in 1972 as a Government-owned Contractor-operated facility. In 1975, the facility was designated as a Federally Funded Research and Development Center (FFRDC) to provide a unique national resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and AIDS. The FFRDC has been renamed the Frederick National Laboratory for Cancer Research (FNLCR). The Committee will review major new projects proposed to be performed at NCI-Frederick and advise the Director, NCI, and Associate Director, NCI-Frederick, about the intrinsic merit of the projects and about whether they should be done at the Frederick facility.

NCI Initial Review Group (IRG). The IRG, composed of four active subcommittees, reviews grant applications for centers, research projects, and research training activities in the areas of cancer cause, prevention, diagnosis, treatment, and control. Members may be appointed as standing committee members with overlapping terms of up to 6 years, or as "temporary" members with all of the rights and obligations of committee membership, including the right to vote on recommendations in which the individual fully participated as a reviewer for a specific meeting. Consultants also may be invited to serve as special experts or *ad hoc* members to provide information or advice. These individuals generally serve on site visit groups or work groups providing critical information to the chartered advisory subcommittees responsible for initial peer review.

NCI Special Emphasis Panels (SEPs). The SEPs advise the NCI Director and the DEA Director regarding research grant and cooperative agreement applications, contract proposals, and concept reviews relating to basic and clinical sciences, and applied research and development programs of special relevance to the NCI. Membership of a SEP is fluid, with individuals designated to serve for individual meetings rather than for fixed terms. These individuals have all of the rights and obligations of committee membership, including the right to vote on recommendations.

Committee Management Activities

The NCI **Committee Management Office** (CMO) is critical to the continued success of all NCI Federal advisory committee activities, including Boards, Advisory Committees, subcommittees, working groups, review panels, and so on. The CMO is located in in the Office of the Director, Division of Extramural Activities (DEA), NCI. This office continues to provide expert advice to the Director, NCI, Deputy Directors, NCI, the Director, DEA, NCI, and other senior-level Institute/Center/Client staff on all rules, regulations, guidelines, policies, procedures, etc. governing the Federal Advisory Committee Act (FACA). The CMO also is an established service center for the management of other Institutes' Federal advisory committees. Currently, the CMO serves as the Service Center for the NIH Council of Councils (CoC).

The CMO successfully manages 14 Federal advisory committees and numerous subcommittees and working groups. The Office also is responsible for providing logistical planning and support of the following: four National Cancer Advisory Board meetings, three Board of Scientific Advisors meetings, and two NCI-Frederick Advisory Committee meetings as well as numerous subcommittees and working groups.

As a service center for the Office of the Director, NIH, the CMO continued to provide exceptional service to this Client-Institute on the management of its Federal advisory committee. The CMO effectively managed a comprehensive ethics program in support of CoC. Ethics services include analysis and review of Special Government Employee OGE-450s of new CoC advisory committee members and preparation of recusal lists and waivers/addendums of current members. Additionally, the CMO prepares charter renewals, analyzes potential nominees, and prepares nomination slates, *Federal Register* notices, and annual and fiscal year reports.

Highlights of CMO activities in FY2013 include the following:

- **OFACP Internal Review**—The NIH Office of Federal Advisory Committee Policy (OFACP) conducted a review of the NCI Service Center Advisory board files. OFACP's review cited the CMO as having developed superior checklists that are utilized for Official Meeting files, nomination slates, and Board member personnel files. Other comments were that files are highly effective and very commendable.
- **Archive and Scanning Project**—Led an effort to archive and scan FACA files in the NCI Service Center CMO file room. This included providing policy guidance to staff on the disposition of historical Advisory Board documents and working with AISB staff to create an L Scan Drive to hold all scanned electronic Official Meeting files of NCI Advisory Boards and nomination slates. In part, this effort came about because of the move to the NCI Shady Grove Facility. However, the National Archives is working on changing the disposition of FACA files so that they can be maintained electronically instead of on hard copy. When this is implemented, NCI CMO will be in a good position to quickly and effectively adhere to this policy.
- **HHS Policy on Promoting Efficient Spending: Use of Appropriated Funds for Conferences and Meetings, Food, Promotional Items, and Printing and Publications (January & June 2012)**—Provided guidance to DEA staff regarding light refreshments and the holding of peer review meetings in Federal space. Guidance included the amendments of hotel contracts to remove light refreshments and review of current hotel contracts to determine whether they could be grandfathered in. The CMO worked closely with SRO staff, CSR SREA Director, and ARC staff to ensure the impact of this new policy did not delay the processing of DEA peer review hotel contracts.

- **Organizational Establishment of the NCI Center for Cancer Training**—The CMO provided guidance to the NCI OMPC regarding FACA compliance as it relates to a reorganization of the Cancer Centers Training Branch.
- **Closure of Program Advisory Committees Meetings**—Program Advisory Committees are typically not closed to the public. In 2012, the CMO worked with OFACP and OGC lawyers to appropriately justify and receive approval for the closure of several NCI Board meetings.
- Met with the ORRPC Associate Director on several occasions to discuss SREA issues; and met with several new DFO/Executive Secretaries to orient them on their roles and responsibilities related to the advisory committees and discuss the policies and procedures. The CMO also participated in several conference calls to discuss various topics such as NIH Ethic's procedures for Special Government Employees (SGEs).
- Responded to several FOIA requests, and oversaw travel authorizations and vouchering of more than 100 SGE travel instances.
- The Committee Management IMPAC II Module is an integral part of the day-to-day activities in the management of advisory committees. As such, the CMO regularly provides feedback to the Committee Management Users Group Representative on potential modifications to the Module. NCI CMO staff also participated in several NIH pilots throughout the year.
- Participated in numerous meetings providing expert advice on working groups, FACA, and SGE rules and regulations.
- Responded to requests from senior NCI and Client staff on various non-FACA meetings and working group concerns.

The CMO conducted several training sessions and participated in curriculum development and as panelists during FY2013. Training highlights include the following:

- NCI Extramural Staff Training Curriculum—Panelist and Training
- PRESTO-NCI/DEA Peer Review Reference Guide for ESAs
- CMO staff participated in a DiSC® assessment and training session. The purpose was to improve teambuilding, understand behaviors, effective communication, and conflict management.
- PRESTO-Sponsored Brown Bag Training titled "DEA FACA and SREA Training"
- PRESTO-Sponsored FACA Training to NCI Extramural Staff

Portfolio Tracking and Analysis

The **DEA's Research Analysis and Evaluation Branch** (RAEB) is the officially designated contact for scientific information on NCI-supported research. The NCI needs to collect and maintain consistent budget-linked scientific information across all of its scientific programs to analyze the Institute's research funding portfolio, make budget projections, and disseminate information about cancer. The DEA conducts analyses to project future NCI research expenditures and to provide budget justifications to Congress. The work of the RAEB allows the DEA to respond immediately to requests for information from NCI staff, the broader NIH community, and requesters nationally and worldwide regarding the NCI Funded Research Portfolio. The RAEB reviews both unfunded applications and funded extramural grants supported by the NCI to consistently link scientific categories to budget categories on all Institute programs. These capabilities are based on a sophisticated system of indexing in which research documentation staff members analyze grant applications to classify each project for its degree of relevance to Special Interest Category (SIC) and Organ Site Codes (SITE). SIC Codes are meant to describe in a consistent way the major scientific disciplines that are of stated or growing interest to the NIH, HHS, Congress, and the public. A critical characteristic of these data is comparability from one fiscal year to the next.

Trends in funding from FY2009 through FY2013 for selected organ sites and SIC Codes are presented in **Tables 15** and **16**. In addition, RAEB staff members serve as DEA or NCI representatives on NCI or NIH-wide scientific reporting initiatives. These groups and committees deal with various aspects of NIH grants and contracts or tracking and reporting on areas of special interest to the NIH, NCI, and/or Congress.

FY2013 Highlights

- In FY2013, the RAEB provided numerous portfolio analyses, for example:
  - NCI Clinical Trials and Translational Research Operations Committee (CTROC): Clinical Trials Portfolio analysis.
  - Ovarian Cancer National Alliance (OCNA) through the NCI Office of Advocacy Relations: Success rates for ovarian cancer grant applications to the NCI compared with other major cancers.
  - NIH Office of Technology Transfer: NCI grants for specific technologies in the mid-1990s.
  - NCI Office of Budget and Finance: NCI extramural funding levels FY2010 through FY2012 for adrenal cortical carcinoma.
  - University of Maryland School of Medicine: University of Maryland funding in clinical trials, compared to other Maryland institutions.
  - NCI Division of Cancer Prevention: FY2012 NCI extramural funding for Chronic Obstructive Pulmonary Disease (COPD).
- Indexed and coded nearly 16,000 funded and unfunded applications.
- Provided scientific indexing for NCI-funded extramural projects to support the NCI-Funded Research Portfolio (NFRP) website (**http://fundedresearch.cancer.gov**).
- Supported the International Cancer Research Partners (ICRP), a group of international cancer funding organizations, by coding NCI extramural projects and cancer grants funded by other NIH institutes to the Common Scientific Outline (CSO), and by participating in the ICRP.

- Continued coordination with the NCI Office of Budget and Finance (OBF) to update and align budget reporting categories.
- Chaired the NCI Accrual Working Group for biennial reporting of NCI compliance with Congressional Health Disparities reporting requirements.
- Served as NCI subject matter expert on the NIH Inclusion Operating Procedures Working Group and its Policy subgroup.
- Served as DEA representative to the NCI Communications Committee.
- Served as DEA representative to the NCI Planning and Evaluation Shared Instrumentation Grant (SIG).

Extramural Research by Foreign Research Institutions and Extramural NCI Research Grants With a Foreign Research Component

In FY2013, the NCI allocated $18.7 million to support 52 grants received by foreign research institutions. These foreign grants are listed by country, mechanism, disease area, and total funding support in Table 17. Canadian institutions received the most funding from the NCI, with 23 grants totaling $6.9 million. R01s were the most common mechanisms funded with 28 grants receiving $7.5 million. Disease areas receiving the most NCI funding to foreign institutions were Lung ($3.1 million), Breast ($2.5 million), and Cervix ($2.3 million).

In FY2013, the NCI supported 294 U.S. domestic grants with 505 foreign components. These grants are listed in Table 18 by country, mechanism, and number of grants. Because many grants have multiple foreign contributors, the total count is greater than the total number of grants. Institutions in Canada (73 grants), the United Kingdom (49 grants), Australia (35 grants), Germany (30 grants), and China (27 grants) were the NCI's most frequent collaborators. R01 is the most common funding mechanism used for collaborations, with 303 grants, followed by U24 (58 grants) and U01 (54 grants).

FY2013 Funding of Foreign Institutions

(See Table 17 for more information.)

Country	Grants #	Funding $
Canada	23	$6,924,676
United Kingdom	8	$4,292,430
France	6	$2,544,099
Costa Rica	1	$2,280,313
Israel	5	$1,119,051
Australia	3	$564,591
Belgium	1	$287,528
Netherlands	1	$204,335
India	1	$183,930
Republic of Korea	1	$160,786
Belarus	1	$95,313
Sweden	1	$44,712

Success Rates of Extramural Science Categories

The RAEB assigns scientific indexing to both funded and unfunded applications, so it is possible to calculate success rates for funding in scientific categories. For example, the following graphs and tables illustrate FY2013 success rates for selected Special Interest Categories and for the highest incidence cancers. The highest incidence cancer rankings are from the SEER rank of top 15 cancer sites, 2004-2008, age-adjusted incidence for all races and sexes.

Success rates were calculated by dividing the total number of applications newly funded in 2013 (type 1 and 2 grants) for that research category (SIC or Organ Site) by the total number of applications for that research category (see Figures 9 and 10).

Figure 9. FY2013 Success Rates for Applications in High Incidence Cancers*

Sorted by Success Rate



Cancer Organ Site	SEER Rank*	Types 1 & 2 Funded in 2013 for This Site	Total Applications Received in 2013 for This Site	2013 Success Rate for This Site	Total Funding for Types 1 & 2 in 2013 for This Site
Uterus	9	24	75	32.00%	$2,843,402
Oral cavity and pharynx	13	27	97	27.84%	$2,673,031
Thyroid	12	17	69	24.64%	$8,404,065
Leukemia	10	148	610	24.26%	$46,053,664
Melanoma	6	123	514	23.93%	$29,169,055
Non-Hodgkin Lymphoma	7	80	337	23.74%	$17,452,774
Kidney	8	34	151	22.52%	$3,597,228
Stomach	14	12	59	20.33%	$2,138,691
Colon, Rectum	4	156	810	19.26%	$41,581,201
Pancreas	11	114	608	18.75%	$24,877,686
Lung	3	174	935	18.61%	$42,342,227
Prostate	1	152	961	15.82%	$42,091,890
Breast	2	336	2,223	15.11%	$88,877,871
Bladder	5	19	128	14.84%	$4,256,370
Liver	15	49	334	14.67%	$8,363,359

*SEER rank of top 15 cancer sites 2004-2008 age-adjusted incidence for all races and sexes.

Figure 10. FY2013 Success Rates for Applications in Selected Special Interest Categories

Sorted by Success Rate



Special Interest Category	Type 1 & 2 Funded in 2013 for This SIC	Total Applications Received in 2013 for This SIC	2013 Success Rate for This SIC	Total Funding for Types 1 & 2 in 2013 for This SIC
Obesity	67	267	25.09%	$13,496,546
Oncogene	322	1,284	25.08%	$78,182,456
Prevention	216	875	24.69%	$58,235,472
Genomics	197	820	24.02%	$52,773,651
Inflammation	125	524	23.85%	$23,403,229
Angiogenesis	82	356	23.03%	$14,425,446
Metastasis	300	1,464	20.49%	$76,870,023
Biomarkers	320	1,636	19.56%	$74,601,573
Early Detection	133	713	18.65%	$34,924,512
Therapy	849	4,627	18.35%	$260,298,861
Diagnosis	312	1,821	17.13%	$92,056,849

Information Resources Management

The **Applied Information Systems Branch** (AISB) provides integrated computer support, information technology expertise, and information systems development for the DEA. The AISB maintains and monitors the DEA Internet and Intranet websites; designs, develops, and maintains Division-specific software applications; administers and maintains various DEA servers; provides help desk support; provides oversight of hardware and connectivity; and serves as a liaison with the NIH Center for Information Technology (CIT) and the NCI Center for Biomedical Informatics and Information Technology (CBIIT). Its mission is critical to the Division in communicating current information technology activities and new developments to all components of the NCI and NIH as well as to external reviewer and applicant communities.

DEA's Information Technology and Information Systems contracts are managed by the AISB. The AISB has a computer support team to track staff requests, manage the Division's computer equipment inventory, and provide computer-related training, as needed. Specific projects utilizing the technologies and services provided by the AISB are described under the appropriate functions of the DEA throughout this report. For FY2013, specific AISB accomplishments are highlighted below.

System Administration and Desktop Support

- Planned and coordinated with CBIIT, CIT, Office of Space and Facilities Management (OSFM) and NCI Frederick the move of DEA servers from the Executive Boulevard complex to the NCI Frederick data center. Implemented a three-phase move to ensure minimal downtime, which consolidated and reduced the number of servers from 26 to 20.
- Supported the Security Assessment and Authorization (SA&A) process for DEA's information systems. The following activities were completed and documented: Contingency Plan (CP); CP Testing and Training; Risk Assessment; Annual Assessment; System Security Plan; Independent Validation and Verification for recertification; and Privacy Impact Analysis.
- Configured and administered new internal Microsoft SharePoint ebsites for the latest *DEA Annual Report*, SA&As for DEA information systems, and the contractor team site.
- Configured new Frederick-located servers with remote access controller cards to administer console commands remotely to reduce off-hour emergency site visits.
- Transitioned DEA staff from Web and presentation software such as GoTo Meeting and Adobe Connect to the Cisco WebEx product.
- Continued the ongoing replacement or upgrade of Windows XP computers to Windows 7.

Application Development Projects

- Implemented expansion of the DEA General Support System (GSS) portfolio with the deployment of four DEA-developed applications; two user-facing (NCI Grant-Related Activities Directory and DEA Blog), and two administrative-facing (Dashboard and Notification).
  - NCI Grant-related Activities Directory (NGRAD) is an authoritative resource for program director management and program director listings while program area specialties are integrated in other DEA-GSS applications.
  - DEA Blog application readily manages and makes available extramural funding information as well as accepts and manages comments from the public.
  - Dashboard is an administrative module for AISB staff and contractors to view status of working aspects of applications, and to alert systems staff of service disruptions.

  - Notification is an administrative module for integration into other DEA applications. It automates alerts to various stakeholders involved in complicated workflows.
- Application Web page modifications—implemented third phase of common Web pages mechanics, including the development of template catalogs to store and repurpose common use elements for Web pages.

Development and Support of Software Applications for the Research Analysis and Evaluation Branch's (RAEB) Scientific Coding and Analysis

- Completed enhancements and upgrades to the FLARE system and environment to allow users to index non-NCI grants for FY2011 and FY2012.

User Training

AISB staff provided user training/materials in the following areas: SharePoint; Adobe Connect, and GoToMeetings for PRESTO and Office of the Director, DEA teams; Screencast; the RPDU application Mailing/Shipping module; and coordinated NCI Records Management Training for the DEA.

AISB Staff Involvement

AISB staff were involved with many NCI and NIH information systems and information technology groups and organizations, including:

- International Cancer Research Portfolio (ICRP) Data Meetings
- NCI BAD codes (Basic and Applied) Working Group
- NCI Coding QA/QC Team
- NCI Science Management Workspace (SMW)
- NCI SMW Special Interest Groups (Business Information Systems and COTS software)
- NIH Electronic Council Book and Query View Reporting (ECB/QVR) Steering Committee
- NIH eRA Technical Users Group (eTUG)
- NIH Review Users Group (RUG)
- Shady Grove IT and Server Consolidation Planning Team
- CBIIT Process Improvement Team
- NCI Computer Upgrade Project (XP transition to Windows 7)
- NCI Division/Office/Center IT Contacts Meeting
- SharePoint Users Forum
- NCI Records Management Team
- NIH NSAT User Group

Organizational Structure of the Division of Extramural Activities

Office of the Director

- Directs and administers the operations of the Division, including those activities relating to grant review and administration, contract review, and Advisory Committee and Board activities.
- Directly coordinates and manages the NCAB and the BSA.
- Coordinates coding of NCI's grant portfolio.
- Initiates, coordinates, and implements Institute policies and procedures relating to grants and contracts reviews.
- Oversees the NCI's Committee Management Office.
- Implements NCI policies regarding extramural research integrity.
- Advises the Scientific Program Leadership (SPL) Committee, NCI, on extramural guidelines, review, advisory activities, and implementation strategies.
- Coordinates NCI extramural staff training requirements with the NIH.
- Represents the NCI on the NIH-wide Extramural Program Management Committee (EPMC) with responsibility for development of extramural policy and procedures across all NIH Institutes and Centers.
- Oversees inclusion of gender, minority, and children.
- Serves as the NCI Research Integrity Office.
- Coordinates, develops, and implements extramural policy.

Paulette Gray, Ph.D. ..... **Director**
Vacant ..... **Deputy Director**
Peter Wirth, Ph.D. ..... **Assistant Director**
Ricardo Rawle, M.B.A. ..... **Special Assistant to the Director**
Dawn Williams ..... **Program Analyst**
Judi Ziegler ..... **Secretary**

Committee Management Office, OD

- Coordinates functionally related Federal advisory committee activities across the Institute and its client-Institutes. The office manages NCI advisory committees, and serves as an NIH service center for the NIH National Center for Complementary and Alternative Medicine (NCCAM), the NIH Council of Councils, and a HHS chartered advisory committee to ensure that appropriate policies and procedures are in place to conduct the designated mission of each committee.
- Acts as a Service Center to provide advisory committee policy and management services to the Office of Biotechnology Activities, Office of the Director, NIH, and the NCCAM.
- Provides policy guidance to the NCI and client-Institute staff on administrative and technical aspects of Federal advisory committees; coordinates activities with all other NCI advisory committees; implements policies and procedures designed to avoid conflicts in the nomination, selection, and recruitment of board members; implements CM Module guidelines and procedures to ensure that all committee-related data are correctly entered into the database for preparation and submission of required annual reports to the President of the United States, HHS, and NIH; provides logistical support for NCAB, NFAC, and BSA meetings, subcommittees, and work groups; and facilitates NCAB and BSA committee-related travel.
- Researches and evaluates conflict of interest and Foreign activities issues for client-Institutes and provides advice on resolutions affecting advisory committee members serving as Special Government Employees.
- Provides administrative support for the peer review system by compensating consultants for their services on NCI IRG subcommittees and SEPs, reimbursing consultants for travel and other expenses, and approving and processing payments for other activities related to review such as hotel contracts and teleconferencing.

Claire Harris ..... **Committee Management Officer**
Andrea Collins* ..... **Deputy Committee Management Officer**
Janet Craigie† ..... **Deputy Committee Management Officer**
Linda Southworth‡ ..... **Senior Committee Management Specialist**
Malaika Staff ..... **Senior Committee Management Specialist**
Etsegenet Abeb§ ..... **Committee Management Specialist**
Natasha Copeland ..... **Committee Management Specialist**
Darnetta King** ..... **Committee Management Specialist**
Hing Lee†† ..... **Committee Management Specialist**
Alonda Lord ..... **Committee Management Specialist**
Kate Reardon‡‡ ..... **Committee Management Specialist**
Kimberly Taylor§§ ..... **Committee Management Specialist**

*Left May 2013.
†Joined July 2013.
‡Left March 2013.
§ Joined January 2013.
**Joined March 2013.
††Left December 2012.
‡‡Left June 2013.
§§ Left December 2012.

Program and Review Extramural Staff Training Office

- Develops and implements both broad-based and focused curricula for NCI Program and Review staff.
- Coordinates training for other extramural staff (e.g., in the Division of Extramural Activities Support) upon request.
- Identifies and develops resources (electronic and human) to facilitate learning and optimal individual, group, and organizational performance.
- Collaborates with NCI Divisions, Offices, Centers, and groups both internal and external to the NCI to provide customized job-related training and career development opportunities.
- Tracks participation of extramural staff in NIH- and NCI-sponsored training activities.

Michael Small, Ph.D. ..... **Chief**
Ivan Ding, M.D. ..... **Health Scientist Administrator**
Gregory Jones ..... **Program Analyst**
Elena Kusterer* ..... **Program Analyst**
Cecily Nelson, M.S. ..... **Program Analyst**
Denise Santeufemio ..... **Program Analyst**

*Left May 2013.

Office of Referral, Review, and Program Coordination

- Coordinates program concept development; publication functions; and receipt, referral, and assignment of all NCI applications.
- Coordinates review activities of the SRLB, RTRB, RPRB, and PCRB.

Shamala Srinivas, Ph.D. ..... **Associate Director**
Paul Gallourakis ..... **Special Assistant to the Associate Director**
Catherine Battistone ..... **Program Analyst**
Linda Brown ..... **Program Specialist**
Linda Coleman ..... **Committee Management Specialist**

Special Review and Logistics Branch

- Plans, manages, and assists in the scientific merit review of special grant and cooperative agreement applications (received in response to RFAs and PARs) and the technical merit review of contract proposals (received in response to RFPs).
- Identifies and recommends appropriate review committee members and site visitors, as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.
- Coordinates second-level review activities of the NCAB with staff of other NCI Divisions, other Branches of the Division, and the NCI Office of Grants Administration.
- Provides logistical support for primary- and second-level review activities in support of other Division and Institute units.

Kirt Vener, Ph.D.† ..... **Chief**
Shamala K. Srinivas, Ph.D.** ..... **Acting Chief**
Thomas Vollberg, Ph.D. ..... **Deputy Chief**
Kenneth Bielat, Ph.D. ..... **Scientific Review Officer**
Eun-Ah Cho, Ph.D ..... **Scientific Review Officer**
Donald Coppock, Ph.D. ..... **Scientific Review Officer**
Jeffrey DeClue, Ph.D. ..... **Scientific Review Officer**
Gerald Lovinger, Ph.D. ..... **Scientific Review Officer**
Savvas Makrides, Ph.D. ..... **Scientific Review Officer**
Isis Mikhail, Ph.D.* ..... **Scientific Review Officer**
Joyce Pegues, Ph.D. ..... **Scientific Review Officer**
Marvin Salin, Ph.D. ..... **Scientific Review Officer**
Ellen Schwartz, Ph.D. ..... **Scientific Review Officer**
Cliff Schweinfest, Ph.D. ..... **Scientific Review Officer**
Viatcheslav Soldatenkov, Ph.D. ..... **Scientific Review Officer**
Adriana Stoica, Ph.D. ..... **Scientific Review Officer**
Thomas Winters, Ph.D. ..... **Scientific Review Officer**
Zhiqiang Zou, Ph.D. ..... **Scientific Review Officer**
Clara Murphy ..... **Program Assistant**
Thu Nguyen ..... **Program Analyst**
Rosalind Niamke ..... **Lead Staff Assistant**
Donnell Wilson ..... **Lead Staff Assistant**
Etsegenet Abebe‡ ..... **Staff Assistant**
Alisha Brown§ ..... **Staff Assistant**
Bratati Chowdhury ..... **Staff Assistant**

*On detail from December 2012.
†Retired May 2013.
‡Moved to CMO January 2013.
§ Left July 2013.
**February 2013.

Alicia Craig ..... **Staff Assistant**
Hanh Julie Hoang ..... **Staff Assistant**
Grace Hughitt ..... **Staff Assistant**
James Thomas** ..... **Staff Assistant**
Adrian Bishop ..... **Mail and File Clerk**
Sanjeeb Choudhry ..... **Mail and File Clerk**
Robert Kruth ..... **Mail and File Clerk**

**Left March 2013.

Program Coordination and Referral Branch

- Serves as the information and coordination point within the NCI for the development, clearance, publication, and tracking of all NCI extramural program (funding) initiatives, which include all RFAs, PAs, and Notices submitted for publication in the *NIH Guide for Grants and Contracts*, and also on Grants.gov, which is a Federal-wide online portal for electronic submission of grant applications.
- Coordinates the development and periodic revision of referral (i.e., application assignment) guidelines within the NCI for both external and internal use.
- Coordinates the development of shared (referral) interest statements with other NIH Institutes and Centers (ICs) so that grant applications of possible or real mutual interest can be properly assigned for receipt, review, and/or funding.
- Serves as liaison to the Center for Scientific Review (CSR), NIH, to ensure the appropriate referrals (i.e., assignments) of grant applications to the Institute and the transfers of grant applications between the NCI and other NIH ICs.
- Refers new (Type 1) applications to the appropriate cancer activity area(s) according to the NCI Internal Referral Guidelines that define the program interests of each of the 50 cancer activity areas (which typically represent program branches in the NCI extramural divisions).
- Semi-automatically refers resubmission (A1) and renewal (Type 2) applications to the cancer activity area that accepted the previously submitted application (with quality control measures performed to ensure the accuracy of referrals).
- Coordinates requests from program staff for application status changes (including corrections of application assignments and numbers, which is done in collaboration with NCI program staff, CSR referral staff, and referral staff of other ICs and agencies) and for acceptance of grant assignments.
- Serves as the NCI contact point and liaison to involved parties at the NIH for approval of the use of cooperative agreement mechanisms and for conversion of grants to cooperative agreements.
- Works with NCI program and review staff and with NIH referral liaisons to address unresolved referral and review issues with the CSR and other NIH ICs.
- Receives and distributes advance copies of applications to review and program staff.
- Receives Letters of Intent from applicants (principal investigators) planning to submit large budget grants (including, but not limited to, program projects and cooperative agreements for clinical trials).
- By handling communications with applicants and NCI program staff members, coordinates approvals (and disapprovals) of the NCI to sponsor the submission of individual conference (R13) grant applications.
- Serves as the primary point of contact and provides assistance at the NCI for applicants who want to apply for an Academic Research Enhancement Award (i.e., the NIH R15 AREA grant mechanism).
- Processes and tracks requests for submissions of large-budget grant applications that allow them to be received at the NIH, peer reviewed, and possibly awarded by the NCI.
- Maintains database records of prospective large-budget grant and conference grant applications for each council round.
- Serves as the primary NCI information and referral point for the extramural scientific community on a broad range of subjects, including grant guidelines, application information, new initiatives announced as RFAs or PAs, and the review process.

- Assists the extramural community in navigating the NIH and NCI Web pages to help users obtain current information, forms, and guidelines.
- Directs applicants to the appropriate SROs and Program Directors for information regarding the status of the review and award of their grant applications.
- Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes.
- Provides data and data analyses on funding opportunities and on the receipt and referral of grant applications to NCI senior staff members and committees.

Christopher L. Hatch, Ph.D. ..... Chief
David Contois..... Referral Officer, NCI/NIH Referral Liaison
Anandarup Gupta, Ph.D..... RFA/PA Coordinator, Scientific Review Officer
Leota Hall..... Referral Officer, NCI/NIH Referral Liaison
Natacha P. Lassègue..... Program Analyst
Bratin Saha, Ph.D. ..... Referral Officer, Scientific Review Officer
Jan Woynarowski, Ph.D. ..... RFA/PA Coordinator, Scientific Review Officer

Research Programs Review Branch

- Plans, coordinates, and manages the scientific merit review of program project grants, specialized centers, and other grant mechanisms, as necessary, by Special Emphasis Panels.
- Identifies and recommends appropriate review committee members for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers and other DEA Branches.

Caron Lyman, Ph.D. ..... Acting Chief
Olivia Bartlett, Ph.D.* ..... Chief
Virginia Wray, Ph.D.† ..... Deputy Chief
Shakeel Ahmad, Ph.D. ..... Scientific Review Officer
Caterina Bianco Ph.D ..... Scientific Review Officer
Monica Congo..... Program Specialist
Majed Hamawy, Ph.D., M.B.A. ..... Scientific Review Officer
Wlodek Lopaczynski, M.D., Ph.D. ..... Scientific Review Officer
David Ransom, Ph.D. ..... Scientific Review Officer
Delia Tang, Ph.D. .....Scientific Review Officer

*Retired February 2013.
†Retired December 2012.

Resources and Training Review Branch

- Plans, coordinates, and manages the scientific merit review of cancer center, training, education, and career development grant and cooperative agreement applications by chartered review committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments of the research capabilities and facilities of selected applicants.
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, and research trends and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers, other DEA Branches, and the Center for Scientific Review.

Robert E. Bird, Ph.D. ..... **Chief**
Lynn Amende, Ph.D. ..... **Scientific Review Officer**
Gail Bryant* ..... **Scientific Review Officer**
Ilda Melo, Ph.D. ..... **Scientific Review Officer**
Timothy Meeker, M.D. ..... **Scientific Review Officer**
Sergei Radaev, Ph.D. ..... **Scientific Review Officer**
Sonya Roberson, Ph.D. ..... **Scientific Review Officer**
Sheila Hester ..... **Program Specialist**

*Retired September 2013.

Office of Extramural Applications

- Coordinates activities of the Research Analysis and Evaluation Branch and the Applied Information Systems Branch.
- Provides budget-linked research portfolio data and coordinates the information management of extramural NCI-supported research.

Amir Sahar-Khiz, Ph.D., M.B.A., PMP ..... **Associate Director**
Justin Rhoderick ..... **Program Analyst**

Research Analysis and Evaluation Branch

- Serves as the Institute's officially designated, centralized source of scientific information and science-based budget information on NCI-supported research.
- Analyzes and classifies the science content of all Institute-supported research projects.
- Analyzes the distribution of funds among research areas; these analyses serve as a basis for budget projections.
- Reports and answers inquiries on the scientific and budgetary aspects of Institute-funded research, including research grants, center grants, training grants, and research contracts.
- Maintains liaisons with other organizations involved in related classification activities.
- Documents the need for proposed RFAs by comparing RFA concepts with existing NCI-supported research and with unsolicited applications.

Marilyn Gaston ..... **Chief**
Edward Kyle ..... **Deputy Chief**

Research Documentation

- Analyzes and indexes grants and contracts for the Branch's computerized systems.
- Analyzes extramural projects for relevance to SICs and Anatomic Sites to determine the officially reported figures for Institute support and to provide a basis for budget projections.
- Maintains liaison with other offices within the Institute to ensure consistent reporting of data.
- Monitors the results of NCI's grant-supported research.
- Assists other NCI organizations by indexing NCI research projects for attributes other than SICs and Sites, for example, Common Scientific Outline (CSO) Codes and AIDS Categories.

Edward Kyle..... Lead Biologist/Team Leader
Beth Buschling ..... Biologist
Beverly Johnson, M.S. ..... Biologist
Ernestyne Watkins, M.S. ..... Biologist
Bernard Whitfield ..... Biologist
Tyrone Wilson..... Biologist

Technical Operations, Inquiry, and Reporting

- Provides specialized data querying, archiving, and reporting functions for the Division and the Institute.
- Coordinates Institute data reporting with the NCI Office of Budget and Financial Management, NIH Population Tracking and Inclusion Committee, and others.
- Answers inquiries from Congress, the public, the press, and others concerning any phase of Institute-supported work.
- Conducts in-depth analyses of extramural research data, including trends analyses.
- Identifies emerging priority areas for data collection and analysis.
- Ensures that terms and categories for indexing are updated and reflect current trends in cancer research, and maintains a thesaurus of term definitions.
- Manages RAEB's FLARE grants documentation and indexing database, ensuring reliability and completeness of its contents.
- Maintains and updates archival document files.
- Works with contractors and the AISB to refine RAEB's computer applications to meet the Branch's needs and resolve FLARE computer application problems for the Branch.
- Represents the DEA as its communications coordinator in the Office of Communications and Education Steering Committee.

Gail Blaufarb, M.S. ..... Lead Biologist/Team Leader
Clarissa Douglas..... Program Specialist
William Clark, M.S. ..... Biologist
Rajasri Roy, PhD..... Epidemiologist
Vacant ..... Biological Statistician

Applied Information Systems Branch

- Fulfills the information technology (IT) requirements of the Division by coordinating information resources management (IRM) activities with other relevant NCI and NIH units, and by providing high-quality information analysis, design, development, and coordination of applications in support of the Division's business processes.
- Serves as the focal point for the Division in the development, deployment, and application of specialized software and databases required for the conduct of review, referral, coding, advisory, and other extramural applications.
- Serves as the liaison with the NCI Center for Biomedical Informatics and Information Technology (CBIIT) staff; NCI computer professionals; NCI units charged with execution of extramural IRM functions; trans-NIH functional units such as the CSR, Office of Policy for Extramural Research Administration (OPERA), and Office of Extramural Research (OER); and the IMPAC II and NIH eRA (electronic Research Administration) staff and systems.
- Supports connectivity and design of Internet and Intranet applications.
- Establishes, administers, and monitors commercial support contracts to provide design, production, and maintenance for microcomputer equipment and information storage and retrieval systems that are not covered by CBIIT.
- Formulates DEA-specific office automation policy.
- Provides staff/lead users with technical support and training for DEA IT applications.
- Coordinates general user support and training with NCI and NIH services.
- Provides Division-specific applications of video teleconferencing and audiovisual services in support of review and Board activities.
- Provides management with recommendations for establishing and implementing policies for conducting Division computer-assisted presentations, as necessary.
- Reviews user-created applications and recommends and/or designs changes to improve efficiency and effectiveness.

Gregory Fischetti ..... Chief

Application Development Team

- Analyzes and coordinates life-cycle software development for the Division.
- Develops and designs applications to support the Division's business processes, including user guides.
- Coordinates security assessment and authorization for the Division's general support system applications.
- Develops, administers, and monitors contracts for acquisition, support, and maintenance of database systems.
- Formulates system development policy and oversees eRA/IMPAC II operations for the Division.
- Coordinates internal user groups and training for specific DEA applications.

Todd Hardin ..... Team Leader
Teresa Park ..... Information Technology Specialist
Vivien Yeh ..... Information Technology Specialist

Information Management Team

- Designs and maintains the Division's Intranet and Internet sites and pages, and identifies documents to be placed on the NCI website to make Division information more accessible to the public.
- Coordinates security assessment and authorization for systems and applications developed and implemented for the Research Analysis and Evaluation Branch (RAEB).
- Develops new Web-based software applications that will enhance the productivity and efficiency of extramural processes within the DEA and the distribution of Division information throughout the NCI.
- Coordinates application development and supports the RAEB in the areas of scientific coding and analysis.
- Administers and implements purchasing for the Division's computer hardware/software, maintenance, and supplies.
- Establishes partnerships and ongoing communications with staff and external customers to foster openness and collaboration in accomplishing the information initiatives of the Division.
- Works with DEA staff to ensure the current utility and linkages of documents placed on the Web.

Elaine Taylor ..... Team Leader
Michael Hu ..... Information Technology Specialist
Joshua Rhoderick ..... Information Technology Specialist
Lorrie Smith ..... Information Technology Specialist

Operations Team

- Administers and maintains the Division's application, database, and Web servers.
- Oversees and provides guidance for IT security policies and regulations.
- Coordinates and implements the Division's security assessment and authorization policies for the server environment.
- Manages the software application environment for development, testing, and production.
- Coordinates network connectivity for the Division with CBIIT.
- Provides user and technical support and training for desktop and laptop computers, office automation products and applications.
- Plans and recommends purchases of all IT-related equipment for the Division.
- Maintains accountable IT equipment inventory for the Division.
- Develops and maintains policies for the use of office automation technology.

Richard Florence ..... Team Leader
Roderick James ..... Information Technology Specialist
Raymond Vidal ..... Information Technology Specialist

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2013

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
11/9/2012	CA13-001	R21	Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	CSSI
	CA13-002	R33	Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	
	CA13-003	R21	Early-Stage Development of Innovative Technologies for Biospecimen Science	
	CA13-004	R33	Validation and Advanced Development of Emerging Technologies for Biospecimen Science	
12/12/2012	CA13-005	UM1	AIDS and Cancer Specimen Resource (ACSR)	OHAM
2/8/2013	CA13-006	UM1	NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN)	DCTD
2/21/2013	CA13-007	UM1	Collaborative Human Tissue Network (CHTN)	DCTD
	CA13-501		Limited Competition: Adult Brain Tumor Consortium (ABTC)	
6/19/2013	CA13-502	UM1	Limited Competition: Pediatric Brain Tumor Consortium	DCTD
	CA13-008	U2C	Person-Centered Outcomes Research Resource	DCCPS
9/30/2013	CA13-016	R01	Research Answers to NCI's Provocative Questions - Group A	ALL DIVISIONS
	CA13-017	R21		
	CA13-018	R01	Research Answers to NCI's Provocative Questions - Group B	
	CA13-019	R21		
	CA13-020	R01	Research Answers to NCI's Provocative Questions - Group C	
	CA13-021	R21		
	CA13-022	R01	Research Answers to NCI's Provocative Questions - Group D	
	CA13-023	R21		
	CA13-024	R01	Research Answers to NCI's Provocative Questions - Group E	
	CA13-025	R21		

Source: Office of Referral, Review and Program Coordination.

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2013

Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
Office of the Director	CA13-016	R01	Research Answers to NCI's Provocative Questions - Group A	9/30/2013
	CA13-017	R21		
	CA13-018	R01	Research Answers to NCI's Provocative Questions - Group B	
	CA13-019	R21		
	CA13-020	R01	Research Answers to NCI's Provocative Questions - Group C	
	CA13-021	R21		
	CA13-022	R01	Research Answers to NCI's Provocative Questions - Group D	
	CA13-023	R21		
	CA13-024	R01	Research Answers to NCI's Provocative Questions - Group E	
	CA13-025	R21		
CSSI	CA13-001	R21	Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	11/9/2012
	CA13-002	R33	Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	
	CA13-003	R21	Early-Stage Development of Innovative Technologies for Biospecimen Science	
	CA13-004	R33	Validation and Advanced Development of Emerging Technologies for Biospecimen Science	
DCCPS	CA13-008	U2C	Person-Centered Outcomes Research Resource	6/19/2013
DCTD	CA13-006	UM1	NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis (ET-CTN)	2/8/2013
	CA13-007		Collaborative Human Tissue Network (CHTN)	2/21/2013
	CA13-501		Limited Competition: Adult Brain Tumor Consortium (ABTC)	
	CA13-502		Limited Competition: Pediatric Brain Tumor Consortium	6/19/2013
OHAM	CA13-005	UM1	AIDS and Cancer Specimen Resource (ACSR)	12/12/2012

Source: Office of Referral, Review and Program Coordination.

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2013

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
11/16/2012	RM12-009	U01	Enhancing GTEx with Molecular Analyses of Stored Biospecimens	NHGRI	NIH-RM
	DA14-001	R21	U.S.-Russia Bilateral Collaborative Research Partnerships (CRP) on the Prevention and Treatment of HIV/AIDS and Co-Morbidities	OHAM	DA
11/21/2012	RM12-024	U01	Determinants and Consequences of Personalized Health Care and Prevention	ALL	NIH-RM
12/18/2012	OD12-007	P30	NIH Revision Applications for Research Relevant to the Family Smoking Prevention and Tobacco Control Act	DCCPS	OD
3/1/2013	DA14-002	K18	Short-Term Mentored Career Enhancement Awards in the Basic Behavioral and Social Sciences: Cross-Training at the Intersection of Animal Models and Human Investigation	CCT	DA
3/8/2013	AI13-010	UM1	Limited Competition - Multicenter AIDS Cohort Study: Center for the Coordination, Analysis, and Management of the MACS (CAMACS)	OHAM	AI
	AI13-011	U01	Limited Competition Multicenter AIDS Cohort Study (MACS) Clinical Research Sites		
3/8/2013	OD13-004	SI2	Lasker Clinical Research Scholars Program	DCEG	OD
3/20/2013	MD13-005	R01	Limited Competition: Revision Applications for Basic Social and Behavioral Research on the Social, Cultural, Biological, and Psychological Mechanisms of Stigma	DCCPS	MD
4/2/2013	RM13-003	R21	Undiagnosed Diseases Gene Function Research	ALL	NIH-RM
4/15/2013	OD13-005	R21	Limited Competition: Restoration of New Investigator Pilot Projects Adversely Affected by Hurricane Sandy	DCB	OD
	OD13-199	333	NIH Administrative Supplements to Recover Losses Due to Hurricane Sandy Under the Disaster Relief Appropriations Act Non-Construction (Administrative Supplement)		
5/3/2013	OD13-009	R25	Short Courses on Innovative Methodologies in the Behavioral and Social Sciences	CCT	NIH
5/17/2013	TW13-002	R21	Research on the Role of Epigenetics in Social, Behavioral, Environmental, and Biological Relationships Throughout the Life-Span and Across Generations	DCCPS	TW
6/20/2013	OD13-010	R21	Tobacco Control Regulatory Research	DCCPS	OD
	OD13-011	R01			
	OD13-012	R03			
6/28/2013	OD13-013	K08	Mentored Clinical Scientist Research Career Development Award in Tobacco Control Regulatory Research	CCT	OD
	OD13-014	K01	Mentored Research Scientist Career Development Award in Tobacco Control Regulatory Research		
	OD13-015	K22	Transition Career Development Award in Tobacco Control Regulatory Research		

continued

Source: Office of Referral, Review and Program Coordination.

Table 2 (cont'd). NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2013

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
6/28/2013	OD13-016	K99, R00	Pathway to Independence Award in Tobacco Control Regulatory Research	CCT	OD
7/15/2013	DA14-014	R01	Revision Applications to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research	DCCPS	DA
7/22/2013	HG13-009	U54	Centers of Excellence for Big Data Computing in the Biomedical Sciences	ALL	HG
7/26/2013	RM13-008	R01	NIH Transformative Research Awards (R01)	ALL	NIH-RM
	TW13-001	U19	Limited Competition: International Cooperative Biodiversity Groups	DCTD	TW
8/7/2013	RM13-012	UH2, UH3	NIH Health Care Systems Research Collaboratory - Demonstration Projects for Pragmatic Clinical Trials Focusing on Multiple Chronic Conditions	DCCPS	NIH-RM
	RM13-018	U01	DNA Sequencing Core for an Undiagnosed Diseases Network (UDN)	ALL	
8/8/2013	RM13-006	DP1	2014 NIH Pioneer Award Program	ALL	NIH-RM
	RM13-007	DP2	2014 NIH Director's New Innovator Award Program		
8/13/2013	TR13-002	U54	Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network	DCB	TR
8/14/2013	RM13-009	DP5	NIH Director's Early Independence Awards	CCT	NIH-RM
8/19/2013	RM13-013	U54	Library of Integrated Network-Based Cellular Signatures (LINCS): Perturbation-Induced Data and Signature Generation Centers	ALL	NIH-RM
9/16/2013	RM13-010	U01	Adaptation of Scalable Technologies to Illuminate the Druggable Genome	ALL	NIH-RM
	RM13-011	U54	Development of a Knowledge Management Center for Illuminating the Druggable Genome	NCI-OD	NIH-RM
9/19/2013	RM13-014	U01	Defining a Comprehensive Reference Profile of Circulating Human Extracellular RNA	ALL	NIH-RM
9/23/2013	OD13-117	U54	Center for Evaluation and Coordination of Training and Research (CECTR) in Tobacco Regulatory Science	DCCPS	OD

Source: Office of Referral, Review and Program Coordination.

Table 3a. Program Announcements (PAs) Published by the NCI in FY2013

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
12/6/2012	PAR13-036	U01	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research	DCP
12/21/2012	PAR13-067	333	Administrative Supplements to NCI-Funded Research Projects: Funding to Advance Research on Cancers in Women (Administrative Supplement)	OD
	PAR13-068	P20	Feasibility Studies to Build Collaborative Partnerships in Cancer Research	CRCHD
1/10/2013	PAR13-081	U01	Bridging the Gap Between Cancer Mechanism and Population Science	DCB, DCCPS
1/28/2013	PAR13-096	P20	Planning for a National Center for Particle Beam Radiation Therapy Research	DCTD
3/19/2013	PAR13-146	R21	NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)	ALL DIVISIONS
4/4/2013	PAR13-159	U01	The Role of Microbial Metabolites in Cancer Prevention and Etiology	DCB, DCP CRCHD
4/5/2013	PAR13-169	R01	Academic-Industrial Partnerships for Translation of *In Vivo* Imaging Systems for Cancer Investigations	DCTD
4/9/2013	PAR13-184	U01	Collaborative Research in Integrative Cancer Biology	DCB
4/10/2013	PAR13-185	R01	Image-Guided Drug Delivery in Cancer	DCTD CSSI
4/11/2013	PAR13-170	P50	Revisions to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	DCP
	PAR13-171	P01	Revisions to P01 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-172	R01	Revision Applications to R01 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-173	U01	Revision Applications to U01 Awards on Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-174	P50	Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	
	PAR13-175	P01	Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	
	PAR13-176	U01	Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	DCTD, DCP
	PAR13-177	R01	Revision Applications to R01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	DCP
	PAR13-190	R01	Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-189	R01	Imaging and Biomarkers for Early Cancer Detection	DCTD, DCP
4/17/2013	PAR13-201	K12	Paul Calabresi Career Development Award for Clinical Oncology	CCT
8/6/2013	PAR13-294	U24	Advanced Development of Informatics Technology	DCTD, DCB DCP, DCCPS
	PAR13-297	P01	Revisions to P01 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	DCP
	PAR13-298	P50	Revisions to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	

continued

Source: Office of Referral, Review and Program Coordination.

Table 3a (cont'd). Program Announcements (PAs) Published by the NCI in FY2013

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
8/7/2013	PAR13-321	P01	National Cancer Institute Program Project FOA	DCTD, DCB DCP, DCCPS
	PAR13-317	P01	Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	DCTD DCP
	PAR13-318	P50	Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	
8/8/2013	PAR13-327	R43, R44	Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR)	SBIRDC
8/12/2013	PAR13-330	P01	Revisions for Early-Stage Development of Informatics Technology	DCTD, DCB DCP, DCCPS

Source: Office of Referral, Review and Program Coordination.

Table 3b. Program Announcements (PAs) Published by the NCI in FY2013

Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
DCTD, DCB DCP, DCCPS	PAR13-321	P01	National Cancer Institute Program Project FOA	8/7/2013
	PAR13-146	R21	NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)	3/19/2013
CCT	PAR13-201	K12	Paul Calabresi Career Development Award for Clinical Oncology	4/17/2013
CRCHD	PAR13-068	P20	Feasibility Studies to Build Collaborative Partnerships in Cancer Research	12/21/2012
DCB	PAR13-184	U01	Collaborative Research in Integrative Cancer Biology	4/9/2013
DCB, DCCPS	PAR13-081	U01	Bridging the Gap Between Cancer Mechanism and Population Science	1/10/2013
DCB, DCP CRCHD	PAR13-159	U01	The Role of Microbial Metabolites in Cancer Prevention and Etiology	4/4/2013
DCP	PAR13-036	U01	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research	12/6/2012
	PAR13-170	P50	Revisions to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	4/11/2013
	PAR13-171	P01	Revisions to P01 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-172	R01	Revision Applications to R01 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-173	U01	Revision Applications to U01 Awards on Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-174	P50	Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	
	PAR13-175	P01	Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	
	PAR13-177	R01	Revision Applications to R01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	
	PAR13-190	R01	Detection of Pathogen-Induced Cancer (DPIC)	
	PAR13-298	P50	Revisions to P50 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	8/6/2013
	PAR13-297	P01	Revisions to P01 Awards for Research on Detection of Pathogen-Induced Cancer (DPIC)	
DCTD	PAR13-096	P20	Planning for a National Center for Particle Beam Radiation Therapy Research	1/28/2013
	PAR13-169	R01	Academic-Industrial Partnerships for Translation of *In Vivo* Imaging Systems for Cancer Investigations	4/5/2013
	PAR13-189	R01	Imaging and Biomarkers for Early Cancer Detection	4/11/2013
DCTD CSSI	PAR13-185	R01	Image-Guided Drug Delivery in Cancer	4/10/2013
DCTD, DCB DCP, DCCPS	PAR13-294	U24	Advanced Development of Informatics Technology	8/6/2013

continued

Source: Office of Referral, Review and Program Coordination.

Table 3b (cont'd). Program Announcements (PAs) Published by the NCI in FY2013

Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
DCTD DCP	PAR13-176	U01	Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	4/11/2013
	PAR13-317	P01	Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	8/7/2013
	PAR13-318	P50	Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection	
DCTD, DCB DCP, DCCPS	PAR13-330	P01	Revisions for Early-Stage Development of Informatics Technology	8/12/2013
Office of the Director	PAR13-067	333	Administrative Supplements to NCI-Funded Research Projects: Funding to Advance Research on Cancers in Women (Administrative Supplement)	12/21/2012
SBIRDC	PAR13-327	R43, R44	Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR)	8/8/2013

Source: Office of Referral, Review and Program Coordination.

Table 4. NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2013

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
11/13/2012	PA13-018	333	Administrative Supplements for Research on Sex/Gender Differences	OD-OSPA	ORWH
11/26/2012	PAR13-027	R25	International Research Ethics Education and Curriculum Development Award	CCT	FIC
11/28/2012	PAR13-029	U01	Opportunities for Collaborative Research at the NIH Clinical Center	DCTD CCR	NIH
1/9/2013	PAR13-054	R21	Dissemination and Implementation Research in Health	DCCPS	NIMH
	PAR13-055	R01			
	PAR13-056	R03			
	PAR13-080	R01	Accelerating the Pace of Drug Abuse Research Using Existing Data		NIDA
1/24/2013	PA13-088	R43, R44	PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA, and ACF for Small Business Innovation Research Grant Applications (Parent SBIR)	SBIRDC	NIH, CDC FDA, ACF
	PA13-089	R41, R42	PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR)		
2/1/2013	PA13-098	R21	School Nutrition and Physical Activity Policies, Obesogenic Behaviors, and Weight Outcomes	DCCPS	NICHD, NCI NHLBI OBSSR
	PA13-099	R03			
	PA13-100	R01			
2/6/2013	PA13-110	R01	Obesity Policy Evaluation Research	DCCPS	NIDDK
	PAR13-109	R01	Mechanistic Insights from Birth Cohorts	ALL	NIH
2/15/2013	PA13-117	R03	Mechanisms, Models, Measurement, and Management in Pain Research	ALL	NINR
	PA13-118	R01			
	PA13-119	R21			
3/1/2013	PAR13-130	R01	Understanding and Promoting Health Literacy	DCCPS	NIH
	PAR13-131	R03			
	PAR13-132	R21			
3/8/2013	PAR13-137	R01	Bioengineering Research Grants (BRG)	ALL	NIBIB
3/13/2013	PA13-140	R43, R44	Development of Highly Innovative Tools and Technology for Analysis of Single Cells	ALL	NIH
3/29/2013	PA13-165	R01	Innovative Research Methods: Prevention and Management of Symptoms in Chronic Illness	DCCPS	NINR
	PA13-166	R15			
	PA13-167	R21			
4/25/2013	PAR13-126	D43	Limited Competition: Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions	OHAM	FIC
5/30/2013	PAR13-233	R01	Chronic Inflammation and Age-Related Disease	DCB	NIAAA

continued

Source: Office of Referral, Review and Program Coordination.

Table 4 (cont'd). NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2013

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
5/30/2013	PA13-234	R43, R44	Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR)	SBIRDC	NIH, CDC FDA, ACF
	PA13-235	R41, R42	Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR)		
6/14/2013	PA13-248	R01	Research to Characterize and Reduce Stigma to Improve Health	CGH DCCPS CRCHD	NIA
	PA13-246	R21			
	PA13-247	R03			
7/15/2013	PA13-275	333	Administrative Supplements to Promote Collaborative Research on Addiction at NIH (CRAN): Comorbidity-Related Research	DCCPS	NIDA
7/19/2013	PA13-276	333	NLM Administrative Supplements for Informationist Services in NIH-Funded Research Projects	ALL	NLM
7/26/2013	PA13-286	R01	Systemic Amyloidosis: Basic, Translational, and Clinical Research	DCB	NIDDK
8/2/2013	PA13-292	R01	Behavioral and Social Science Research on Understanding and Reducing Health Disparities	DCCPS CRCHD	OBSSR
	PA13-288	R21		DCCPS	
	PA13-302	R01	Research Project Grant (Parent)	ALL	NIH
9/11/2013	PA13-347	R13, U13	NIH Support for Conferences and Scientific Meetings (Parent)	ALL	NIH
	PA13-313	R15	Academic Research Enhancement Award (Parent R15)		
9/19/2013	PA13-354	R01	Advancing the Science of Geriatric Palliative Care (R03)	ALL	NIA, NINR NCCAM, NCI
	PA13-355	R21			
	PA13-356	R03			
9/20/2013	PAR13-358	U01	Opportunities for Collaborative Research at the NIH Clinical Center	CCR DCTD	NIH
	PAR13-357	X02	Pre-Application: Opportunities for Collaborative Research at the NIH Clinical Center		
9/23/2013	PA13-359	R01	Nutrition and Alcohol-Related Health Outcomes	ALL	NIAAA
	PA13-361	R21			
	PA13-360	R03			
9/27/2013	PAR13-364	R01	Development of Assays for High-Throughput Screening for Use in Probe and Pre-therapeutic Discovery	DCTD	NIMH

Source: Office of Referral, Review and Program Coordination.

Table 5. Applications Received for Referral by the NCI/DEA in FY2013

Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by NCAB			Total Costs Requested First Year
			Feb	June	Sept	
International Training Grants in Epidemiology (FIC)	D43	31	31	0	0	$9,204,663
NIH Director's Pioneer Award (NDPA)	DP1	2	0	2	0	$5,000,000
NIH Director's New Innovator Awards	DP2	9	0	9	0	$13,500,000
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA)	F30	115	33	46	36	$0
Predoctoral Individual National Research Service Award	F31	454	134	177	143	$0
Postdoctoral Individual National Research Service Award	F32	382	102	175	105	$0
National Research Service Award for Senior Fellows	F33	1	1	0	0	$0
Research Scientist Development Award – Research and Training	K01	36	14	8	14	$4,389,682
Research Scientist Award	K05	14	5	6	3	$1,217,885
Academic/Teacher Award	K07	78	21	32	25	$10,912,685
Clinical Investigator Award	K08	84	23	35	26	$13,869,743
Physician Scientist Award (Program)	K12	11	11	0	0	$7,344,363
Career Transition Award	K22	97	25	31	41	$15,157,601
Mentored Patient-Oriented Research Development Award	K23	46	11	23	12	$8,076,312
Midcareer Investigator Award in Patient-Oriented Research	K24	6	0	3	3	$1,076,609
Mentored Quantitative Research Career Development	K25	24	7	8	9	$3,520,973
Career Transition Award	K99	194	63	62	69	$20,558,895
Research Program Projects	P01	76	30	29	17	$177,953,239
Exploratory Grants	P20	14	0	0	14	$2,685,968
Center Core Grants	P30	41	11	5	25	$111,656,744
Specialized Center	P50	91	15	25	51	$280,467,324
Research Project	R01	5,725	1,862	2,151	1,712	$2,718,367,534
Small Research Grants	R03	732	311	217	204	$56,529,117
Conferences	R13	115	47	40	28	$3,497,051
Academic Research Enhancement Awards (AREA)	R15	296	96	112	88	$123,031,263
Exploratory/Developmental Grants	R21	3,215	1,051	1,133	1,031	$727,087,917
Resource-Related Research Projects	R24	3	2	0	1	$1,337,089
Education Projects	R25	68	26	22	20	$19,219,223
Exploratory/Developmental Grants – Phase II	R33	96	23	44	29	$41,957,016
Method to Extend Research in Time (MERIT) Award	R37	3	3	0	0	$1,953,862
Small Business Technology Transfer (STTR) Grants – Phase I	R41	191	53	67	71	$37,654,105

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (477) were not included in the total count.

Table 5 (cont'd). Applications Received for Referral by the NCI/DEA in FY2013

Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by NCAB			Total Costs Requested First Year
			Feb	June	Sept	
Small Business Technology Transfer (STTR) Grants – Phase II	R42	25	7	10	8	$10,268,996
Small Business Innovation Research (SBIR) Grants – Phase I	R43	863	285	267	311	$182,672,627
Small Business Innovation Research (SBIR) Grants – Phase II	R44	177	61	61	55	$92,229,452
High Priority, Short Term Project Award	R56	4	3	1	0	$0
Minority Biomedical Research Support (MBRS)	S06	23	23	0	0	$21,334,685
Research Enhancement Award	SC1	13	12	0	1	$4,204,935
Pilot Research Project	SC2	3	3	0	0	$382,097
Research Continuance Award	SC3	1	1	0	0	$109,958
Institutional National Research Service Award	T32	64	24	28	12	$26,036,162
Research Project (Cooperative Agreements)	U01	211	89	39	83	$150,701,467
Cooperative Clinical Research (Cooperative Agreements)	U10	106	24	0	82	$290,695,979
Conference (Cooperative Agreement)	U13	2	0	1	1	$75,000
Research Program (Cooperative Agreement)	U19	23	0	23	0	$35,426,507
Resource-Related Research Project (Cooperative Agreements)	U24	18	1	0	17	$31,359,184
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	37	11	0	26	$6,999,990
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	4	2	0	2	$2,259,318
Specialized Center (Cooperative Agreements)	U54	10	0	0	10	$13,721,995
Exploratory/Developmental Cooperative Agreement – Phase I	UH2	1	0	1	0	$249,034
Multi-Component Research Project Cooperative Agreements	UM1	17	4	4	9	$36,979,480
Overall Totals		**13,852**	**4,561**	**4,897**	**4,394**	**$5,322,933,729**

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (477) were not included in the total count.

Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2013

Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by NCAB			Total Costs Requested First Year
			Feb	June	Sept	
Research Scientist Development Award – Research and Training	K01	36	14	8	14	$4,389,682
Research Scientist Award	K05	14	5	6	3	$1,217,885
Academic/Teacher Award	K07	78	21	32	25	$10,912,685
Clinical Investigator Award	K08	74	20	30	24	$12,386,575
Physician Scientist Award	K12	11	11	0	0	$7,344,363
Career Transition Award	K22	97	25	31	41	$15,157,601
Mentored Patient-Oriented Research Development Award	K23	39	8	20	11	$6,911,070
Midcareer Investigator Award in Patient-Oriented Research	K24	6	0	3	3	$1,076,609
Mentored Quantitative Research Career Development	K25	21	5	7	9	$3,031,364
Career Transition Award	K99	148	46	52	50	$16,454,791
Research Program Projects	P01	74	30	27	17	$172,561,561
Exploratory Grants	P20	14	0	0	14	$2,685,968
Center Core Grants	P30	14	4	5	5	$81,390,075
Specialized Center	P50	46	15	25	6	$114,722,315
Research Project	R01	187	6	173	8	$90,369,674
Small Research Grants	R03	677	289	198	190	$52,254,728
Conferences	R13	70	28	22	20	$2,133,110
Exploratory/Developmental Grants	R21	1,902	542	694	666	$430,559,321
Education Projects	R25	68	26	22	20	$19,219,223
Exploratory/Developmental Grants – Phase II	R33	96	23	44	29	$41,957,016
Small Business Innovation Research Grants (SBIR) – Phase II	R44	11	0	6	5	$13,358,190
Institutional National Research Service Award	T32	62	23	27	12	$23,191,241
Research Project (Cooperative Agreements)	U01	156	69	15	72	$120,928,057
Cooperative Clinical Research (Cooperative Agreements)	U10	106	24	0	82	$290,695,979
Conference (Cooperative Agreement)	U13	1	0	0	1	$50,000
Research Program (Cooperative Agreement)	U19	1	0	1	0	$1,374,812
Resource-Related Research Project (Cooperative Agreements)	U24	18	1	0	17	$31,359,184
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	37	11	0	26	$6,999,990
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	4	2	0	2	$2,259,318
Specialized Center (Cooperative Agreements)	U54	10	0	0	10	$13,721,995
Multi-Component Research Project Cooperative Agreements	UM1	16	3	4	9	$34,635,683
Overall Totals		**4,094**	**1,251**	**1,452**	**1,391**	**$1,625,310,065**

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (207) were not included in the total count.

Table 7. Applications Reviewed by NCI IRG Subcommittees and Special Emphasis Panels (SEPs) in FY2013

NCI IRG Subcommittee	Types of Applications Reviewed	Number of Applications	Total Costs Requested First Year
A - Cancer Centers	P30	14	$81,390,075
F - Institutional Training and Education	K12, R25, T32	138	$48,423,234
I - Transition to Independence	K01, K22, K25, K99	287	$36,828,484
J - Career Development	K05, K07, K08, K23, K24	207	$31,823,236
Totals - NCI IRG Subcommittees		**646**	**$198,465,029**
Totals - SEPs	K01, K05, K07, K08, K12, K22, K23, K24, K25, K99, P01, P20, P50, R01, R03, R13,R21, R33, R44, T32, UM1, U01, U10, U13, U19, U24, U43, U44, U54	**3,448**	**$1,426,845,036**
TOTAL		**4,094**	**$1,625,310,065**

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (207) were not included in the total count.

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed in FY2013

Type of Application	Applications by Board			FY 2013 Total
	February 2013	June 2013	September 2013	
New	9	10	4	23
Resubmitted New	8	6	4	18
Renewal	8	8	6	22
Resubmitted Renewal	4	3	2	9
Revisions	1	0	1	2
Total	**30**	**27**	**17**	**74**

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications.

Table 9. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2013

Program Division	Number of Applications	Total Costs Requested First Year	Total Costs for Requested Period
Division of Cancer Biology (DCB)	32	$67,531,463	$349,003,394
Division of Cancer Control and Population Sciences (DCCPS)	3	$6,962,724	$35,672,076
Division of Cancer Prevention (DCP)	7	$16,331,111	$78,214,220
Division of Cancer Treatment and Diagnosis (DCTD)	32	$81,736,263	$423,372,181
Total	**74**	**$172,561,561**	**$886,261,871**

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2013

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Feb	June	Sept	
U.S.-China Program for Biomedical Collaborative Research	AI12-021	R01	51	0	51	0	$10,618,029
Early-Stage Innovative Technology Development for Cancer Research	CA12-002	R21	98	32	66	0	$26,507,827
Validation and Advanced Development of Emerging Technologies for Cancer Research	CA12-003	R33	59	19	40	0	$25,227,848
Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	CA12-004	R21	28	15	13	0	$7,829,835
	CA12-005	R33	8	4	4	0	$3,459,946
Cancer Target Discovery and Development (CTDD) Network	CA12-006	U01	39	39	0	0	$45,372,818
Community Clinical Oncology Program Groups	CA12-007	U10	15	15	0	0	$13,341,025
Minority-Based Community Clinical Oncology Program Groups	CA12-008	U10	8	8	0	0	$5,413,474
NCI National Clinical Trials Network – Network Group Operations Centers	CA12-010	U10	5	0	0	5	$157,583,101
NCI National Clinical Trials Network – Network Group Statistics and Data Management Centers	CA12-011	U10	5	0	0	5	$53,240,587
NCI National Clinical Trials Network – Network Group Integrated Translational Science Centers	CA12-012	U10	12	0	0	12	$10,354,009
NCI National Clinical Trials Network – Network Lead Academic Participating Sites	CA12-013	U10	59	0	0	59	$46,949,667
NCI National Clinical Trials Network – Network Radiotherapy and Imaging Core Services Centers	CA12-014	U24	1	0	0	1	$15,253,103
Research Answers to NCI's Provocative Questions – Group A	CA12-015	R01	36	0	36	0	$19,487,928
	CA12-016	R21	20	0	20	0	$4,539,850
Research Answers to NCI's Provocative Questions – Group B	CA12-017	R01	33	0	33	0	$17,336,340
	CA12-018	R21	26	0	26	0	$5,659,113
Research Answers to NCI's Provocative Questions – Group C	CA12-019	R01	26	0	26	0	$13,817,096
	CA12-020	R21	19	0	19	0	$4,272,606
Research Answers to NCI's Provocative Questions – Group D	CA12-021	R01	22	0	22	0	$11,372,368
	CA12-022	R21	14	0	14	0	$3,025,501
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	CA12-023	R44	11	0	6	5	$13,358,190
A Data Resource for Analyzing Blood and Marrow Transplants (Limited Competition)	CA12-503	U24	1	1	0	0	$3,620,000

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (144) were not included in the total count.

Table 10 (cont'd). Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2013

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Feb	June	Sept	
NCI National Clinical Trials Network – Canadian Collaborating Clinical Trials Network (Limited Competition)	CA12-504	U10	1	0	0	1	$3,023,058
Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research	CA13-001	R21	58	0	0	58	$15,549,211
Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research	CA13-002	R33	24	0	0	24	$11,035,804
Early-Stage Development of Innovative Technologies for Biospecimen Science	CA13-003	R21	9	0	0	9	$2,631,434
Validation and Advanced Development of Emerging Technologies for Biospecimen Science	CA13-004	R33	5	0	0	5	$2,233,418
AIDS and Cancer Specimen Resource (ACSR)	CA13-005	UM1	1	0	0	1	$3,900,000
Totals			**1,054**	**133**	**376**	**545**	**$556,013,186**

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (144) were not included in the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2013

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Feb	June	Sept	
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (Parent T32)	PA11-184	T32	62	23	27	12	$23,191,241
Mentored Clinical Scientist Research Career Development Award (Parent K08)	PA11-193	K08	68	16	29	23	$11,423,569
Mentored Patient-Oriented Research Career Development Award (Parent K23)	PA11-194	K23	36	8	18	10	$6,312,089
Midcareer Investigator Award in Patient-Oriented Research (Parent K24)	PA11-195	K24	6	0	3	3	$1,076,609
Mentored Quantitative Research Development Award (Parent K25)	PA11-196	K25	21	5	7	9	$3,031,364
NIH Pathway to Independence Award (Parent K99/R00)	PA11-197	K99	148	46	52	50	$16,454,791
Research Project Grant (Parent R01)	PA11-260	R01	15	4	4	7	$15,590,014
Translational Research at the Aging/Cancer Interface (TRACI)	PA12-136	R01	1	0	1	0	$763,566
NIH Support for Conferences and Scientific Meetings (Parent R13/U13)	PA12-212	R13	70	28	22	20	$2,133,110
		U13	1	0	0	1	$50,000
Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011, and 2012	PAR10-003	P50	40	15	25	0	$99,942,158
Paul Calabresi Career Development Award for Clinical Oncology	PAR10-155	K12	11	11	0	0	$7,344,363
NCI Cancer Education and Career Development Program	PAR10-165	R25	16	4	7	5	$5,303,153
Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR)	PAR10-286	U43	37	11	0	26	$6,999,990
		U44	4	2	0	2	$2,259,318
Cancer Center Support Grants (CCSGs) for NCI-Designated Cancer Centers	PAR11-005	P30	9	4	5	0	$50,324,464
Cancer Prevention Research Small Grant Program	PAR11-079	R03	113	58	34	21	$8,673,673
Quantitative Imaging for Evaluation of Responses to Cancer Therapies	PAR11-150	U01	19	5	5	9	$12,079,333
Strategic Partnering to Evaluate Cancer Signatures (SPECS II)	PAR11-151	U01	24	24	0	0	$23,641,352
The Role of Microbial Metabolites in Cancer Prevention and Etiology	PAR11-152	U01	10	0	10	0	$5,382,308
Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	PAR11-167	UM1	15	3	4	8	$30,735,683
NCI Program Project Applications	PAR12-005	P01	74	30	27	17	$172,561,561
		U19	1	0	1	0	$1,374,812
Small Grants for Behavioral Research in Cancer Control	PAR12-035	R03	60	29	31	0	$4,577,820
Small Grants Program for Cancer Epidemiology	PAR12-039	R03	141	52	50	39	$10,978,369
		U01	1	1	0	0	$84,750

continued

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (84) were not included in the total count.

Table 11 (cont'd). Program Announcements (PAs) Reviewed by the NCI/DEA in FY2013

Title of Initiative	RFA Number	Activity Code	Applications by NCAB				Total Costs Requested First Year
			Totals	Feb	June	Sept	
Cancer Education Grants Program	PAR12-049	R25	52	22	15	15	$13,916,070
NCI Mentored Research Scientist Development Award to Promote Diversity	PAR12-050	K01	36	14	8	14	$4,389,682
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	PAR12-051	K08	6	4	1	1	$963,006
NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	PAR12-052	K23	3	0	2	1	$598,981
Limited Competition: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)	PAR12-055	U54	10	0	0	10	$13,721,995
The NCI Transition Career Development Award to Promote Diversity	PAR12-062	K22	21	4	12	5	$3,209,948
NCI Established Investigator Award in Cancer Prevention and Control	PAR12-065	K05	14	5	6	3	$1,217,885
Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award	PAR12-067	K07	78	21	32	25	$10,912,685
The NCI Transition Career Development Award	PAR12-121	K22	76	21	19	36	$11,947,653
NCI Small Grants Program for Cancer Research (NCI Omnibus)	PAR12-144	R03	363	150	83	130	$28,024,866
NCI Exploratory/Developmental Research Grant Program (NCI Omnibus)	PAR12-145	R21	1,629	494	536	599	$360,263,096
Revisions for Early-Stage Development of Informatics Technology	PAR12-286	R01	1	0	0	1	$184,333
Advanced Development of Informatics Technology	PAR12-287	U24	16	0	0	16	$12,486,081
Early-Stage Development of Informatics Technology	PAR12-288	U01	25	0	0	25	$9,887,086
Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014	PAR12-296	P50	6	0	0	6	$14,780,157
Cancer Center Support Grants (CCSGs) for NCI-Designated Cancer Centers	PAR12-298	P30	5	0	0	5	$31,065,611
Opportunities for Collaborative Research at the NIH Clinical Center	PAR13-029	U01	14	0	0	14	$9,703,678
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research	PAR13-036	U01	17	0	0	17	$10,113,770
Feasibility Studies to Build Collaborative Partnerships in Cancer Research	PAR13-068	P20	14	0	0	14	$2,685,968
Bridging the Gap Between Cancer Mechanism and Population Science	PAR13-081	U01	7	0	0	7	$4,662,962
Totals			**3,396**	**1,114**	**1,076**	**1,206**	**$1,067,024,973**

Source: Office of Referral, Review and Program Coordination. IMPAC II. Includes NCI Primary and Secondary assigned applications. Withdrawn applications (84) were not included in the total count.

Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2013*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
Topic 313 (Phase I & FastTrack)	RNAi Cancer Therapeutics Using Nanotechnology	Mar-13	25 (2 FT)
Topic 314 (Phase I & FastTrack)	Development of Human Tissue Culture Systems That Mimic the Tumor Microenvironment	Mar-13	23 (1 FT)
Topic 315 (Phase I & FastTrack)	Development of Companion Diagnostics: Enabling Precision Medicine in Cancer Therapy	Mar-13	31 (4 FT)
Topic 316 (Phase I & FastTrack)	Development of CTC Isolation Technologies Enabling Downstream Single Cell Molecular Analysis	Mar-13	21 (4 FT)
Topic 317	Wound Healing Preparations Incorporating Nitric Oxide-Releasing Materials (NIH Technology Transfer)	Mar-13	13
Topic 318	Test to Predict Effectiveness of Docetaxel Treatment for Prostate Cancer (NIH Technology Transfer)	Mar-13	5
Topic 319 (Phase I & FastTrack)	Technology to Generate Anti-Peptide Capture Reagents for Affinity-Enriched Proteomic Studies	Mar-13	16 (2 FT)
Topic 320	High Quality Cancer-Related Standards for Metabolomics Research	Mar-13	1
Topic 321 (Phase I & FastTrack)	Chemically Defined Glycan Libraries for Reference Standards and Glycomics Research (Joint NCI-NIGMS Program)	Mar-13	11 (2 FT)
Topic 322 (Phase I & FastTrack)	Real-Time Integration of Sensor and Self-Report Data for Clinical and Research Applications	Mar-13	25 (9 FT)
Topic 323 (Phase I & FastTrack)	Development of Radiation Modulators for Use During Radiotherapy	Mar-13	9 (3 FT)
Topic 324 (Phase I & FastTrack)	Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment	Mar-13	12 (2 FT)
Topic 325 (Phase I & FastTrack)	Innovative Radiation Sources for Advanced Radiotherapy Equipment	Mar-13	7 (2 FT)
Other Solicitations Reviewed in DEA			
N01 RC31005-27	Identification, Referral, and Follow-Up of Patients Who Have HTLV	Mar-13	1
L30 (Clinical Research)	Loan Repayment Program	May-13	284
L40 (Pediatric Research)		May-13	84
Phase II Proposals From Earlier Phase I Awards			
Topic 255	Development of Anticancer Agents	Jun-13	3
Topic 272	Point of Care Analysis of Circulating Tumor Cells for Cancer Diagnostics, Prognosis, and Treatment	Jun-13	1
Topic 273	Process Analytic Technologies (PAT) for Biologics: Innovative Methods for Monitoring and Analyzing Product Quality and Safety During Manufacture of Cancer Therapeutics	Jun-13	1
Topic 277	Development of Companion Diagnostics	Jun-13	4

continued

* The NCI reviewed a total of 644 proposals. The proposals were in response to SBIR Contract Solicitations—Phase I (199) and Fast Track Phase I/II (31), Phase II (45), RFP (1), and Loan Repayment (368) Fast Track (FT).
Source: Office of Referral, Review and Program Coordination.

Table 12 (cont'd). Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2013*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
Topic 281	Biosensors for Early Cancer Detection and Risk Assessment	Jun-13	1
Topic 283	Development of a Molecular Diagnostic Assay to Detect Basal-Like Breast Cancer	Jun-13	1
Topic 291	Development of Radiation Modulators for Use During Radiotherapy	Jun-13	3
Topic 292	Development of Molecular Pharmacodynamic Assays for Targeted Therapies	Jun-13	1
Topic 293	Development of Devices for Point of Care Analysis of Circulating Tumor Cells	Jun-13	3
Topic 294	Development of Glycosylation-Specific Research Reagents (Antibodies and Aptamers)	Jun-13	5
Topic 296	Systems for Automated Storage, Analysis, and Reporting of Objective Behavioral Exposures	Jun-13	4
Topic 297	Methods and Tools for Quantitatively Measuring Non-Coding RNAs in Cancer Early Detection, Prediction, and Diagnosis	Jun-13	1
Topic 298	Low-Field Electron Paramagnetic Resonance Imaging Device to Optimize Development of Anti-Angiogenic Therapeutics in Cancer Animal Models (NIH Technology Transfer)	Jun-13	0
Topic 300	Reformulation of Cancer Therapeutics Using Nanotechnology	Jun-13	3
Topic 301	Probing Tumor Microenvironment Using *In Vivo* Nanotechnology-Based Sensors	Jun-13	2
Topic 302	Development of Clinical Automated Multiplex Affinity Capture Technology for Detecting Low Abundance Cancer-Related Proteins/Peptides	Jun-13	4
Topic 304	Development of Blood-Based Methods for the Detection of Cancer Recurrence in Post-Therapy Breast Cancer Patients	Jun-13	1
Topic 305	Novel Digital X-Ray Sources for Cancer Imaging Applications	Jun-13	2
Topic 306	Development of Innovative Algorithms for Processing and Analysis of *In Vivo* Images	Jun-13	2
Topic 307	Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment	Jun-13	3
Total			**644**

* The NCI reviewed a total of 644 proposals. The proposals were in response to SBIR Contract Solicitations—Phase I (199) and Fast Track Phase I/II (31), Phase II (45), RFP (1), and Loan Repayment (368)
Source: Office of Referral, Review and Program Coordination.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2013*†

Fund Type: Appropriated Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants Number	 Dollars	Competing Requested	Competing Awarded	Success Rate
Research Project Grants								
Traditional Research Grants – R01/RL1	3,306	1,182,491,179	357,680	52.16%	39.6 %	4,003	582	14.54%
Program Projects – P01	124	231,617,750	1,867,885	1.96%	7.76%	76	24	31.58%
Small Grants – R03	199	15,285,769	76,813	3.14%	0.51%	687	100	14.56%
Exploratory/Developmental Research – R21	441	82,798,564	187,752	6.96%	2.77%	2,334	241	10.33%
Phased Innovation Grant (Phase 2) – R33	2	661,702	330,851	0.03%	0.02%	2	0	0.0 %
Pathway to Independence – R00	72	16,639,279	231,101	1.14%	0.56%	2	1	50.0 %
Exploratory/Development Cooperative Agreements – UH2/UH3	1	306,745	306,745	0.02%	0.01%	1	1	100.0 %
Merit Awards – R37	38	16,899,736	444,730	0.6 %	0.57%	5	5	100.0 %
NIH Director Pioneer Award (NDPA) – DP1	5	2,528,950	505,790	0.08%	0.08%	0	0	0.0 %
NIH Director New Innovator Awards – DP2	2	4,755,250	2,377,625	0.03%	0.16%	2	2	100.0 %
NIH Director's Early Independence Awards – DP5	5	1,845,818	369,164	0.08%	0.06%	0	0	0.0 %
Academic Research Enhancement Awards (AREA) – R15	28	11,938,622	426,379	0.44%	0.4 %	215	28	13.02%
Multi-Component Research Project Cooperative Agreements – UM1	11	23,553,933	2,141,267	0.17%	0.79%	16	6	37.5 %
Cooperative Agreements – U01/U19	99	58,197,206	587,851	1.56%	1.95%	128	23	17.97%
Request for Applications	207	72,101,917	348,318	3.27%	2.41%	464	74	15.95%
Cooperative Agreements – RFA-U01/U19	117	131,921,600	1,127,535	1.85%	4.42%	40	8	20.0 %
Small Business Innovation Research – R43/R44	132	58,593,217	443,888	2.08%	1.96%	719	81	11.27%
Small Business Technology Transfer – R41/R42	27	12,666,657	469,135	0.43%	0.42%	118	19	16.1 %
Program Evaluation – R01	0	75,357,000	75,357,000	0.0 %	2.52%	0	0	0.0 %
Subtotal Research Project Grants	**4,816**	**2,000,160,894**	**415,316**	**75.99%**	**66.98%**	**8,812**	**1,195**	**13.56%**
Other Research								
Clinical Cooperative Groups – U10	120	231,351,950	1,927,933	1.89%	7.75%	24	15	62.5 %
Clinical Cooperative Groups – U10 Specials	0	3,522,400	3,522,400	0.0 %	0.12%	0	0	0.0 %
Clinical Cooperative Groups – CCCT	0	568,847	568,847	0.0 %	0.02%	0	0	0.0 %
Cooperative Conference Grants – U13	1	32,500	32,500	0.02%	0.0 %	1	1	100.0 %
Conference Grants – R13	57	830,962	14,578	0.9 %	0.03%	77	39	50.65%
International Research Training Grants – D43	0	2,845,015	2,845,015	0.0 %	0.1 %	0	0	0.0 %
Continuing Education Training Grants – T15/RL9	1	88,154	88,154	0.02%	0.0 %	0	0	0.0 %
Cancer Education Awards – R25	96	34,465,803	359,019	1.51%	1.15%	67	16	23.88%
Research/Resource Grant – R24/U24/U2C	39	45,931,303	1,177,726	0.62%	1.54%	17	5	29.41%
Subtotal Other Research	314	319,636,934	1,017,952	4.95%	10.7 %	186	76	40.86%

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

Table 13 (cont'd). Summary of NCI Grant Awards by Mechanism in FY2013*†

Fund Type: Appropriated Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants		Competing Requested	Competing Awarded	Success Rate
				Number	Dollars			
Centers								
Core/Planing – P20/P30	82	257,417,765	3,139,241	1.29%	8.62%	25	11	44.0 %
Core – CCCT	0	3,728,627	3,728,627	0.0 %	0.12%	0	0	0.0 %
Center for AIDS Research-CFAR-OHAM – P30	0	1,085,396	1,085,396	0.0 %	0.04%	0	0	0.0 %
Spore Grants – P50	54	104,295,712	1,931,402	0.85%	3.49%	48	16	33.33%
Other P50/P20	13	21,466,753	1,651,289	0.21%	0.72%	0	0	0.0 %
Specialized Center (Cooperative Agreement)	111	145,216,963	1,308,261	1.75%	4.86%	11	6	54.55%
Subtotal Centers	**260**	**533,211,216**	**2,050,812**	**4.1 %**	**17.86%**	**84**	**33**	**39.29%**
NRSA								
NRSA Institution – T32/T35	135	48,684,932	360,629	2.13%	1.63%	68	21	30.88%
NRSA Fellowships – F31/F32	426	17,103,433	40,149	6.72%	0.57%	749	218	29.11%
Subtotal NRSA	561	65,788,365	117,270	8.85%	2.2 %	817	239	29.25%
Careers								
Career Enhancement Award for Stem Cell Research – K18	0	0	0	0.0 %	0.0 %	1	0	0.0 %
Mentored Clinical Scientist – K08	100	16,093,540	160,935	1.58%	0.54%	65	16	24.62%
Preventive Oncology Award – K07	63	9,419,268	149,512	0.99%	0.32%	74	17	22.97%
Mentored Career Award – K12	18	12,762,922	709,051	0.28%	0.43%	10	4	40.0 %
Mentored Research Scientist Development Awards/Mentored Career Development/Temin – K01	51	6,530,996	128,059	0.8 %	0.22%	25	10	40.0 %
Clinical Research Track – K22	21	3,562,488	169,642	0.33%	0.12%	70	7	10.0 %
Mentored Patient-Oriented Research Career Development Award – K23	35	5,823,054	166,373	0.55%	0.19%	34	7	20.59%
Mid-Career Investigator in Patient-Oriented Research Award – K24	15	2,599,150	173,277	0.24%	0.09%	6	2	33.33%
Mentored Quantitative Research Career Development Award – K25	15	2,061,251	137,417	0.24%	0.07%	14	4	28.57%
Established Investigator Award in Cancer Prevention & Control – K05	19	2,742,252	144,329	0.3 %	0.09%	13	2	15.38%
Pathway to Independence – K99	50	5,929,861	118,597	0.79%	0.2 %	134	34	25.37%
Subtotal Careers	**387**	**67,524,782**	**174,483**	**6.11%**	**2.26%**	**446**	**103**	**23.09%**
Total	**6,338**	**2,986,322,191**	**471,177**	**100.0%**	**100.0%**	**10,345**	**1,646**	**15.91%**

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2009 - FY2013‡

Budget Mechnism/ Division	FY 2009		FY 2010		FY 2011		FY 2012		FY 2013		Percent Change 2009 - 2013	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
R01 Average Cost of Award												
NCI Overall	3,573	350	3,655	362	3,648	365	3,526	374	3,306	358	-7.47%	2.29%
DCB	1,792	308	1,783	313	1,748	317	1,660	323	1,555	312	-13.2 %	1.4 %
DCP	246	388	261	399	258	400	245	421	226	389	-8.1 %	0.2 %
DCTD	1,042	327	1,107	336	1,141	343	1,139	355	1,078	342	3.5 %	4.5 %
DCCPS	478	515	486	561	485	553	468	559	436	521	-8.8 %	1.3 %
OD (CRCHD, OCAM, CSSI, CCT,OHAM, etc.)	15	977	18	911	16	901	14	924	11	1,221	-26.7 %	25.0 %
P01 Average Cost of Award												
NCI Overall	151	2,002	140	2,004	129	2,010	122	1,997	124	1,868	-17.88%	-6.69%
DCB	60	1,729	56	1,783	53	1,804	54	1,771	54	1,612	-10.0 %	-6.8 %
DCP	9	1,931	7	1,737	8	1,814	8	1,579	7	1,414	-22.2 %	-26.7 %
DCTD	69	2,215	64	2,188	58	2,164	49	2,194	53	2,063	-23.2 %	-6.9 %
DCCPS	12	2,174	12	2,161	10	2,298	11	2,502	10	2,517	-16.7 %	15.8 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	1	2,220	1	2,576	0	638	0	306	0	155	-100.0 %	-93.0 %
R03 Average Cost of Award												
NCI Overall	239	77	181	78	127	76	172	76	199	77	-16.74%	0.0 %
DCB	15	76	8	78	3	75	10	76	11	75	-26.7 %	-1.9 %
DCP	91	78	56	78	38	75	61	78	63	77	-30.8 %	-0.2 %
DCTD	12	76	10	77	6	76	10	78	15	76	25.0 %	0.8 %
DCCPS	119	77	107	79	80	77	91	75	110	77	-7.6 %	-0.6 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	2	47	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
R21 Average Cost of Award												
NCI Overall	447	205	415	202	442	200	439	197	441	188	-1.34%	-8.29%
DCB	75	193	77	188	79	181	80	187	90	185	20.0 %	-4.5 %
DCP	50	174	50	187	51	183	54	188	54	181	8.0 %	4.1 %
DCTD	236	218	198	218	207	220	188	215	190	194	-19.5 %	-11.3 %
DCCPS	85	195	82	185	80	178	89	176	78	179	-8.2 %	-8.3 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	1	204	8	217	25	205	28	186	29	195	2,800 %	-4.6 %

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14 (cont'd). Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2009 - FY2013‡

Budget Mechnism/ Division	FY 2009		FY 2010		FY 2011		FY 2012		FY 2013		Percent Change 2009 - 2013	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
U01/U19 Average Cost of Award												
NCI Overall	110	1,035	131	1,091	130	1,062	132	989	115	1,093	4.55%	5.6 %
DCB	28	776	28	776	29	721	28	714	28	665	0.0 %	-14.4 %
DCP	7	366	35	741	35	671	36	681	36	674	414.3 %	83.9 %
DCTD	39	1,417	28	1,461	26	1,313	23	939	5	3,621	-87.2 %	155.6 %
DCCPS	32	678	23	1,598	23	1,752	22	1,761	22	1,593	-31.3 %	134.9 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	4	3,159	17	1,039	17	1,135	23	1,119	24	1,235	500.0 %	-60.9 %
R13 Average Cost of Award												
NCI Overall	80	36	95	76	92	65	64	89	57	15	-28.75%	-58.33%
DCB	33	10	36	9	35	4	22	6	24	5	-27.3 %	-46.7 %
DCP	8	15	8	12	9	15	5	19	6	18	-25.0 %	17.9 %
DCTD	19	13	19	12	16	11	14	14	15	8	-21.1 %	-41.1 %
DCCPS	14	24	17	20	17	14	11	21	7	19	-50.0 %	-20.6 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	6	307	15	418	15	349	12	418	5	69	-16.7 %	-77.4 %
U10 Average Cost of Award												
NCI Overall	134	1,750	131	1,937	135	1,801	128	1,789	120	1,958	-10.45%	11.89%
DCP	73	1,254	71	1,330	77	1,160	75	1,165	75	1,130	2.7 %	-9.9 %
DCTD	61	2,344	60	2,655	58	2,653	53	2,671	45	3,337	-26.2 %	42.4 %
P30 Average Cost of Award												
NCI Overall	65	4,337	66	4,446	66	4,168	67	4,134	68	3,823	4.62%	-11.85%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	65	4,337	66	4,446	66	4,168	67	4,133	68	3,823	4.6 %	-11.8 %
P50 Average Cost of Award												
NCI Overall	71	1,967	75	2,081	74	1,979	69	2,010	66	1,895	-7.04%	-3.66%
DCP	0	0	0	400	0	400	0	400	0	388	0.0 %	100.0 %
DCTD	64	2,025	65	2,101	64	1,999	59	2,044	59	1,907	-7.8 %	-5.8 %
DCCPS	7	1,334	10	1,847	10	1,739	10	1,686	7	1,651	0.0 %	23.8 %
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	766	0	617	0	701	0	813	0	600	0.0 %	-21.7 %

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.
†In thousands.
‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14 (cont'd). Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2009 - FY2013‡

Budget Mechnism/ Division	FY 2009		FY 2010		FY 2011		FY 2012		FY 2013		Percent Change 2009 - 2013	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
SBIR Average Cost of Award												
NCI Overall	219	367	180	411	123	587	151	422	132	444	-39.73%	20.98%
CRCHD	0	0	0	85	0	83	0	0	0	0	0.0 %	0.0 %
DCTD	4	318	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
DCCPS	0	0	0	0	0	32	0	0	0	0	0.0 %	0.0 %
SBIRDC	215	368	180	411	123	586	151	422	132	444	-38.6 %	20.7 %
STTR Average Cost of Award												
NCI Overall	42	277	27	431	21	562	39	350	27	469	-35.71%	69.31%
DCTD	1	138	0	0	0	0	0	0	0	0	-100.0 %	-100.0 %
SBIRDC	0	0	0	0	21	562	39	350	27	469	100.0 %	100.0 %
STTRDC	41	280	27	431	0	0	0	0	0	0	-100.0 %	-100.0 %
U54 Average Cost of Award												
NCI Overall	56	1,939	93	1,453	101	1,523	103	1,709	106	1,316	89.29%	-32.13%
CRCHD	21	1,274	51	1,066	47	1,152	49	1,110	50	940	138.1 %	-26.2 %
CSSI	16	3,311	18	2,776	21	2,468	21	3,630	21	2,155	31.3 %	-34.9 %
DCB	15	1,327	20	1,492	22	1,400	22	1,441	24	1,343	60.0 %	1.2 %
DCCPS	4	2,238	4	230	11	1,551	11	1,244	11	1,365	175.0 %	-39.0 %

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.
†In thousands.
‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Adrenal	***Number of Grants***	***7***	***9***	***6***	***6***	***3***	
	Relevant Grant Dollars	443,049	908,434	557,068	694,479	334,332	
	Total Count	***7***	***9***	***6***	***6***	***3***	
	Total Relevant Dollars	443,049	908,434	557,086	694,479	334,332	16.53
Anus	***Number of Grants***	***17***	***14***	***16***	***18***	***19***	
	Relevant Grant Dollars	2,585,470	1,996,111	2,740,690	2,539,326	3,730,597	
	Number of Contracts	***5***	‡	***3***	‡	‡	
	Relevant Contract Dollars	778,300	‡	446,435	‡	‡	
	Total Count	***22***	***14***	***19***	***18***	***19***	
	Total Relevant Dollars	3,363,770	1,996,111	3,187,125	2,539,326	3,730,597	-5.79
Bladder	***Number of Grants***	***219***	***208***	***176***	***143***	***124***	
	Relevant Grant Dollars	20,834,546	18,941,518	15,777,763	18,493,415	15,767,632	
	Number of Contracts	***16***	***3***	***1***	***1***	***1***	
	Relevant Contract Dollars	340,792	25,113	176,266	749,947	561,614	
	Total Count	***235***	***211***	***177***	***144***	***125***	
	Total Relevant Dollars	21,175,338	18,966,631	15,954,029	19,243,362	16,329,246	-2.21
Bone Marrow	***Number of Grants***	***75***	***92***	***76***	***55***	***67***	
	Relevant Grant Dollars	16,586,714	13,124,422	17,343,897	8,938,608	8,109,194	
	Total Count	***75***	***92***	***76***	***55***	***67***	
	Total Relevant Dollars	16,586,714	13,124,422	17,343,897	8,938,608	8,109,194	-11.28
Bone, Cartilage	***Number of Grants***	***84***	***98***	***90***	***72***	***68***	
	Relevant Grant Dollars	16,835,159	18,014,359	14,539	10,824,238	7,034,582	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***84***	***98***	***90***	***72***	***68***	
	Total Relevant Dollars	16,835,159	18,014,359	14,539,162	10,824,238	7,034,582	-10.70
Brain	***Number of Grants***	***464***	***498***	***500***	***512***	***544***	
	Relevant Grant Dollars	125,530,253	131,178,363	143,786,108	148,032,345	152,082,930	
	Number of Contracts	***14***	***3***	***3***	***5***	***2***	
	Relevant Contract Dollars	215,004	217,734	698,895	672,916	1,639,630	
	Total Count	***478***	***501***	***503***	***517***	***546***	
	Total Relevant Dollars	125,745,257	131,396,097	144,485,003	148,705,261	153,722,560	4.13
Breast	***Number of Grants***	***1,958***	***1,934***	***1,859***	***1,835***	***1,792***	
	Relevant Grant Dollars	542,409,702	569,062,367	552,999,395	536,444,140	501,581,607	
	Number of Contracts	***36***	***32***	***20***	***25***	***20***	
	Relevant Contract Dollars	7,420,959	7,908,595	9,370,644	12,810,843	11,117,661	
	Total Count	***1,994***	***1,966***	***1,879***	***1,860***	***1,812***	
	Total Relevant Dollars	549,830,661	576,970,962	562,370,039	549,254,983	512,699,268	-0.01
Central Nervous System	***Number of Grants***	***42***	***43***	***35***	***51***	***59***	
	Relevant Grant Dollars	5,765,488	6,255,071	5,370,246	4,169,107	3,630,469	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	374,998	‡	‡	‡	‡	
	Total Count	***43***	***43***	***35***	***51***	***59***	
	Total Relevant Dollars	6,140,486	6,255,071	5,770,246	4,169,107	3,630,469	-8.60

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Cervix	***Number of Grants***	***298***	***298***	***295***	***298***	***283***	
	Relevant Grant Dollars	51,605,675	61,579,940	60,341,462	58,198,274	50,597,621	
	Number of Contracts	***23***	***5***	***4***	***3***	***1***	
	Relevant Contract Dollars	7,479,618	4,759,619	4,729,585	3,366,401	2,280,313	
	Total Count	***321***	***303***	***299***	***301***	***284***	
	Total Relevant Dollars	59,085,293	66,339,559	65,071,047	61,564,675	52,877,934	1.20
Childhood Leukemia	***Number of Grants***	***123***	***148***	***157***	***178***	***151***	
	Relevant Grant Dollars	42,335,965	49,924,922	33,329,128	51,786,291	51,230,678	
	Total Count	***123***	***148***	***157***	***178***	***151***	
	Total Relevant Dollars	42,335,965	49,924,922	33,291,283	51,786,291	51,230,678	5.88
Colon, Rectum	***Number of Grants***	***963***	***984***	***951***	***937***	***916***	
	Relevant Grant Dollars	237,991,020	245,295,756	242,486,775	227,386,183	213,714,476	
	Number of Contracts	***38***	***16***	***11***	***14***	***9***	
	Relevant Contract Dollars	7,934,699	6,412,331	4,299,256	6,246,343	4,230,994	
	Total Count	***1,001***	***1,000***	***962***	***951***	***925***	
	Total Relevant Dollars	245,925,719	251,708,087	246,786,031	233,632,526	217,945,470	-1.26
Connective Tissue	***Number of Grants***	***55***	***51***	***56***	***44***	***21***	
	Relevant Grant Dollars	10,709,782	10,417,011	9,999,338	8,185,709	3,310,900	
	Total Count	***55***	***51***	***56***	***44***	***21***	
	Total Relevant Dollars	10,709,782	10,417,011	9,999,338	8,185,709	3,310,900	-6.41
Embryonic Tissue, Cells	***Number of Grants***	***6***	***10***	***8***	***5***	***3***	
	Relevant Grant Dollars	694,792	1,477,847	1,325,565	368,936	340,919	
	Total Count	***6***	***10***	***8***	***5***	***3***	
	Total Relevant Dollars	694,792	1,477,847	1,325,565	368,936	340,919	7.24
Esophagus	***Number of Grants***	***129***	***100***	***118***	***147***	***175***	
	Relevant Grant Dollars	24,435,190	25,599,073	28,238,207	23,801,157	23,146,386	
	Number of Contracts		***‡***	***1***	***2***	***1***	
	Relevant Contract Dollars	‡	‡	20,000	229,905	12,726	
	Total Count	***129***	***100***	***119***	***149***	***176***	
	Total Relevant Dollars	24,435,190	25,599,073	28,258,207	24,031,062	23,159,112	-0.21
Eye	***Number of Grants***	***11***	***13***	***12***	***14***	***16***	
	Relevant Grant Dollars	1,910,869	2,168,685	2,161,882	2,008,983	2,362,025	
	Total Count	***11***	***13***	***12***	***14***	***16***	
	Total Relevant Dollars	1,910,869	2,168,685	2,161,882	2,008,983	2,362,025	1.57
Gall Bladder	***Number of Grants***	***4***	***1***	***16***	***2***	***2***	
	Relevant Grant Dollars	372,129	212,356	199,485	156,086	146,805	
	Total Count	***4***	***1***	***16***	***2***	***2***	
	Total Relevant Dollars	372,129	212,356	199,485	156,086	146,805	-17.80
Gastrointestinal Tract	***Number of Grants***	***62***	***51***	***48***	***50***	***45***	
	Relevant Grant Dollars	9,143,226	8,649,596	8,306,179	9,181,848	7,398,956	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***62***	***51***	***48***	***50***	***45***	
	Total Relevant Dollars	9,143,226	8,649,596	8,306,179	9,181,848	7,398,956	0.20

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Genital System, Female	***Number of Grants***	***9***	***12***	***19***	***38***	***43***	
	Relevant Grant Dollars	578,518	1,255,368	1,708,702	2,136,318	2,875,521	
	Number of Contracts	***5***	***5***	***1***	‡	‡	
	Relevant Contract Dollars	666,439	336,493	187,496	‡	‡	
	Total Count	***14***	***17***	***20***	***38***	***43***	
	Total Relevant Dollars	1,244,957	1,591,861	1,896,198	2,136,318	2,875,521	14.23
Genital System, Male	***Number of Grants***	***6***	***6***	***5***	***6***	***2***	
	Relevant Grant Dollars	1,466,575	549,031	334,581	350,827	237,891	
	Number of Contracts	***5***	***5***	‡	‡	‡	
	Relevant Contract Dollars	666,439	336,493	‡	‡	‡	
	Total Count	***11***	***11***	***5***	***6***	***2***	
	Total Relevant Dollars	2,133,014	885,524	334,581	350,827	237,891	-54.65
Head and Neck	***Number of Grants***	***214***	***204***	***201***	***217***	***248***	
	Relevant Grant Dollars	41,932,591	41,468,691	39,623,318	37,034,455	33,677,355	
	Number of Contracts	***5***	***7***	***3***	***7***	***5***	
	Relevant Contract Dollars	1,433,714	1,897,174	1,337,385	4,032,932	717,810	
	Total Count	***219***	***211***	***204***	***224***	***253***	
	Total Relevant Dollars	43,366,305	43,365,865	40,960,703	41,067,387	34,395,165	-1.44
Heart	***Number of Grants***	***20***	***15***	***16***	***12***	***10***	
	Relevant Grant Dollars	2,361,956	2,148,483	1,737,287	1,971,428	1,792,289	
	Total Count	***20***	***15***	***16***	***12***	***10***	
	Total Relevant Dollars	2,361,956	2,148,483	1,737,287	1,971,428	1,792,289	-4.83
Hodgkins Lymphoma	***Number of Grants***	***72***	***54***	***77***	***94***	***83***	
	Relevant Grant Dollars	13,631,008	9,846,229	8,994,562	9,649,890	9,563,149	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***72***	***54***	***77***	***94***	***83***	
	Total Relevant Dollars	13,631,008	9,846,229	8,994,562	9,649,890	9,563,149	-7.49
Kaposi Sarcoma	***Number of Grants***	***81***	***92***	***87***	***82***	***77***	
	Relevant Grant Dollars	18,551,830	17,444,041	20,205,869	19,241,042	18,354,076	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***81***	***92***	***87***	***82***	***77***	
	Total Relevant Dollars	18,551,830	17,444,041	20,205,869	19,241,042	18,354,076	0.72
Kidney	***Number of Grants***	***210***	***226***	***241***	***246***	***250***	
	Relevant Grant Dollars	26,856,193	26,734,935	29,194,089	32,449,153	31,320,199	
	Number of Contracts	***1***	***2***	***2***	‡	‡	
	Relevant Contract Dollars	47,891	274,436	390,889	‡	‡	
	Total Count	***211***	***228***	***243***	***246***	***250***	
	Total Relevant Dollars	26,904,084	27,009,371	29,584,978	32,449,153	31,320,199	4.69
Larynx	***Number of Grants***	***5***	***3***	***4***	***6***	***6***	
	Relevant Grant Dollars	387,226	99,159	203,215	464,533	1,259,413	
	Total Count	***5***	***3***	***4***	***6***	***6***	
	Total Relevant Dollars	387,226	99,159	203,215	464,533	1,259,413	26.78

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Leukemia	***Number of Grants***	***703***	***680***	***683***	***724***	***755***	
	Relevant Grant Dollars	192,236,365	210,799,140	199,610,401	208,324,142	209,330,335	
	Number of Contracts	***2***	***3***	***4***	***2***	***7***	
	Relevant Contract Dollars	228,944	1,495,139	1,098,646	213,752	3,612,561	
	Total Count	***705***	***683***	***687***	***726***	***762***	
	Total Relevant Dollars	192,465,309	212,294,279	200,709,047	208,537,894	212,942,896	2.11
Liver	***Number of Grants***	***280***	***294***	***302***	***322***	***321***	
	Relevant Grant Dollars	58,730,034	60,616,338	54,071	52,508,097	48,910,887	
	Number of Contracts	***1***	‡	***1***	***2***	***8***	
	Relevant Contract Dollars	124,807	‡	299,353	115,700	4,653,688	
	Total Count	***281***	***294***	***303***	***324***	***329***	
	Total Relevant Dollars	58,854,841	60,616,338	54,370,763	52,623,797	53,564,575	-2.92
Lung	***Number of Grants***	***961***	***965***	***968***	***993***	***1,003***	
	Relevant Grant Dollars	210,440,490	243,602,747	260,155,893	268,028,541	243,708,636	
	Number of Contracts	***35***	***23***	***16***	***26***	***21***	
	Relevant Contract Dollars	7,217,782	7,815,307	4,919,129	12,146,630	11,323,702	
	Total Count	***996***	***988***	***984***	***1,019***	***1,024***	
	Total Relevant Dollars	217,658,272	251,418,054	265,075,022	280,175,171	255,032,338	6.57
Lymph Node	***Number of Grants***	***18***	***15***	***13***	***9***	***9***	
	Relevant Grant Dollars	4,206,917	2542477	2,017,737	1,975,041	608,275	
	Total Count	***18***	***15***	***13***	***9***	***9***	
	Total Relevant Dollars	4,206,917	2,542,477	2,017,737	1,975,041	608,275	-17.09
Lymphatic System	***Number of Grants***	***9***	***4***	***5***	***4***	***3***	
	Relevant Grant Dollars	972,288	472,471	788,609	803,722	489,999	
	Total Count	***9***	***4***	***5***	***4***	***3***	
	Total Relevant Dollars	972,288	472,471	788,609	803,722	489,999	-2.45
Melanoma	***Number of Grants***	***454***	***457***	***435***	***423***	***474***	
	Relevant Grant Dollars	86,581,615	85,429,532	96,537,993	99,713,846	101,678,996	
	Number of Contracts	***2***	***4***	***1***	***2***	***2***	
	Relevant Contract Dollars	276,130	698,413	50,000	1,349,977	1,764,768	
	Total Count	***456***	***461***	***436***	***425***	***476***	
	Total Relevant Dollars	86,857,745	86,127,945	96,587,993	101,063,823	103,443,764	3.66
Mesothelioma	***Number of Grants***	***18***	***15***	***16***	***18***	***19***	
	Relevant Grant Dollars	4,954,819	5,530,460	3,457,493	4,863,814	4,452,535	
	Total Count	***18***	***15***	***16***	***18***	***19***	
	Total Relevant Dollars	4,954,819	5,530,460	3,457,493	4,863,814	4,452,535	-1.94
Muscle	***Number of Grants***	***37***	***37***	***48***	***58***	***41***	
	Relevant Grant Dollars	6,535,783	6,049,875	8,018,193	6,914,232	3,361,305	
	Total Count	***37***	***37***	***48***	***58***	***41***	
	Total Relevant Dollars	6,535,783	6,049,875	8,018,193	6,914,232	3,361,305	0.71
Myeloma	***Number of Grants***	***234***	***234***	***242***	***249***	***160***	
	Relevant Grant Dollars	40,008,777	41,740,236	48,195,056	52,667,345	37,120,602	
	Number of Contracts	‡	***1***	‡	***1***	‡	
	Relevant Contract Dollars	‡	199,860	‡	1,499,746	‡	
	Total Count	***234***	***235***	***242***	***250***	***160***	
	Total Relevant Dollars	40,008,777	41,940,096	48,195,056	54,167,091	37,120,602	7.47

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Nervous System	***Number of Grants***	***29***	***30***	***28***	***26***	***24***	
	Relevant Grant Dollars	4,847,016	5,271,048	6,787,090	6,438,816	4,163,832	
	Number of Contracts	‡	‡	***1***	‡	‡	
	Relevant Contract Dollars	‡	‡	8,250	‡	‡	
	Total Count	***29***	***30***	***29***	***26***	***24***	
	Total Relevant Dollars	4,847,016	5,271,048	6,795,340	6,438,816	4,163,832	6.39
Neuroblastoma	***Number of Grants***	***100***	***98***	***98***	***105***	***99***	
	Relevant Grant Dollars	17,189,208	17,861,575	20,974,714	24,697,656	16,492,753	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	299,993	‡	
	Total Count	***100***	***98***	***98***	***106***	***99***	
	Total Relevant Dollars	17,189,208	17,861,575	20,974,714	24,997,649	16,492,753	9.40
Non-Hodgkins Lymphoma	***Number of Grants***	***523***	***455***	***472***	***473***	***480***	
	Relevant Grant Dollars	100,604,178	97,937,059	101,566,115	93,857,913	89,044,122	
	Number of Contracts	‡	‡	***1***	***1***	***1***	
	Relevant Contract Dollars	‡	‡	1,500,000	125,000	749,986	
	Total Count	***523***	***455***	***473***	***474***	***481***	
	Total Relevant Dollars	100,604,178	97,937,059	103,066,115	93,982,913	89,794,108	-1.63
Nose, Nasal Passages	***Number of Grants***	***10***	***14***	***8***	***10***	***10***	
	Relevant Grant Dollars	676,153	1,627,236	904,491	1,117,904	987,215	
	Total Count	***10***	***14***	***8***	***10***	***10***	
	Total Relevant Dollars	676,153	1,627,236	904,491	1,117,904	987,215	21.06
Not Site Specific§	***Number of Grants***	***2,196***	***2,079***	***1,952***	***1,889***	***1,727***	
	Relevant Grant Dollars	604,058,911	608,746,346	573,631,342	572,734,563	495,343,572	
	Number of Contracts	***186***	***162***	***166***	***192***	***201***	
	Relevant Contract Dollars	432,722,194	191,360,124	192,657,199	187,026,369	205,498,650	
	Total Count	***2,382***	***2,241***	***2,118***	***2,081***	***1,928***	
	Total Relevant Dollars	1,036,781,105	800,106,470	766,288,541	759,760,932	700,842,222	-7.04
Oral Cavity	***Number of Grants***	***49***	***52***	***49***	***59***	***66***	
	Relevant Grant Dollars	8,783,998	11,138,288	8,209,050	11,657,227	10,151,964	
	Number of Contracts	***‡***	***‡***	***‡***	***‡***	***‡***	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***49***	***52***	***49***	***59***	***66***	
	Total Relevant Dollars	8,783,998	11,138,288	8,209,050	11,657,227	10,151,964	8.25
Ovary	***Number of Grants***	***398***	***413***	***413***	***385***	***384***	
	Relevant Grant Dollars	92,438,385	96,565,010	96,600,440	95,732,146	85,110,664	
	Number of Contracts	***16***	***11***	***6***	***7***	***5***	
	Relevant Contract Dollars	6,099,306	5,217,503	2,015,726	2,496,203	3,421,603	
	Total Count	***414***	***424***	***419***	***392***	***389***	
	Total Relevant Dollars	98,537,691	101,782,513	98,616,166	98,228,349	88,532,267	-0.10
Pancreas	***Number of Grants***	***401***	***424***	***417***	***421***	***465***	
	Relevant Grant Dollars	83,917,076	90,502,908	91,095,822	97,245,213	93,541,191	
	Number of Contracts	***1***	***1***	***3***	***3***	***2***	
	Relevant Contract Dollars	124,807	159,140	673,594	306,780	1,249,838	
	Total Count	***402***	***425***	***420***	***424***	***467***	
	Total Relevant Dollars	84,041,883	90,662,048	91,769,416	97,551,993	94,791,029	3.84

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
§Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies. There is no cancer site focus; however, it is relevant to cancer research.)
Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Parathyroid	***Number of Grants***	***4***	***2***	***1***	***2***	***2***	
	Relevant Grant Dollars	103,991	‡	‡	216,587	199,513	
	Total Count	***4***	***2***	***1***	***2***	***2***	
	Total Relevant Dollars	103,991	‡	‡	216,587	199,513	33.46
Penis	***Number of Grants***	***4***	***5***	***6***	***6***	***6***	
	Relevant Grant Dollars	752,499	2,667,920	2,249,216	2,424,675	2,435,008	
	Total Count	***4***	***5***	***6***	***6***	***6***	
	Total Relevant Dollars	752,499	2,667,920	2,249,216	2,424,675	2,435,008	60.93
Pharynx	***Number of Grants***	***52***	***14***	***18***	***74***	***63***	
	Relevant Grant Dollars	4,449,521	1,521,576	1,692,375	3,427,507	4,442,944	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***52***	***14***	***18***	***74***	***63***	
	Total Relevant Dollars	4,449,521	1,521,576	1,692,375	3,427,507	4,442,944	11.78
Pituitary	***Number of Grants***	***7***	***7***	***7***	***5***	***6***	
	Relevant Grant Dollars	482,208	627,219	1,032,440	695,788	649,567	
	Total Count	***7***	***7***	***7***	***5***	***6***	
	Total Relevant Dollars	482,208	627,219	1,032,440	695,788	649,567	9.16
Prostate	***Number of Grants***	***1,028***	***1,030***	***960***	***968***	***923***	
	Relevant Grant Dollars	250,572,712	265,054,420	254,592,786	231,897,860	223,571,212	
	Number of Contracts	***38***	***24***	***13***	***10***	***12***	
	Relevant Contract Dollars	8,857,832	8,108,959	5,670,388	3,076,292	6,244,033	
	Total Count	***1,066***	***1,054***	***973***	***978***	***935***	
	Total Relevant Dollars	259,430,544	273,163,379	260,263,174	234,974,152	229,815,245	-2.35
Reticuloendothelial System	***Number of Grants***	***30***	***24***	***23***	***12***	***9***	
	Relevant Grant Dollars	7,424,753	4,220,047	4,207,337	3,007,301	1,097,687	
	Total Count	***30***	***24***	***23***	***12***	***9***	
	Total Relevant Dollars	7,424,753	4,220,047	4,207,337	3,007,301	1,097,687	-18.16
Respiratory System	***Number of Grants***	***3***	***3***	***5***	***4***	‡	
	Relevant Grant Dollars	484,204	400,921	433,241	424,144	‡	
	Total Count	***3***	***3***	***5***	***4***	‡	
	Total Relevant Dollars	484,204	400,921	433,241	424,144	‡	-3.21
Retinoblastoma	***Number of Grants***	***23***	***20***	***14***	***13***	***14***	
	Relevant Grant Dollars	3,582,106	2,599,952	2,291,465	2,335,494	2,225,018	
	Total Count	***23***	***20***	***14***	***13***	***14***	
	Total Relevant Dollars	3,582,106	2,599,952	2,291,465	2,335,494	2,225,018	-9.75
Salivary Glands	***Number of Grants***	***4***	***5***	***2***	***3***	***3***	
	Relevant Grant Dollars	219,489	281,931	122,931	582,113	515,075	
	Total Count	***4***	***5***	***2***	***3***	***3***	
	Total Relevant Dollars	219,489	281,931	122,931	582,113	515,075	68.13

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Skin	***Number of Grants***	***243***	***227***	***206***	***209***	***205***	
	Relevant Grant Dollars	44,850,024	43,190,271	39,781,606	38,979,774	36,075,772	
	Number of Contracts	***1***	‡	***1***	***1***	***1***	
	Relevant Contract Dollars	200,000	‡	999,000	299,993	608,798	
	Total Count	***244***	***227***	***207***	***210***	***206***	
	Total Relevant Dollars	45,050,024	43,190,271	40,780,606	39,279,767	36,684,570	-3.45
Small Intestine	***Number of Grants***	***21***	***19***	***21***	***22***	***19***	
	Relevant Grant Dollars	2,322,269	2,154,757	2,523,663	2,601,072	2,440,030	
	Total Count	***22***	***19***	***21***	***22***	***19***	
	Total Relevant Dollars	2,371,765	2,154,757	2,523,663	2,601,072	2,440,030	2.12
Spleen	***Number of Grants***	***4***	***3***	***1***	‡	‡	
	Relevant Grant Dollars	190,652	243,170	41,226	‡	‡	
	Total Count	***4***	***3***	***1***	‡	‡	
	Total Relevant Dollars	190,652	243,170	41,226	‡	‡	-27.75
Stomach	***Number of Grants***	***64***	***65***	***58***	***46***	***43***	
	Relevant Grant Dollars	11,212,686	10,776,732	9,227,080	8,068,624	8,064,193	
	Number of Contracts	‡	‡	‡	***2***	‡	
	Relevant Contract Dollars	‡	‡	‡	85,605	‡	
	Total Count	***64***	***65***	***58***	***48***	***43***	
	Total Relevant Dollars	11,212,686	10,776,732	9,227,080	8,154,229	8,064,193	-8.08
Testis	***Number of Grants***	***30***	***27***	***23***	***12***	***8***	
	Relevant Grant Dollars	4,704,354	4,216,762	2,966,075	3,825,536	3,850,005	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***30***	***27***	***23***	***12***	***8***	
	Total Relevant Dollars	4,704,354	4,216,762	2,966,075	3,825,536	3,850,005	-5.89
Thymus	***Number of Grants***	***6***	***4***	***4***	***4***	***5***	
	Relevant Grant Dollars	702,233	397,192	504,940	615,252	609,747	
	Total Count	***6***	***4***	***4***	***4***	***5***	
	Total Relevant Dollars	702,233	397,192	504,940	615,252	609,747	-0.07
Thyroid	***Number of Grants***	***47***	***52***	***51***	***48***	***52***	
	Relevant Grant Dollars	10,773,542	10,900,704	10,394,218	10,082,148	14,641,877	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	95313	
	Total Count	***47***	***52***	***51***	***48***	***53***	
	Total Relevant Dollars	10,773,542	10,900,704	10,394,218	10,082,148	14,737,190	-1.56
Trachea, Bronchus	***Number of Grants***	***3***	***2***	***4***	***3***	***3***	
	Relevant Grant Dollars	332,875	112,364	927,176	707,722	523,065	
	Total Count	***3***	***2***	***4***	***3***	***3***	
	Total Relevant Dollars	332,875	112,364	927,176	707,722	523,065	-0.57
Uterus	***Number of Grants***	***107***	***80***	***90***	***107***	***104***	
	Relevant Grant Dollars	14,708,946	12,006,415	13,617,358	16,911,090	15,653,222	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	142712	
	Total Count	***107***	***80***	***90***	***107***	***105***	
	Total Relevant Dollars	14,708,946	12,006,415	13,617,358	16,911,090	15,795,934	4.39

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 15 (cont'd). NCI Organ and Related Site-Specific Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Vagina	***Number of Grants***	***3***	***4***	***5***	***5***	***4***	
	Relevant Grant Dollars	374,910	275,471	284,762	336,623	317,026	
	Total Count	***3***	***4***	***5***	***5***	***4***	
	Total Relevant Dollars	374,910	275,471	284,762	336,623	317,026	-1.28
Vascular	***Number of Grants***	***65***	***55***	***48***	***40***	***30***	
	Relevant Grant Dollars	13,022,343	12,429,452	11,108,479	7,523,998	3,990,351	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***65***	***55***	***48***	***40***	***30***	
	Total Relevant Dollars	13,022,343	12,429,452	11,108,479	7,523,998	3,990,351	-12.30
Wilms Tumor	***Number of Grants***	***16***	***15***	***17***	***14***	***7***	
	Relevant Grant Dollars	4,249,920	3,792,626	3,166,418	2,563,467	1,341,539	
	Total Count	***16***	***15***	***17***	***14***	***7***	
	Total Relevant Dollars	4,249,920	3,792,626	3,166,418	2,563,467	1,341,539	-12.51

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Adoptive Cell Immunotherapy	***Number of Grants***	***250***	***249***	***226***	***231***	***216***	
	Relevant Grant Dollars	65,455,904	71,169,780	68,415,543	64,459,206	55,186,231	
	Number of Contracts	‡	‡	***1***	‡	***1***	
	Relevant Contract Dollars	‡	‡	247,568	‡	1,499,971	
	Total Count	***250***	***249***	***227***	***231***	***217***	
	Total Relevant Dollars	65,455,904	71,169,780	68,663,021	64,459,206	56,686,202	-3.24
Advanced Manufacturing Technology	***Number of Grants***	***16***	***15***	***13***	***10***	***7***	
	Relevant Grant Dollars	3,032,054	3,285,087	2,770,889	2,945,075	2,460,945	
	Number of Contracts	***7***	***1***	‡	***1***	‡	
	Relevant Contract Dollars	2,189,910	106,000	‡	498,626	‡	
	Total Count	***23***	***16***	***13***	***11***	***7***	
	Total Relevant Dollars	5,221,964	3,391,087	2,770,889	3,443,701	2,460,945	-14.40
Aging	***Number of Grants***	***1,311***	***1,066***	***854***	***689***	***577***	
	Relevant Grant Dollars	135,080,359	113,349,368	99,438,832	79,998,304	69,649,282	
	Number of Contracts	***26***	***7***	***5***	***2***	***1***	
	Relevant Contract Dollars	4,221,489	2,424,616	631,073	82,113	27,250	
	Total Count	***1,337***	***1,073***	***859***	***691***	***578***	
	Total Relevant Dollars	139,301,848	115,773,984	100,069,905	80,080,417	69,676,532	-15.86
AIDS	***Number of Grants***	***413***	***412***	***65***	***60***	***45***	
	Relevant Grant Dollars	98,869,614	91,837,776	13,092,878	12,538,472	10,917,513	
	Number of Contracts	***10***	***3***	‡	‡	‡	
	Relevant Contract Dollars	4,070,295	504,083	‡	‡	‡	
	Total Count	***423***	***415***	***65***	***60***	***45***	
	Total Relevant Dollars	102,939,909	92,341,859	13,092,878	12,538,472	10,917,513	-28.32
Alternative Medicine, Direct	***Number of Grants***	***371***	***373***	***347***	***343***	***304***	
	Relevant Grant Dollars	85,029,188	89,420,040	83,106,708	73,033,996	57,639,318	
	Number of Contracts	***3***	***2***	‡	***3***	‡	
	Relevant Contract Dollars	610	1,149,412	‡	266,500	‡	
	Total Count	***374***	***375***	***347***	***346***	***304***	
	Total Relevant Dollars	85,029,798	90,569,452	83,106,708	73,300,496	57,639,318	-28.32
Alternative Medicine, Indirect	***Number of Grants***	***48***	***44***	***47***	***31***	***23***	
	Relevant Grant Dollars	8,017,376	8,714,472	8,363,143	6,981,196	4,798,508	
	Total Count	***48***	***44***	***47***	***31***	***23***	
	Total Relevant Dollars	8,017,376	8,714,472	8,363,143	6,981,196	4,798,508	-10.78
Alzheimers Dementia	***Number of Grants***	***7***	***4***	***4***	***3***	***3***	
	Relevant Grant Dollars	643,620	508,810	565,699	96,204	186,357	
	Total Count	***7***	***4***	***4***	***3***	***3***	
	Total Relevant Dollars	643,620	508,810	565,699	96,204	186,357	0.24
Arctic Research	***Number of Grants***	***5***	***3***	***3***	***5***	***7***	
	Relevant Grant Dollars	593,726	684,462	692,817	570,649	1,048,649	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	471,532	‡	
	Total Count	***5***	***3***	***3***	***6***	***7***	
	Total Relevant Dollars	593,726	684,462	692,817	1,042,181	1,048,649	16.89

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Arthritis	***Number of Grants***	***6***	***4***	***5***	***7***	***6***	
	Relevant Grant Dollars	269,326	400,562	396,477	1,066,691	881,952	
	Total Count	***6***	***4***	***5***	***7***	***6***	
	Total Relevant Dollars	269,326	400,562	396,477	1,066,691	881,952	49.86
Asbestos	***Number of Grants***	***10***	***11***	***12***	***13***	***13***	
	Relevant Grant Dollars	2,598,119	3,428,084	2,591,109	3,609,082	2,872,753	
	Total Count	***10***	***11***	***12***	***13***	***13***	
	Total Relevant Dollars	2,598,119	3,428,084	2,591,109	3,609,082	2,872,753	6.60
Ataxia Telangiectasia	***Number of Grants***	***21***	***19***	***17***	***11***	***7***	
	Relevant Grant Dollars	3,679,780	2,938,837	1,769,222	1,369,928	1,238,529	
	Total Count	***21***	***19***	***17***	***11***	***7***	
	Total Relevant Dollars	3,679,780	2,938,837	1,769,222	1,369,928	1,238,529	-23.02
Autoimmune Diseases	***Number of Grants***	***45***	***37***	***35***	***33***	***28***	
	Relevant Grant Dollars	5,221,927	4,320,535	4,076,442	3,767,007	2,747,501	
	Total Count	***45***	***37***	***35***	***33***	***28***	
	Total Relevant Dollars	5,221,927	4,320,535	4,076,442	3,767,007	2,747,501	-14.39
Behavior Research	***Number of Grants***	***1,093***	***1,104***	***1,098***	***1,106***	***1,093***	
	Relevant Grant Dollars	297,188,165	314,205,359	322,649,017	328,483,291	288,411,741	
	Number of Contracts	***14***	***10***	***12***	***18***	***19***	
	Relevant Contract Dollars	4,360,635	3,248,062	7,177,481	7,750,198	11,278,961	
	Total Count	***1,108***	***1,116***	***1,110***	***1,124***	***1,112***	
	Total Relevant Dollars	301,598,796	318,626,425	329,826,498	336,233,489	299,690,702	0.06
Bioengineering	***Number of Grants***	***593***	***543***	***478***	***471***	***438***	
	Relevant Grant Dollars	146,299,426	143,101,038	136,659,850	128,170,758	116,606,055	
	Number of Contracts	***19***	***19***	***28***	***14***	***14***	
	Relevant Contract Dollars	9,802,298	5,212,765	7,104,296	7,721,382	6,142,128	
	Total Count	***612***	***562***	***506***	***485***	***452***	
	Total Relevant Dollars	156,101,724	148,313,803	143,764,146	135,892,140	122,748,183	-5.80
Bioinformatics	***Number of Grants***	***609***	***613***	***620***	***691***	***655***	
	Relevant Grant Dollars	162,286,911	175,538,540	195,579,757	220,626,261	188,164,686	
	Number of Contracts	***21***	***16***	***20***	***25***	***31***	
	Relevant Contract Dollars	23,191,871	18,412,975	20,328,761	20,993,037	24,968,039	
	Total Count	***630***	***629***	***640***	***716***	***686***	
	Total Relevant Dollars	185,478,782	193,951,515	215,908,518	241,619,298	213,132,725	4.00
Biological Carcinogenesis Non-Viral	***Number of Grants***	***68***	***65***	***68***	***75***	***77***	
	Relevant Grant Dollars	13,031,273	13,043,584	14,509,921	15,387,505	14,300,282	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***68***	***65***	***68***	***75***	***77***	
	Total Relevant Dollars	13,031,273	13,043,584	14,509,921	15,387,505	14,300,282	2.58

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Biologics/Biological Response Modifiers	***Number of Grants***	***2,122***	***1,900***	***1,668***	***1,484***	***1,353***	
	Relevant Grant Dollars	696,719,623	670,058,289	603,303,533	530,129,682	477,320,267	
	Number of Contracts	***36***	***22***	***15***	***10***	***10***	
	Relevant Contract Dollars	42,544,872	21,405,546	16,939,205	10,691,980	9,671,661	
	Total Count	***2,158***	***1,922***	***1,683***	***1,494***	***1,363***	
	Total Relevant Dollars	739,264,495	691,463,835	620,242,738	540,821,662	486,991,928	-9.88
Biomaterials Research	***Number of Grants***	***131***	***141***	***114***	***104***	***1,579***	
	Relevant Grant Dollars	27,561,068	21,212,069	17,519,246	15,414,009	389,749,664	
	Number of Contracts	‡	***4***	‡	***2***	***28***	
	Relevant Contract Dollars	‡	1,548,783	‡	1,186,186	18,544,691	
	Total Count	***131***	***145***	***114***	***106***	***1,607***	
	Total Relevant Dollars	27,561,068	22,760,852	17,519,246	16,600,195	408,294,355	578.47
Biomedical Computing	***Number of Grants***	***467***	***532***	***542***	***596***	***588***	
	Relevant Grant Dollars	113,451,117	137,845,989	144,567,142	164,726,922	161,506,346	
	Number of Contracts	***21***	***19***	***30***	***31***	***35***	
	Relevant Contract Dollars	61,682,516	61,163,296	76,247,799	53,261,742	37,914,467	
	Total Count	***488***	***551***	***572***	***627***	***623***	
	Total Relevant Dollars	175,133,633	199,009,285	220,814,941	217,988,664	199,420,813	3.70
Birth Defects	***Number of Grants***	***61***	***64***	***56***	***46***	***33***	
	Relevant Grant Dollars	11,547,343	12,310,466	10,773,700	8,086,859	5,021,213	
	Total Count	***61***	***64***	***56***	***46***	***33***	
	Total Relevant Dollars	11,547,343	12,310,466	10,773,700	8,086,859	5,021,213	-17.18
Bone Marrow Transplantation	***Number of Grants***	***146***	***140***	***146***	***112***	***130***	
	Relevant Grant Dollars	52,111,916	54,507,621	50,005,537	37,328,235	39,871,538	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	49,496	‡	‡	‡	‡	
	Total Count	***147***	***140***	***146***	***112***	***130***	
	Total Relevant Dollars	52,161,412	54,507,621	50,005,537	37,328,235	39,871,538	-5.58
Breast Cancer Detection	***Number of Grants***	***508***	***498***	***458***	***441***	***411***	
	Relevant Grant Dollars	104,769,617	99,759,605	91,023,962	88,105,336	81,666,201	
	Number of Contracts	***22***	***13***	***15***	***12***	***4***	
	Relevant Contract Dollars	2,928,506	3,632,816	6,478,783	5,863,578	3,543,475	
	Total Count	***530***	***511***	***473***	***453***	***415***	
	Total Relevant Dollars	107,698,123	103,392,421	97,502,745	93,968,914	85,209,676	-5.66
Breast Cancer Early Detection	***Number of Grants***	***219***	***225***	***196***	***197***	***180***	
	Relevant Grant Dollars	45,876,009	47,143,457	48,915,492	46,685,468	43,528,756	
	Number of Contracts	***1***	***3***	***4***	***6***	***2***	
	Relevant Contract Dollars	420,996	1,506,703	2,561,486	3,764,617	2,295,819	
	Total Count	***220***	***228***	***200***	***203***	***182***	
	Total Relevant Dollars	46,297,005	48,650,160	51,476,978	50,450,085	45,824,575	-0.07
Breast Cancer Education	***Number of Grants***	***142***	***149***	***131***	***117***	***106***	
	Relevant Grant Dollars	17,412,166	16,743,662	16,114,826	13,390,623	9,550,272	
	Total Count	***142***	***149***	***131***	***117***	***106***	
	Total Relevant Dollars	17,412,166	16,743,662	16,114,826	13,390,623	9,550,272	-13.29

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Breast Cancer Epidemiology	***Number of Grants***	***182***	***189***	***195***	***215***	***219***	
	Relevant Grant Dollars	54,666,482	64,674,588	67,767,559	79,021,942	74,082,885	
	Number of Contracts	***1***	***5***	***1***	***2***	***6***	
	Relevant Contract Dollars	51,500	336,493	1,620,669	1,728,711	3,348,609	
	Total Count	***183***	***194***	***196***	***217***	***225***	
	Total Relevant Dollars	54,717,982	65,011,081	69,388,228	80,750,653	77,431,494	9.45
Breast Cancer Genetics	***Number of Grants***	***429***	***453***	***482***	***510***	***509***	
	Relevant Grant Dollars	104,276,046	116,708,177	116,790,479	130,302,574	116,592,352	
	Number of Contracts	***8***	***5***	***6***	***5***	***4***	
	Relevant Contract Dollars	2,655,595	2,418,766	2,277,691	2,143,190	2,739,232	
	Total Count	***437***	***458***	***488***	***515***	***513***	
	Total Relevant Dollars	106,931,641	119,126,943	119,068,170	132,445,764	119,331,584	3.17
Breast Cancer Prevention	***Number of Grants***	***223***	***211***	***193***	***190***	***182***	
	Relevant Grant Dollars	23,625,542	20,573,617	19,425,993	18,454,078	18,639,346	
	Number of Contracts	‡	‡	***2***	***1***	***1***	
	Relevant Contract Dollars	‡	‡	161745	35,700	68,000	
	Total Count	***223***	***211***	***195***	***191***	***183***	
	Total Relevant Dollars	23,625,542	20,573,617	19,587,738	18,489,778	18,707,346	-5.53
Breast Cancer Rehabilitation	***Number of Grants***	***156***	***165***	***180***	***169***	***160***	
	Relevant Grant Dollars	22,053,106	23,414,402	23,491,341	23,354,588	19,304,588	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	200,000	
	Total Count	***156***	***165***	***180***	***169***	***161***	
	Total Relevant Dollars	22,053,106	23,414,402	23,491,341	23,354,588	19,504,588	-2.64
Breast Cancer Screening	***Number of Grants***	***182***	***194***	***178***	***178***	***170***	
	Relevant Grant Dollars	21,132,490	22,564,554	24,098,034	26,090,155	24,889,715	
	Number of Contracts	‡	‡	‡	***1***	***1***	
	Relevant Contract Dollars	‡	‡	1,599,992	1,400,000	1,300,000	
	Total Count	***182***	***194***	***179***	***179***	***171***	
	Total Relevant Dollars	21,132,490	22,564,554	25,698,026	27,490,155	26,189,715	5.73
Breast Cancer Treatment	***Number of Grants***	***676***	***699***	***671***	***679***	***664***	
	Relevant Grant Dollars	175,287,152	191,699,483	182,244,051	151,868,982	142,815,791	
	Number of Contracts	***20***	***11***	***3***	***8***	***5***	
	Relevant Contract Dollars	2,908,754	1,962,093	461,244	4,169,128	2,525,833	
	Total Count	***696***	***710***	***674***	***687***	***669***	
	Total Relevant Dollars	178,195,906	193,661,576	182,705,295	156,038,110	145,341,624	-4.61
Breast Cancer-Basic	***Number of Grants***	***773***	***781***	***758***	***744***	***767***	
	Relevant Grant Dollars	161,805,933	168,864,512	168,911,481	175,587,977	164,833,399	
	Number of Contracts	***9***	***9***	***2***	***5***	***3***	
	Relevant Contract Dollars	1,532,199	1,977,194	648,203	1,013,726	1,431,744	
	Total Count	***782***	***790***	***760***	***749***	***770***	
	Total Relevant Dollars	163,338,132	170,841,706	169,559,684	176,601,703	166,265,143	0.54
Cancer Survivorship	***Number of Grants***	***596***	***627***	***669***	***669***	***628***	
	Relevant Grant Dollars	197,965,376	233,784,991	244,829,411	247,349,527	245,984,817	
	Number of Contracts	***22***	***7***	***11***	***13***	***15***	
	Relevant Contract Dollars	2,901,978	2,202,035	10,974,854	12,698,851	11,019,708	
	Total Count	***618***	***634***	***680***	***682***	***643***	
	Total Relevant Dollars	200,867,354	235,987,026	255,804,265	260,048,378	257,004,525	6.59

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Carcinogenesis, Environmental	***Number of Grants***	***1,407***	***1,316***	***1,237***	***1,163***	***1,116***	
	Relevant Grant Dollars	388,760,406	395,790,431	384,795,833	367,617,534	313,980,620	
	Number of Contracts	***26***	***19***	***9***	***13***	***17***	
	Relevant Contract Dollars	10,219,303	7,165,859	3,411,768	4,057,751	5,565,513	
	Total Count	***1,433***	***1,335***	***1,246***	***1,176***	***1,133***	
	Total Relevant Dollars	398,979,709	402,956,290	388,207,601	371,675,285	319,546,133	-5.24
Cervical Cancer Education	***Number of Grants***	***42***	***49***	***44***	***39***	***30***	
	Relevant Grant Dollars	5,288,307	6,669,506	6,289,116	6,569,930	4,529,757	
	Total Count	***42***	***49***	***44***	***39***	***30***	
	Total Relevant Dollars	5,288,307	6,669,506	6,289,116	6,569,930	4,529,757	-1.54
Chemoprevention	***Number of Grants***	***581***	***554***	***513***	***521***	***490***	
	Relevant Grant Dollars	122,199,190	110,809,302	110,334,008	106,270,652	97,428,457	
	Number of Contracts	***20***	***9***	***9***	***9***	***6***	
	Relevant Contract Dollars	34,586,263	14,907,908	12,224,778	7,745,895	8,399,689	
	Total Count	***601***	***563***	***522***	***530***	***496***	
	Total Relevant Dollars	156,785,453	125,717,210	122,558,786	114,016,547	105,828,146	-9.12
Chemoprevention, Clinical	***Number of Grants***	***134***	***136***	***129***	***129***	***118***	
	Relevant Grant Dollars	32,365,770	31,292,583	30,974,445	26,207,896	24,973,361	
	Number of Contracts	***7***	***2***	***4***	***5***	‡	
	Relevant Contract Dollars	11,187,869	1,568,183	6,660,343	1,809,372	‡	
	Total Count	***141***	***138***	***133***	***134***	***118***	
	Total Relevant Dollars	43,553,639	32,860,766	37,634,788	28,017,268	24,973,361	-11.61
Chemotherapy	***Number of Grants***	***1,318***	***1,265***	***1,268***	***1,309***	***1,232***	
	Relevant Grant Dollars	491,407,371	486,445,892	487,783,247	483,927,715	439,082,427	
	Number of Contracts	***24***	***23***	***23***	***21***	***18***	
	Relevant Contract Dollars	18,985,236	16,237,585	15,509,777	15,400,076	10,450,686	
	Total Count	***1,342***	***1,288***	***1,291***	***1,330***	***1,250***	
	Total Relevant Dollars	510,392,607	502,683,477	503,293,024	499,327,791	449,533,113	-3.04
Child Health	***Number of Grants***	***173***	***180***	***146***	***132***	***123***	
	Relevant Grant Dollars	41,893,936	35,485,301	30,619,348	29,367,355	23,265,126	
	Number of Contracts	***1***	***1***	***1***	***3***	***5***	
	Relevant Contract Dollars	94,045	100,000	500,000	632,000	2,181,318	
	Total Count	***174***	***181***	***147***	***135***	***128***	
	Total Relevant Dollars	41,987,981	35,585,301	31,119,348	29,999,355	25,446,444	-11.64
Childhood Cancers	***Number of Grants***	***477***	***495***	***517***	***532***	***525***	
	Relevant Grant Dollars	163,353,861	166,272,586	165,281,278	177,934,130	155,945,246	
	Number of Contracts	***1***	***1***	***1***	***2***	***3***	
	Relevant Contract Dollars	1,990,858	2,938,868	2,791,925	2,999,993	4,212,177	
	Total Count	***478***	***496***	***518***	***534***	***528***	
	Total Relevant Dollars	165,344,719	169,211,454	168,073,203	180,934,123	160,157,423	-0.54
Chronic Myeloproliferative Disorders	***Number of Grants***	***115***	***129***	***143***	***143***	***143***	
	Relevant Grant Dollars	31,864,056	33,259,274	40,413,091	38,980,403	36,692,865	
	Total Count	***115***	***129***	***143***	***143***	***143***	
	Total Relevant Dollars	31,864,056	33,259,274	40,413,091	38,980,403	36,692,865	4.12

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Clinical Trials, Diagnosis	***Number of Grants***	***177***	***158***	***157***	***142***	***136***	
	Relevant Grant Dollars	46,050,747	49,365,161	50,104,212	38,090,132	30,815,744	
	Number of Contracts	***15***	***14***	***3***	***2***	***3***	
	Relevant Contract Dollars	20,599,926	21,295,518	4,929,393	2,264,053	1,651,880	
	Total Count	***192***	***172***	***160***	***144***	***139***	
	Total Relevant Dollars	66,650,673	70,660,679	55,033,605	40,354,185	32,467,624	-15.58
Clinical Trials, Other	***Number of Grants***	***196***	***231***	***220***	***241***	***237***	
	Relevant Grant Dollars	55,185,455	64,532,028	69,256,696	73,756,321	65,812,460	
	Number of Contracts	***2***	***3***	***4***	***8***	***5***	
	Relevant Contract Dollars	1,800,000	2,199,778	5,627,105	4,870,009	12,253,565	
	Total Count	***198***	***234***	***224***	***249***	***242***	
	Total Relevant Dollars	56,985,455	66,731,806	74,883,801	78,626,330	78,066,025	8.40
Clinical Trials, Prevention	***Number of Grants***	***160***	***162***	***227***	***140***	***115***	
	Relevant Grant Dollars	52,476,013	56,851,445	142,302,439	51,726,135	40,042,677	
	Number of Contracts	***10***	***4***	***6***	***8***	‡	
	Relevant Contract Dollars	17,750,174	10,044,105	11,401,878	2,682,866	‡	
	Total Count	***170***	***166***	***233***	***148***	***115***	
	Total Relevant Dollars	70,226,187	66,895,550	153,704,317	54,409,001	40,042,677	8.50
Clinical Trials, Therapy	***Number of Grants***	***657***	***636***	***523***	***574***	***532***	
	Relevant Grant Dollars	381,371,267	383,892,811	321,816,935	326,779,192	323,103,308	
	Number of Contracts	***16***	***17***	***20***	***16***	***14***	
	Relevant Contract Dollars	45,809,933	43,398,794	57,748,533	38,008,573	22,662,279	
	Total Count	***673***	***653***	***543***	***590***	***546***	
	Total Relevant Dollars	427,181,200	427,291,605	379,565,468	364,787,765	345,765,587	-5.06
Combined Treatment Modalities	***Number of Grants***	***601***	***679***	***769***	***922***	***1,022***	
	Relevant Grant Dollars	330,893,890	366,302,744	388,561,125	407,422,052	412,395,044	
	Number of Contracts	***1***	***4***	***7***	***8***	***8***	
	Relevant Contract Dollars	1,990,858	3,372,144	6,442,620	7,776,273	7,259,529	
	Total Count	***602***	***683***	***776***	***930***	***1,030***	
	Total Relevant Dollars	332,884,748	369,674,888	395,003,745	415,198,325	419,654,573	6.02
Cost Effectiveness	***Number of Grants***	***172***	***173***	***177***	***181***	***155***	
	Relevant Grant Dollars	27,223,170	27,186,831	29,938,700	29,528,911	23,509,038	
	Number of Contracts	***3***	***2***	***1***	***1***	***†***	
	Relevant Contract Dollars	610	186,230	248,461	2,479,561	†	
	Total Count	***175***	***175***	***178***	***182***	***155***	
	Total Relevant Dollars	27,223,780	27,373,061	30,187,161	32,008,472	23,509,038	-2.42
Diabetes	***Number of Grants***	***53***	***47***	***36***	***49***	***68***	
	Relevant Grant Dollars	6,202,451	3,530,526	4,851,425	7,823,131	9,846,534	
	Number of Contracts	***†***	***†***	***†***	***†***	***1***	
	Relevant Contract Dollars	†	†	†	†	207,952	
	Total Count	***53***	***47***	***36***	***49***	***69***	
	Total Relevant Dollars	6,202,451	3,530,526	4,851,425	7,823,131	10,054,486	21.03
Diagnosis	***Number of Grants***	***1,911***	***1,855***	***1,779***	***1,758***	***1,695***	
	Relevant Grant Dollars	559,042,065	553,036,713	559,531,772	538,315,913	492,426,013	
	Number of Contracts	***71***	***66***	***51***	***52***	***54***	
	Relevant Contract Dollars	36,236,631	38,373,345	24,273,760	32,848,866	40,112,891	
	Total Count	***1,982***	***1,921***	***1,830***	***1,810***	***1,749***	
	Total Relevant Dollars	595,278,696	591,410,058	583,805,532	571,164,779	532,538,904	-2.72

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Diethylstilbestrol	***Number of Grants***	‡	***2***	***3***	***3***	***3***	
	Relevant Grant Dollars	‡	210,443	330,257	323,182	308,506	
	Number of Contracts	***5***	***5***	‡	‡	‡	
	Relevant Contract Dollars	1,332,877	1,345,965	‡	‡	‡	
	Total Count	***5***	***7***	***3***	***3***	***3***	
	Total Relevant Dollars	1,332,877	1,556,408	330,257	323,182	308,506	-17.17
Dioxin	***Number of Grants***	***10***	***12***	***13***	***9***	***8***	
	Relevant Grant Dollars	1,268,488	1,736,256	869,725	936,088	612,850	
	Total Count	***10***	***12***	***13***	***9***	***8***	
	Total Relevant Dollars	1,268,488	1,736,256	869,725	936,088	612,850	-9.98
DNA Repair	***Number of Grants***	***633***	***600***	***555***	***540***	***512***	
	Relevant Grant Dollars	122,923,808	128,813,944	122,952,777	111,276,907	102,121,375	
	Number of Contracts	‡	***2***	‡	***1***	‡	
	Relevant Contract Dollars	‡	399,599	‡	999,596	‡	
	Total Count	***633***	***602***	***555***	***541***	***512***	
	Total Relevant Dollars	122,923,808	129,213,543	122,952,777	112,276,503	102,121,375	-4.36
Drug Development	***Number of Grants***	***2,087***	***2,091***	***2,095***	***2,233***	***2,310***	
	Relevant Grant Dollars	538,758,282	550,899,818	582,044,480	593,685,849	583,484,075	
	Number of Contracts	***75***	***82***	***84***	***69***	***64***	
	Relevant Contract Dollars	51,239,667	50,932,059	44,439,383	58,367,271	43,062,404	
	Total Count	***2,162***	***2,173***	***2,179***	***2,302***	***2,374***	
	Total Relevant Dollars	589,997,949	601,831,877	626,483,863	652,053,120	626,546,479	1.57
Drug Discovery	***Number of Grants***	***364***	***377***	***380***	***426***	***423***	
	Relevant Grant Dollars	81,268,839	74,170,074	71,551,561	77,078,178	76,661,475	
	Number of Contracts	***11***	***18***	***11***	***7***	***14***	
	Relevant Contract Dollars	13,478,230	11,779,829	2,805,286	2,752,844	5,018,328	
	Total Count	***375***	***395***	***391***	***433***	***437***	
	Total Relevant Dollars	94,747,069	85,949,903	74,356,847	79,831,022	81,679,803	-3.27
Drug Resistance	***Number of Grants***	***631***	***634***	***638***	***697***	***712***	
	Relevant Grant Dollars	111,827,085	117,323,805	126,166,864	137,912,021	133,575,885	
	Number of Contracts	***1***	***2***	***2***	***2***	***3***	
	Relevant Contract Dollars	37,181	395,550	388,667	399,349	3,198,559	
	Total Count	***632***	***636***	***640***	***699***	***715***	
	Total Relevant Dollars	111,864,266	117,719,355	126,555,531	138,311,370	136,774,444	5.23
Drugs – Natural Products	***Number of Grants***	***634***	***640***	***603***	***577***	***556***	
	Relevant Grant Dollars	150,196,945	143,114,167	140,027,475	123,779,207	109,888,176	
	Number of Contracts	***4***	***4***	***5***	***2***	‡	
	Relevant Contract Dollars	593,175	1,375,565	1,298,440	396,938	‡	
	Total Count	***638***	***644***	***608***	***579***	***556***	
	Total Relevant Dollars	150,790,120	144,489,732	141,325,915	124,176,145	109,888,176	-7.50
Early Detection	***Number of Grants***	***869***	***839***	***799***	***788***	***755***	
	Relevant Grant Dollars	222,168,970	227,060,938	231,169,872	220,140,713	204,867,734	
	Number of Contracts	***20***	***17***	***10***	***17***	***14***	
	Relevant Contract Dollars	21,156,276	21,353,066	9,463,743	15,164,662	13,803,863	
	Total Count	***889***	***856***	***809***	***805***	***769***	
	Total Relevant Dollars	243,325,246	248,414,004	240,633,615	235,305,375	218,671,597	-2.58

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Effectiveness Research	***Number of Grants***	***156***	***199***	***241***	***329***	***318***	
	Relevant Grant Dollars	52,087,249	59,933,366	88,645,132	95,620,963	90,764,479	
	Number of Contracts	***1***	***2***	***2***	***7***	***8***	
	Relevant Contract Dollars	252,597	560,081	303,094	5,463,193	12,172,772	
	Total Count	***157***	***201***	***243***	***336***	***326***	
	Total Relevant Dollars	52,339,846	60,493,447	88,948,226	101,084,156	102,937,251	19.52
Endocrinology	***Number of Grants***	***787***	***716***	***669***	***619***	***572***	
	Relevant Grant Dollars	160,349,292	144,586,939	134,691,456	127,583,367	111,913,229	
	Number of Contracts	***6***	***5***	***2***	***4***	***1***	
	Relevant Contract Dollars	2,042,874	1,345,965	365,780	813,140	1,307,520	
	Total Count	***793***	***721***	***671***	***623***	***573***	
	Total Relevant Dollars	162,392,166	145,932,904	135,057,236	128,396,507	113,220,749	-8.58
Energy Balance	***Number of Grants***	***109***	***104***	***105***	***112***	***91***	
	Relevant Grant Dollars	34,684,820	30,844,556	33,474,016	32,621,115	27,758,787	
	Number of Contracts	***2***	***1***	‡	‡	***1***	
	Relevant Contract Dollars	1,575,000	4,885	‡	‡	31,250	
	Total Count	***111***	***105***	***105***	***112***	***92***	
	Total Relevant Dollars	36,259,820	30,849,441	33,474,016	32,621,115	27,790,037	-5.94
Epid.-Biochemical	***Number of Grants***	***560***	***544***	***513***	***525***	***516***	
	Relevant Grant Dollars	186,146,991	207,004,532	196,371,213	200,458,114	183,330,345	
	Number of Contracts	***11***	***9***	***10***	***10***	***4***	
	Relevant Contract Dollars	22,350,084	22,230,209	27,302,955	32,063,034	12,320,111	
	Total Count	***571***	***553***	***523***	***535***	***520***	
	Total Relevant Dollars	208,497,075	229,234,741	223,674,168	232,521,148	195,650,456	-1.10
Epidemiology	***Number of Grants***	***203***	***238***	***248***	***257***	***245***	
	Relevant Grant Dollars	48,391,387	58,955,769	58,456,327	75,023,578	76,193,758	
	Number of Contracts	***11***	***12***	***9***	***19***	***42***	
	Relevant Contract Dollars	6,923,651	7,967,822	6,370,296	13,162,987	42,219,232	
	Total Count	***214***	***250***	***257***	***276***	***287***	
	Total Relevant Dollars	55,315,038	66,923,591	64,826,623	88,186,565	118,412,990	22.04
Epidemiology, Environmental	***Number of Grants***	***518***	***487***	***442***	***402***	***380***	
	Relevant Grant Dollars	157,183,612	169,765,154	158,195,340	146,924,987	117,386,653	
	Number of Contracts	***21***	***16***	***10***	***14***	***6***	
	Relevant Contract Dollars	24,581,051	24,953,396	22,833,401	27,082,561	13,262,667	
	Total Count	***539***	***503***	***452***	***416***	***386***	
	Total Relevant Dollars	181,764,663	194,718,550	181,028,741	174,007,548	130,649,320	-7.17
Epigenetics	***Number of Grants***	***722***	***771***	***859***	***893***	***901***	
	Relevant Grant Dollars	139,887,622	161,834,223	182,952,932	197,448,892	183,377,930	
	Number of Contracts	***4***	***3***	‡	***1***	***1***	
	Relevant Contract Dollars	653,292	549,598	‡	80,000	80,000	
	Total Count	***726***	***774***	***859***	***894***	***902***	
	Total Relevant Dollars	140,540,914	162,383,821	182,952,932	197,528,892	183,457,930	7.26
Gene Mapping, Human	***Number of Grants***	***493***	***436***	***402***	***349***	***283***	
	Relevant Grant Dollars	153,658,315	158,894,763	149,903,735	112,977,260	75,989,190	
	Total Count	***493***	***436***	***402***	***349***	***283***	
	Total Relevant Dollars	153,658,315	158,894,763	149,903,735	112,977,260	75,989,190	-14.91

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Gene Mapping, Non-Human	***Number of Grants***	***274***	***243***	***215***	***183***	***157***	
	Relevant Grant Dollars	40,329,713	37,746,569	35,807,176	30,805,418	24,907,163	
	Total Count	***274***	***243***	***215***	***183***	***157***	
	Total Relevant Dollars	40,329,713	37,746,569	35,807,176	30,805,418	24,907,163	-11.16
Gene Transfer Clinical	***Number of Grants***	***37***	***28***	***33***	***28***	***23***	
	Relevant Grant Dollars	11,261,635	8,086,568	8,242,594	6,398,890	5,731,303	
	Total Count	***37***	***28***	***33***	***28***	***23***	
	Total Relevant Dollars	11,261,635	8,086,568	8,242,594	6,398,890	5,731,303	-14.77
Genetic Testing Research, Human	***Number of Grants***	***380***	***335***	***286***	***250***	***195***	
	Relevant Grant Dollars	128,833,823	115,367,220	97,622,451	78,970,309	60,583,797	
	Number of Contracts	***3***	***3***	***4***	***4***	‡	
	Relevant Contract Dollars	1,308,355	1,325,744	1,531,022	2,838,423	‡	
	Total Count	***383***	***338***	***290***	***254***	***195***	
	Total Relevant Dollars	130,142,178	116,692,964	99,153,473	81,808,732	60,583,797	-17.20
Genomics	***Number of Grants***	***758***	***837***	***936***	***1,090***	***1,113***	
	Relevant Grant Dollars	233,634,493	276,653,749	312,504,344	355,990,253	315,909,113	
	Number of Contracts	***11***	***9***	***10***	***9***	***8***	
	Relevant Contract Dollars	2,893,716	2,573,478	3,992,902	3,769,491	3,463,628	
	Total Count	***769***	***846***	***946***	***1,099***	***1,121***	
	Total Relevant Dollars	236,528,209	279,227,227	316,497,246	359,759,744	319,372,741	8.46
Health Literacy	***Number of Grants***	***78***	***93***	***104***	***107***	***106***	
	Relevant Grant Dollars	19,259,445	21,151,000	23,322,845	25,702,360	20,195,573	
	Number of Contracts	***2***	***1***	***1***	***1***	***1***	
	Relevant Contract Dollars	2,242,507	2,225,682	2,034,678	2,026,250	2,298,614	
	Total Count	***80***	***94***	***105***	***108***	***107***	
	Total Relevant Dollars	21,501,952	23,376,682	25,357,523	27,728,610	22,494,187	1.92
Health Promotion	***Number of Grants***	***550***	***535***	***492***	***459***	***434***	
	Relevant Grant Dollars	189,856,649	156,169,759	158,653,454	152,900,603	125,530,387	
	Number of Contracts	***29***	***12***	***5***	***9***	***6***	
	Relevant Contract Dollars	12,155,514	8,239,835	4,853,740	5,078,162	7,193,454	
	Total Count	***579***	***547***	***497***	***468***	***440***	
	Total Relevant Dollars	202,012,163	164,409,594	163,507,194	157,978,765	132,723,841	-9.63
Health Care Delivery	***Number of Grants***	***260***	***323***	***361***	***370***	***360***	
	Relevant Grant Dollars	79,491,611	99,249,496	111,213,954	116,521,815	108,978,920	
	Number of Contracts	***7***	***9***	***10***	***12***	***14***	
	Relevant Contract Dollars	4,206,677	4,637,640	6,239,884	6,285,437	12,762,591	
	Total Count	***267***	***332***	***371***	***382***	***374***	
	Total Relevant Dollars	83,698,288	103,887,136	117,453,838	122,807,252	121,741,511	10.22
Helicobacter	***Number of Grants***	***39***	***34***	***33***	***32***	***31***	
	Relevant Grant Dollars	8,224,164	8,078,008	8,081,826	7,685,880	6,972,140	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***39***	***34***	***33***	***32***	***31***	
	Total Relevant Dollars	8,224,164	8,078,008	8,081,826	7,685,880	6,972,140	-3.98

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Hematology	***Number of Grants***	***1,531***	***1,472***	***1,423***	***1,440***	***1,411***	
	Relevant Grant Dollars	451,773,304	466,847,932	464,441,339	454,740,603	428,144,424	
	Number of Contracts	***6***	***6***	***6***	***7***	***9***	
	Relevant Contract Dollars	906,834	1,967,879	2,797,458	3,100,209	5,851,583	
	Total Count	***1,537***	***1,478***	***1,429***	***1,447***	***1,420***	
	Total Relevant Dollars	452,680,138	468,815,811	467,238,797	457,840,812	433,996,007	-1.00
Hematopoietic Stem Cell Research	***Number of Grants***	***467***	***396***	***465***	***449***	***431***	
	Relevant Grant Dollars	114,121,151	113,380,226	122,611,326	105,983,734	101,488,276	
	Number of Contracts	***5***	***1***	‡	‡	‡	
	Relevant Contract Dollars	727,386	999,936	‡	‡	‡	
	Total Count	***472***	***397***	***465***	***449***	***431***	
	Total Relevant Dollars	114,848,537	114,380,162	122,611,326	105,983,734	101,488,276	-2.75
Hormone Replacement Therapy	***Number of Grants***	***41***	***33***	***31***	***23***	***21***	
	Relevant Grant Dollars	7,098,888	3,175,346	3,987,675	2,695,611	2,396,798	
	Total Count	***41***	***33***	***31***	***23***	***21***	
	Total Relevant Dollars	7,098,888	3,175,346	3,987,675	2,695,611	2,396,798	-18.29
Hospice	***Number of Grants***	***45***	***45***	***33***	***34***	***31***	
	Relevant Grant Dollars	8,363,251	9,344,380	8,276,000	7,183,290	5,960,311	
	Number of Contracts	‡	***1***	‡	‡	‡	
	Relevant Contract Dollars	‡	999,998	‡	‡	‡	
	Total Count	***45***	***46***	***33***	***34***	***31***	
	Total Relevant Dollars	8,363,251	10,344,378	8,276,000	7,183,290	5,960,311	-6.63
Human Genome	***Number of Grants***	***408***	***533***	***631***	***762***	***831***	
	Relevant Grant Dollars	157,617,076	224,387,803	262,277,096	303,194,306	285,048,104	
	Number of Contracts	***3***	***2***	***2***	***4***	***6***	
	Relevant Contract Dollars	2,392,888	2,260,666	1,398,722	1,744,057	2,922,371	
	Total Count	***411***	***535***	***633***	***766***	***837***	
	Total Relevant Dollars	160,009,964	226,648,469	263,675,818	304,938,363	287,970,475	17.02
Iatrogenesis	***Number of Grants***	***275***	***257***	***247***	***264***	***240***	
	Relevant Grant Dollars	65,399,334	61,577,955	62,271,326	70,740,383	63,359,024	
	Number of Contracts	***7***	***5***	***3***	***4***	***15***	
	Relevant Contract Dollars	2,532,672	1,345,965	487,983	1,406,258	9,252,324	
	Total Count	***282***	***262***	***250***	***268***	***255***	
	Total Relevant Dollars	67,932,006	62,923,920	62,759,309	72,146,641	72,611,348	1.99
Imaging	***Number of Grants***	***1,047***	***1,045***	***1012***	***1,014***	***977***	
	Relevant Grant Dollars	289,428,387	298,744,722	309,142,019	287,214,478	262,826,270	
	Number of Contracts	***27***	***32***	***20***	***14***	***18***	
	Relevant Contract Dollars	18,714,802	21,851,672	7,316,896	7,351,691	13,479,943	
	Total Count	***1,074***	***1,077***	***1032***	***1,028***	***995***	
	Total Relevant Dollars	308,143,189	320,596,394	316,458,915	294,566,169	276,306,213	-2.59
Immunization	***Number of Grants***	***420***	***442***	***449***	***469***	***443***	
	Relevant Grant Dollars	109,830,817	116,267,543	122,814,703	127,780,151	108,339,472	
	Number of Contracts	***2***	‡	***4***	***1***	***5***	
	Relevant Contract Dollars	1,370,729	‡	3,429,651	1,996,084	8,810,556	
	Total Count	***422***	***442***	***453***	***470***	***448***	
	Total Relevant Dollars	111,201,546	116,267,543	126,244,354	129,776,235	117,150,028	1.55

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Inflammation	***Number of Grants***	***365***	***418***	***467***	***532***	***594***	
	Relevant Grant Dollars	66,040,358	81,746,863	99,553,973	113,039,549	107,278,269	
	Number of Contracts	***1***	‡	‡	‡	***1***	
	Relevant Contract Dollars	98,991	‡	‡	‡	318,141	
	Total Count	***366***	***418***	***467***	***532***	***595***	
	Total Relevant Dollars	66,139,349	81,746,863	99,553,973	113,039,549	107,596,410	13.53
Information Dissemination	***Number of Grants***	***853***	***861***	***835***	***787***	***755***	
	Relevant Grant Dollars	247,182,186	231,787,714	237,305,178	247,159,725	224,368,430	
	Number of Contracts	***57***	***38***	***36***	***56***	***22***	
	Relevant Contract Dollars	72,776,903	72,642,039	70,246,091	76,556,706	19,915,843	
	Total Count	***910***	***899***	***871***	***843***	***777***	
	Total Relevant Dollars	319,959,089	304,429,753	307,551,269	323,716,431	244,284,273	-5.78
Metastasis	***Number of Grants***	***1,574***	***1,527***	***1,534***	***1,543***	***1,550***	
	Relevant Grant Dollars	365,861,233	361,870,802	381,229,457	370,139,067	339,242,680	
	Number of Contracts	***8***	***7***	***6***	***6***	***6***	
	Relevant Contract Dollars	1,183,914	1,325,290	1,024,332	3,434,990	2,322,483	
	Total Count	***1,582***	***1,534***	***1,540***	***1,549***	***1,556***	
	Total Relevant Dollars	367,045,147	363,196,092	382,253,789	373,574,057	341,565,163	-1.66
Mind/Body Research	***Number of Grants***	***82***	***75***	***83***	***83***	***78***	
	Relevant Grant Dollars	14,158,379	17,883,028	16,149,064	18,436,251	13,881,407	
	Number of Contracts	‡	‡	‡	***2***	‡	
	Relevant Contract Dollars	‡	‡	‡	89,759	‡	
	Total Count	***82***	***75***	***83***	***85***	***78***	
	Total Relevant Dollars	14,158,379	17,883,028	16,149,064	18,526,010	13,881,407	1.56
Molecular Disease	***Number of Grants***	***5,003***	***4,962***	***4,879***	***4,945***	***5,158***	
	Relevant Grant Dollars	1,615,324,573	1,670,263,492	1,660,747,605	1,646,243,216	1,611,962,239	
	Number of Contracts	***35***	***31***	***35***	***34***	***49***	
	Relevant Contract Dollars	12,253,807	9,144,621	14,337,338	19,893,543	30,025,697	
	Total Count	***5,038***	***4,993***	***4,914***	***4,979***	***5,207***	
	Total Relevant Dollars	1,627,578,380	1,679,408,113	1,675,084,943	1,666,136,759	1,641,987,936	0.24
Molecular Imaging	***Number of Grants***	***617***	***650***	***701***	***724***	***672***	
	Relevant Grant Dollars	174,956,716	164,707,342	181,500,075	184,280,121	160,435,399	
	Number of Contracts	***11***	***15***	***15***	***4***	***5***	
	Relevant Contract Dollars	2,239,610	4,042,324	5,602,005	798,078	2,940,739	
	Total Count	***628***	***665***	***716***	***728***	***677***	
	Total Relevant Dollars	177,196,326	168,749,666	187,102,080	185,078,199	163,376,138	-1.67
Molecular Targeted Prevention	***Number of Grants***	***237***	***252***	***248***	***269***	***260***	
	Relevant Grant Dollars	46,986,672	39,235,184	47,765,297	47,214,496	48,209,422	
	Number of Contracts	‡	***1***	***1***	***2***	***2***	
	Relevant Contract Dollars	‡	74,750	248,461	212,500	1,647,216	
	Total Count	***237***	***253***	***249***	***271***	***262***	
	Total Relevant Dollars	46,986,672	39,309,934	48,013,758	47,426,996	49,856,638	2.43
Molecular Targeted Therapy	***Number of Grants***	***1,483***	***1,515***	***1,577***	***1,775***	***1,888***	
	Relevant Grant Dollars	404,674,238	407,096,513	442,319,529	475,531,951	470,992,018	
	Number of Contracts	***9***	***21***	***18***	***18***	***12***	
	Relevant Contract Dollars	2,305,444	6,175,491	7,588,080	12,174,642	8,499,344	
	Total Count	***1,492***	***1,536***	***1,595***	***1,793***	***1,900***	
	Total Relevant Dollars	406,979,682	413,272,004	449,907,609	487,706,593	479,491,362	4.28

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Nanotechnology	***Number of Grants***	***430***	***461***	***444***	***480***	***476***	
	Relevant Grant Dollars	113,651,594	122,072,696	119,336,493	121,450,044	109,920,780	
	Number of Contracts	***10***	***20***	***11***	***14***	***6***	
	Relevant Contract Dollars	3,523,067	7,338,362	5,161,598	7,104,793	2,045,407	
	Total Count	***440***	***481***	***455***	***494***	***482***	
	Total Relevant Dollars	117,174,661	129,411,058	124,498,091	128,554,837	111,966,187	-0.75
Neurofibromatosis	***Number of Grants***	***26***	***34***	***15***	***15***	***11***	
	Relevant Grant Dollars	6,209,557	7,560,557	2,915,817	2,745,637	1,584,767	
	Total Count	***26***	***34***	***15***	***15***	***11***	
	Total Relevant Dollars	6,209,557	7,560,557	2,915,817	2,745,637	1,584,767	-21.95
Nursing Research	***Number of Grants***	***58***	***54***	***49***	***45***	***37***	
	Relevant Grant Dollars	12,056,800	13,918,717	11,599,142	11,366,624	9,407,781	
	Total Count	***58***	***54***	***49***	***45***	***37***	
	Total Relevant Dollars	12,056,800	13,918,717	11,599,142	11,366,624	9,407,781	-5.12
Nutrition-Fiber	***Number of Grants***	***21***	***19***	***19***	***13***	***10***	
	Relevant Grant Dollars	6,750,851	2,058,728	3,019,322	1,881,369	1,147,521	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	56,250	‡	
	Total Count	***21***	***19***	***19***	***14***	***10***	
	Total Relevant Dollars	6,750,851	2,058,728	3,019,322	1,937,619	1,147,521	-24.86
Nutrition	***Number of Grants***	***866***	***830***	***779***	***735***	***698***	
	Relevant Grant Dollars	202,932,362	198,165,748	201,597,394	176,394,674	152,339,204	
	Number of Contracts	***16***	***14***	***5***	***19***	***9***	
	Relevant Contract Dollars	13,115,073	13,792,873	9,069,226	12,900,479	11,924,668	
	Total Count	***882***	***844***	***784***	***754***	***707***	
	Total Relevant Dollars	216,047,435	211,958,621	210,666,620	189,295,153	164,263,872	-6.47
Nutrition Monitoring	***Number of Grants***	***46***	***45***	***42***	***36***	***30***	
	Relevant Grant Dollars	14,363,776	11,311,406	15,194,549	9,995,060	10,354,902	
	Number of Contracts	***3***	‡	‡	***7***	***2***	
	Relevant Contract Dollars	800,214	‡	‡	1,107,515	1,277,146	
	Total Count	***49***	***45***	***42***	***43***	***32***	
	Total Relevant Dollars	15,163,990	11,311,406	15,194,549	11,102,575	11,632,048	-3.31
Obesity	***Number of Grants***	***232***	***251***	***251***	***258***	***283***	
	Relevant Grant Dollars	52,150,701	47,992,367	58,308,346	63,008,280	62,423,989	
	Number of Contracts	***5***	‡	***3***	***4***	‡	
	Relevant Contract Dollars	801,220	‡	689394	1,012,349	‡	
	Total Count	***237***	***251***	***254***	***262***	***283***	
	Total Relevant Dollars	52,951,921	47,992,367	59,006,740	64,020,629	62,423,989	4.90
Occupational Cancer	***Number of Grants***	***51***	***57***	***49***	***42***	***36***	
	Relevant Grant Dollars	8,119,594	10,901,093	8,727,377	7,737,704	6,712,701	
	Number of Contracts	***3***	***2***	‡	‡	‡	
	Relevant Contract Dollars	850,154	224,000	‡	‡	‡	
	Total Count	***54***	***59***	***49***	***42***	***36***	
	Total Relevant Dollars	8,969,748	11,125,093	8,727,377	7,737,704	6,712,701	-5.53

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Oncogenes	***Number of Grants***	***2,194***	***2,031***	***1,934***	***1,883***	***1,828***	
	Relevant Grant Dollars	518,552,721	515,190,558	498,144,267	473,323,034	413,130,527	
	Number of Contracts	***6***	***3***	***5***	***8***	***6***	
	Relevant Contract Dollars	2,229,506	2,074,867	1,072,456	2,534,277	5,307,498	
	Total Count	***2,200***	***2,034***	***1,939***	***1,891***	***1,834***	
	Total Relevant Dollars	520,782,227	517,265,425	499,216,723	475,857,311	418,438,025	-5.23
Organ Transplant Research	***Number of Grants***	***192***	***182***	***194***	***164***	***175***	
	Relevant Grant Dollars	65,966,217	66,404,117	67,155,158	49,923,229	55,542,375	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	49,496	‡	‡	‡	‡	
	Total Count	***193***	***182***	***194***	***164***	***175***	
	Total Relevant Dollars	66,015,713	66,404,117	67,155,158	49,923,229	55,542,375	-3.17
Osteoporosis	***Number of Grants***	***9***	***8***	***6***	***6***	***5***	
	Relevant Grant Dollars	913,593	411,172	317,668	925,324	722,771	
	Total Count	***9***	***8***	***6***	***6***	***5***	
	Total Relevant Dollars	913,593	411,172	317,668	925,324	722,771	22.92
Pain	***Number of Grants***	***161***	***147***	***152***	***154***	***159***	
	Relevant Grant Dollars	16,576,535	16,468,439	16,300,996	18,155,638	17,703,099	
	Number of Contracts	‡	***2***	‡	‡	***1***	
	Relevant Contract Dollars	‡	1,299,610	‡	‡	100,000	
	Total Count	***161***	***149***	***152***	***154***	***160***	
	Total Relevant Dollars	16,576,535	17,768,049	16,300,996	18,155,638	17,803,099	2.09
Palliative Care	***Number of Grants***	***167***	***161***	***153***	***153***	***152***	
	Relevant Grant Dollars	22,111,289	20,897,707	21,247,383	21,916,672	18,689,924	
	Number of Contracts	‡	***2***	***1***	***1***	***1***	
	Relevant Contract Dollars	‡	2,198,445	52,655	21,000	53,991	
	Total Count	***167***	***163***	***154***	***154***	***153***	
	Total Relevant Dollars	22,111,289	23,096,152	21,300,038	21,937,672	18,743,915	-3.72
PAP Testing	***Number of Grants***	***105***	***106***	***105***	***111***	***98***	
	Relevant Grant Dollars	10,352,147	10,627,523	11,695,680	11,312,785	10,168,380	
	Number of Contracts	‡	***1***	‡	‡	‡	
	Relevant Contract Dollars	‡	45,000	‡	‡	‡	
	Total Count	***105***	***107***	***105***	***111***	***98***	
	Total Relevant Dollars	10,352,147	10,672,523	11,695,680	11,312,785	10,168,380	-0.18
Pediatric Research	***Number of Grants***	***685***	***685***	***581***	***636***	***681***	
	Relevant Grant Dollars	212,351,643	212,337,590	146,844,741	179,363,922	193,100,899	
	Number of Contracts	***3***	***7***	***2***	***5***	***8***	
	Relevant Contract Dollars	2,134,899	4,384,833	3,291,925	3,631,993	6,488,808	
	Total Count	***688***	***692***	***583***	***641***	***689***	
	Total Relevant Dollars	214,486,542	216,722,423	150,136,666	182,995,915	199,589,707	0.32
Personalized Health Care	***Number of Grants***	***632***	***630***	***638***	***685***	***661***	
	Relevant Grant Dollars	199,252,033	183,230,229	180,445,101	184,951,025	164,974,350	
	Number of Contracts	***17***	***21***	***17***	***20***	***12***	
	Relevant Contract Dollars	35,742,085	37,543,010	32,351,821	37,283,739	8,158,581	
	Total Count	***649***	***651***	***655***	***705***	***673***	
	Total Relevant Dollars	234,994,118	220,773,239	212,796,922	222,234,764	173,132,931	-6.83

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Pesticides	***Number of Grants***	***14***	***12***	***13***	***10***	***4***	
	Relevant Grant Dollars	909,530	531,371	471,294	460,087	59,725	
	Number of Contracts	***2***	***2***	‡	‡	‡	
	Relevant Contract Dollars	701,197	224,000	‡	‡	‡	
	Total Count	***16***	***14***	***13***	***10***	***4***	
	Total Relevant Dollars	1,610,727	755,371	471,294	460,087	59,725	-45.03
Pharmacogenetics	***Number of Grants***	***310***	***312***	***276***	***266***	***248***	
	Relevant Grant Dollars	70,646,463	53,813,379	52,795,552	54,346,257	49,570,728	
	Number of Contracts	***2***	‡	***1***	***2***	‡	
	Relevant Contract Dollars	150,000	‡	193,637	670,000	‡	
	Total Count	***312***	***312***	***277***	***268***	***248***	
	Total Relevant Dollars	70,796,463	53,813,379	52,989,189	55,016,257	49,570,728	-7.90
Prevention	***Number of Grants***	***1,294***	***1,246***	***1,220***	***1,235***	***1,240***	
	Relevant Grant Dollars	346,953,036	324,621,692	332,988,470	338,729,425	324,824,552	
	Number of Contracts	***36***	***20***	***23***	***35***	***27***	
	Relevant Contract Dollars	46,984,156	28,993,208	30,211,780	25,780,603	30,875,471	
	Total Count	***1,330***	***1,266***	***1,243***	***1,270***	***1,267***	
	Total Relevant Dollars	393,937,192	353,614,900	363,200,250	364,510,028	355,700,023	-2.40
Proteomics	***Number of Grants***	***543***	***564***	***648***	***718***	***700***	
	Relevant Grant Dollars	98,691,096	105,713,144	128,504,517	143,749,069	133,187,112	
	Number of Contracts	***14***	***13***	***12***	***8***	***14***	
	Relevant Contract Dollars	4,666,075	3,710,715	2,364,169	3,506,652	5,364,611	
	Total Count	***557***	***577***	***660***	***726***	***714***	
	Total Relevant Dollars	103,357,171	109,423,859	130,868,686	147,255,721	138,551,723	8.02
Radiation, Electromagnetic Fields	***Number of Grants***	***5***	***5***	***5***	***2***	***1***	
	Relevant Grant Dollars	235,460	794,902	274,880	208,400	195,214	
	Total Count	***5***	***5***	***5***	***2***	***1***	
	Total Relevant Dollars	235,460	794,902	274,880	208,400	195,214	35.42
Radiation, Ionizing	***Number of Grants***	***143***	***137***	***118***	***109***	***99***	
	Relevant Grant Dollars	24,747,402	24,942,689	22,587,580	20,437,132	15,415,636	
	Number of Contracts	***1***	‡	‡	***1***	***1***	
	Relevant Contract Dollars	200,000	‡	‡	91,808	95,313	
	Total Count	***144***	***137***	***118***	***110***	***100***	
	Total Relevant Dollars	24,947,402	24,942,689	22,587,580	20,528,940	15,510,949	-10.75
Radiation, Ionizing Diagnosis	***Number of Grants***	***236***	***284***	***288***	***297***	***291***	
	Relevant Grant Dollars	60,711,962	67,228,830	83,355,570	78,440,948	69,835,784	
	Number of Contracts	***3***	***2***	***6***	***4***	***6***	
	Relevant Contract Dollars	465,803	1,127,414	3,682,723	2,664,706	4,565,381	
	Total Count	***239***	***286***	***294***	***301***	***297***	
	Total Relevant Dollars	61,177,765	68,356,244	86,038,293	81,105,654	74,401,165	5.90
Radiation, Ionizing Radiotherapy	***Number of Grants***	***635***	***605***	***594***	***595***	***578***	
	Relevant Grant Dollars	199,422,427	197,773,842	215,668,304	178,645,894	168,829,680	
	Number of Contracts	***4***	***3***	***6***	***6***	***14***	
	Relevant Contract Dollars	545,157	226,116	852,523	1,860,053	7,299,204	
	Total Count	***639***	***608***	***600***	***601***	***592***	
	Total Relevant Dollars	199,967,584	197,999,958	216,520,827	180,505,947	176,128,884	-2.67

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Radiation, Low-Level Ionizing	***Number of Grants***	***20***	***16***	***15***	***11***	***8***	
	Relevant Grant Dollars	6,500,454	3,564,004	2,684,415	2,790,815	1,703,359	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	200,000	‡	‡	‡	‡	
	Total Count	***21***	***16***	***15***	***11***	***8***	
	Total Relevant Dollars	6,700,454	3,564,004	2,684,415	2,790,815	1,703,359	-26.62
Radiation, Magnetic Resonance Imaging	***Number of Grants***	***324***	***309***	***311***	***316***	***302***	
	Relevant Grant Dollars	75,059,941	71,053,694	72,516,747	66,373,621	71,059,404	
	Number of Contracts	***3***	***2***	***3***	***4***	***3***	
	Relevant Contract Dollars	416,415	625,760	810,966	1,649,709	813,452	
	Total Count	***327***	***311***	***314***	***320***	***305***	
	Total Relevant Dollars	75,476,356	71,679,454	73,327,713	68,023,330	71,872,856	-1.08
Radiation, Mammography	***Number of Grants***	***203***	***211***	***186***	***183***	***173***	
	Relevant Grant Dollars	31,642,663	26,824,376	30,249,026	29,124,083	27,564,637	
	Number of Contracts	***1***	***1***	***2***	***1***	***1***	
	Relevant Contract Dollars	464	999,985	1,845,486	1,400,000	1,300,000	
	Total Count	***204***	***212***	***188***	***184***	***174***	
	Total Relevant Dollars	31,643,127	27,824,361	32,094,512	30,524,083	28,864,637	-1.76
Radiation, Non-Ionizing	***Number of Grants***	***177***	***167***	***160***	***149***	***129***	
	Relevant Grant Dollars	27,357,488	26,918,563	26,910,915	25,283,118	21,566,717	
	Number of Contracts	‡	***3***	***1***	***1***	‡	
	Relevant Contract Dollars	‡	476,414	999,000	137,350	‡	
	Total Count	***177***	***170***	***161***	***150***	***129***	
	Total Relevant Dollars	27,357,488	27,394,977	27,909,915	25,420,468	21,566,717	-5.52
Radiation, Non-Ionizing Diagnosis	***Number of Grants***	***502***	***471***	***467***	***491***	***469***	
	Relevant Grant Dollars	136,372,426	125,702,669	131,948,820	126,670,584	114,249,805	
	Number of Contracts	***3***	***9***	***5***	***6***	***6***	
	Relevant Contract Dollars	416,415	1,675,452	1,260,269	2,735,231	4,045,191	
	Total Count	***505***	***480***	***472***	***497***	***475***	
	Total Relevant Dollars	136,788,841	127,378,121	133,209,089	129,405,815	118,294,996	-3.44
Radiation, Non-Ionizing Radiotherapy	***Number of Grants***	***161***	***195***	***190***	***187***	***187***	
	Relevant Grant Dollars	41,460,636	40,077,552	48,439,155	45,869,628	42,314,931	
	Number of Contracts	***1***	***3***	‡	***1***	***2***	
	Relevant Contract Dollars	199,735	599,386	‡	1,499,896	1,573,324	
	Total Count	***162***	***198***	***190***	***188***	***189***	
	Total Relevant Dollars	41,660,371	40,676,938	48,439,155	47,369,524	43,888,255	1.79
Radiation, UV+A814	***Number of Grants***	***152***	***149***	***144***	***133***	***121***	
	Relevant Grant Dollars	23,732,686	23,686,597	24,555,465	23,909,838	20,530,426	
	Number of Contracts	‡	***3***	***1***	***1***	‡	
	Relevant Contract Dollars	‡	476,414	‡	137,350	‡	
	Total Count	***152***	***152***	***145***	***134***	***121***	
	Total Relevant Dollars	23,732,686	24,163,011	25,554,465	24,047,188	20,530,426	-3.24
Radon	***Number of Grants***	***5***	***2***	***3***	***5***	***4***	
	Relevant Grant Dollars	1,976,301	48,624	326,441	490,407	399,608	
	Total Count	***5***	***2***	***3***	***5***	***4***	
	Total Relevant Dollars	1,976,301	48,624	326,441	490,407	399,608	126.38

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Rare Diseases	***Number of Grants***	***138***	***140***	***119***	***100***	***73***	
	Relevant Grant Dollars	26,634,147	29,192,350	23,592,946	18,712,924	12,159,075	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	74,592	
	Total Count	***138***	***140***	***119***	***100***	***74***	
	Total Relevant Dollars	26,634,147	29,192,350	23,592,946	18,712,924	12,233,667	-16.22
Rehabilitation	***Number of Grants***	***221***	***221***	***230***	***234***	***229***	
	Relevant Grant Dollars	37,960,259	38,584,600	40,748,671	45,308,533	40,076,940	
	Number of Contracts	***14***	***2***	***1***	***1***	***4***	
	Relevant Contract Dollars	1,131,599	76,452	52,655	21,000	475,141	
	Total Count	***235***	***223***	***231***	***235***	***233***	
	Total Relevant Dollars	39,091,858	38,661,052	40,801,326	45,329,533	40,552,081	1.25
Rural Populations	***Number of Grants***	***95***	***103***	***103***	***100***	***91***	
	Relevant Grant Dollars	38,996,059	35,157,309	34,658,560	31,874,931	28,293,909	
	Number of Contracts	***12***	***12***	***10***	***8***	‡	
	Relevant Contract Dollars	9,846,502	10,416,108	8,535,867	7,269,316	‡	
	Total Count	***107***	***115***	***113***	***108***	***91***	
	Total Relevant Dollars	48,842,561	45,573,417	43,194,427	39,144,247	28,293,909	-12.25
Sexually Transmitted Diseases	***Number of Grants***	***192***	***183***	***185***	***175***	***154***	
	Relevant Grant Dollars	31,951,321	30,488,788	29,789,110	28,189,148	21,439,368	
	Number of Contracts	***1***	***2***	***1***	***1***	‡	
	Relevant Contract Dollars	3,701,779	4,439,576	3,836,717	870,317	‡	
	Total Count	***193***	***185***	***186***	***176***	***154***	
	Total Relevant Dollars	35,653,100	34,928,364	33,625,827	29,059,465	21,439,368	-11.39
Sleep Disorders	***Number of Grants***	***54***	***70***	***64***	***54***	***46***	
	Relevant Grant Dollars	7,775,308	9,183,149	7,810,486	6,729,657	5,420,968	
	Number of Contracts	‡	‡	‡	***1***	***3***	
	Relevant Contract Dollars	‡	‡	‡	300,000	550,000	
	Total Count	***54***	***70***	***64***	***55***	***49***	
	Total Relevant Dollars	7,775,308	9,183,149	7,810,486	7,029,657	5,970,968	-5.47
Small Molecules	***Number of Grants***	***386***	***407***	***416***	***513***	***556***	
	Relevant Grant Dollars	73,465,245	70,693,138	81,708,151	100,631,305	95,910,356	
	Number of Contracts	***1***	***10***	***9***	***4***	***6***	
	Relevant Contract Dollars	30,860	2,203,593	3,726,105	1,449,375	1,140,627	
	Total Count	***387***	***417***	***425***	***517***	***562***	
	Total Relevant Dollars	73,496,105	72,896,731	85,434,256	102,080,680	97,050,983	7.74
Smokeless Tobacco	***Number of Grants***	***26***	***34***	***19***	***24***	***33***	
	Relevant Grant Dollars	5,933,701	6,896,702	4,743,669	5,175,673	4,087,588	
	Number of Contracts	‡	***1***	***1***	***1***	***1***	
	Relevant Contract Dollars	†	453,965	385,000	385,000	332,500	
	Total Count	***26***	***35***	***20***	***25***	***34***	
	Total Relevant Dollars	5,933,701	7,350,667	5,128,669	5,560,673	4,420,088	-4.61
Smoking, Passive	***Number of Grants***	***30***	***24***	***15***	***14***	***18***	
	Relevant Grant Dollars	3,425,541	3,459,579	2,250,884	2,491,604	3,160,590	
	Number of Contracts	‡	***1***	***1***	***1***	***1***	
	Relevant Contract Dollars	‡	453,965	385,000	385,000	332,500	
	Total Count	***30***	***25***	***16***	***15***	***19***	
	Total Relevant Dollars	3,425,541	3,913,544	2,635,884	2,876,604	3,493,090	3.04

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Structural Biology	***Number of Grants***	***1,456***	***1,337***	***1,242***	***1,199***	***1,103***	
	Relevant Grant Dollars	280,014,980	269,191,027	258,099,045	235,455,633	206,932,623	
	Number of Contracts	***17***	***11***	***15***	***3***	***4***	
	Relevant Contract Dollars	2,434,109	1,512,388	1,522,607	615,101	1,595,591	
	Total Count	***1,473***	***1,348***	***1,257***	***1,202***	***1,107***	
	Total Relevant Dollars	282,449,089	270,703,415	259,621,652	236,070,734	208,528,214	-7.25
Surgery	***Number of Grants***	***352***	***327***	***333***	***328***	***326***	
	Relevant Grant Dollars	63,498,562	72,591,577	85,655,815	76,917,479	77,598,007	
	Number of Contracts	‡	***2***	***2***	***3***	***5***	
	Relevant Contract Dollars	‡	1,200,000	373,417	545,979	2,527,184	
	Total Count	***352***	***329***	***335***	***331***	***331***	
	Total Relevant Dollars	63,498,562	73,791,577	86,029,232	77,463,458	80,125,191	6.57
Taxol	***Number of Grants***	***284***	***305***	***285***	***273***	***270***	
	Relevant Grant Dollars	68,741,615	73,441,347	70,198,681	60,447,024	52,963,267	
	Number of Contracts	‡	***1***	‡	***1***	‡	
	Relevant Contract Dollars	‡	50,000	‡	199,714	‡	
	Total Count	***284***	***306***	***285***	***274***	***270***	
	Total Relevant Dollars	68,741,615	73,491,347	70,198,681	60,646,738	52,963,267	-5.96
Telehealth	***Number of Grants***	***364***	***351***	***311***	***292***	***288***	
	Relevant Grant Dollars	76,214,970	83,738,070	76,191,259	76,478,419	65,169,688	
	Number of Contracts	***26***	***10***	***11***	***7***	***7***	
	Relevant Contract Dollars	15,922,057	12,502,513	11,912,660	9,755,606	9,541,363	
	Total Count	***390***	***361***	***322***	***299***	***295***	
	Total Relevant Dollars	92,137,027	96,240,583	88,103,919	86,234,025	74,711,051	-4.87
Therapy	***Number of Grants***	***3,736***	***3,668***	***3,626***	***3,738***	***3,838***	
	Relevant Grant Dollars	1,253,530,990	1,289,919,675	1,295,238,778	1,293,761,000	1,246,559,964	
	Number of Contracts	***104***	***102***	***94***	***92***	***104***	
	Relevant Contract Dollars	100,995,788	97,314,391	93,641,732	88,810,315	71,823,475	
	Total Count	***3,840***	***3,770***	***3,720***	***3,830***	***3,942***	
	Total Relevant Dollars	1,354,526,778	1,387,234,066	1,388,880,510	1,382,571,315	1,318,383,439	-0.64
Tobacco	***Number of Grants***	***493***	***470***	***449***	***416***	***417***	
	Relevant Grant Dollars	106,446,317	121,389,946	127,614,366	122,594,345	98,441,413	
	Number of Contracts	***7***	***8***	***4***	***4***	***8***	
	Relevant Contract Dollars	804,235	2,479,840	1,419,652	1,302,350	2,268,519	
	Total Count	***500***	***478***	***453***	***420***	***425***	
	Total Relevant Dollars	107,250,552	123,869,786	129,034,018	123,896,695	100,709,932	-0.76
Tobacco Use Behavior	***Number of Grants***	***250***	***250***	***239***	***259***	***276***	
	Relevant Grant Dollars	65,696,233	81,176,603	83,456,895	87,985,064	73,128,257	
	Number of Contracts	***2***	***4***	***2***	***4***	***6***	
	Relevant Contract Dollars	144,041	1,868,571	1,320,000	1,302,350	2,066,485	
	Total Count	***252***	***254***	***241***	***263***	***282***	
	Total Relevant Dollars	65,840,274	83,045,174	84,776,895	89,287,414	75,194,742	4.44
Tropical Diseases	***Number of Grants***	***31***	***29***	***25***	***21***	***16***	
	Relevant Grant Dollars	7,697,801	6,535,704	5,619,635	5,588,012	2,226,158	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***31***	***29***	***25***	***21***	***16***	
	Total Relevant Dollars	7,697,801	6,535,704	5,619,635	5,588,012	2,226,158	-22.46

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Tumor Markers	***Number of Grants***	***846***	***731***	***626***	***508***	***393***	
	Relevant Grant Dollars	218,547,902	189,955,095	161,691,676	124,259,866	88,015,396	
	Number of Contracts	***19***	***12***	***4***	***3***	‡	
	Relevant Contract Dollars	6,788,354	4,365,645	2,569,530	2,693,245	‡	
	Total Count	***865***	***743***	***630***	***511***	***393***	
	Total Relevant Dollars	225,336,256	194,320,740	164,531,206	126,953,111	88,015,396	-20.65
Underserved Populations	***Number of Grants***	***563***	***607***	***595***	***585***	***556***	
	Relevant Grant Dollars	193,637,731	210,560,355	210,385,470	216,074,187	189,290,919	
	Number of Contracts	***34***	***21***	***16***	***16***	***2***	
	Relevant Contract Dollars	14,072,123	12,245,405	10,306,244	11,469,992	2,354,483	
	Total Count	***597***	***628***	***611***	***601***	***558***	
	Total Relevant Dollars	207,709,854	222,805,760	220,691,714	227,544,179	191,645,402	-1.59
Vaccine Development	***Number of Grants***	***168***	***163***	***159***	***151***	***130***	
	Relevant Grant Dollars	27,688,541	21,218,754	21,105,678	20,714,291	17,452,232	
	Number of Contracts	***2***	‡	***1***	‡	***1***	
	Relevant Contract Dollars	1,370,729	‡	199,988	‡	739,425	
	Total Count	***170***	***163***	***160***	***151***	***131***	
	Total Relevant Dollars	29,059,270	21,218,754	21,305,666	20,714,291	18,191,657	-10.38
Vaccine Production	***Number of Grants***	***4***	***8***	***6***	***3***	***2***	
	Relevant Grant Dollars	1,679,991	1,046,919	661,049	589,530	152,239	
	Number of Contracts	‡	‡	***1***	‡	***1***	
	Relevant Contract Dollars	‡	‡	1,499,001	‡	739,425	
	Total Count	***4***	***8***	***7***	***3***	***3***	
	Total Relevant Dollars	1,679,991	1,046,919	2,160,050	589,530	891,664	11.80
Vaccine Research	***Number of Grants***	***201***	***201***	***195***	***183***	***167***	
	Relevant Grant Dollars	37,047,110	33,377,072	34,117,779	31,279,880	25,866,062	
	Number of Contracts	***1***	***1***	***2***	***1***	***3***	
	Relevant Contract Dollars	30,860	23,100	1,502,003	1,996,084	5,831,735	
	Total Count	***202***	***202***	***197***	***184***	***170***	
	Total Relevant Dollars	37,077,970	33,400,172	34,619,782	33,275,964	31,697,797	-3.72
Vaccine Testing	***Number of Grants***	***138***	***130***	***111***	***101***	***82***	
	Relevant Grant Dollars	29,771,312	21,759,604	18,745,944	17,217,816	13,797,753	
	Number of Contracts	***1***	***1***	***1***	***1***	‡	
	Relevant Contract Dollars	3,701,779	4,394,576	3,836,717	870,317	‡	
	Total Count	***139***	***131***	***112***	***102***	***82***	
	Total Relevant Dollars	33,473,091	26,154,180	22,582,661	18,088,133	13,797,753	-19.79
Virus – Cancer Research	***Number of Grants***	***558***	***541***	***505***	***481***	***458***	
	Relevant Grant Dollars	151,074,096	153,628,908	142,438,045	133,815,083	123,611,800	
	Number of Contracts	***3***	***3***	***1***	***4***	***2***	
	Relevant Contract Dollars	5,230,139	4,549,461	3,836,717	4,066,305	2,478,454	
	Total Count	***561***	***544***	***506***	***485***	***460***	
	Total Relevant Dollars	156,304,235	158,178,369	146,274,762	137,881,388	126,090,254	-5.15
Virus – Epstein-Barr	***Number of Grants***	***110***	***110***	***104***	***96***	***81***	
	Relevant Grant Dollars	26,563,416	24,362,117	24,499,924	22,756,337	20,096,683	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***110***	***110***	***104***	***96***	***81***	
	Total Relevant Dollars	26,563,416	24,362,117	24,499,924	22,756,337	20,096,683	-6.63

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Virus – Genital Herpes	***Number of Grants***	***4***	***4***	***4***	***3***	***163***	
	Relevant Grant Dollars	477,647	379,575	372,188	290,654	41,683,291	
	Total Count	***4***	***4***	***4***	***3***	***163***	
	Total Relevant Dollars	477,647	379,575	372,188	290,654	41,683,291	3549.21
Virus – Hepatitis B	***Number of Grants***	***54***	***51***	***50***	***42***	***39***	
	Relevant Grant Dollars	12,166,996	11,337,066	6,370,613	4,928,799	3,929,183	
	Total Count	***54***	***51***	***50***	***42***	***39***	
	Total Relevant Dollars	12,166,996	11,337,066	6,370,613	4,928,799	3,929,183	-23.39
Virus – Hepatitis C	***Number of Grants***	***35***	***34***	***31***	***40***	***39***	
	Relevant Grant Dollars	6,405,143	5,719,779	4,600,379	5,332,014	3,990,130	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***35***	***34***	***31***	***40***	***39***	
	Total Relevant Dollars	6,405,143	5,719,779	4,600,379	5,332,014	3,990,130	-9.88
Virus – Herpes	***Number of Grants***	***208***	***206***	***190***	***182***	***163***	
	Relevant Grant Dollars	54,527,236	47,274,246	48,127,519	44,080,597	41,683,291	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***208***	***206***	***190***	***182***	***163***	
	Total Relevant Dollars	54,527,236	47,274,246	48,127,519	44,080,597	41,683,291	-6.34
Virus – HHV8	***Number of Grants***	***81***	***87***	***78***	***74***	***66***	
	Relevant Grant Dollars	19,737,355	18,532,843	17,725,584	15,764,211	18,719,752	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***81***	***87***	***78***	***74***	***66***	
	Total Relevant Dollars	19,737,355	18,532,843	17,725,584	15,764,211	18,719,752	-0.69
Virus – HTLV-I	***Number of Grants***	***23***	***22***	***24***	***22***	***20***	
	Relevant Grant Dollars	7,313,840	6,183,612	6,171,762	6,563,215	3,679,947	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***23***	***22***	***24***	***22***	***20***	
	Total Relevant Dollars	7,313,840	6,183,612	6,171,762	6,563,215	3,679,947	-13.31
Virus – HTLV-II	***Number of Grants***	***1***	‡	***2***	***1***	***1***	
	Relevant Grant Dollars	135,552	†	2,000	171,471	160,325	
	Total Count	***1***	‡	***2***	***1***	***1***	
	Total Relevant Dollars	135,552	‡	2,000	171,471	160,325	2789.50
Virus – Papilloma	***Number of Grants***	***166***	***169***	***168***	***165***	***162***	
	Relevant Grant Dollars	39,602,459	46,214,177	43,559,761	41,276,749	40,445,208	
	Number of Contracts	***3***	***1***	***1***	***3***	***2***	
	Relevant Contract Dollars	5,230,139	4,394,576	3,836,717	3,866,401	2,478,454	
	Total Count	***169***	***170***	***169***	***168***	***164***	
	Total Relevant Dollars	44,832,598	50,608,753	47,396,478	45,143,150	42,923,662	-0.78

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16 (cont'd). NCI Special Interest Category (SIC) Dollars for FY2009 - FY2013 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2009	2010	2011	2012	2013	Average Percent Change/Yr.
Virus– Papova	***Number of Grants***	***206***	***207***	***200***	***190***	***185***	
	Relevant Grant Dollars	49,970,034	55,528,827	52,541,742	49,415,531	49,217,700	
	Number of Contracts	***3***	***2***	***1***	***3***	***2***	
	Relevant Contract Dollars	5,230,139	4,544,576	3,836,717	3,866,401	2,478,454	
	Total Count	***209***	***209***	***201***	***193***	***187***	
	Total Relevant Dollars	55,200,173	60,073,403	56,378,459	53,281,932	51,696,154	-1.45
Virus– SV40	***Number of Grants***	***36***	***29***	***25***	***21***	***15***	
	Relevant Grant Dollars	5,967,645	5,171,617	5,163,432	3,525,677	3,313,239	
	Total Count	***36***	***29***	***25***	***21***	***15***	
	Total Relevant Dollars	5,967,645	5,171,617	5,163,432	3,525,677	3,313,239	-12.81
Vitamin A	***Number of Grants***	***89***	***66***	***55***	***42***	***40***	
	Relevant Grant Dollars	11,622,987	8,863,103	9,150,008	6,336,364	6,714,906	
	Number of Contracts	***1***	***1***	***1***	‡	‡	
	Relevant Contract Dollars	300,000	391,285	99,917	‡	‡	
	Total Count	***90***	***67***	***56***	***42***	***40***	
	Total Relevant Dollars	11,922,987	9,254,388	9,249,925	6,336,364	6,714,906	-11.99
Vitamin C	***Number of Grants***	***24***	***21***	***15***	***16***	***11***	
	Relevant Grant Dollars	2,234,318	1,843,823	1,106,973	1,323,825	1,327,243	
	Total Count	***24***	***21***	***15***	***16***	***11***	
	Total Relevant Dollars	2,234,318	1,843,823	1,106,973	1,323,825	1,327,243	-9.40
Vitamin D	***Number of Grants***	***32***	***45***	***70***	***76***	***70***	
	Relevant Grant Dollars	9,218,013	11,837,723	20,457,495	20,791,513	17,759,137	
	Number of Contracts	***1***	‡	‡	***1***	***1***	
	Relevant Contract Dollars	200,000	‡	‡	56,250	918,685	
	Total Count	***33***	***45***	***70***	***77***	***71***	
	Total Relevant Dollars	9,418,013	11,837,723	20,457,495	20,847,763	18,677,822	22.50
Vitamins, Other	***Number of Grants***	***72***	***55***	***44***	***25***	***15***	
	Relevant Grant Dollars	15,499,403	12,310,882	10,076,781	6,252,528	4,252,163	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	56,250	‡	
	Total Count	***72***	***55***	***44***	***26***	***15***	
	Total Relevant Dollars	15,499,403	12,310,882	10,076,781	6,308,778	4,252,163	-27.18

*Some categories are not mutually exclusive, resulting in overlap in reported funding. As a result, dollar totals may exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 17. NCI Funding of Foreign Research Grants in FY2013

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country/ Cancer Site	Mechanism										
AUSTRALIA	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants # *Funding $*				*2* *456,397*			*1* *108,194*				*3* *564,591*
Breast				210,655							210,655
Hodgkins Lymphoma							36,786				36,786
Lung				245,742							245,742
Myeloma							34,622				34,622
Non-Hodgkins Lymphoma							36,786				36,786
BELARUS	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants # *Funding $*			*1* *95,313*								*1* *95,313*
Thyroid			95,313								95,313
BELGIUM	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants # *Funding $*									*1* *287,528*		*1* *287,528*
Bone, Cartilage									2,500		2,500
Brain									7,501		7,501
Breast									80,008		80,008
Central Nervous System									2,500		2,500
Cervix									2,500		2,500
Childhood Leukemia									37,504		37,504
Colon, Rectum									7,501		7,501
Esophagus									2,500		2,500
Head And Neck									2,500		2,500
Kidney									12,501		12,501
Leukemia									37,504		37,504
Liver									2,500		2,500
Lung									22,502		22,502
Muscle									2,500		2,500
Neuroblastoma									5,001		5,001
Non-Hodgkins Lymphoma									2,500		2,500
Not Site Specific*									5,001		5,001
Ovary									15,002		15,002
Pancreas									2,500		2,500
Pharynx									2,500		2,500
Prostate									20,002		20,002
Urinary System									2,500		2,500
Uterus									10,001		10,001

continued

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.)
Source: Research Analysis and Evaluation Branch.

Table 17 (cont'd). NCI Funding of Foreign Research Grants in FY2013

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country/ Cancer Site	Mechanism										
CANADA	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*		*15*	*1*	*1*	*1*	*2*	*1*	*1*	*23*
Funding $		*526,199*		*3,977,820*	*70,167*	*129,195*	*311,659*	*856,544*	*753,093*	*300,000*	*6,924,677*
Bladder				20,724							20,724
Breast				477,391	70,167		155,829		715,438		1,418,825
Kidney				180,805							180,805
Leukemia				596,662							596,662
Lung				1,326,167			77,915				1,404,082
Melanoma							77,915				77,915
Not Site Specific*		526,199		1,013,599				607,562		300,000	2,447,360
Ovary								248,982	37,655		286,637
Pancreas						129,195					129,195
Prostate				362,472							362,472
COSTA RICA	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*									*1*
Funding $		*2,280,313*									*2,280,313*
Cervix		2,280,313									2,280,313
FRANCE	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #					*2*			*4*			*6*
Funding $					*103,417*			*2,440,681*			*2,544,098*
Bladder								117,128			117,128
Breast					49,273						49,273
Kidney								932,434			932,434
Lung								790,376			790,376
Melanoma					54,144						54,144
Nose, Nasal Passages								27,072			27,072
Not Site Specific*								546,599			546,599
Pharynx								27072			27072
INDIA	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #				*1*							*1*
Funding $				*183,930*							*183,930*
Breast				183,930							183,930
ISRAEL	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #				*4*			*1*				*5*
Funding $				*902,662*			*216,389*				*1,119,051*
Breast				49,259			216,389				265,648
Colon, Rectum				130,930							130,930
Lung				49,259							49,259
Not Site Specific*				445,679							445,679
Ovary				96,605							96,605
Pancreas				81,671							81,671
Skin				49,259							49,259

continued

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.)
Source: Research Analysis and Evaluation Branch.

Table 17 (cont'd). NCI Funding of Foreign Research Grants in FY2013

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country/ Cancer Site	Mechanism										
KOREA, REPUBLIC OF	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #				*1*							*1*
Funding $				*160,786*							*160,786*
Lung				160,786							160,786
NETHERLANDS	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #				*1*							*1*
Funding $				*204,335*							*204,335*
Colon, Rectum				204,335							204,335
SWEDEN	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #					*1*						*1*
Funding $					*44,712*						*44,712*
Bone, Cartilage					4,968						4,968
Brain					4,968						4,968
Childhood Leukemia					4,968						4,968
Leukemia					4,968						4,968
Liver					4,968						4,968
Neuroblastoma					4,968						4,968
Non-Hodgkins Lymphoma					4,968						4,968
Retinoblastoma*					4,968						4,968
Wilms Tumor					4,968						4,968
UNITED KINGDOM	**F31**	**N01**	**N02**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #	*1*	*2*		*4*						*1*	*8*
Funding $	*42,232*	*2,428,727*		*1,579,344*						*242,127*	*4,292,430*
Breast	42,232			209,418							251,650
Eye				385,521							385,521
Lung		11,185		394,549							405,734
Melanoma				385,521							385,521
Myeloma				204,335							204,335
Not Site Specific*		2,417,542									2,417,542
Thyroid										242,127	242,127
Total Grants	**1**	**4**	**1**	**28**	**4**	**1**	**3**	**6**	**2**	**2**	**52**
Total $ Per Grant type	**42,232**	**5,235,239**	**95,313**	**7,465,274**	**218,296**	**129,195**	**636,242**	**3,297,225**	**1,040,621**	**542,127**	**18,701,764**

*Not Site Specific = research that lacks a focus on a particular type of cancer/cancer site (e.g., basic research on the role of a protein in cellular DNA damage in fruit flies and has no cancer site focus; however, it is relevant to cancer research.)

Source: Research Analysis and Evaluation Branch.

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2013

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country	Funding Mechanism																									Sub-total
	D43	F30	F31	F32	K01	K05	K07	K08	K22	K23	K99	N02	P01	R00	R01	R03	R13	R21	R25	R37	R42	R43	U01	U24	UH2	UM1	
Africa (unspecified)															1												**1**
Argentina					1										1									1			**3**
Asia (unspecified)															2	1		1									**4**
Australia				1	1	1					1				23								4	3		1	**35**
Austria															3									1			**4**
Bangladesh															3												**3**
Belarus												1															**1**
Belgium															1									1			**2**
Benin															1												**1**
Brazil															3				1				1	1			**6**
Cameroon	1														1												**2**
Canada						1			1				1		46	3		6	2			1	8	3		1	**73**
Caribbean (unspecified)															1												**1**
Central America (unspecified)															1												**1**
Chile															2												**2**
China							1								17	3				1			2	2		1	**27**
Columbia															1									1			**2**
Czech Republic																							1	1			**2**
Denmark															5								1	1			**7**
Dominican Republic															1												**1**
Egypt															3									1			**4**
Europe (unspecified)															1			1									**2**
Finland															2								1	1			**4**
France															11	2		1					5	1			**20**
Germany											1				21			1				1	3	2	1		**30**
Greece															3			1									**4**
Honduras																1											**1**
Hungary																								2			**2**
Iceland																							1				**1**
India				1		1									4	1								1			**8**
Iran																								1			**1**
Ireland															2									1			**3**
Israel			1											1	8				1	1				2			**14**
Italy						1									9								2	2			**14**
Japan															12									1			**13**
Kenya	1	1													2								1				**5**
Kuwait																								1			**1**
Latin America (unspecified)																		1									**1**
Malawi															1			1									**2**

continued

Source: Research Analysis and Evaluation Branch.

Table 18 (cont'd). Foreign Components of U.S. Domestic Research Grants in FY2013

(This table reports extramural grants and contracts only; intramural grants and contracts are excluded.)

Country	Funding Mechanism																										Sub-total
	D43	F30	F31	F32	K01	K05	K07	K08	K22	K23	K99	N02	P01	R00	R01	R03	R13	R21	R25	R37	R42	R43	U01	U24	UH2	UM1	
Malaysia															1								1	1			**3**
Mexico															6			1						1			**8**
Middle East (unspecified)															1												**1**
Netherlands													1		13			1		1			5	1			**22**
New Zealand															2			1						2			**5**
Nicaragua																1											**1**
Nigeria	1			1														1									**3**
North America (unspecified)															1												**1**
Norway															6								3				**9**
Oceania (unspecified)															1												**1**
Pakistan																								1			**1**
Panama																								1			**1**
Poland															1									1			**2**
Portugal															1									1			**2**
Romania																							1				**1**
Russia															1								1	1			**3**
Rwanda	1																										**1**
Saudi Arabia																								1			**1**
Singapore							1								7	1								1			**10**
Slovenia																								1			**1**
South Africa	1																	1					1	2			**5**
South America (unspecified)															1												**1**
South Korea															2									1			**3**
Spain															6		1	1	1			1		2			**12**
Sweden															7								3	2			**12**
Switzerland								1							4	1							1	2			**9**
Taiwan															4									1			**5**
Tanzania	1														1												**2**
Thailand															3												**3**
Turkey			1												2									1			**4**
Uganda	2									1					3								1				**7**
United Kingdom															33	3	2	2	1		1		6	1			**49**
Uraguay															1									1			**2**
Venezuela																								1			**1**
Vietnam															1												**1**
Zambia	1														2												**3**
Zimbabwe																							1				**1**
Totals	**9**	**1**	**2**	**3**	**2**	**4**	**2**	**1**	**1**	**1**	**2**	**1**	**2**	**1**	**303**	**17**	**3**	**21**	**6**	**3**	**1**	**3**	**54**	**58**	**1**	**3**	**505***

* Because many grants and contracts have multiple foreign contributors, the total count (505) is greater than the total number of grants and contracts (294).

Source: Research Analysis and Evaluation Branch.

Appendix A: Activities of the National Cancer Advisory Board

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 18 members who are appointed by the President and 12 nonvoting *ex officio* members. The NCAB advises, assists, consults with, and makes recommendations to the Secretary, HHS, and to the NCI Director with respect to the activities carried out by and through the Institute and on policies pertaining to these activities. It is authorized to recommend support for grants and cooperative agreements following technical and scientific peer review. The Director of the DEA serves as Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all peer reviewed applications, the Board reviewed a total of 6,630 applications in 2013 requesting $2,151,961,774 in direct costs with appropriated funds from the total of 12,648 applications requesting $3,504,391,672.

The Board heard presentations, discussed, and provided advice on a variety of topics and NCI activities in FY2013, such as:

- NCI Director's Report
- President's Cancer Panel Report
- Legislative Update
- Annual Delegations of Authority
- Bypass Budget Overview
- Obesity and Cancer
- Biennial Review of Inclusion of Women and Minorities in Clinical Research
- Impact of the Implementation of the Operational Efficiency Working Groups (OEWG) Report on the Clinical Trials Systems
- RAS Project
- National Lung Screening Trial (NLST) Subset Analysis
- NCI Community Oncology Research Program (NCORP)
- The PROSPR Initiative: Population-Based Research Optimizing Screening Through Personalized Regimes - Competitive Revision for the Collection of Cervical Cancer Screening Data
- Sub-Saharan African Collaborative HIV and Cancer Research Consortia
- Cancer Detection and Diagnostic Technologies for Global Health
- NCI Cancer Genomics Cloud Pilots
- Cancer Centers Working Group Report
- Establishing an Outstanding Investigator Award
- Overview of the Division of Cancer Epidemiology and Genetics (DCEG)
- Colorectal Cancer Screening
- Matching Therapy to Diagnostics Report
- Update: Recent Actions, Re-Organization, and Initiatives
- NCAB Subcommittee Reports: Communications, Global Cancer Research, Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) Malignancy

As part of its mandate for oversight of NCI activities, the NCAB receives regular updates from the NCI Director, the NCI Office of Legislation and Congressional Activities, and the President's Cancer Panel.

Another major role of the Board is to monitor the overall advisory and oversight activities of the NCI as a whole. In that regard, it annually reviews the site visit outcomes of intramural review and the extramural RFA and RFP concepts acted on by the BSA. The NCAB also participates in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities as expressed by the allocation of the annual operating budget.

The full text of recent NCAB meeting summaries is available on the NCI website at **http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm**

Appendix B: Activities of the Board of Scientific Advisors

The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of NCI's extramural research programs, and concept review of extramural program initiatives.

In addition to approving a number of extramural program initiatives (see below), the BSA also heard presentations on the following in FY2013:

- Report of the NCI Director
- Data Replication
- Post TCGA (The Cancer Genome Atlas)
- An Experiment in Crowd-Sourcing Science: the NCI-Dream Challenge
- Status Report: Physical Sciences-Oncology Centers (PS-OC) Program

RFA/Cooperative Agreements Approved

Office of the Director

- Sub-Saharan African Collaborative HIV and Cancer Research Consortia
- Cancer Detection and Diagnostic Technologies for Global Health
- NCI Cancer Genomics Cloud Pilots
- Innovative Molecular Analysis Technologies Program (IMAT)

Division of Cancer Control and Population Sciences

- The PROSPR Initiative: Population-Based Research Optimizing Screening Through Personalized Regimes – Competitive Revision for the Collection of Cervical Cancer Screening Data
- Using Social Media to Understand and Address Substance Use and Addiction (on behalf of NIH Collaborative Research on Nicotine and Addiction Effort with NIDA and NIAAA)

Division of Cancer Prevention and Division of Cancer Biology

- Molecular Characterization of Screen-Detected Lesions
- Metabolic Reprogramming to Improve Immunotherapy

Division of Cancer Treatment and Diagnosis

Pediatric Brain Tumor Consortium (PBTC)
Biospecimen Bank to Support NCI-Clinical Trials Networks (NCTN)

Appendix C: List of Chartered Committees

President's Cancer Panel

Chair

Barbara K. Rimer, Dr.P.H. ..... The University of North Carolina at Chapel Hill

Members

Hill Harper, J.D. .....Author, Actor, Philanthropist
Owen N. Witte, M.D. ..... University of California at Los Angeles

Executive Secretary

Abby B. Sandler, Ph.D. .....National Cancer Institute , NIH

National Cancer Advisory Board

Chair

Tyler E. Jacks, Ph.D. ..... Massachusetts Institute of Technology

Members

Victoria L. Champion, D.N.S. .....Indiana University
David C. Christiani, M.D., M.P.H. .....Harvard Medical School
Marcia R. Cruz-Correa, M.D., Ph.D. .....University of Puerto Rico
Kevin J. Cullen, M.D. ..... University of Maryland, Baltimore
Judy E. Garber, M.D., M.P.H. .....Harvard Medical School
William H. Goodwin, Jr., M.B.A. ..... CCA Industries, Inc.
Waun K. Hong, M.D. ..... The University of Texas MD Anderson Cancer Center
Elizabeth M. Jaffee, M.D. ..... The Johns Hopkins University
Beth Y. Karlan, M.D. ..... University of California, Los Angeles
Ms. Mary Vaughan Lester ..... University of California, San Francisco Foundation
H. Kim Lyerly, M.D. .....Duke University
Olufunmilayo F. Olopade, M.B.B.S., F.A.C.P. ..... The University of Chicago
Jennifer A. Pietenpol, Ph.D. ..... Vanderbilt University
Mack Roach III, M.D., F.A.C.R. .....University of California, San Francisco
Jonathan M. Samet, M.D., M.S. .....The University of Southern California Keck School of Medicine
Charles L. Sawyers, M.D.Weill .....Cornell Medical College of Cornell University
William R. Sellers, M.D. .....Novartis Institutes for Biomedical Research, Inc.

Ex Officio Members of the National Cancer Advisory Board

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. .....National Institute of Environmental Health Sciences, NIH
Francis S. Collins, M.D., Ph.D. .....National Institutes of Health
Margaret A. Hamburg, M.D. .....U.S. Food and Drug Administration

John P. Holdren, Ph.D. ..... Office of Science and Technology Policy
John Howard, M.D., M.P.H., J.D., L.L.M. .....National Institute for Occupational Safety and Health
Lisa P. Jackson, M.S. .....U.S. Environmental Protection Agency
Gina McCarthy, M.S. .....U.S. Environmental Protection Agency
The Honorable Thomas E. Perez .....U.S. Department of Labor
Robert A. Petzel, M.D. .....U.S. Department of Veterans Affairs
The Honorable Kathleen Sebelius, M.P.A. ..... U.S. Department of Health and Human Services
The Honorable Hilda L. Solis .....U.S. Department of Labor
Inez Tenenbaum, M.Ed. .....U.S. Consumer Product Safety Commission
Sharlene Weatherwax, Ph.D. ..... U.S. Department of Energy
Jonathan Woodson, M.D. ..... U.S. Department of Defense

Alternates to *Ex Officio* Members of the National Cancer Advisory Board

Robert T. Anderson, Ph.D. ..... U.S. Department of Energy
Michael A. Babich, Ph.D. .....U.S. Consumer Product Safety Commission
Patricia Bray, M.D., M.P.H. .....OSHA /U.S. Department of Labor
Vincent J. Cogliano, Ph.D. .....U.S. Environmental Protection Agency
Michael Kelley, M.D., F.A.C.P. .....U.S. Department of Veterans Affairs
Aubrey Miller, M.D. .....National Institutes of Environmental Health Sciences, NIH
Richard Pazdur, M.D. F.A.C.P. .....U.S. Food and Drug Administration
Craig D. Shriver, M.D., F.A.C.S., COL., M.C. ..... U.S. Department of Defense
Kerry Souza, Sc.D., M.P.H. ..... National Institute for Occupational Safety and Health
Michael Stebbins, Ph.D. ..... Office of Science and Technology Policy
Lawrence A. Tabak, D.D.S., Ph.D. .....National Institutes of Health

Executive Secretary

Paulette S. Gray, Ph.D. .....National Cancer Institute, NIH

NCI – Frederick Advisory Committee

Current Chair

Joe W. Gray, Ph.D. ..... Oregon Health & Science University

Past Chair

Zach H. Hall, Ph.D. .....University of California, San Francisco

Members

J. Carl Barrett, Ph.D. .....AstraZeneca
David Botstein, Ph.D. ..... Princeton University
Vicki L. Colvin, Ph.D. .....Rice University
Levi A. Garraway, M.D., Ph.D. .....Harvard Medical School
Beatrice H. Hahn, M.D. ..... The University of Pennsylvania
Monica J. Justice, Ph.D. ..... The Hospital for Sick Children
Lawrence J. Marnett, Ph.D. .....Vanderbilt University

Jill P. Mesirov, Ph.D. ..... The Broad Institute of MIT and Harvard University
Garry P. Nolan, Ph.D. ..... Stanford University
Kenneth Olden, Ph.D., Sc.D., L.H.D. ..... U.S. Environmental Protection Agency
Kenneth J. Pienta, M.D. ..... The Johns Hopkins University
Steven T. Rosen , M.D., F.A.C.P. ..... City of Hope National Medical Center

Representatives

A. Thomas. Look, M.D. ..... Dana-Farber Cancer Insitutute
Jennifer A. Pietenpol, Ph.D. ..... Vanderbilt University
Cheryl Willman, M.D. ..... The University of New Mexico

Ex Officio Members of the NCI – Frederick Advisory Committee

Stephen J. Chanook, M.D. ..... National Cancer Institute, NIH
John Czajkowski, M.P.A. ..... National Cancer Institute, NIH
James H. Doroshow, M.D. ..... National Cancer Institute, NIH
Paulette S. Gray, Ph.D. ..... National Cancer Institute, NIH
Douglas R. Lowy, M.D. ..... National Cancer Institute, NIH
Alan Rabson, M.D. ..... National Cancer Institute, NIH
Craig W. Reynolds, Ph.D. ..... National Cancer Institute, NIH
Margaret A. Tucker, M.D. ..... National Cancer Institute, NIH
Robert H. Wiltrout, Ph.D. ..... National Cancer Institute, NIH

Executive Secretary

Thomas M. Vollberg, Sr., Ph.D. ..... National Cancer Institute, NIH

NCI Board of Scientific Advisors

Chair

Todd R. Golub, M.D. ..... The Broad Institute of MIT and Harvard University

Members

Francis Ali-Osman, D.Sc. ..... Duke University Medical Center
Kenneth C. Anderson, M.D., Ph.D. ..... Dana-Farber Cancer Institute
Dafna Bar-Sagi, Ph.D. ..... New York University School of Medicine
Ethan M. Basch, M.D., M.Sc. ..... The University of North Carolina at Chapel Hill
Sangeeta N. Bhatia, M.D., Ph.D. ..... Massachusetts Institute of Technology
Andrea Califano, Ph.D. ..... Columbia University Medical Center
Arul M. Chinnaiyan, M.D., Ph.D. ..... University of Michigan
Curt. I. Civin, M.D. ..... University of Maryland, Baltimore
Graham A. Colditz, M.D., Dr.P.H. ..... Washington University School of Medicine
Chi V. Dang, M.D., Ph.D. ..... The University of Pennsylvania
Robert B. Diasio, M.D. ..... Mayo Clinic Cancer Center
Daniel C. DiMaio, M.D., Ph.D. ..... Yale University School of Medicine
Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S. ..... The University of Pennsylvania
Brian J. Druker, M.D. ..... Oregon Health & Science University

Karen M. Emmons, Ph.D. ..... Kaiser Foundation Research Institute
Betty R. Ferrell, Ph.D., RN, F.A.A.N. ..... City of Hope National Medical Center
Kathleen M. Foley, M.D. ..... Memorial Sloan-Kettering Cancer Center
Stanton L. Gerson, M.D. ..... Case Western Reserve University
Joe W. Gray, Ph.D. ..... Oregon Health & Science University
Chanita Hughes-Halbert, Ph.D. ..... Medical University of South Carolina
Joshua LaBaer, M.D.,Ph.D. ..... Arizona State University
Theodore S. Lawrence, M.D., Ph.D. ..... University of Michigan
Mr. Donald Listwin ..... Canary Foundation
Maria E. Martinez, M.P.H., Ph.D. ..... University of California, San Diego
Luis F. Parada, Ph.D. ..... The University of Texas Southwestern Medical Center
Martine F. Roussel (Sherr), Ph.D. ..... St. Jude Children's Research Hospital
Kevin M. Shannon, M.D. ..... University of California, San Francisco
Mary L. Smith, J.D., M.B.A. ..... Research Advocacy Network
Lincoln Stein, M.D., Ph.D. ..... Ontario Institute for Cancer Research
Bruce W. Stillman, Ph.D. ..... Cold Spring Harbor Laboratory
Louise C. Strong, M.D. ..... The University of Texas MD Anderson Cancer Center
Frank M. Torti, M.D., M.P.H. ..... University of Connecticut Health Center
Gregory L. Verdine, Ph.D. ..... Harvard University
Cheryl L. Walker, Ph.D., A.T.S., F.A.A.A.S. ..... Texas A&M Health Science Center
Irving L. Weissman, M.D. ..... Stanford University

Executive Secretary

Paulette S. Gray, Ph.D. ..... National Cancer Institute, NIH

Clinical Trials and Translational Research Advisory Committee

Chair

James L. Abbruzzese, M.D., F.A.C.P. ..... The University of Texas MD Anderson Cancer Center

Members

Peter C. Adamson, M.D. ..... The Children's Hospital of Philadelphia
Susan G. Arbuck, M.D., M.Sc., F.A.C.P. ..... Susan G. Arbuck M.D., LLC
Monica M. Bertagnolli, M.D. .....Dana-Farber Cancer Institute
Susan G. Braun, M.A. ..... The V Foundation for Cancer Research
Curt I. Civin, M.D. ..... University of Maryland, Baltimore
Kenneth H. Cowan, Ph.D. .....University of Nebraska Medical Center
Kevin J. Cullen, M.D. ..... University of Maryland, Baltimore
Nancy E. Davidson, M.D. .....The University of Pittsburgh
Olivera J. Finn, Ph.D. .....The University of Pittsburgh
J. Philip Kuebler, M.D., Ph.D. ..... Columbus Oncology Associates, Inc.
Scott M. Lippman, M.D. .....University of California, San Diego
Mary S. McCabe, R.N., M.A. .....Memorial Sloan-Kettering Cancer Center
Edith P. Mitchell, M.D., F.A.C.P. ..... Thomas Jefferson University
Nikhil C. Munshi, M.D. .....Harvard Medical School
Lisa A. Newman, M.D., M.P.H., F.A.C.S. ..... University of Michigan Comprehensive Cancer Center
Ms. Nancy Roach ..... Fight Colorectal Cancer
Daniel J. Sargent, Ph.D. .....Mayo Clinic Foundation
Mitchell D. Schnall, M.D., Ph.D. .....The University of Pennsylvania Medical Center
Peter G. Shields, M.D. .....The Ohio State University Comprehensive Cancer Center
George W. Sledge, Jr., M.D. .....Stanford University
Chris H. Takimoto, M.D., Ph.D. .....Janssen Pharmaceuticals, Inc.
Gillian M. Thomas, M.D., F.R.C.P.C., F.R.C.R. ..... University of Toronto
Frank M. Torti, M.D., M.P.H. ..... University of Connecticut Health Center
Miguel A. Villalona-Calero, M.D. ..... The Ohio State University
George J. Weiner, M.D. .....The University of Iowa

Ex Officio Members

James H. Doroshow, M.D. .....National Cancer Institute, NIH
Paulette S. Gray, Ph.D. .....National Cancer Institute, NIH
Rosemarie B. Hakim, Ph.D., M.S. .....U.S. Centers for Medicare and Medicaid Services
Lee J. Helman, M.D. .....National Cancer Institute, NIH
Michael J. Kelley, M.D., F.A.C.P. U.S. ..... Department of Veterans Affairs
Richard Pazdur, M.D., F.A.C.P. .....U.S. Food and Drug Administration
Alan S. Rabson, M.D. .....National Cancer Institute, NIH

Executive Secretary

Sheila A. Prindiville, M.D., M.P.H. .....National Cancer Institute, NIH

Board of Scientific Counselors for Clinical Sciences and Epidemiology, NCI

Current Chair

Louis M. Weiner, M.D. ..... Georgetown University Medical Center

Past Chair

Ethan Dmitrovsky, M.D. ..... Dartmouth Medical School

Members

Edgar Ben-Josef, M.D. ..... The University of Pennsylvania
Jonine L. Bernstein, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Arthur W. Blackstock, Jr., M.D. ..... Wake Forest University
Tim Byers, M.D. ..... University of Colorado Cancer Center
Nicola J. Camp, M.D., Ph.D. ..... The University of Utah
Susan L. Cohn, M.D. ..... The University of Chicago
John F. DiPersio, M.D., Ph.D., F.A.C.P. ..... Washington University in St. Louis School of Medicine
Kojo S.J. Elenitoba-Johnson, M.D. ..... The University of Michigan Medical School
Michael L. Freeman, Ph.D. ..... Vanderbilt University
Marc T. Goodman, Ph.D, M.P.H. ..... Cedars-Sinai Medical Center
Nancy Goodman, J.D. ..... Kids V Cancer
Bernard Harlow, Ph.D. ..... University of Minnesota
Carl June, M.D. ..... The University of Pennsylvania
Karen L. Kelly, M.D. ..... University of California, Davis
Hongzhe Lee, Ph.D. ..... The University of Pennsylvania
Alexandra M. Levine, M.D., M.A.C.P. ..... City of Hope National Medical Center
Sanford Markowitz, M.D., Ph.D. ..... Case Western Reserve University
David A. Norris, M.D. ..... University of Colorado School of Medicine
Augusto Ochoa, M.D. ..... Louisiana State University Health Sciences Center
Kenneth Offit, M.D., M.P.H. ..... Memorial Sloan-Kettering Cancer Center
Raphael E. Pollock, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
David Poplack, M.D. ..... Baylor College of Medicine
Jeremy N. Rich, M.D., M.H.Sc. ..... Case Western Reserve University
Thomas Rohan, M.D., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Darryl K. Shibata, M.D. ..... The University of Southern California
Walter M. Stadler, M.D., F.A.C.P. ..... The University of Chicago Medical Center
Elizabeth Ward, Ph.D. ..... American Cancer Society
George Wilding, M.D. ..... University of Wisconsin, Madison
Cheryl L. Willman, M.D. ..... The University of New Mexico Cancer Research Facility

Executive Secretary

Brian E. Wojcik, Ph.D. ..... National Cancer Institute, NIH

Board of Scientific Counselors for Basic Sciences, NCI

Chair

Joan W. Conaway, Ph.D. ..... Stowers Institute for Medical Research

Members

Lorena S. Beese, Ph.D.*.....Duke University Medical Center
Paul D. Bieniasz, Ph.D. .....The Rockefeller University
John C. Cambier, Ph.D. .....University of Colorado, Denver
Lawrence Corey, M.D. ..... Fred Hutchinson Cancer Research Center
Sara A. Courtneidge, Ph.D. ..... Sanford-Burnham Medical Research Institute
Norman Drinkwater, Ph.D. ..... University of Wisconsin, Madison
Nelson Fausto, M.D.†..... University of Washington
Errol Friedberg, M.D. .....The University of Texas Southwestern Medical Center
Joanna Groden, Ph.D ..... The Ohio State University
Daria J. Hazuda, Ph.D. ..... Merck and Company Inc.
Eric Hunter, Ph.D. ..... Emory University
Stephen D. Hursting, Ph.D., M.P.H. .....The University of Texas at Austin
Alexandra L. Joyner, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Marcelo G. Kazanietz, Ph.D. ..... The University of Pennsylvania
Brian C. Lewis, Ph.D. ..... University of Massachusetts Medical School
Robert E. Lewis, Ph.D. .....University of Nebraska Medical Center
Jonathan D. Licht, M.D. ..... Northwestern University Feinberg School of Medicine
Sergio A. Lira, M.D., Ph.D. .....Mount Sinai School of Medicine
Ian G. Macara, Ph.D. .....Vanderbilt University Medical Center
Roeland Nusse, Ph.D. ..... Stanford University
Suzanne Ostrand-Rosenberg, Ph.D. .....University of Maryland, Baltimore County
Thomas L. Poulos, Ph.D. .....University of California, Irvine
Kenneth L. Rock, M.D. ..... University of Massachusetts Medical School
Daniel Romo, Ph.D.* ..... Texas A&M University
Tzyy-Choou Wu, M.D., Ph.D. ..... The Johns Hopkins University School of Medicine
James A. Wells, Ph.D. .....University of California, San Francisco
Wayne M. Yokoyama, M.D. ..... Washington University in St. Louis School of Medicine
Virginia A. Zakian, Ph.D. ..... Princeton University
Dong-Er Zhang, Ph.D. .....University of California, San Diego

Executive Secretary

Mehrdad Tondravi, Ph.D. ..... National Cancer Institute, NIH

*Pending.
†Deceased.

NCI Director's Consumer Liaison Group

Chair

Max N. Wallace, J.D. .....Accelerated Brain Cancer Cure, Inc.

Members

Jeffrey Allen, Ph.D. ..... Friends of Cancer Research
David F. Arons, J.D. ..... National Brain Tumor Society
Susan G. Braun, M.A. ..... The V Foundation for Cancer Research
Adam M. Clark, Ph.D. ..... U.S. Department of Health and Human Services
Martha Gaines, J.D., ...LLM Academic Affairs and Experiential Learning
Joya Delgado Harris, M.P.H. .....American Cancer Society
Linda S. House, R.N., B.S.N., M.S.M. .....Cancer Support Community
Jeffrey A. Kaufman, M.B.A, M.I.A. .....Adenoid Cystic Carcinoma Research Foundation
Ms. Mila McCurrach ..... The Lustgarten Foundation
Michelle T. McMurry-Heath, M.D., Ph.D. .....U.S. Food and Drug Administration
Jon G. Retzlaff, M.P.A., M.B.A. ..... American Association for Cancer Research
Mr. Josh Sommer .....The Chordoma Foundation
Andrea E. Ferris Stern, M.B.A. ..... LUNGevity Foundation
Regina M. Vidaver, Ph.D. ..... National Lung Cancer Partnership

Executive Secretary

Ms. Amy Bulman ..... National Cancer Institute, NIH

NCI Initial Review Group Scientific Review Committees

Subcommittee A—Cancer Centers

Current Chair

Timothy L. Ratliff, Ph.D. ..... Purdue University, West Lafayette

Past Chair

Edward Chu, M.D. ..... The University of Pittsburgh

Members

Alex A. Adjei, M.D., Ph.D., F.A.C.P. ..... Roswell Park Cancer Institute
Terrance L. Albrecht, Ph.D. ..... Wayne State University
Howard H. Bailey, M.D. ..... University of Wisconsin, Madison
Robert C. Bast Jr., M.D. ..... The University of Texas MD Anderson Cancer Center
Barbara J. Beckwith, M.A. ..... The Ohio State University
Marianne Berwick, Ph.D., M.P.H. ..... The University of New Mexico
Donald J. Buchsbaum, Ph.D. ..... The University of Alabama at Birmingham
William E. Carson, III, M.D. ..... The Ohio State University
Moon S. Chen, Jr., Ph.D., M.P.H. ..... University of California, Davis
Margie L. Clapper, Ph.D. ..... Fox Chase Cancer Center
Robert S. DiPaola, M.D. ..... Rutgers, The State University of New Jersey
S. Gail Eckhardt, M.D. ..... University of Colorado, Denver
Robert J. Gillies, Ph.D.H. ..... Lee Moffitt Cancer Center and Research Institute
Dennis E. Hallahan, M.D. ..... Washington University in St. Louis
Mark A. Israel, M.D. ..... Dartmouth-Hitchcock Medical Center
King C. Li, M.D. ..... Wake Forest University
Beverly S. Mitchell, M.D. ..... Stanford University
Alfred W. Rademaker, Ph.D. ..... Northwestern University
Jerome Ritz, M.D. ..... Dana-Farber Cancer Institute
Victor M. Santana, M.D. ..... St. Jude Children's Research Hospital
Victoria L. Seewaldt, M.D. ..... Duke University
Richard L. Seither, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Eric J. Small, M.D. ..... University of California, San Francisco
Eduardo M. Sotomayor, M.D. ..... H. Lee Moffit & Cancer Research Institute
Kenneth D. Tew, Ph.D., D.Sc. ..... Medical University of South Carolina
Ian M. Thompson, Jr., M.D. ..... The University of Texas Health Science Center at San Antonio
Barnarese Wheatley, Dr.Ed., M.P.H. ..... BPW Consulting Services
Patti Wiley, M.B.A. ..... On the Wings of Angels Pediatric Cancer Foundation

Current Scientific Review Officer

Sonya V. Roberson, Ph.D. ..... National Cancer Institute, NIH

Past Scientific Review Officer

Gail J. Bryant, M.D. ..... National Cancer Institute, NIH

Subcommittee F—Institutional Training and Education

Chair

Herbert Chen, M.D. ..... University of Wisconsin, Madison

Members

Moray J. Campbell, Ph.D. ..... Roswell Park Cancer Institute
Cathy S. Carlson, D.V.M., Ph.D. ..... University of Minnesota
Rebecca S. Hartley, Ph.D. ..... The University of New Mexico Health Sciences Center
Marlene L. Hauck, D.V.M., Ph.D. ..... North Carolina State University
Jennifer J. Hu, Ph.D. ..... University of Miami Miller School of Medicine
Aminah Jatoi, M.D. ..... Mayo Clinic
Mark R. Kelley, Ph.D. ..... Indiana University-Purdue University Indianapolis
Annette R. Khaled, Ph.D. ..... University of Central Florida
Molly F. Kulesz-Martin, Ph.D. ..... Oregon Health & Science University
Edmund C. Lattime, Ph.D. ..... Rutgers, The State University of New Jersey
Stephen L. Lessnick, M.D., Ph.D. ..... The University of Utah
Christopher I. Li, M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Deborah B. McGuire, Ph.D., R.N., F.A.A.N. ..... University of Maryland, Baltimore
Nipun B. Merchant, M.D., F.A.C.S. ..... Vanderbilt University
Funda Meric-Bernstam, M.D. ..... The University of Texas MD Anderson Cancer Center
Shiraz I. Mishra M.B.B.S, Ph.D. ..... The University of New Mexico
Polly A. Newcomb, Ph.D. ..... University of Washington
Daniel P. Normolle, Ph.D. ..... The University of Pittsburgh
Babatunde O. Oyajobi, M.D., Ph.D. ..... The University of Texas Health Sciences Center at San Antonio
Mark P. Pfeifer, M.D. ..... University of Louisville
Janet S. Rader, M.D., F.A.C.O.G. ..... Medical College of Wisconsin
Gavin P. Robertson, Ph.D. ..... Pennsylvania State University
Kathryn H. Schmitz, Ph.D., M.P.H. ..... The University of Pennsylvania School of Medicine
Gayle E. Woloschak, Ph.D. ..... Northwestern University

Scientific Review Officer

Timothy C. Meeker, M.D. ..... National Cancer Institute, NIH

Subcommittee I—Transition to Independence

Current Chair

Neil Osheroff, Ph.D. ..... Vanderbilt University Medical Center

Past Chair

William E. Gillanders, M.D. ..... Washington University in St. Louis

Members

Emmanuel T. Akporiaye, Ph.D. ..... Providence Portland Medical Center
Deepak Bastia, Ph.D. ..... Medical University of South Carolina
Sujit Basu M.D., Ph.D. ..... The Ohio State University
Lawrence H. Boise, Ph.D. ..... Emory University
Jennifer P. Clarke, Ph.D. ..... University of Nebraska-Lincoln
James M. Ford, M.D. ..... Stanford University
Jessica J. Kandel, M.D. ..... Columbia University
Charles Keller, M.D. ..... Oregon Health & Science University
Kenneth A. Krohn, Ph.D. ..... University of Washington
Sophie A. Lelievre, D.V.M., Ph.D. ..... Purdue University, West Lafayette
Anna E. Lokshin, Ph.D. ..... The University of Pittsburgh
Daniela E. Matei, M.D. ..... Indiana University – Purdue University Indianapolis
Carlos S. Moreno, Ph.D. ..... Emory University
Keith D. Paulsen, Ph.D. ..... Dartmouth College
Manuel L. Penichet, M.D., Ph.D. ..... University of California, Los Angeles
Rajagopal Ramesh, Ph.D. ..... The University of Oklahoma Health Science Center
Tiffany N. Seagroves, Ph.D. ..... The University of Tennessee Health Science Center
David B. Solit, M.D. ..... Memorial Sloan-Kettering Cancer Center
Bakhos A. Tannous, Ph.D. ..... Harvard Medical School
E. Aubrey Thompson, Ph.D. ..... Mayo Clinic, Jacksonville
Shizhen E. Wang, Ph.D. ..... City of Hope National Medical Center
Robert A.Winn, M.D. ..... University of Illinois at Chicago
Wen-Cheng Xiong, Ph.D. ..... Medical College of Georgia
Yu-Chung Yang, Ph.D. ..... Case Western Reserve University

Scientific Review Officer

Sergei Radaev, Ph.D. ..... National Cancer Institute, NIH

Subcommittee J – Career Development

Current Chair

Christopher H. Lowrey, M.D. ..... Dartmouth-Hitchcock Medical Center

Past Chair

Johanna W. Lampe, Ph.D. ..... University of Washington

Members

Barbara L. Andersen, Ph.D. ..... The Ohio State University
Michael A. Andrykowski, Ph.D. .....University of Kentucky
Virginia F. Borges, M.D. MM.Sc. .....University of Colorado, Denver
Deborah W. Bruner, R.N., Ph.D. .....Emory University School of Nursing
John C. Byrd, M.D., Ph.D. ..... The Ohio State University
Fernando A. Ferrer, M.D. .....University of Connecticut School of Medicine
Christopher R. Friese, A.O.C.N., R.N., Ph.D. .....University of Michigan
Michael E. Hagansee, M.D., Ph.D. .....Louisiana State University
Shawna V. Hudson, Ph.D. ..... Rutgers, The State University of New Jersey
Santosh Kesari M.D., Ph.D. .....University of California, San Diego
Alexander Krupnick, M.D. ..... Washington University in Saint Louis
Beverly L. Laird, Ph.D. ..... 3D Medical Concepts, LLC
Gertraud Maskarinec, M.D., Ph.D., M.P.H. ..... The University of Hawaii
Guy H. Montgomery, Ph.D. .....Mount Sinai School of Medicine
Chaya S. Moskowitz, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Kirsten B. Moysich, Ph.D. ..... Roswell Park Cancer Institute
C. Daniel Mullins, Ph.D. ..... University of Maryland, Baltimore
Lillian L. Siu, M.D. .....Princess Margaret Hospital
Scott A. Waldman, M.D., ... Ph.D.Thomas Jefferson University
Zuo-Feng Zhang, M.D., Ph.D., M.P.H. ..... University of California, Los Angeles

Scientific Review Officer

Ilda F.S. Melo, Ph.D. .....National Cancer Institute, NIH

Appendix D: NCI Initial Review Group Consultants

1. Consultants Serving as Temporary Members on IRG Subcommittees in FY2013

A

Adams-Campbell, Lucile L., Ph.D. ..... Georgetown University
Andersen, Barbara L., Ph.D..... The Ohio State University

B

Bae-Jump, Victoria L., M.D., Ph.D..... The University of North Carolina at Chapel Hill
Barsevick, Andrea M., Ph.D., B.S.N. ..... Thomas Jefferson University
Bass, Adam J., M.D..... Dana-Farber Cancer Institute
Bast, Robert C., M.D. ..... Harvard Medical School
Bastani, Roshan, Ph.D. ..... University of California, Los Angeles
Beckwith, Barbara J., M.A. ..... The Ohio State University
Behbod, Fariba, Pharm.D., Ph.D. ..... The University of Kansas
Berry, Donna L., Ph.D., R.N. ..... Dana-Farber Cancer Institute
Berwick, Marianne, Ph.D., M.P.H. ..... The University of New Mexico
Bhattacharya, Resham, Ph.D. ..... The University of Oklahoma Health Sciences Center
Black, Jennifer D., Ph.D. ..... University of Nebraska Medical Center
Bodduluri, Haribabu, Ph.D. ..... University of Louisville
Boise, Lawrence H., Ph.D. ..... Emory University
Boussiotis, Vassiliki A., M.D., Ph.D. ..... Beth Israel Deaconess Medical Center
Bouton, Amy H., Ph.D..... University of Virginia
Bruner, Deborah W., Ph.D., R.N..... Emory University
Buatti, John M., M.D. ..... The University of Iowa
Bui, Jack D., M.D., Ph.D. ..... University of California, San Diego
Busch, Theresa M., Ph.D..... University of Rochester

C

Chang, Eric C., Ph.D. ..... Baylor College of Medicine
Chen, Moon S., Jr., Ph.D., M.P.H. ..... University of California, Davis
Chen-Kiang, Selina Y., Ph.D. ..... Weill Cornell Medical College of Cornell University
Chiao, Elizabeth, M.D., M.P.H. ..... Baylor College of Medicine
Chiao, Paul J., Ph.D..... The University of Texas MD Anderson Cancer Center
Chu, Edward, M.D..... The University of Pittsburgh
Chung, Leland W.K., Ph.D..... Cedars-Sinai Medical Center
Clarke, Jennifer P., Ph.D. ..... University of Nebraska, Lincoln
Coleman, William B., Ph.D. ..... The University of North Carolina at Chapel Hill
Corry, Peter M., Ph.D..... University of Arkansas for Medical Sciences
Crane, Lori A., Ph.D., M.P.H. ..... University of Colorado, Denver

D

Daskalakis, Constantine, Sc.D. ..... Thomas Jefferson University
Datta, Kaustubh, Ph.D. ..... University of Nebraska Medical Center
Davis, Ian J., M.D., Ph.D. ..... The University of North Carolina at Chapel Hill
Dennis, Phillip A., M.D., Ph.D. ..... The Johns Hopkins University
DiSaia, Philip J., M.D. ..... University of California, Irvine
Dorazio, John A., M.D., Ph.D. ..... University of Kentucky
Doubeni, Chyke A., M.D., M.P.H. ..... The University of Pennsylvania

E

Elmer, Patricia J., Ph.D. ..... Kaiser Foundation Research Institute

F

Ferrer, Fernando A., M.D. ..... Connecticut Children's Medical Center
Figlin, Robert A., M.D., F.A.C.P. ..... Cedars-Sinai Medical Center
Foreman, Kimberly E., Ph.D. ..... Loyola University, Chicago
Friese, Christopher R., Ph.D., R.N. ..... University of Michigan
Futscher, Bernard W., Ph.D. ..... The University of Arizona

G

Garbow, Joel R., Ph.D. ..... Washington University in St. Louis
Gaspar, Laurie E., M.D. ..... University of Colorado, Denver
Gewirtz, David A., Ph.D. ..... Virginia Commonwealth University
Gillies, Robert J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Goga, Andrei, M.D., Ph.D. ..... University of California, San Francisco
Golemis, Erica A., Ph.D. ..... Fox Chase Cancer Center
Govindan, Ramaswamy, M.D. ..... Washington University in St. Louis
Goydos, James S., M.D. ..... Rutgers Biomedical and Health Sciences Cancer Institute of New Jersey
Grandis, Jennifer R., M.D. ..... The University of Pittsburgh
Graves, Kristi D., Ph.D. ..... Georgetown University

H

Hallahan, Dennis E., M.D. ..... Washington University in St. Louis
Hanna, Nader N., M.D. ..... University of Maryland, Baltimore
Henry, Norah L., M.D., Ph.D. ..... University of Michigan
Hezel, Aram F., M.D. ..... University of Rochester
Hichwa, Richard D., Ph.D. ..... The University of Iowa
Hohl, Raymond J., M.D. Ph.D. ..... The University of Iowa
Hu, Jennifer J., Ph.D. ..... University of Miami Miller School of Medicine
Hughes, Daniel C., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Huh, Warner K., M.D. ..... The University of Alabama at Birmingham
Hwang, Rosa F., M.D. ..... The University of Texas MD Anderson Cancer Center

I

Israel, Mark A., M.D. ..... Dartmouth-Hitchcock Medical Center

J

Jatoi, Aminah, M.D. ..... Mayo Clinic
Jim, Heather S.L., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Jones, Kevin B., M.D. ..... The University of Utah
Ju, Jingfang, Ph.D..... The State University of New York at Stony Brook
Juon, Hee-Soon, Ph.D. ..... The Johns Hopkins University

K

Karin, Michael, Ph.D..... University of California, San Diego
Kaufman, Russel E., M.D..... The Wistar Institute
Kazak, Anne E., Ph.D..... Alfred I. DuPont Hospital for Children, Wilmington
Kesari, Santosh, M.D., Ph.D. ..... University of California, Davis
Klassen, Ann C., Ph.D..... Drexel University
Kline, Justin P., M.D. ..... The University of Chicago
Kridel, Steven J. Ph.D. ..... Wake Forest University Health Sciences Center
Kroenke, Christopher D., Ph.D. ..... Oregon Health & Science University
Krohn, Kenneth A., Ph.D. ..... University of Washington Medical Center
Krupnick, Alexander S., M.D. ..... Washington University in St. Louis
Kulesz-Martin, Molly F., Ph.D. ..... Oregon Health & Science University

L

LaFlamme, Susan, Ph.D. ..... Albany Medical College
Lang, James C., Ph.D. ..... The Ohio State University
Ljungman, Mats, Ph.D. ..... University of Michigan
Lord, Edith M., Ph.D. ..... University of Rochester Medical Center

M

Malkas, Linda H., Ph.D. ..... City of Hope National Medical Center
Manfredi, James J., Ph.D. ..... Mount Sinai School of Medicine
Manjili, Masoud H., D.V.M., Ph.D. ..... Virginia Commonwealth University
Marshall, James, Ph.D. ..... Roswell Park Cancer Institute
Martin, Marybeth, Ph.D. ..... Georgetown University
Matsui, William H., M.D. ..... The Johns Hopkins University
Mcguire, Deborah B., Ph.D., R.N., F.A.A.N. ..... Virginia Commonwealth University
Mcmahon, Steven B., Ph.D. ..... Thomas Jefferson University
Meneses, Karen, Ph.D., R.N., F.A.A.N..... The University of Alabama at Birmingham
Meric-Bernstam, Funda, M.D. ..... The University of Texas MD Anderson Cancer Center
Messersmith, Wells A., M.D. ..... University of Colorado, Denver

Meyn, Raymond E., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Mills, Alea A., Ph.D. ..... Cold Spring Harbor Laboratory
Mishra, Lopa, M.D. ..... The University of Texas MD Anderson Cancer Center
Mishra, Shiraz I., Ph.D. ..... The University of New Mexico Health Sciences Center
Mortimer, Joanne E., M.D. ..... City of Hope National Medical Center
Mukherjee, Priyabrata, Ph.D. ..... The University of Oklahoma Health Sciences Center
Murphy, William J., Ph.D. ..... University of Nevada, Reno

N

Napel, Sandy A., Ph.D. ..... Stanford University
Newcomb, Polly A., Ph.D., M.P.H. ..... Fred Hutchinson Cancer Research Center
Nitiss, John L., Ph.D. ..... University of Illinois
Normolle, Daniel P., Ph.D. ..... The University of Pittsburgh
Nwogu, Chukwumere E., M.D., Ph.D. ..... Roswell Park Cancer Institute

O

Ondrey, Frank G., M.D., Ph.D. ..... University of Minnesota
Osheroff, Neil, Ph.D. ..... Vanderbilt University
Ostroff, Jamie S., Ph.D. ..... Memorial Sloan-Kettering Cancer Center

P

Pal, Soumitro, Ph.D. ..... Children's Hospital Corporation
Paulsen, Keith D., Ph.D. ..... Dartmouth College
Pfeifer, Mark P., M.D. ..... University of Louisville
Platanias, Leonidas C., M.D., Ph.D. ..... Northwestern University

Q

Quaranta, Vito, M.D. ..... Vanderbilt University Medical Center
Quarles, Christopher C., Ph.D. ..... Vanderbilt University Medical Center

R

Radermacher, Michael, Ph.D. ..... The University of Vermont & State Agriculture College
Rall, Glenn F., Ph.D. ..... Fox Chase Cancer Center
Ramalingam, Suresh S., M.D. ..... Emory University
Ramus, Susan J., Ph.D. ..... The University of Southern California
Rathmell, Wendy K., M.D., Ph.D. ..... The University of North Carolina at Chapel Hill
Raz, Avraham, Ph.D. ..... Wayne State University
Reginato, Mauricio J., Ph.D. ..... Drexel University College of Medicine
Ritz, Jerome, M.D. ..... Dana-Farber Cancer Institute
Ronai, Ze'ev A., Ph.D. ..... Sanford-Burnham Medical Research Institute

S

Sausville, Edward A., M.D., Ph.D. ..... University of Maryland, Baltimore
Schootman, Mario, Ph.D. ..... Saint Louis University
Seagroves, Tiffany N., Ph.D. ..... The University of Tennessee Health Sciences Center
Seo, Youngho, Ph.D. ..... University of California, San Francisco
Shawber, Carrie J., Ph.D. ..... Columbia University Health Sciences
Shen, Zhiyuan, M.D. Ph.D. ..... Rutgers Biomedical and Health Sciences
Shibata, David, M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Siminoff, Laura A., Ph.D. ..... Virginia Commonwealth University
Singh, Pomila, Ph.D. ..... The University of Texas Medical Branch at Galveston
Snetselaar, Linda G., Ph.D. ..... The University of Iowa
Spitz, Douglas R., Ph.D. ..... The University of Iowa
Swaminathan, Sankar, M.D. ..... The University of Utah

T

Tannous, Bakhos A., Ph.D. ..... Massachusetts General Hospital
Tew, Kenneth D., Ph.D., D.Sc. ..... Medical University of South Carolina
Thompson, E. Aubrey, Ph.D. ..... Mayo Clinic, Jacksonville

V

Varambally, Sooryanarayana, Ph.D. ..... University of Michigan
Vega-Vazquez, Francisco, M.D. Ph.D. ..... The University of Texas MD Anderson Cancer Center

W

Wagner, Lynne I., Ph.D. ..... Northwestern University
Waller, Edmund K., M.D. Ph.D. ..... Emory University
Walter, Roland B., M.D. Ph.D. ..... Fred Hutchinson Cancer Research Center
Wang, Shizhen E., Ph.D. ..... City of Hope National Medical Center
Weiss, Geoffrey R., M.D. ..... University of Virginia
White, Kevin P., Ph.D. ..... The University of Chicago
White, Rebekah, M.D. ..... Duke University
Wilson-Sanders, Susan E., D.V.M., M.S. ..... The University of Arizona

Y

Yang, Yu-Chung, Ph.D. ..... Case Western Reserve University

Z

Zhang, Rugang, Ph.D. ..... The Wistar Institute
Zhou, Pengbo, Ph.D. ..... Weill Medical College of Cornell University

Total Number of Reviewers: 155

2. Consultants Serving as *Ad Hoc* Committee Members on Non-FACA/IRG Meetings in FY2013

A

Adams-Campbell, Lucile L., Ph.D. ..... Georgetown University
Adjei, Alex A., M.D., Ph.D., F.A.C.P. ..... Roswell Park Cancer Institute
Ahn, Chul W., Ph.D. ..... The University of Texas Southwestern Medical Center
Akerley, Wallace L., M.D. ..... University of Utah
Albrecht, Terrance L., Ph.D. ..... Wayne State University

B

Bailey, Howard H., M.D. ..... University of Wisconsin, Madison
Ball, Edward D., M.D. ..... University of California, San Diego
Band, Vimla, Ph.D. ..... University of Nebraska Medical Center
Barker, Linda L. ..... Rutgers Biomedical and Health Sciences
Bast, Robert C., M.D. ..... Harvard University
Batra, Surinder K., Ph.D. ..... University of Nebraska Medical Center
Beckerle, Mary C., Ph.D. ..... The University of Utah
Beckwith, Barbara J., M.A. ..... The Ohio State University
Bedrick, Edward J., Ph.D. ..... The University of New Mexico
Benedict, Michael K., Pharm.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Bergan, Raymond C., M.D. ..... Northwestern University at Chicago
Berlin, Jordan D., M.D. ..... Vanderbilt University Medical Center
Bernacki, Ralph J., Ph.D. ..... Roswell Park Cancer Institute
Berr, Stuart S., Ph.D. ..... University of Virginia
Berwick, Marianne, Ph.D., M.P.H. ..... The University of New Mexico
Bhatia, Ravi, M.D. ..... Beckman Research Institute of City of Hope
Black, Jennifer D., Ph.D. ..... University of Nebraska Medical Center
Bond, Jeffrey P., Ph.D. ..... University of Vermont & State Agriculture College
Borgstahl, Gloria, Ph.D. ..... University of Nebraska Medical Center
Bouvier, Marlene, Ph.D. ..... University of Illinois at Chicago
Bowen, Deborah J., Ph.D. ..... Boston University Medical Campus
Brattain, Michael G., Ph.D. ..... University of Nebraska Medical Center
Brem, Steven, M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Buatti, John M., M.D. ..... The University of Iowa
Buchsbaum, Donald J., Ph.D. ..... The University of Alabama at Birmingham
Byers, Tim E., Ph.D., M.P.H. ..... University of Colorado Health Sciences Center

C

Carson, William E.,III, M.D. ..... The Ohio State University
Chaillet, J. Richard, M.D., Ph.D. ..... The University of Pittsburgh
Chen, Moon S., Jr., Ph.D., M.P.H. ..... University of California, Davis
Chernoff, Jonathan D., Ph.D. ..... Research Institute of Fox Chase Cancer Center
Chu, Edward, M.D. ..... The University of Pittsburgh

Chung, Leland W.K., Ph.D. ..... Cedars-Sinai Medical Center
Ciolino, Henry P., Ph.D. ..... The University of Texas at Austin
Clapper, Margie L., Ph.D. ..... Research Institute of Fox Chase Cancer Center
Clurman, Bruce E., Ph.D., M.D. ..... Fred Hutchinson Cancer Research Center
Cooney, Kathleen A., M.D. ..... University of Michigan

D

Davisson, V. Jo, Ph.D. ..... Purdue University, West Lafayette
Debinski, Waldemar, Ph.D. ..... Wake Forest University Health Sciences
DeClerck, Yves A., M.D. ..... The University of Southern California
DiGiovanni, John, Ph.D. ..... The University of Texas at Austin
DiPaola, Robert S., M.D. ..... Rutgers, The State University of New Jersey
DiSaia, Philip J., M.D. ..... University of California, Irvine
Dorr, Robert T., Ph.D. ..... The University of Arizona
Dorshkind, Kenneth A., Ph.D. ..... University of California, Los Angeles
Duli, Anne, M.P.A. ..... Case Western Reserve University

E

Earp, Henry S., III, M.D. ..... The University North Carolina at Chapel Hill
Eckhardt, S. Gail M.D. ..... University of Colorado, Denver
El-Deiry, Wafik S., Ph.D. ..... Pennsylvania State University
El-Rifai, Wael, Ph.D. ..... Vanderbilt University Medical Center

F

Fan, Hung Y., Ph.D. ..... University of California, Irvine
Farag, Sherif S., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Figlin, Robert A., M.D., F.A.C.P. ..... Cedars-Sinai Medical Center
Fisher, Richard I., M.D. ..... Fox Chase Cancer Center
Ford, James M., M.D. ..... Stanford University
Fracasso, Paula M., Ph.D. ..... University of Virginia
Futscher, Bernard W., Ph.D. ..... The University of Arizona

G

Geiger, Ann M., M.P.H, Ph.D. ..... Wake Forest University Health Sciences
Gerlach, Robert W., M.P.A. ..... Dartmouth College
Gewirtz, David A., Ph.D. ..... Virginia Commonwealth University
Gillies, Robert J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Gimotty, Phyllis A., Ph.D. ..... The University of Pennsylvania
Ginsburg, Beverly R., M.B.A. ..... Dana-Farber Cancer Institute
Girotti, Albert, Ph.D. ..... Medical College of Wisconsin
Gmitro, Arthur F., Ph.D. ..... The University of Arizona
Goodfellow, Paul J., Ph.D. ..... The Ohio State University
Govindan, Ramaswamy, M.D. ..... Washington University in St. Louis

H

Hackett, Lauren, B.A. ..... Vanderbilt University Medical Center
Haffty, Bruce G., M.D. ..... Rutgers Biomedical and Health Sciences
Hallahan, Dennis E., M.D. ..... Washington University in St. Louis
Halme, Dina G., Ph.D. ..... University Of Virginia
Harpole, David H., M.D. ..... Duke University
Harrison, Anita L., M.P.A. ..... Medical University of South Carolina
Hartmann, Lynn C., M.D. ..... Mayo Clinic
Heasley, Lynn E., Ph.D. ..... University of Colorado, Denver
Heslop, Helen E., M.D. ..... Baylor College of Medicine
Hiebert, Scott W., Ph.D. ..... Vanderbilt University Medical Center
Hill, David E., Ph.D. ..... Dana-Farber Cancer Institute
Hilsenbeck, Susan G., Ph.D. ..... Baylor College of Medicine
Hinds, Philip W., Ph.D. ..... Tufts Medical Center
Hockenbery, David M., M.D. ..... Fred Hutchinson Cancer Research Center
Hollingsworth, Michael A., Ph.D. ..... University of Nebraska Medical Center
Hoopes, Jack, Ph.D. ..... Dartmouth College
Howe, Philip H., Ph.D. ..... Medical University of South Carolina
Hsu, Edward W., Ph.D. ..... The University of Utah
Huang, Tim H., Ph.D. ..... The University of Texas Health Science Center at San Antonio

I

Israel, Mark A., M.D. ..... Dartmouth-Hitchcock Medical Center

J

Jaiswal, Anil K., Ph.D. ..... University of Maryland, Baltimore
Johnson, Candace S., Ph.D. ..... Roswell Park Cancer Institute
Jones, David A., Ph.D. ..... The University of Utah
Jones, Richard J., M.D. ..... The Johns Hopkins University

K

Kaufman, Russel E., M.D. ..... The Wistar Institute
Kelley, Mark R., Ph.D. ..... Indiana University-Purdue University, Indianapolis
Kerr, William Garrow, Ph.D. ..... Upstate Medical University
Kipps, Thomas J., Ph.D. ..... University of California, San Diego
Kopelman, Raoul, Ph.D. ..... University of Michigan
Korc, Murray, M.D. ..... Indiana University-Purdue University, Indianapolis
Koutcher, Jason Arthur, Ph.D. ..... Sloan-Kettering Institute Cancer Research
Kung, Hsing-Jien, Ph.D. ..... University of California, Davis

L

Lam, Kit S., Ph.D. ..... University of California, Davis
Lenkinski, Robert E., Ph.D. ..... The University of Texas Southwestern Medical Center
Li, King C., M.D. ..... Wake Forest University Health Sciences

Liggitt, Harry D., Ph.D. ..... University of Washington
Loffredo, Christopher A., Ph.D. ..... Georgetown University
Lowe, Scott W., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Lowe, Val J., M.D. ..... Mayo Clinic
Lum, Lawrence G., M.D. ..... Wayne State University

M

Mahmood, Umar, Ph.D. ..... Massachusetts General Hospital
Malkas, Linda H., Ph.D. ..... City of Hope National Medical Center
Mao, Li, M.D. ..... University of Maryland, Baltimore
Marshall, James, Ph.D. ..... Roswell Park Cancer Institute
McCarthy, James B., Ph.D. ..... University of Minnesota
McKnight, Steven L., Ph.D. ..... The University of Texas Southwestern Medical Center
McTiernan, Anne M., Ph.D. ..... Fred Hutchinson Cancer Research Center
Mermelstein, Robin J., Ph.D. ..... University of Illinois at Chicago
Meyn, Raymond E., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Miller, Jeffrey S., Ph.D. ..... Boston Biomedical Research Institute
Minko, Tamara, Ph.D. ..... Rutgers, The State University of New Jersey
Mitchell, Beverly S., M.D. ..... Stanford University
Mori, Motomi, Ph.D. ..... Oregon Health & Science University
Mule, James J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Mullen, Craig A., M.D., Ph.D. ..... University of Rochester
Munster, Pamela N., M.D. ..... University of California, San Francisco

N

Negrin, Robert S., M.D. ..... Stanford University
Neuhausen, Susan L., Ph.D. ..... City of Hope National Medical Center
Nimer, Stephen David, M.D. ..... University of Miami Miller School of Medicine

O

O'Malley, Michael S., Ph.D. ..... The University of North Carolina at Chapel Hill
Odunsi, Kunle O., Ph.D. ..... Roswell Park Cancer Institute
Okada, Hideho, Ph.D. ..... The University of Pittsburgh
Olshan, Andrew, Ph.D. ..... The University of North Carolina at Chapel Hill
Ondrey, Frank G., Ph.D. ..... University of Minnesota

P

Pagano, Joseph S., M.D. ..... The University of North Carolina at Chapel Hill
Partridge, Edward, Ph.D. ..... The University of Alabama at Birmingham
Pasick, Rena J., Dr.P.H. ..... University of California, San Francisco
Paskett, Electra D., Ph.D. ..... The Ohio State University
Patierno, Steven R., Ph.D. ..... George Washington University
Patterson, Ruth E., Ph.D. ..... University of California, San Diego
Piazza, Gary A., Ph.D. ..... University of South Alabama
Pierce, John P., Ph.D. ..... University of California, San Diego

Pili, Roberto, M.D. ..... Roswell Park Cancer Institute
Pinski, Jacek, Ph.D. ..... The University of Southern California
Prados, Michael D., M.D. ..... University of California, San Francisco

Q

Quaranta, Vito, M.D. ..... Vanderbilt University Medical Center
Quelle, Dawn E., Ph.D. ..... The University of Iowa

R

Raben, Daniel M., Ph.D. ..... The Johns Hopkins University
Rademaker, Alfred W., Ph.D. ..... Northwestern University at Chicago
Ratliff, Timothy L., Ph.D. ..... Purdue University, West Lafayette
Remick, Scot C., M.D. ..... West Virginia University
Richman, Carol M., M.D. ..... University of California, Davis
Ritz, Jerome, M.D. ..... Dana-Farber Cancer Institute
Rosenzweig, Steven Alan, Ph.D. ..... Medical University of South Carolina

S

Santana, Victor M., M.D. ..... St. Jude Children's Research Hospital
Sarkar, Fazlul H., Ph.D. ..... Wayne State University
Sausville, Edward A., Ph.D. ..... University of Maryland, Baltimore
Scardino, Peter T., M.D. ..... Memorial Sloan Kettering Cancer Center
Schuchter, Lynn M., M.D. ..... The University of Pennsylvania
Schwartz, Ann G., Ph.D. ..... Wayne State University
Seewaldt, Victoria L., M.D. ..... Duke University
Seither, Richard L., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Sherman, Simon, Ph.D. ..... University of Nebraska Medical Center
Shields, Anthony Frank, Ph.D. ..... Wayne State University
Showe, Louise C., Ph.D. ..... The Wistar Institute
Shyr, Yu, Ph.D. ..... Vanderbilt University Medical Center
Small, Eric J., M.D. ..... University of California, San Francisco
Snetselaar, Linda G., Ph.D. ..... The University of Iowa
Sotomayor, Eduardo M., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Stafforini, Diana M., Ph.D. ..... The University of Utah
Stahl, Douglas C., Ph.D. ..... City of Hope National Medical Center
Stern, David F., Ph.D. ..... Yale University
Strome, Scott E., M.D. ..... University of Maryland, Baltimore

T

Tan, Ming Tony, Ph.D. ..... Georgetown University
Taparowsky, Elizabeth J., Ph.D. ..... Purdue University, West Lafayette
Terry, Mary Beth, Ph.D. ..... Columbia University Health Sciences
Tew, Kenneth D., Ph.D., D.Sc. ..... Medical University of South Carolina
Thompson, Ian M., Jr., M.D. ..... The University of Texas Health Science Center at San Antonio
Thompson, Patricia Ann, Ph.D. ..... The University of Arizona

Tomkinson, Alan E., Ph.D. ..... The University of New Mexico
Tycko, Benjamin, M.D., Ph.D. ..... Columbia University

U

Unger, Evan C., M.D. ..... NuvOx Pharma, LLC.

V

Valerie, Kristoffer C., Ph.D. ..... Virginia Commonwealth University
Van Breemen, Richard B., Ph.D. ..... University of Illinois at Chicago
Van Etten, Richard A., Ph.D. ..... Tufts Medical Center

W

Wagner, Carston R., Ph.D. ..... University of Minnesota
Wallace, Robert B., M.D. ..... The University of Iowa
Wallace, Susan S., Ph.D. ..... The University of Vermont & State Agriculture College
Waller, Edmund K.,M.D., Ph.D. ..... Emory University
Watson, Dennis K., Ph.D. ..... Medical University of South Carolina
Weichert, Jamey P., Ph.D. ..... University of Wisconsin, Madison
Weiss, Geoffrey R., M.D. ..... University of Virginia
Wheatley, Barnarese P., Ed.D. ..... Alameda County Medical Center
Wiley, Patti, M.B.A. ..... On The Wings of Angels Pediatric Cancer Foundation
Willett, Christopher G., M.D. ..... Duke University
Willson, James K.V., M.D. ..... The University of Texas Southwestern Medical Center
Wilson-Sanders, Susan E., D.V.M., M.S. ..... The University of Arizona
Woods, William G., M.D. ..... Children's Healthcare of Atlanta, Incorporated

Y

Yu, Alice L., Ph.D. ..... University of California, San Diego

Z

Zutter, Mary M., M.D. ..... Vanderbilt University Medical Center

Total Number of Reviewers: 201

3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2013

A

Abatemarco, Diane J., Ph.D. ..... Thomas Jefferson University
Abbruzzese, James L., M.D. ..... The University of Texas MD Anderson Cancer Center
Abdi, Salahadin, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Abdulkadir, Sarki A., M.D., Ph.D. ..... Vanderbilt University Medical Center
Abraham, George N., M.D., Ph.D. ..... University of Rochester
Abrams, Judith, Ph.D ..... Wayne State University
Abrams, Scott I., Ph.D. ..... Roswell Park Cancer Institute
Adams Campbell, Lucile L., Ph.D. ..... Georgetown University
Adebamowo, Clement A., Sc.D. ..... University of Maryland, Baltimore
Agarwal, Rajesh, Ph.D. ..... University of Colorado, Denver
Ahmed, Khalil, Ph.D. ..... University of Minnesota
Ajani, Jaffer A., M.D. ..... The University of Texas MD Anderson Cancer Center
Akala, Emmanuel O., Ph.D. ..... The University of Utah
Al'Absi, Mustafa N., Ph.D. ..... University of Minnesota
Albelda, Steven, M.D. ..... The University of Pennsylvania
Albert, Reka Z., Ph.D. ..... The Pennsylvania State University, University Park
Albertini, Mark R., M.D. ..... University of Wisconsin, Madison
Alberts, David S., M.D., Ph.D. ..... The University of Arizona
Albertson, Donna G., Ph.D. ..... New York University
Alexandrow, Mark G., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Ali-Osman, Francis, D.Sc. ..... Duke University Medical Center
Allan, Alison L., Ph.D. ..... London Health Sciences Center
Almasan, Alexandru, Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Alonso, Alvaro, M.D., Ph.D. ..... University of Minnesota
Altman, Norman, V.M.D. ..... University of Miami Miller School of Medicine
Altomare, Deborah A., Ph.D. ..... University of Central Florida
Alvarez, Ronald D., M.D. ..... The University of Alabama at Birmingham
Alwine, James C., Ph.D. ..... The University of Pennsylvania
Amundson, Sally A., Ph.D. ..... Columbia University Health Sciences
Andersen, Bogi, M.D. ..... University of California, Irvine
Andersen, Robyn, Ph.D. ..... Fred Hutchinson Cancer Research Center
Anderson, Carolyn J., Ph.D. ..... The University of Pittsburgh
Anderson, Peter M., M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Andre, Michael P., Ph.D. ..... University of California, San Diego
Andrisani, Ourania M., Ph.D. ..... Purdue University
Androphy, Elliot J., M.D. ..... Indiana University
Andrykowski, Michael A., Ph.D. ..... University of Kentucky
Anton-Culver, Hoda A., Ph.D. ..... University of California, Irvine
Apel, Klaus, Ph.D. ..... Boyce Thompson Institute for Plant Research
Aplenc, Richard, M.D., Ph.D. ..... The University of Pennsylvania
Aplin, Andrew E., Ph.D. ..... Thomas Jefferson University
Appelhans, Bradley M., Ph.D. ..... Rush University Medical Center

Arceci, Robert J., M.D., Ph.D. ..... The University of Arizona
Archer, Kellie J., Ph.D. ..... Virginia Commonwealth University
Arenaz, Pablo, Ph.D. ..... Texas A&M International University
Armstrong, Floyd D., Ph.D. ..... University of Miami Miller School of Medicine
Armstrong, Gregory, M.D. ..... St. Jude Children's Research Hospital
Arnold, Connie L., Ph.D. ..... Louisiana State University Health Sciences Center, Shreveport
Artemov, Dmitri, Ph.D. ..... The Johns Hopkins University
Arun, Banu K., M.D. ..... The University of Texas MD Anderson Cancer Center
Ashendel, Curtis L., Ph.D. ..... Purdue University, West Lafayette
Ashikaga, Takamaru, Ph.D. ..... The University of Vermont
Ashktorab, Hassan, Ph.D. ..... Howard University
Asmann, Yan W., Ph.D. ..... Mayo Clinic
Aster, Jon C., M.D., Ph.D. ..... Brigham and Women's Hospital
Asthagiri, Anand R., Ph.D. ..... Northeastern University
Atalar, Ergin, Ph.D. ..... The Johns Hopkins University
Atasoy, Ulus, M.D. ..... University of Missouri, Columbia
Athar, Mohammad, Ph.D. ..... The University of Alabama at Birmingham
Attisano, Liliana, Ph.D. ..... University of Toronto
Au, Jessie L. Ph.D. ..... Optimum Therapeutics, LLC
Auerbach, Robert, Ph.D. ..... University of Wisconsin, Madison
Augenlicht, Leonard H., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Austin, Robert H., Ph.D. ..... Princeton University
Awasthi, Vibhudutta, Ph.D. ..... The University of Oklahoma Health Sciences Center
Axelrod, David E., Ph.D. ..... Rutgers, The State University of New Jersey
Azcarate-Peril, M. Ph.D. ..... The University of North Carolina at Chapel Hill

B

Bachmann, Andre S., Ph.D. ..... The University of Hawaii at Hilo
Bader, Andreas G., Ph.D. ..... Mirna Therapeutics, Inc.
Bagiella, Emilia, Ph.D. ..... Mount Sinai School of Medicine
Bahary, Nathan, M.D., Ph.D. ..... The University of Pittsburgh
Bai, Wenlong, Ph.D. ..... University of South Florida
Baker, Amanda F., Ph.D. ..... The University of Arizona
Baker, Sharyn D., Ph.D. ..... St. Jude Children's Research Hospital
Bakkenist, Christopher J., Ph.D. ..... The University of Pittsburgh
Balducci, Lodovico, M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Baldwin, Dee M., Ph.D. ..... Georgia State University
Balgley, Brian M., Ph.D. ..... Bioproximity, LLC
Balk, Steven P., M.D., Ph.D. ..... Beth Israel Deaconess Medical Center
Ballesteros-Tato, Andre, Ph.D. ..... The University of Alabama at Birmingham
Band, Hamid, M.D., Ph.D. ..... University of Nebraska Medical Center
Bandera, Elisa V., M.D., Ph.D. ..... Rutgers Biomedical and Health Sciences
Bantum, Erin O'Carroll, Ph.D. ..... The University of Hawaii at Manoa
Baquet, Claudia R., M.D. ..... University of Maryland, Baltimore
Baranova, Anna V., Ph.D. ..... George Mason University
Baranowski, Tom, Ph.D. ..... Baylor College of Medicine
Barrett, Michael T., Ph.D. ..... Translational Genomics Research Institute

Barth, Rolf F., M.D. ..... The Ohio State University
Barton, William A., Ph.D. ..... Virginia Commonwealth University
Baskaran, Harihara, Ph.D. ..... Case Western Reserve University
Bastani, Roshan, Ph.D. ..... University of California, Los Angeles
Bastia, Deepak, Ph.D. ..... Medical University of South Carolina
Basu, Alakananda, Ph.D. ..... The University of North Texas Health Science Center
Basu, Hirak S., Ph.D. ..... University of Wisconsin, Madison
Batra, Surinder K., Ph.D. ..... University of Nebraska Medical Center
Batrakova, Elena, Ph.D. ..... The University of North Carolina at Chapel Hill
Bauer, Brent A., M.D. ..... Mayo Clinic
Bauer, Joseph A., Ph.D. ..... Bauer Research Foundation
Bauer-Wu, Susan M., Ph.D. ..... University of Virginia
Baum, Marianna K., Ph.D. ..... Florida International University
Baumann, William T., Ph.D. ..... Virginia Technologies, Inc.
Baxter, Nancy N., M.D., Ph.D. ..... St. Michael's Hospital
Baxter-Lowe, Lee A., Ph.D. ..... Palmetto Health Richland
Beck, George R., Ph.D. ..... Emory University
Beck, John R., M.D. ..... Fox Chase Cancer Center
Beck, William T., Ph.D. ..... University of Illinois at Chicago
Becker, Michael W., M.D. ..... University of Rochester
Beckman, Robert A., M.D., Ph.D. ..... Daiichi-Sankyo Pharma Development
Beg, Amer Aziz, Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Behbod, Fariba, Ph.D. ..... The University of Kansas
Beilke, Mark A., M.D. ..... Medical College of Wisconsin
Belani, Chandra, M.D. ..... The Pennsylvania State University
Belbin, Thomas J., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Belinsky, Steven A., Ph.D. ..... Lovelace Biomedical & Environmental Research
Bellgrau, Donald, Ph.D. ..... University of Colorado, Denver
Belury, Martha A., Ph.D. ..... The Ohio State University
Beningo, Karen A., Ph.D. ..... University of Massachusetts Medical School, Worcester
Bennett, Charles L., M.D., Ph.D. ..... University of South Carolina, Columbia
Berens, Michael E., Ph.D. ..... Translational Genomics Research Institute
Berezin, Mikhail Y., Ph.D. ..... Washington University in St. Louis
Berg, Stacey L., M.D. ..... Baylor College of Medicine
Bergan, Raymond C., M.D. ..... Northwestern University
Bergen, Harold R., Ph.D. ..... Mayo Proteomic Research Center
Berger, Nathan A., M.D. ..... Case Western Reserve University
Berget, Peter B., Ph.D. ..... University of the Sciences, Philadelphia
Bergmann, Andreas, Ph.D. ..... University of Massachusetts Medical School, Worcester
Bernal-Mizrachi, Leon, M.D. ..... Emory University
Bernstam, Elmer V., M.D. ..... The University of Texas Health Science Center at Houston
Bernstein, Irwin D., M.D. ..... Fred Hutchinson Cancer Research Center
Berr, Stuart S., Ph.D. ..... University of Virginia
Berridge, Marc S., Ph.D. ..... 3D Imaging, LLC
Berry, Donna L., Ph.D. ..... Dana-Farber Cancer Institute
Bertenshaw, Greg, Ph.D. ..... Biomarker Strategies, LLC
Bertino, Joseph R., M.D. ..... Stem Cell Institute of New Jersey
Bhat, Mohammad S., Ph.D. ..... University of Minnesota

Bhatia, Smita, M.D. ..... City of Hope National Medical Center
Bhowmick, Neil A., Ph.D. .....Cedars-Sinai Medical Center
Bigatti, Silvia M., Ph.D. .....Indiana University
Bikram, Malavosklish, Ph.D. .....The University of Houston
Birge, Raymond B., Ph.D. .....New Jersey Medical School
Black, Jennifer D., Ph.D. .....University of Nebraska Medical Center
Blackburn, Gary, Ph.D. .....Claremont Biosolutions, LLC
Blagg, Brian S., Ph.D. .....The University of Kansas, Lawrence
Blanchard, Thomas G., Ph.D. ..... University of Maryland, Baltimore
Bland, Kirby I., M.D. ..... The University of Alabama at Birmingham
Block, Timothy M., Ph.D. ..... Callisto Pharmaceuticals, Inc.
Bocchetta, Maurizio, Ph.D. .....Loyola University, Chicago
Bock, Beth C., Ph.D. .....Miriam Hospital
Bock, Cathryn H., Ph.D. .....Wayne State University
Bodduluri, Haribabu, Ph.D. ..... University of Louisville
Bode, Ann M., Ph.D. .....University of Minnesota
Boise, Lawrence H., Ph.D. .....Emory University
Bokar, Joseph A., M.D., Ph.D. ..... Consultant
Bold, Richard J., M.D. ..... University of California, Davis
Bollard, Catherine M., M.D. .....Children's National Medical Center
Boman, Bruce M., M.D., Ph.D. .....Christiana Care Health Services, Inc.
Bonavida, Benjamin, Ph.D. ..... University of California, Los Angeles
Bondy, Melissa L., Ph.D. .....Baylor College of Medicine
Boothman, David A., Ph.D. .....The University of Texas Southwestern Medical Center
Borgia, Jeffrey A., Ph.D. ..... Rush University Medical Center
Bostwick, David G., M.D., M.B.A. .....Bostwick Laboratories, Inc.
Bourguignon, Lilly, Ph.D. ..... Northern California Institute for Research and Education
Bourque, Guillaume, Ph.D. ..... McGill University
Boushey, Carol J., Ph.D. .....The University of Hawaii at Manoa
Boussiotis, Vassiliki A., M.D., Ph.D. ..... Beth Israel Deaconess Medical Center
Bouton, Amy H., Ph.D. ..... University of Virginia
Bouvet, Michael, M.D. .....University of California, San Diego
Boyd, Douglas D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Boyd, Jeffrey, Ph.D. ..... Fox Chase Cancer Center
Boysen, Gunnar, Ph.D. .....University of Arkansas for Medical Sciences
Braden, Carrie J., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Brandt, Heather M., Ph.D. .....University of South Carolina
Brat, Daniel J., M.D., Ph.D. .....Emory University
Brattain, Michael G., Ph.D. .....University of Nebraska Medical Center
Braziel, Rita M., M.D. ..... Oregon Health & Science University
Brenner, Dean E., M.D. .....University of Michigan
Brewer, Molly A., M.D. ..... University of Connecticut Health Center
Bright, Robert K., Ph.D. ..... Texas Tech University Health Science Center
Broaddus, William C., M.D., Ph.D. .....Virginia Commonwealth University
Brodie, Angela M., Ph.D. ..... University of Maryland, Baltimore
Bromberg, Jacqueline F., M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Brooks, Jennifer D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Brown, Elizabeth, Ph.D. ..... The University of Alabama at Birmingham

Brown, Kathlynn C., Ph.D. ..... The University of Texas Southwestern Medical Center
Brown, Stephen L., Ph.D. ..... Henry Ford Hospital
Brown, Stuart M., Ph.D. ..... New York University School of Medicine
Brunengraber, Henri, M.D., Ph.D. ..... Case Western Reserve University
Brunicardi, Francis C., M.D. ..... University of California, Los Angeles
Bryant, Joseph L., D.V.M. ..... University of Maryland, Baltimore
Buatti, John M., M.D. ..... The University of Iowa
Buchsbaum, Donald J., Ph.D. ..... The University of Alabama at Birmingham
Bugni, Timothy S., Ph.D. ..... University of Wisconsin, Madison
Bui, Jack D., M.D., Ph.D. ..... University of California, San Diego
Bullock, Timothy N., Ph.D. ..... University of Virginia
Buolamwini, John K., Ph.D. ..... The University of Tennessee Health Science Center
Burdette, Everette C., Ph.D. ..... Acoustic Medical Systems, LLC
Burk, Robert D., M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Burns, Charles P., M.D. ..... The University of Iowa
Burns, Linda J., M.D. ..... University of Minnesota
Burtness, Barbara, M.D. ..... Fox Chase Cancer Center
Butler, Grace L., Ph.D. ..... Hope Through Grace, Inc.
Butler, Lesley M., Ph.D. ..... The University of Pittsburgh
Butterfield, Lisa H., Ph.D. ..... The University of Pittsburgh
Byers, Stephen W., Ph.D. ..... Georgetown University
Bylund, Carma L., Ph.D. ..... Memorial Sloan-Kettering Cancer Center

C

Cabot, Myles C., Ph.D. ..... John Wayne Cancer Institute
Cafferata, Robert, Ph.D. ..... Boston BioDiligence, LLC
Caffrey, Michael S., Ph.D. ..... University of Illinois at Chicago
Cagan, Ross L., Ph.D. ..... Mount Sinai School of Medicine
Cairo, Mitchell S., M.D. ..... New York Medical College
Calderwood, David A., Ph.D. ..... Yale University
Calin, George A., M.D., Ph.D. ..... The Johns Hopkins University
Callas, Peter, Ph.D. ..... The University of Vermont
Calvi, Brian R., Ph.D. ..... Indiana University Bloomington
Calvi, Laura M., M.D. ..... University of Rochester
Cameron, Carrie A., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Campbell, Patrick K., M.D., Ph.D. ..... St. Jude Children's Research Hospital
Cannon, Martin J., Ph.D. ..... DCV Technologies, Inc.
Cantor, Scott B., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Cantor, Sharon B., Ph.D. ..... University of Massachusetts Medical School
Capobianco, Anthony J., Ph.D. ..... University of Miami Miller School of Medicine
Carbone, David P., M.D., Ph.D. ..... Vanderbilt University Medical Center
Cardone, Michael H., Ph.D. ..... Eutropics Pharmaceuticals
Carducci, Michael A., M.D. ..... The Johns Hopkins University
Carey, Robert, M.B.A. ..... RPC Associates, Inc.
Carney, Darrell H., Ph.D. ..... Chrysalis BioTherapeutics, Inc.
Carrier, France, Ph.D. ..... University of Maryland, Baltimore
Carroll, Martin, M.D. ..... Children's Hospital of Philadelphia

Carroll, William L., M.D. ..... New York University School of Medicine
Carson, James A., Ph.D. ..... University of South Carolina, Columbia
Carson, William E., M.D. ..... The Ohio State University
Casavant, Thomas L., Ph.D. ..... The University of Iowa
Casey, John L., Ph.D. ..... Georgetown University
Castilla, Lucio H., Ph.D. ..... University of Massachusetts Medical School, Worcester
Castor, Trevor P., Ph.D. ..... Aphios Corporation
Catalfamo, Marta L., Ph.D. ..... National Institute of Allergy and Infectious Diseases
Celebi, Julide T, M.D. ..... Mount Sinai School of Medicine
Celi, Francesco S., M.D. ..... National Institute of Diabetes and Digestive and Kidney Diseases
Celis, Esteban, M.D., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Cengel, Keith A., M.D., Ph.D. ..... The University of Pennsylvania
Chaillet, J. Richard, M.D., Ph.D. ..... The University of Pittsburgh
Chak, Amitabh, M.D. ..... Case Western Reserve University
Chamberlain, Marc C., M.D. ..... University of Washington
Chambers, Setsuko K., M.D. ..... The University of Arizona
Champlin, Richard E., M.D. ..... The University of Texas MD Anderson Cancer Center
Chan, Evelyn C.Y., M.D. ..... The University of Texas Health Science Center at Houston
Chan, Leo, Ph.D. ..... Nexcelom Biosciences LLC.
Chandra, Joya, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Chang, Chawnshang, Ph.D. ..... University of Rochester
Chang, Chien-Hsing K., M.D., Ph.D. ..... Immunomedics, Inc.
Chang, Jenny C-N, M.D. ..... Houston Methodist
Chaplin, David D, M.D., Ph.D. ..... The University of Alabama at Birmingham
Charest, Joseph L., Ph.D. ..... The Charles Stark Draper Laboratory, Inc.
Chatterjee, Devasis, Ph.D. ..... Rhode Island Hospital
Chaudhary, Preet M., M.D., Ph.D. ..... The University of Southern California
Chellappan, Srikumar P., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Chen, Bo, Ph.D. ..... Nellcor Puritan Bennett LLC
Chen, Chang-Zheng, Ph.D. ..... Stanford University
Chen, Herbert, M.D. ..... University of Wisconsin, Madison
Chen, Jason J., Ph.D. ..... University of Massachusetts Medical School, Worcester
Chen, Jian J., Ph.D. ..... Novartis Institutes of Biomedical Research
Chen, Jing, Ph.D. ..... Emory University
Chen, Junjie, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Chen, Kuang Yu, Ph.D. ..... Rutgers, The State University of New Jersey
Chen, Ru, Ph.D. ..... University of Washington
Chen, Shiuan, Ph.D. ..... City of Hope National Medical Center
Chen, Suzie, Ph.D. ..... Rutgers, The State University of New Jersey
Chen, Taosheng, Ph.D. ..... St. Jude Children's Research Hospital
Chen, Thomas C., M.D., Ph.D. ..... The University of Southern California
Chen, Wenyong, Ph.D. ..... City of Hope National Medical Center
Chen, Xinbin, D.V.M., Ph.D. ..... University of California, Davis
Chen, Ying Q., Ph.D. ..... Fred Hutchinson Cancer Research Center
Chen, Yong Q., Ph.D. ..... Wake Forest University
Chen, Yuan, Ph.D. ..... City of Hope National Medical Center
Chen, Zhuo G., Ph.D. ..... Emory University
Cheng, Jin, Ph.D. ..... Moffitt Cancer Center

Cheng, Keith C., M.D., Ph.D. ..... The Pennsylvania State University
Cheng, Liang, M.D. ..... Indiana University
Cheng, Shi-Yuan, Ph.D. ..... Northwestern University, Chicago
Cher, Michael L., M.D. ..... Wayne State University
Chi, Jen-Tsan A., M.D., Ph.D. ..... Duke University
Chia, David S., Ph.D. ..... University of California, Los Angeles
Chiang, Cheng-Ming, Ph.D. ..... The University of Texas Southwestern Medical Center
Chiles, Thomas C., Ph.D. ..... Boston College
Chiosis, Gabriela, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Chirgwin, John M., Ph.D. ..... The University of Texas
Chlebowski, Rowan T., M.D., Ph.D. ..... University of California, Los Angeles
Cho, Clifford, M.D. ..... University of Wisconsin, Madison
Cho, Hyunyi, Ph.D. ..... Purdue University, West Lafayette
Cho, Kathleen R., M.D. ..... University of Michigan
Choi, Changho, Ph.D. ..... The University of Texas Southwestern Medical Center
Choi, Won S., Ph.D. ..... The University of Kansas
Christensen, Brock C., Ph.D. ..... Dartmouth College
Christie, Debra W., M.B.A. ..... University of Mississippi Medical Center
Chung, Fung-Lung, Ph.D. ..... Georgetown University
Cichewicz, Robert H., Ph.D. ..... The University of Oklahoma
Clarke, Jennifer P., Ph.D. ..... University of Nebraska-Lincoln
Clary, Bryan M., M.D. ..... Duke University
Clawson, Gary A., M.D., Ph.D. ..... The Pennsylvania State University
Cleary, Margot P., Ph.D. ..... University of Minnesota
Cobb, Brian A., Ph.D. ..... Case Western Reserve University
Cochran, Brent H., Ph.D. ..... Tufts University
Cohen, Edward P., M.D. ..... University of Illinois at Chicago
Cohen, Ezra, M.D. ..... The University of Chicago
Cohen, Michael B., M.D. ..... The University of Utah
Cohn, Wendy F., Ph.D. ..... University of Virginia
Colcher, David M., Ph.D. ..... City of Hope National Medical Center
Coleman, William B., Ph.D. ..... The University of North Carolina at Chapel Hill
Collins, Scott D., Ph.D. ..... The University of Maine, Orono
Comai, Lucio, Ph.D. ..... The University of Southern California
Connolly, Denise C., Ph.D. ..... Fox Chase Cancer Center
Cooley, Philip C., M.S. ..... Research Triangle Institute
Cooper, Gregory S., M.D. ..... Case Western Reserve University
Copelan, Edward A., M.D. ..... Cleveland Clinic Foundation
Copland, John A., Ph.D. ..... Mayo Clinic, Jacksonville
Corey, Seth J., M.D., M.P.H. ..... Northwestern University, Chicago
Cortez, David K., Ph.D. ..... Vanderbilt University Medical Center
Costanzo, Erin, Ph.D. ..... University of Wisconsin, Madison
Cote, Gilbert J., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Cote, Michele L., Ph.D. ..... Wayne State University
Cote, Richard J., M.D. ..... University of Miami Miller School of Medicine
Cox, Dianne, Ph.D. ..... The University of Illinois at Chicago
Craft, Alan W., M.D. ..... Royal Victoria Infirmary
Craighead, Harold G., Ph.D. ..... Cornell University

Crawford, Jason, Ph.D. ..... Yale University
Crawford, Sybil L., Ph.D. ..... University of Massachusetts Medical School, Worcester
Cress, Anne E., Ph.D. ..... The University of Arizona
Crews, Phil, Ph.D. ..... University of California, Santa Cruz
Crittenden, Marka, M.D., Ph.D. ..... Providence Portland Medical Center
Cronan, Thereasa A., Ph.D. ..... San Diego State University
Crott, Jimmy W., Ph.D. ..... Tufts University
Cukierman, Edna, Ph.D. ..... Fox Chase Cancer Center
Culbertson, Christopher T., Ph.D. ..... Kansas State University
Cummings, Kenneth M., Ph.D. ..... Roswell Park Cancer Institute
Cunningham, John M., M.D. ..... The University of Chicago
Curiel, Tyler J., M.D. ..... The University of Texas Health Science Center at San Antonio
Cutler, Stephen J., M.D., Ph.D. ..... The University of Vermont
Czerniak, Bogdan A., M.D., Ph.D. ..... The University of Texas Health Science Center at Houston

D

Daaka, Yehia, Ph.D. ..... University of Florida
Dadachova, Ekaterina, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Dadras, Soheil S., Ph.D. ..... University of Connecticut Health Center
Dagostino, Ralph B., Ph.D. ..... Wake Forest University
Dahiya, Rajvir, Ph.D. ..... Northern California Institute of Research and Education
Damodaran, Chendil, Ph.D. ..... Texas Tech University Health Science Center
Danielpour, David, Ph.D. ..... Case Western Reserve University
Dashwood, Roderick H., Ph.D. ..... Texas A&M University Health Science Center
Datar, Ram H., Ph.D. ..... University of Miami Miller School of Medicine
Datta, Susmita, Ph.D. ..... University of Louisville
Davatzikos, Christos, Ph.D. ..... The University of Pennsylvania
Dave, Sandeep, M.D. ..... Duke University
Davidson, Kelly M., M.D. ..... University of Virginia
Davila, Eduardo, Ph.D. ..... University of Maryland, Baltimore
Davis, Jean E., Ph.D. ..... Wayne State University
Davisson, Vincent J., Ph.D. ..... Purdue University, West Lafayette
Deb, Sumitra, Ph.D. ..... Virginia Commonwealth University
Debinski, Waldemar, M.D., Ph.D. ..... Wake Forest University Health Sciences
Debnath, Jayanta, M.D. ..... University of California, San Francisco
DeCoster, Mark A., Ph.D. ..... Louisiana Tech University
Decuzzi, Paolo, Ph.D. ..... Houston Methodist
Dedon, Peter C., M.D., Ph.D. ..... Massachusetts Institute of Technology
Deeken, John F., M.D. ..... Georgetown University
Dees, Elizabeth C., M.D. ..... The University of North Carolina at Chapel Hill
De Graffenried, Linda A., Ph.D. ..... The University of Texas at Austin
Deininger, Prescott L., Ph.D. ..... Tulane University
Delaney, Thomas F., M.D. ..... Massachusetts General Hospital
De Leon, Marino, Ph.D. ..... Loma Linda University
Del Valle, Juan R., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Demaria, Sandra, M.D. ..... New York University School of Medicine
Demirci, Utkan, Ph.D. ..... Brigham and Women's Hospital

DeNardo, David G., Ph.D. ..... Washington University in St. Louis
Denny, Christopher T., M.D. ..... University of California, Los Angeles
Deshazo, Jonathan, Ph.D. .....Virginia Commonwealth University
De Shields, Mary S., M.D. .....Oncologist
Deshong, Philip, Sc.D. .....University of Maryland, College Park
de Vere White, Ralph W., M.D. ..... University of California, Davis
De Winter, Alex, Ph.D. .....GE Ventures, Healthymagination Fund
Diamond, Alan, Ph.D. .....University of Illinois at Chicago
Diaz, Manuel O., M.D. .....Loyola University Chicago
Diaz-Arrastia, Concepcion R., M.D. .....Baylor College of Medicine
Di Cristofano, Antonio, Ph.D. .....Albert Einstein College of Medicine of Yeshiva University
Diefenbach, Michael A., Ph.D. .....Mount Sinai School of Medicine
Diehl, John Alan, Ph.D. ..... The University of Pennsylvania
Diehl, Michael R., Ph.D. .....Rice University
Dignan, Mark B., Ph.D. .....University of Kentucky
Diller, Lisa R., M.D. .....Dana-Farber Cancer Institute
Ding, Wei-Qun, Ph.D. .....The University of Oklahoma Health Sciences Center
Dino, Geri A., Ph.D. ..... West Virginia University
Dinov, Ivo D., Ph.D. .....University of Michigan
DiPersio, John F., M.D., Ph.D. ..... Washington University in St. Louis
Divgi, Chaitanya R., M.D. .....Columbia University Health Sciences
Dixit, Rakesh, Ph.D. .....MedImmune, Inc.
Djeu, Julie Y., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Doetsch, Paul W., Ph.D. .....Emory University
Doherty, Gerard M., M.D. ..... Boston University Medical Campus
Donehower, Lawrence A., Ph.D. .....Baylor College of Medicine
Dong, Jin-Tang, Ph.D. .....Emory University
Donovan, Maureen D., Ph.D. .....University of Iowa
Dorgan, Joanne F., Ph.D. ..... University of Maryland, Baltimore
Dorsey, Susan G., Ph.D. ..... University of Maryland, Baltimore
Doyley, Marvin M., Ph.D. .....University of Rochester
Drabkin, Harry A., M.D. .....Medical University of South Carolina
Drake, Richard R., Ph.D. .....Medical University of South Carolina
Driehuys, Bastiaan, Ph.D. .....Duke University
Driscoll, Kimberly, Ph.D. .....Florida State University
Dritschilo, Anatoly, M.D. .....Georgetown University
Du, Hong, Ph.D. .....Indiana University
Dubbs, Robert M., J.D. ..... Obermayer Rebmann Maxwell & Hippel LLP
Dubeau, Louis, M.D., Ph.D. ..... The University of Southern California
Dubinett, Steven M., M.D. ..... VA Greater Los Angeles Healthcare System
Ducatman, Barbara S., M.D. ..... West Virginia University
Duerksen-Hughes, Penelope J., Ph.D. .....Loma Linda University
Duffy, David C., Ph.D. ..... Quanterix Corporation
Duffy, Sonia A., Ph.D. .....University of Michigan
Dunbar, Cynthia E., M.D. ..... National Heart, Lung, and Blood Institute
Dunkel, Ira J., M.D. .....Memorial Sloan-Kettering Cancer Center
Dunton, Genevieve F., Ph.D. ..... The University of Southern California

Dupuy, Adam J., Ph.D. ..... The University of Iowa
Dvorak, Katerina, Ph.D. ..... The University of Arizona

E

Earle, Craig C., M.D. ..... Sunnybrook Health Sciences Centre
Eary, Janet F., M.D. ..... Seattle Children's Hospital
Eaton, Kathryn A., Ph.D. ..... University of Michigan
Ebbert, Jon O., M.D. ..... Mayo Clinic
Eberhart, Charles G., M.D., Ph.D. ..... The Johns Hopkins University
Eckelman, William C., Ph.D. ..... Molecular Tracer, LLC
Eckhart, Walter, Ph.D. ..... Salk Institute for Biological Studies
Edwards, D. Scott, Ph.D. ..... Scifluor Life Sciences, LLC
Edwards, Jeremy S., Ph.D. ..... The University of New Mexico
Eibl, Guido, M.D. ..... University of California, Los Angeles
Eisenberger, Naomi I., Ph.D. ..... University of California, Los Angeles
Eklund, Elizabeth A., M.D. ..... Northwestern University at Chicago
El-Ashry, Dorraya, Ph.D. ..... University of Miami Miller School of Medicine
El-Deiry, Wafik S., M.D., Ph.D. ..... The Pennsylvania State University
El Fakhri, Georges, Ph.D. ..... Massachusetts General Hospital
Elias, Anthony D., M.D. ..... University of Colorado, Denver
Eliason, James F., Ph.D. ..... Wayne State University
Ellenberger, Tom E., Ph.D. ..... Washington University
Ellenson, Lora H., M.D. ..... Weill Cornell Medical College
Elliott, Thomas E., M.D. ..... Essentia Institute of Rural Health
Ellis, Nathan A., Ph.D. ..... University of Illinois at Chicago
El-Rifai, Wael, M.D., Ph.D. ..... Vanderbilt University Medical Center
El-Sayed, Ivan H., M.D. ..... University of California, San Francisco
Elson, Paul J., Sc.D. ..... Cleveland Clinic Foundation
Eltoum, Isameldin A., M.D. ..... The University of Alabama at Birmingham
Emanuel, Peter D., M.D. ..... University of Arkansas for Medical Sciences
Engelhard, Victor H., Ph.D. ..... University of Virginia
Engelman, Jeffrey A., M.D., Ph.D. ..... Massachusetts General Hospital
Epplein, Meira, Ph.D. ..... Vanderbilt University Medical Center
Erdei, Esther, Ph.D. ..... University of New Mexico Health Science Center
Erdreich-Epstein, Anat, M.D., Ph.D. ..... Children's Hospital of Los Angeles
Erickson, Bradley J., M.D., Ph.D. ..... Mayo Clinic
Esterowitz, Leon, Ph.D. ..... National Science Foundation
Evans, Lyndon V., RN. ..... Cancer Centers of the Carolinas
Evans, Sydney M., D.V.M. ..... Perelman School of Medicine
Evers, Kerry, Ph.D. ..... Pro-Change Behavior Systems, Inc.

F

Fan, Guang, M.D., Ph.D. ..... Oregon Health & Science University
Fan, Hung Y., Ph.D. ..... University of California, Irvine
Fan, Rong, Ph.D. ..... Yale University
Fan, Teresa W-M., Ph.D. ..... University of Louisville

Fan, Timothy M., Ph.D. ..... University of Illinois at Urbana-Champaign
Fan, Weimin, M.D. ..... Medical University of South Carolina
Fan, Z. Hugh, Ph.D. ..... University of Florida
Fang, Carolyn Y., Ph.D. ..... Fox Chase Cancer Center
Fang, Xianjun, Ph.D. ..... Virginia Commonwealth University
Farag, Sherif S., M.D., Ph.D. ..... Indiana University
Febbo, Phillip G., M.D. ..... University of California, San Francisco
Fedorov, Andriy, Ph.D. ..... Brigham and Women's Hospital
Feigelson, Heather S., Ph.D. ..... Kaiser Foundaton Health Clinic
Felding, Brunhilde, Ph.D. ..... Scripps Research Institute
Felton, James S., Ph.D. ..... University of California, Davis
Feng, Felix Y., M.D. ..... University of Michigan
Fenical, William, Ph.D. ..... University of California, San Diego
Fernander, Anita F., Ph.D. ..... University of Kentucky
Ferrance, Jerome P., Ph.D. ..... J2F Engineering
Ferris, Robert L., M.D., Ph.D. ..... The University of Pittsburgh
Ferrone, Soldano, M.D., Ph.D. ..... Massachusetts General Hospital
Fields, Alan P., Ph.D. ..... Mayo Clinic, Jacksonville
Figlin, Robert A., M.D. ..... Cedars-Sinai Medical Center
Figueiredo, Jane C., Ph.D. ..... The University of Southern California
Fine, Donald L., Ph.D. ..... DynPort Vaccine Company LLC
Fink, Mitchell P., M.D. ..... Beth Israel Deaconess Medical Center
Finkelstein, Dianne M., Ph.D. ..... Massachusetts General Hospital
Firtel, Richard A., Ph.D. ..... University of California, San Diego
Fischbach, Claudia, Ph.D. ..... Cornell University
Fisher, Brian David, Ph.D. ..... Simon Fraser University
Fisher, Christopher, Ph.D. ..... NanoVir, LLC.
Fishman, David A., M.D. ..... Mount Sinai School of Medicine
Fitzgerald-Bocarsly, Patricia, Ph.D. ..... Rutgers Biomedical and Health Sciences
Fleming, Jason B., M.D. ..... The University of Texas MD Anderson Cancer Center
Fleming, Jonathan J., M.P.A. ..... Oxford Bioscience Partners
Flemington, Erik K., Ph.D. ..... Tulane University
Fonseca, Rafael, M.D. ..... Mayo Clinic, Arizona
Fontham, Elizabeth H., Dr.P.H., M.P.H. ..... Louisiana State University Health Sciences Center, New Orleans
Forbes, Neil S., Ph.D. ..... University of Massachusetts, Amherst
Ford, Jennifer S, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Foreman, Kimberly E., Ph.D. ..... Loyola University, Chicago
Forsyth, Peter A., M.D. ..... University of South Florida
Foss, Francine M., M.D. ..... Yale University
Fraass, Benedick A., Ph.D. ..... Cedars-Sinai Medical Center
Fracasso, Paula M., M.D., Ph.D. ..... University of Virginia
Franzini, Luisa, Ph.D. ..... The University of Texas Health Science Center at Houston
Franzmann, Elizabeth J., M.D. ..... University of Miami Miller School of Medicine
Freedland, Stephen J., M.D. ..... Duke University
Freeman, James W., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Freeman, Michael L., Ph.D. ..... Vanderbilt University Medical Center
Freeman, Michael R., Ph.D. ..... Cedars-Sinai Medical Center

Freitas, Michael A., Ph.D. ..... The Ohio State University
Frey, Alan B., Ph.D. .....New York University School of Medicine
Frias-Lopez, Jorge, Ph.D. .....Forsyth Institute
Fridman, Rafael A., Ph.D. .....Wayne State University
Friedenreich, Christine M., Ph.D. ..... University of Calgary
Friedman, Adam J., M.D. .....Albert Einstein College of Medicine of Yeshiva University
Friedman, Daniela B., Ph.D. ..... University of South Carolina, Columbia
Friedman, Debra L., M.D. ..... Fred Hutchinson Cancer Research Center
Friedman, Mark B., Ph.D. ..... AugmenTech, Inc.
Frost, Andra R., M.D. ..... The University of Alabama at Birmingham
Fry, David C., Ph.D. .....Chemistry Research Solution, LLC
Fu, Mei R., Ph.D. .....New York University
Fu, Rongwei, Ph.D. ..... Oregon Health & Science University
Fu, Yang-Xin, M.D., Ph.D. ..... The University of Chicago
Fuchs, Serge Y., M.D., Ph.D. ..... The University of Pennsylvania
Fueyo, Juan, M.D. ..... The University of Texas MD Anderson Cancer Center
Fukumura, Dai, M.D., Ph.D. .....Massachusetts General Hospital
Fuloria, Jyotsna, M.D. ..... Ochsner Clinic Foundation
Fulton, Amy M., Ph.D. ..... University of Maryland, Baltimore
Furge, Kyle A., Ph.D. .....Van Andel Research Institute
Furnari, Frank B., Ph.D. .....Ludwig Institute for Cancer Research
Furth, Priscilla A., M.D. .....Georgetown University

G

Gabrilove, Janice L., M.D. .....Mount Sinai School of Medicine
Gabrilovich, Dmitry I., M.D., Ph.D. ..... The Wistar Institute
Gafken, Philip R., Ph.D. ..... Fred Hutchinson Cancer Research Center
Gajewski, Thomas F., M.D., Ph.D. ..... The University of Chicago
Gajjar, Amar, M.D. .....St. Jude Children's Research Hospital
Galili, Uri G., Ph.D. .....University of Massachusetts Medical School, Worcester
Gallagher, Patricia E., Ph.D. ..... Wake Forest University Health Sciences
Gallo, James M., Ph.D. .....Mount Sinai School of Medicine
Gammon, Marilie D., Ph.D. ..... The University of North Carolina at Chapel Hill
Gannett, Peter M., Ph.D. ..... West Virginia University
Gao, Allen C., M.D., Ph.D. ..... University of California, Davis
Garcia-Moreno, Bertrand, Ph.D. ..... The Johns Hopkins University
Gardiner, Joseph C., Ph.D. .....Michigan State University
Garippa, Ralph J., Ph.D. .....Roche Institute of Molecular Biology
Garner, Harold R., Ph.D. ..... Virginia Polytechnic Institute and State University
Garshick, Eric, M.D. ..... VA Boston Health Care System
Gaskins, H. Rex, Ph.D. ..... University of Illinois at Urbana-Champaign
Gaston, Sandra M., Ph.D. ..... Beth Israel Deaconess Medical Center
Gatenby, Robert A., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Gatewood, Joe M., Ph.D. .....Acoustic Biosystems, Inc.
Gatley, Samuel J., Ph.D. .....Northeastern University
Gatsonis, Constantine A., Ph.D. .....Brown University
Gau, Vincent Jen-Jr, Ph.D. .....Genefluidics, Inc.

Gaudet, Mia M., Ph.D. ..... American Cancer Society, Inc.
Gaur, Rakesh, M.D., M.P.H. ..... Kansas City Clinical Oncology Program
Gautier, Jean, Ph.D. ..... Columbia University Health Sciences
Gavai, Ashvinikumar, Ph.D. ..... Bristol-Myers Squibb Pharmaceutical
Geiger, Hartmut, Ph.D. ..... Cincinnati Childrens Hospital Medical Center
George, Daniel J., M.D. ..... Duke University
George, Jay, Ph.D. ..... Trevigen, Inc.
Gerber, Scott A., Ph.D. ..... Dartmouth College
Gewirtz, Andrew T., Ph.D. ..... Georgia State University
Gewirtz, David A., Ph.D. ..... Virginia Commonwealth University
Ghosh, Debashis, Ph.D. ..... The Pennsylvania State University, University Park
Ghosh, Paramita M., Ph.D. ..... University of California, Davis
Giam, Chou-Zen, Ph.D. ..... Uniformed Services University of the Health Sciences
Giannakakou, Paraskevi, Ph.D. ..... Weill Cornell Medical College of Cornell University
Giardina, Charles A., Ph.D. ..... University of Connecticut, Storrs
Gibson, Raymond E., Ph.D. ..... Gibson Consulting
Gilchrist, Gerald S., M.D. ..... Mayo Clinic
Gillanders, William E., M.D. ..... Washington University in St. Louis
Gilliland, Frank D., M.D., Ph.D. ..... The University of Southern California
Gimotty, Phyllis A., Ph.D. ..... The University of Pennsylvania
Girotti, Albert, Ph.D. ..... Medical College of Wisconsin
Giuliano, Anna R., Ph.D. ..... The University of Arizona
Given, Barbara A., Ph.D. ..... Michigan State University
Glass, Charles A., Ph.D. ..... Zacharon Pharmaceuticals, Inc.
Glazer, Peter M., M.D., Ph.D. ..... Yale University
Gleiberman, Anatoli S., Ph.D. ..... Cleveland Biolabs, Inc.
Glick, Adam B., Ph.D. ..... The Pennsylvania State University, University Park
Glorioso, Joseph C., Ph.D. ..... The University of Pittsburgh
Glunde, Kristine, Ph.D. ..... The Johns Hopkins Hospital
Go, Ronald S., M.D. ..... Mayo Clinic
Goel, Ajay, Ph.D. ..... Baylor University Medical Center
Goggins, Michael G., M.D. ..... The Johns Hopkins University
Gold, Ellen B., Ph.D. ..... University of California, Davis
Goldberg, Judith D., Sc.D. ..... New York University School of Medicine
Golemis, Erica A., Ph.D. ..... Fox Chase Cancer Center
Gollnick, Sandra O., Ph.D. ..... Roswell Park Cancer Institute
Golovlev, Val V., Ph.D. ..... Sci-Tec, Inc.
Gomer, Charles J., Ph.D. ..... Children's Hospital of Los Angeles
Gong, Yun, M.D. ..... The University of Texas MD Anderson Cancer Center
Goodin, Susan, Pharm.D. ..... Rutgers Biomedical and Health Sciences
Gooding, Gretchen A., M.D. ..... University of California, San Francisco
Goodman, Steven L., Ph.D. ..... 10H Technology, Inc.
Goodwin, Edwin H., Ph.D. ..... Kromatid, Inc.
Gordon, Leo I., M.D. ..... Northwestern University
Gospodarowicz, Mary K., M.D. ..... Princess Margaret Hospital
Gotay, Carolyn C., Ph.D. ..... University of British Columbia
Gottschalk, Stephen, M.D. ..... Baylor College of Medicine
Govindan, Ramaswamy, M.D. ..... Washington University in St. Louis

Goydos, James S., M.D. ..... Rutgers Biomedical and HealthSciences-Cancer Institute of New Jersey
Graeber, Thomas G., Ph.D. ..... University of California, Los Angeles
Graham, Michael M., M.D., Ph.D. .....The University of Iowa
Grandis, Jennifer R., M.D. .....The University of Pittsburgh
Grann, Victor R., M.D., M.P.H. ..... Columbia University Health Sciences
Grant, Marcia L., R.N. ..... City of Hope National Medical Center
Grant, Steven, M.D. .....Virginia Commonwealth University
Gravekamp, Claudia, Ph.D. .....Albert Einstein College of Medicine of Yeshiva University
Gravitt, Patti E., Ph.D. ..... The Johns Hopkins University
Grdina, David J., Ph.D. ..... The University of Chicago
Green, Jordan J., Ph.D. ..... The Johns Hopkins University
Green, Stephanie J., Ph.D. .....Pfizer, Inc.
Greer, Alexander, Ph.D. .....Brooklyn College
Gregg, Jeffrey P., M.D. ..... University of California, Davis
Gregory, Richard I., Ph.D. ..... Children's Hospital Corporation
Griffin, Timothy J., Ph.D. .....University of Minnesota
Gromeier, Matthias, M.D. .....Duke University
Gross, Mitchell E., M.D., Ph.D. ..... The University of Southern California
Gross, Myron D., Ph.D. .....University of Minnesota
Gross, Steven S., Ph.D. ..... Weill Cornell Medical College of Cornell University
Grossman, Douglas, M.D., Ph.D. ..... The University of Utah
Grufferman, Seymour, M.D., M.P.H. .....The University of New Mexico
Grundfest, Warren S., M.D. ..... University of California, Los Angeles
Gu, Jian, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Gu, Wei, Ph.D. ..... Columbia University Health Sciences
Gu, Xinbin, M.D., Ph.D. .....Howard University
Guan, Jun-Lin, Ph.D. .....University of Michigan
Guda, Chittibabu, Ph.D. .....University of Nebraska Medical Center
Gudkov, Andrei V., Ph.D. ..... Roswell Park Cancer Institute
Guidry, Jeffrey J., Ph.D. ..... Texas A&M University
Guillemin, Karen J., Ph.D. ..... The Ohio State University
Guo, Grace L., Ph.D. ..... Rutgers, The State University of New Jersey
Guo, Peixuan, Ph.D. .....University of Kentucky
Guthold, Martin, Ph.D. ..... Wake Forest University
Gutkind, J. Silvio, Ph.D. .....National Institute of Dental and Craniofacial Research
Guttman, Mitchell, Ph.D. ..... California Institute of Technology

H

Haab, Brian B., Ph.D. ..... Van Andel Research Institute
Hagedorn, Curt H., M.D. .....University of Arkansas for Medical Sciences
Hahnfeldt, Philip, Ph.D. ..... Steward St. Elizabeth's Medical Center
Haines, Dale S., Ph.D. .....Temple University
Hakansson, Kristina, Ph.D. .....University of Michigan
Haley, John D., Ph.D. .....Oncogene Science Incorporated
Hamilton, Thomas C., Ph.D. ..... Fox Chase Cancer Center
Han, Sang M., Ph.D. .....The University of New Mexico

Hande, Kenneth R., M.D. ..... Vanderbilt University Medical Center
Hansen, Marc F., Ph.D. ..... University of Connecticut Health Center
Hardy, Jerry L. ..... Self Employed
Harhaj, Edward W., Ph.D. ..... The Johns Hopkins University
Harpole, David H., M.D. ..... Duke University
Harrington, Maureen A., Ph.D. ..... Indiana University School of Medicine
Harris, Randall E., M.D., Ph.D. ..... The Ohio State University
Hart, Gerald W., Ph.D. ..... The Johns Hopkins University
Hartley, Rebecca S., Ph.D. ..... The University of New Mexico Health Science Center
Hartmann, Lynn C., M.D. ..... Mayo Clinic
Hartshorn, Kevan L, M.D. ..... Boston Medical Center
Hartsough, Neal E., Ph.D. ..... DxRay, Inc.
Harvey, Jennifer A., M.D. ..... University of Virginia
Haugen, Bryan R., M.D. ..... University of Colorado, Denver
Hawk, Ernest, M.D., M.P.H. ..... The University of Texas MD Anderson Cancer Center
Hawkins, Douglas S., M.D. ..... Seattle Children's Hospital
Hazbun, Tony, Ph.D. ..... Purdue University, West Lafayette
Hazlehurst, Lori A., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
He, Qiuhong, Ph.D. ..... Irnex
Hecht, Gail A., M.D. ..... Loyola University, Chicago
Hegel, Mark T., Ph.D. ..... Dartmouth College
Hei, Tom K., Ph.D. ..... Columbia University
Held, Jason M., Ph.D. ..... Washington University in St. Louis
Held, Kathryn Dale, Ph.D. ..... Massachusetts General Hospital
Hellstrom, Ingegerd E., M.D., Ph.D. ..... University of Washington
Herlyn, Meenhard F., D.V.M., D.Sc. ..... The Wistar Institute
Hernando, Eva, Ph.D. ..... New York University School of Medicine
Hesketh, Peter J., Ph.D. ..... Georgia Institute of Technology
Heslop, Helen E., M.D. ..... Baylor College of Medicine
Hess, Jay L., M.D., Ph.D. ..... University of Michigan
Heston, Warren D., Ph.D. ..... Cleveland Clinic Foundation
Hettich, Robert L., Ph.D. ..... Oak Ridge National Laboratory
Hickey, Matthew S., Ph.D. ..... Colorado State University
Hickey, Robert J., Ph.D. ..... City of Hope National Medical Center
Hicks, Chindo, Ph.D. ..... The University of Mississippi Medical Center
Hiebert, Scott W., Ph.D. ..... Vanderbilt University Medical Center
Higgins, Paul J., Ph.D. ..... Albany Medical College
Hilakivi-Clarke, Leena A., Ph.D. ..... Georgetown University
Hill, Elizabeth G., Ph.D. ..... Medical University of South Carolina
Hillhouse, Joel J., Ph.D. ..... East Tennessee State University
Hillman, Bruce J., M.D. ..... University of Virginia School of Medicine
Hinds, Philip W., Ph.D. ..... Tufts Medical Center
Hiroi, Noboru, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Hirschowitz, Edward A., M.D. ..... University of Kentucky
Hla, Timothy T., Ph.D. ..... Weill Cornell Medical College of Cornell University
Hlatky, Lynn, Ph.D. ..... Genesys Research Institute, Inc.
Ho, Shuk-Mei, Ph.D. ..... University of Cincinnati
Hoatlin, Maureen E., Ph.D. ..... Oregon Health & Science University

Hockenbery, David M., M.D. ..... Fred Hutchinson Cancer Research Center
Hoek, Joannes B., Ph.D. ..... Thomas Jefferson University
Hoerr, Robert A., M.D., Ph.D. ..... Nanocopoeia, Inc.
Hoffman, Aaron E., Ph.D. ..... Tulane University
Hoffmann, Kenneth R., Ph.D. ..... The State University of New York at Buffalo
Hogan, Michael E., Ph.D. ..... Baylor College of Medicine
Hohenlohe, Paul A., Ph.D. ..... University of Idaho
Hohl, Raymond J., M.D., Ph.D. ..... The University of Iowa
Holiday, David B., Ph.D. ..... Research Triangle Institute
Holl, Mark R., Ph.D. ..... Arizona State University, Tempe
Holland, Eric C., M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Holmen, Sheri L., Ph.D. ..... The University of Utah
Holmes, John H., Ph.D. ..... The University of Pennsylvania
Holsworth, Daniel, Ph.D. ..... StemNext, LLC
Holt, Jeffrey T., M.D. ..... The Commonwealth Medical College
Hoopes, Jack, D.V.M., Ph.D. ..... Dartmouth College
Hopper-Borge, Elizabeth, Ph.D. ..... Fox Chase Cancer Center
Hoque, Ashraful, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Hord, Norman G., Ph.D., M.P.H. ..... Michigan State University
Houchen, Courtney W., M.D. ..... The University of Oklahoma Health Sciences Center
Houghton, Jeanmarie, M.D., Ph.D. ..... University of Massachusetts Medical School, Worcester
Houlette, Judy K., M.A. ..... Friend for Life Cancer Support Network
Hourigan, Christopher S., M.D., Ph.D. ..... National Heart, Lung, and Blood Institute
Howell, Amy R., Ph.D. ..... University of Connecticut, Storrs
Howell, Gillian M., Ph.D. ..... University of Nebraska Medical Center
Hruban, Ralph H., M.D. ..... The Johns Hopkins University
Hsieh, Jer-Tsong, Ph.D. ..... The University of Texas Southwestern Medical Center
Hsu, Tien, Ph.D. ..... Boston Medical Center
Hu, Jennifer J., Ph.D. ..... University of Miami Miller School of Medicine
Hu, Longqin, Ph.D. ..... Rutgers, The State University of New Jersey
Huang, Emina H., M.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Huang, L. Eric, M.D., Ph.D. ..... The University of Utah
Huang, Peng, Ph.D. ..... The Johns Hopkins University
Huang, Shuang, Ph.D. ..... Georgia Regents University
Huang, Suyun, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Huang, Wei, Ph.D. ..... Oregon Health & Science University
Huang, Xiaohua, Ph.D. ..... University of California, San Diego
Hubbard, Karen, Ph.D. ..... City College of New York
Hubel, Allison, Ph.D. ..... University of Minnesota
Huebner, Kay, Ph.D. ..... The Ohio State University
Hughes, Christopher C.W., Ph.D. ..... University of California, Irvine
Hung, Chien-Fu, Ph.D. ..... The Johns Hopkins University
Hunt, C. Anthony, Ph.D. ..... University of California, San Francisco
Hunter, Jennifer L., R.N., Ph.D. ..... University of Missouri, Kansas City
Huo, Qun T., Ph.D. ..... University of Central Florida
Husain, Aliya N., M.D. ..... The University of Chicago
Huth, James F., M.D. ..... The University of Texas Southwestern Medical Center

Hutson, Alan D., Ph.D. ..... The State University of New York at Buffalo
Huycke, Mark M., M.D. ..... The University of Oklahoma Health Sciences Center
Hwang, Rosa F., M.D. ..... The University of Texas MD Anderson Cancer Center
Hyslop, Terry, Ph.D. ..... Thomas Jefferson University

I

Iftimia, Nicusor, Ph.D. ..... Physical Sciences, Inc.
Iglehart, James D., M.D. ..... Dana-Farber Cancer Institute
Inaba, Hiroto, M.D., Ph.D. ..... St. Jude Children's Research Hospital
Irvine, Kenneth D., Ph.D. ..... Rutgers, The State University of New Jersey
Isaacs, Jennifer S., Ph.D. ..... Medical University of South Carolina
Isenberg, Jeffrey S., M.D., M.P.H. ..... The University of Pittsburgh
Issa, Jean-Pierre J., M.D. ..... Temple University
Ittmann, Michael M., M.D., Ph.D. ..... Baylor College of Medicine

J

Jabado, Nada, M.D., Ph.D. ..... McGill University
Jacinto, Estela, Ph.D. ..... Rutgers Biomedical and Health Sciences
Jacobs, Michael A., Ph.D. ..... The Johns Hopkins University
Jacobson, Geraldine M., M.D., M.P.H. ..... West Virginia University
Jadvar, Hossein, M.D., Ph.D. ..... The University of Southern California
Jain, Faquir C., Ph.D. ..... University of Connecticut, Storrs
Jain, Rakesh K., Ph.D. ..... American Association for Cancer Research
James, Aimee S., M.P.H., Ph.D. ..... Washington University in St. Louis
Jay, Daniel G., Ph.D. ..... Tufts University
Jeffery, Elizabeth H., Ph.D. ..... University of Illinois at Urbana-Champaign
Jerry, D. Joseph, Ph.D. ..... University of Massachusetts, Amherst
Jewell, Scott D., Ph.D. ..... The Ohio State University
Jewell, William R., M.D. ..... University of Kansas Medical Center
Jiang, Binghua, Ph.D. ..... West Virginia University
Jiang, Steve B., Ph.D. ..... University of California, San Diego
Jimbo, Masahito, M.P.H., M.D., Ph.D. ..... University of Michigan
Jimeno, Antonio, M.D., Ph.D. ..... University of Colorado, Denver
Jobin, Christian, Ph.D. ..... University of Florida
Johnson, Bruce E., M.D. ..... Dana-Farber Cancer Institute
Johnson, David G., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Johnson, Gary L., Ph.D. ..... The University of North Carolina at Chapel Hill
Johnson, Mark E, Ph.D. ..... Mark E.Johnson Consulting, LLC
Johnson, Todd R., Ph.D. ..... University of Kentucky
Jones, Elizabeth C., M.D. ..... NIH Clinical Center
Jones, Jonathan C., Ph.D. ..... Washington State University
Jones, Judy A., M.A. ..... Cutaneous Lymphoma Foundation
Jones, Laundette P., Ph.D. ..... University of Maryland, Baltimore
Jones, Richard J., M.D. ..... The Johns Hopkins University
Jones, Roy B., M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Jones, Stephen, Ph.D. ..... University of Massachusetts Medical School, Worcester

Joyal, John L., Ph.D. ..... Brigham and Women's Hospital
Ju, Jingfang, Ph.D. ..... The State University New York at Stony Brook
Junghans, Richard P., M.D., Ph.D. ..... Roger Williams Medical Center
Jurisson, Silvia S., Ph.D. ..... University of Missouri, Columbia

K

Kable, Joseph W., Ph.D. ..... The University of Pennsylvania
Kadlubar, Susan A., Ph.D. ..... Roswell Park Cancer Institute
Kaelin, William G., M.D. ..... Dana-Farber Cancer Institute
Kalemkerian, Gregory P., M.D. ..... University of Michigan
Kalinski, Pawel, M.D.., Ph.D. ..... The University of Pittsburgh
Kameoka, Jun, Ph.D. ..... Texas Engineering Experiment Station
Kaminski, Joseph M., M.D. ..... Mercy Hospital
Kandel, Eugene S., Ph.D. ..... Roswell Park Cancer Institute
Kane, Madeleine A., M.D., Ph.D. ..... University of Colorado, Denver
Kane, Susan E., Ph.D. ..... City of Hope National Medical Center
Kang, Min H., Pharm.D. ..... Texas Tech University Health Sciences Center
Kaplan, Alan, Ph.D. ..... University of Kentucky
Kapp, Julie M., Ph.D., M.P.H. ..... University of Missouri, St. Louis
Kapur, Ravi, Ph.D. ..... George Mason University
Karellas, Andrew, Ph.D. ..... University of Massachusetts Medical School, Worcester
Karp, Seth J., M.D. ..... Vanderbilt University Medical Center
Kaskel, Frederick, M.D., Ph.D. ..... Montefiore Medical Center
Kasper, Susan, Ph.D. ..... University of Cincinnati
Kassis, Amin I., Ph.D. ..... Harvard Medical School
Kast, Wijbe M., Ph.D. ..... The University of Southern California
Kattan, Michael W., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Katz, Matthew H. G., M.D. ..... The University of Texas MD Anderson Cancer Center
Katz, Mira L., Ph.D., M.P.H. ..... The Ohio State University
Kaumaya, Pravin T.P., Ph.D. ..... The Ohio State University
Kaur, Balveen, Ph.D. ..... The Ohio State University
Kaye, Kenneth M., M.D. ..... Harvard Medical School
Kaytor, Michael D., Ph.D. ..... Humanetics Corporation
Keku, Temitope O., Ph.D., M.P.H. ..... The University of North Carolina at Chapel Hill
Keler, Tibor P., Ph.D. ..... Celldex Therapeutics, Inc.
Keller, Evan T., D.V.M., M.P.H., Ph.D. ..... University of Michigan
Kelley, Amy S., M.D. ..... Mount Sinai School of Medicine
Kelley, Mark R., Ph.D. ..... Indiana University-Purdue University at Indianapolis
Kelley, William, Ph.D. ..... Dartmouth College
Keri, Ruth A., Ph.D. ..... Case Western Reserve University
Kern, Scott E., M.D. ..... The Johns Hopkins University
Kernie, Steven G., M.D. ..... Columbia University Health Sciences Campus
Kerscher, Aurora E., Ph.D. ..... Eastern Virginia Medical School
Kester, Mark, Ph.D. ..... The Pennsylvania State University
Keyomarsi, Khandan, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Khan, Seema A., M.D. ..... Northwestern University Feinberg School of Medicine
Khan, Wasif N, Ph.D. ..... University of Miami Miller School of Medicine

Khare, Sharad, Ph.D. ..... University of Missouri, Columbia
Khayat, Anita F., Ph.D. ..... National Childhood Cancer Foundation
Khosla, Chaitan, Ph.D. ..... Stanford University
Khvorova, Anastasia, Ph.D. ..... University of Massachusetts Medical School, Worcester
Kiani, Mohammad F., Ph.D. ..... Temple University
Kibbe, Warren A., Ph.D. ..... Northwestern University
Kieff, Elliott D., M.D., Ph.D. ..... Brigham and Women's Hospital
Kiem, Hans-Peter, M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Kikyo, Nobuaki, M.D., Ph.D. ..... University of Minnesota
Killackey, Maureen A., M.D. ..... Memorial Sloan-Kettering Cancer Center
Kilpatrick, Michael W., Ph.D. ..... Ikonisys, Inc.
Kim, Jae H., M.D., Ph.D. ..... Henry Ford Hospital
Kim, William Y., M.D. ..... The University of North Carolina at Chapel Hill
Kim, Youngmee, Ph.D. ..... University of Miami, Coral Gables
Kimler, Bruce F., Ph.D. ..... The University of Kansas
Kinsella, Timothy J., M.D. ..... Rhode Island Hospital
Kinter, Michael T., Ph.D. ..... Oklahoma Medical Research Foundation
Kirkness, Ewen, Ph.D. ..... Institute for Genomic Research
Kissil, Joseph, Ph.D. ..... The Scripps Research Institute
Klein, Alison P., Ph.D. ..... The Johns Hopkins University
Kline, Justin P., M.D. ..... The University of Chicago
Klinge, Carolyn M., Ph.D. ..... University of Louisville
Klingelhutz, Aloysius J., Ph.D. ..... The University of Iowa
Klinke, David J., Ph.D. ..... West Virginia University
Klosky, James, Ph.D. ..... St. Jude Children's Research Hospital
Knipp, Gregory T., Ph.D. ..... Purdue University, West Lafayette
Knudsen, Karen E., Ph.D. ..... Thomas Jefferson University
Knutson, Keith L., Ph.D. ..... Mayo Clinic
Koelle, David M., M.D. ..... University of Washington
Koh, James, Ph.D. ..... Duke University
Kohler, Heinz, M.D., Ph.D. ..... University of Kentucky
Koide, Shohei, Ph.D. ..... The University of Chicago
Komanduri, Krishna V., M.D. ..... University of Miami Miller School of Medicine
Kong, Ah-Ng T., Ph.D. ..... Rutgers, The State University of New Jersey
Konstantinopoulos, Panagiotis, M.D., Ph.D. ..... Dana-Farber Cancer Institute
Koomen, John M., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Kopelman, Raoul, Ph.D. ..... University of Michigan
Korbelik, Mladen, Ph.D. ..... British Columbia Cancer Agency
Koul, Hari K., Ph.D. ..... University of Colorado, Denver
Kramer, Fred R., Ph.D. ..... Public Health Research Institute
Kratzke, Robert A., M.D. ..... University of Minnesota
Krejza, Jaroslaw, M.D., Ph.D. ..... The University of Pennsylvania
Kresty, Laura A., Ph.D. ..... Upstate Medical University
Kreuter, Matthew W., Ph.D., M.P.H. ..... Washington University in St. Louis
Krichevsky, Anna M., Ph.D. ..... Brigham and Women's Hospital
Kris, Mark G., M.D. ..... Memorial Sloan-Kettering Cancer Center
Krishnan-Sarin, Suchitra, Ph.D. ..... Yale University
Krishnaswamy, Venkataramanan, Ph.D. ..... Dartmouth College

Kritzer, Mary F., Ph.D. ..... The State University New York at Stony Brook
Krizman, David B., Ph.D. ..... Expression Pathology, Inc.
Krohn, Kenneth A., Ph.D. ..... University of Washington
Krolewski, John J., M.D., Ph.D. ..... University of Rochester Medical Center
Kron, Stephen J., M.D., Ph.D. ..... The University of Chicago
Krontiris, Theodore G., M.D., Ph.D. ..... City of Hope National Medical Center
Krupinski, Elizabeth A., Ph.D. ..... The University of Arizona
Krymskaya, Vera P., Ph.D. ..... The University of Pennsylvania
Kulesz-Martin, Molly F., Ph.D. ..... Oregon Health & Science University
Kumar, Challa S., Ph.D. ..... Louisiana State University and Agricultural & Mechanical College, Baton Rouge
Kumar, Nagi B., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Kumar, Shaji K., M.D. ..... Mayo Clinic
Kunicki, Thomas J., Ph.D. ..... Children's Hospital of Orange County
Kushi, Lawrence H., Sc.D. ..... Kaiser Foundation Research Institute
Kuwana, Tomomi, M.D., Ph.D. ..... La Jolla Institute for Allergy & Immunology
Kwiatkowski, David J., M.D., Ph.D. ..... Brigham and Women's Hospital
Kwock, Lester, Ph.D. ..... The University of North Carolina at Chapel Hill
Kyprianou, Iacovos S., Ph.D. ..... U.S. Food and Drug Administration
Kyprianou, Natasha, Ph.D. ..... University of Kentucky

L

LaBarge, Mark A., Ph.D. ..... Lawrence Berkeley National Laboratory
Labhasetwar, Vinod D., Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Lacey, Michelle R., Ph.D. ..... Tulane University
Lacy, Maureen, Ph.D. ..... The University of Chicago
Lad, Thomas, M.D. ..... Hektoen Institute for Medical Research
Ladisch, Stephan, M.D. ..... Children's National Medical Center
Lai, Jonathan, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Lai, Rose K., M.D. ..... The University of Southern California
Lai, Yi-Chen, M.D. ..... Baylor College of Medicine
Laird, Beverly L., Ph.D. ..... 3D Medical Concepts, LLC
Laird-Offringa, Ite A., Ph.D. ..... The University of Southern California
Lake, Douglas, Ph.D. ..... Arizona State University, Tempe
Lam, Wan L., Ph.D. ..... British Columbia Cancer Agency
Lampson, Lois A., Ph.D. ..... Brigham and Women's Hospital
Landgraf, Ralf, Ph.D. ..... University of Miami Miller School of Medicine
Landowski, Terry H., Ph.D. ..... The University of Arizona
Landsittel, Douglas P., Ph.D. ..... The University of Pittsburgh
Lane, Andrew N., Ph.D. ..... University of Louisville
Langer, Mark P., M.D. ..... Indiana University-Purdue University at Indianapolis
Langer, Steve G., Ph.D. ..... Mayo Clinic
Languino, Lucia R., Ph.D. ..... Thomas Jefferson University
Lanier, Keith S., M.D. ..... Providence Portland Medical Center
Lannigan, Deborah, Ph.D. ..... Vanderbilt University Medical Center
Lanza-Jacoby, Susan P., Ph.D. ..... Thomas Jefferson University

Lara, Primo N., M.D. ..... University of California, Davis
Larkey, Linda K., Ph.D. ..... Arizona State University, Tempe
Larner, James M., M.D. ..... University of Virginia
Larson, Dale N., M.S.M.E. ..... The Charles Stark Draper Laboratory, Inc.
Larson, Richard A., M.D. ..... The University of Chicago
Larson, Richard S., M.D., Ph.D. ..... The University of New Mexico Health Sciences Center
Larson, Steven M., M.D. ..... Memorial Sloan-Kettering Cancer Center
Lash, Timothy L., D.Sc., M.P.H. ..... Emory University
Laudenslager, Mark L., Ph.D. ..... University of Colorado, Denver
Lavange, Lisa, Ph.D. ..... U.S. Food and Drug Administration
Lawrence, David A., Ph.D. ..... Wadsworth Center
Lazo, John S., Ph.D. ..... University of Virginia
Lazovich, DeAnn, Ph.D., M.P.H. ..... University of Minnesota
Leachman, Sancy, M.D., Ph.D. ..... Oregon Health & Science University
Lebien, Tucker W., Ph.D. ..... University of Minnesota
LeBoeuf, Steven F., Ph.D. ..... Valencell, Inc.
Lechuga, Julia, Ph.D. ..... The University of Texas at El Paso
Lee, Adrian V., Ph.D. ..... The University of Pittsburgh
Lee, Amy S., Ph.D. ..... The University of Southern California
Lee, Chung, Ph.D. ..... University of California, Irvine
Lee, Ethan, M.D., Ph.D. ..... Vanderbilt University Medical Center
Lee, Francis Y., M.D., Ph.D. ..... Columbia University Health Sciences
Lee, Kathryn, R.N., Ph.D., F.A.A.N. ..... University of California, San Francisco
Lee, Laura A., M.D., Ph.D. ..... Vanderbilt University Medical Center
Lee, Menq-Jer, Ph.D. ..... Wayne State University
Lee, Robert J., Ph.D. ..... The Ohio State University
Lee, Sang E., Ph.D. ..... The University of Texas Health Sciences Center at San Antonio
Lee, Stephen, Ph.D. ..... University of Ottawa
Lee, Todd A., Ph.D. ..... University of Illinois at Chicago
Lehman, John M., Ph.D. ..... East Carolina University
Leibovich, Samuel J., Ph.D. ..... Rutgers Biomedical and Health Sciences
Leiby, Benjamin, Ph.D. ..... Thomas Jefferson University
Leisenring, Wendy M., Sc.D. ..... Fred Hutchinson Cancer Research Center
Lelievre, Sophie A., D.V.M., Ph.D. ..... Purdue University, West Lafayette
Lengerich, Eugene J., D.V.M. ..... The Pennsylvania State University
Leof, Edward B., Ph.D. ..... Mayo Clinic
Leong, Stephen, M.D. ..... University of Colorado, Denver
Lesinski, Gregory B., Ph.D., M.P.H. ..... The Ohio State University
Leslie, Christina S., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Letai, Anthony G., M.D., Ph.D. ..... Dana-Farber Cancer Institute
Leung, Wing, Ph.D. ..... St. Jude Children's Research Hospital
Levenson, Richard M., M.D. ..... University of California, Davis
Levine, Alexandra M., M.D. ..... University of California, Los Angeles
Levine, Douglas A., M.D. ..... Memorial Sloan-Kettering Cancer Center
Levy, Laura S., Ph.D. ..... Tulane University
Lewellen, Thomas K., Ph.D. ..... University of Washington
Lewis, Brian C., Ph.D. ..... University of Massachusetts Medical School, Worcester
Lewis, Michael T., Ph.D. ..... Baylor College of Medicine

Li, Christopher I., M.D., Ph.D., M.P.H. ..... Fred Hutchinson Cancer Research Center
Li, Hong-Yu, Ph.D. ..... The University of Arizona
Li, Jian-Jian, M.D., Ph.D. ..... University of California, Davis
Li, King C., M.D. ..... Wake Forest University
Li, Lei, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Li, Liwu, Ph.D. ..... Virginia Polytechnic Institute and State University
Li, Min, Ph.D. ..... The University of Texas Health Science Center at Houston
Li, Rong, Ph.D. ..... The University of Texas Health Science Center at San Antonio
Li, Shaoguang, M.D., Ph.D. ..... University of Massachusetts Medical School, Worcester
Li, Tianhong, M.D., Ph.D. ..... University of California, Davis
Li, Yi, Ph.D. ..... Baylor College of Medicine
Liang, Jie, Ph.D. ..... University of Illinois at Chicago
Libermann, Towia A., Ph.D. ..... Beth Israel Deaconess Medical Center
Lichtor, Terence R., M.D., Ph.D. ..... Rush University Medical Center
Lieberman, Howard B., Ph.D. ..... Columbia University Health Sciences
Lieberman, Paul M., Ph.D. ..... The Wistar Institute
Lightdale, Charles J., M.D. ..... Columbia University
Lim, Mark, Ph.D. ..... Ambergen, Inc.
Lim, Megan S., M.D., Ph.D. ..... University of Michigan
Lin, Daniel W., M.D. ..... Fred Hutchinson Cancer Research Center
Lin, Haiqun, M.D., Ph.D. ..... Yale University
Lin, Hui-Kuan, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Lin, Jiayuh, Ph.D. ..... The Research Institute at Nationwide Children's Hospital
Lin, Shiaw-Yih, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Lin, Xihong, Ph.D. ..... Harvard School of Public Health
Lin, Yan, Ph.D. ..... The University of Pittsburgh
Link, Brian K., M.D. ..... The University of Iowa
Liotta, Lance A., M.D., Ph.D. ..... George Mason University
Lipkin, Steven M., M.D., Ph.D. ..... Weill Cornell Medical College of Cornell University
Lipshultz, Steven E., M.D. ..... University of Miami Miller School of Medicine
Litle, Virginia R., M.D. ..... Boston University Medical Campus
Littenberg, Benjamin, M.D. ..... The University of Vermont and State Agricultural College
Little, Julian, Ph.D. ..... University of Ottawa
Liu, Andrew C., Ph.D. ..... University of Memphis
Liu, Bin, Ph.D. ..... University of California, San Francisco
Liu, Chen, M.D., Ph.D. ..... University of Florida
Liu, Gilbert C., M.D. ..... University of Louisville
Liu, Glenn, M.D. ..... University of Wisconsin, Madison
Liu, Jinsong, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Liu, Paul, M.D., Ph.D. ..... National Human Genome Research Institute
Liu, Yunlong, Ph.D. ..... Indiana University-Purdue University, Indianapolis
Livolsi, Virginia A., M.D. ..... The University of Pennsylvania
Ljung, Britt-Marie E., M.D. ..... University of California, San Francisco
Loboa, Elizabeth G., Ph.D. ..... North Carolina State University, Raleigh
Locher, Julie L., Ph.D. ..... The University of Alabama at Birmingham
Logsdon, Craig D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Loh, Stewart N., Ph.D. ..... Upstate Medical University
Lokeshwar, Vinata B., Ph.D. ..... University of Miami Miller School of Medicine

Lokshin, Anna E., Ph.D. ..... The University of Pittsburgh
Loomis, Cynthia A., M.D., Ph.D. ..... New York University
Lossos, Izidore S., M.D. ..... University of Miami Miller School of Medicine
Lothstein, Leonard, Ph.D. ..... The University of Tennessee Health Science Center
Lounsbury, David W., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Lowengrub, John, Ph.D. ..... University of California, Irvine
Lowrey, Christopher H., M.D. ..... Dartmouth-Hitchcock Medical Center
Lu, Bo, M.D., Ph.D. ..... Thomas Jefferson University
Lu, Chensheng, Ph.D. ..... Harvard School of Public Health
Lu, Hua, Ph.D. ..... Tulane University
Lu, Lee-Jane W., Ph.D. ..... The University of Texas Medical Branch at Galveston
Lubaroff, David M., Ph.D. ..... The University of Iowa
Luberto, Chiara, Ph.D. ..... Medical University of South Carolina
Luebke, Kevin J., Ph.D. ..... The University of Texas Southwestern Medical Center
Luesch, Hendrik, Ph.D. ..... University of Florida
Luta, Gheorghe, Ph.D. ..... Georgetown University
Lyman, Gary H., M.D., Ph.D. ..... Duke University
Lynch, John P., M.D., Ph.D. ..... The University of Pennsylvania

M

Ma, Grace X., Ph.D. ..... Temple University
Maccoss, Michael J., Ph.D. ..... University of Washington
Macian, Fernando, M.D., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Mackeigan, Jeffrey P., Ph.D. ..... Van Andel Research Institute
Macleod, Kay F., Ph.D. ..... The University of Chicago
Madsen, Mark T., Ph.D. ..... The University of Iowa
Maggard-Gibbons, Melinda A., M.D. ..... University of California, Los Angeles
Magrini, Vincent J., Ph.D. ..... Washington University
Maheswaran, Shyamala, Ph.D. ..... Massachusetts General Hospital
Mahmood, Umar, M.D., Ph.D. ..... Massachusetts General Hospital
Maihle, Nita J., Ph.D. ..... Yale University
Makale, Milan T., Ph.D. ..... University of California, San Diego
Makrigiorgos, G. M., Ph.D. ..... Dana-Farber Cancer Institute
Malek, Sami Nimer, M.D. ..... University of Michigan
Malkas, Linda H., Ph.D. ..... City of Hope National Medical Center
Manak, Mark M., Ph.D. ..... Henry M. Jackson Foundation
Mandelblatt, Jeanne, M.D. ..... Georgetown University
Manfredi, James J., Ph.D. ..... Mount Sinai School of Medicine
Mani, Sridhar, M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Manjili, Masoud H., Ph.D. ..... Virginia Commonwealth University
Mankoff, David A., M.D., Ph.D. ..... The University of Pennsylvania
Manne, Sharon L., Ph.D. ..... Rutgers, The State University of New Jersey
Manne, Upender, Ph.D. ..... The University of Alabama at Birmingham
Manning, Henry C., Ph.D. ..... Vanderbilt University
Manoharan, Muthiah, Ph.D. ..... Isis Pharmaceuticals, Inc.
Mansbridge, Jonathan N., Ph.D. ..... Advanced Tissue Sciences, Inc.
Mansfield, Elaine S., Ph.D. ..... Affymetrix

Mao, Li, M.D. ..... University of Maryland, Baltimore
Mapes, James P., Ph.D. ..... Rules-Based Medicine, Inc.
Marchetti, Dario, Ph.D. ..... Baylor College of Medicine
Marcucci, Guido, M.D. ..... The Ohio State University
Marcus, Stevan, Ph.D. ..... The University of Alabama
Maris, John M., M.D. ..... The Children's Hospital of Philadelphia
Mariuzza, Roy A., Ph.D. ..... University of Maryland, College Park
Marks, Daniel L., M.D., Ph.D. ..... Oregon Health & Science University
Marks, Jeffrey R., Ph.D. ..... Duke University
Marr, David W.M., Ph.D. ..... Colorado School of Mines
Marriott, Susan J., Ph.D. ..... Baylor College of Medicine
Marsh, Sharon, Ph.D. ..... University of Alberta
Martin, Brian J., M.P.A. ..... University of Rochester
Martin, Jeffrey N., M.P.H., M.D. ..... University of California, San Francisco
Martin, Stuart S., Ph.D. ..... University of Maryland, Baltimore
Martinez, Olivia M., Ph.D. ..... Stanford University
Martin-Harris, Bonnie J., Ph.D. ..... Medical University of South Carolina
Mason, Joel B., M.D. ..... Tufts University
Mason, William, Ph.D. ..... Fox Chase Cancer Center
Matei, Daniela E., M.D. ..... Indiana University-Purdue University, Indianapolis
Mather, Patrick T., Ph.D. ..... Syracuse Biomaterials Institute
Mathis, Chester A., Ph.D. ..... The University of Pittsburgh
Matlashov, Andrei N., Ph.D. ..... Los Alamos National Laboratory
Matsui, William H., M.D. ..... The Johns Hopkins University
Matta, Jaime L., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Matthay, Katherine K., M.D. ..... University of California, San Francisco
Matthews, Dwight E., Ph.D. ..... .The University of Vermont and State Agricultural College
Matthews, Ellyn E., Ph.D. ..... University of Colorado, Denver
Mattingly, Raymond R., Ph.D. ..... Wayne State University
Mayer, Ingrid A., M.D. ..... Vanderbilt University
Mayo, Kevin H., Ph.D. ..... University of Minnesota
Mayo, Matthew S., Ph.D. ..... The University of Kansas Medical Center
Maytin, Edward V., M.D., Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
McCabe, George P., Ph.D. ..... Purdue University, West Lafayette
McCann, Susan E., Ph.D. ..... Roswell Park Cancer Institute
McCarthy, James B., Ph.D. ..... University of Minnesota
McCarthy-Beckett, Donna O., Ph.D. ..... Marquette University
McCarty, Owen J., Ph.D. ..... Oregon Health & Science University
McConkey, David J., Ph.D. ..... The University of Texas MD Anderson Cancer Center
McDaid, Hayley M., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
McGown, Linda B., Ph.D. ..... Rensselaer Polytechnic Institute
McGrath, Michael S., M.D., Ph.D. ..... Pathologica, LLC
McMahon, Pamela M., Ph.D. ..... Massachusetts General Hospital
McMahon, Steven B., Ph.D. ..... Thomas Jefferson University
Mehrotra, Shikhar, Ph.D. ..... Medical University of South Carolina
Mendonca, Paulo R., Ph.D. ..... General Electric Global Research Center
Merajver, Sofia D., M.D., Ph.D. ..... University of Michigan

Merchant, Nipun B., M.D., F.A.C.S. ..... Vanderbilt University
Mescher, Matthew F., Ph.D. ..... Oregon Health & Science University
Mesri, Enrique A., Ph.D. ..... University of Miami Miller School of Medicine
Messmer, Bradley T., Ph.D. ..... University of California, San Diego
Metaxas, Dimitris N., Ph.D. ..... Rutgers, The State University of New Jersey
Metelitsa, Leonid S., M.D., Ph.D. ..... Baylor College of Medicine
Metzger, Gregory J., Ph.D. ..... University of Minnesota
Meyer, Charles R., Ph.D. ..... University of Michigan
Meyer, Laurence J., M.D., Ph.D. ..... The University of Utah
Meyn, Raymond E., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Meyskens, Frank L., M.D. ..... University of California, Irvine
Michaelson, Dror, M.D., Ph.D. ..... Massacusetts General Hospital
Michaud, Dominique S., Sc.D. ..... Brown University
Miele, Lucio, M.D., Ph.D. ..... University of Mississippi Medical Center
Mignatti, Paolo, M.D. ..... Mount Sinai School of Medicine
Mikhael, Joseph R., M.D. ..... Mayo Clinic
Mikkelsen, Tom, M.D. ..... Henry Ford Health System
Miller, Carl W., Ph.D. ..... Cedars-Sinai Medical Center
Miller, Kathy D., M.D. ..... Indiana University-Purdue University, Indianapolis
Mills, David K., Ph.D. ..... Louisiana Tech University
Mills, Kevin D., Ph.D. ..... Jackson Laboratory
Mills, Paul J., Ph.D. ..... University of California, San Diego
Milner, Teresa A., Ph.D. ..... Weill Cornell Medical College of Cornell University
Minden, Mark D., M.D., Ph.D. ..... University Health Network
Mitchell, Edith P., M.D. ..... Thomas Jefferson University
Mitchell, Malcolm S., M.D. ..... Wayne State University
Mitra, Ashim K., Ph.D. ..... University of Missouri Kansas City
Mitra, Sankar, Ph.D. ..... Houston Methodist
Mittal, Vivek, Ph.D. ..... Weill Cornell Medical College of Cornell University
Mivechi, Nahid F., Ph.D. ..... Georgia Regents University
Miyamoto, Suzanne, Ph.D. ..... University of California, Davis
Mo, Yin-Yuan, Ph.D. ..... University of Mississippi Medical Center
Modiano, Jaime F., VM.D., Ph.D. ..... University of Minnesota
Mohammad, Ramzi M., Ph.D. ..... Wayne State University
Mohler, James L., M.D. ..... Roswell Park Cancer Institute
Moley, Jeffrey F., M.D. ..... Washington University
Monnat, Raymond J., M.D. ..... University of Washington
Monti, Stefano, Ph.D. ..... Boston University
Mooberry, Susan L., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Mooney, Kathleen H., Ph.D. ..... Oncology Nursing Society
Moore, Charity G., Ph.D. ..... The University of Pittsburgh
Moore, Malcolm J., M.D. ..... Ontario Cancer Institute
Moore, Melissa, Ph.D. ..... Sofie Biosciences, Inc.
Morachis, Jose M., Ph.D. ..... NanoCellect Biomedical, Inc.
Moraru, Ion I., M.D., Ph.D. ..... University of Connecticut School of Medicine
Morgan, Lee R., M.D., Ph.D. ..... Tigris Pharmaceuticals, Inc.
Mori, Motomi, Ph.D. ..... Oregon Health & Science University

Moritz, Robert L., Ph.D. ..... Institute for Systems Biology
Moros, Eduardo G., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Morris, David R., Ph.D. ..... University of Washington
Morris, Jeffrey S., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Morrow, Gary R., Ph.D. ..... University of Rochester
Morse, Michael A., M.D. ..... Duke University
Mortimer, Joanne E., M.D. ..... City of Hope National Medical Center
Moscicki, Anna-Barbara, M.D. ..... University of California, San Francisco
Moses, Ashlee V., Ph.D. ..... Oregon Health & Science University
Moses, Harold L., M.D. ..... Vanderbilt University
Motamedi, Massoud, Ph.D. ..... The University of Texas Medical Branch at Galveston
Mountz, James M., M.D., Ph.D. ..... The University of Pittsburgh
Mourtada, Firas, Ph.D. ..... Christiana Care Health Services, Inc.
Moynihan, Jan A., Ph.D. ..... University of Rochester Medical Center
Mrksich, Milan, Ph.D. ..... The University of Chicago
Muise-Helmericks, Robin C., Ph.D. ..... Medical University of South Carolina
Mukherjee, Bhramar, Ph.D. ..... University of Michigan
Mukherji, Bijay, M.D. ..... University of Connecticut Health Center
Mukhopadhyay, Bibhash, Ph.D. ..... Johnson and Johnson
Mukhopadhyay, Debabrata, Ph.D. ..... Mayo Clinic
Mukhtar, Hasan, Ph.D. ..... University of Wisconsin, Madison
Muller, Carolyn Y., M.D. ..... The University of New Mexico
Mullersman, Jerald E., M.D., Ph.D. ..... East Tennessee State University
Mullins, David W., Ph.D. ..... Dartmouth College
Mulloy, James C., Ph.D. ..... Cincinnati Children's Hospital Medical Center
Mulvihill, John J., M.D. ..... The University of Oklahoma Health Sciences Center
Munden, Reginald F., M.D. ..... The University of Texas MD Anderson Cancer Center
Munger, Karl, Ph.D. ..... Brigham and Women's Hospital
Munn, David H., M.D. ..... Georgia Regents University
Munshi, Hidayatullah G., M.D. ..... Northwestern University
Munshi, Nikhil C., M.D. ..... Dana-Farber Cancer Institute
Munster, Pamela N., M.D. ..... University of California, San Francisco
Murphy, Maureen E., Ph.D. ..... The Wistar Institute
Murphy, Michael C., Ph.D. ..... Louisiana State University
Murphy, William J., Ph.D. ..... University of Nevada, Reno
Murtaugh, Lewis C., Ph.D. ..... The University of Utah
Muschel, Ruth J., M.D., Ph.D. ..... University of Oxford
Musselman, Dominique L., M.D. ..... University of Miami Miller School of Medicine
Mustian, Karen M., Ph.D. ..... University of Rochester
Myers, Jeffrey N., M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Myers, Leann, Ph.D. ..... Tulane University
Myers, Steven R., Ph.D. ..... University of Louisville

N

Nabors, Louis B., M.D. ..... The University of Alabama at Birmingham
Nadkarni, Prakash M., M.D. ..... The University of Iowa
Nakshatri, Harikrishna, Ph.D. ..... Indiana University

Natarajan, Viswanathan, Ph.D. ..... University of Illinois at Chicago
Nathanson, Katherine L., M.D. ..... The University of Pennsylvania
Naughton, Michelle J., Ph.D. ..... Wake Forest University Health Sciences
Naugler, Christopher T., M.D. ..... University of Calgary
Navone, Nora M., M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Naz, Rajesh K., Ph.D. ..... West Virginia University
Nelson, Celeste M., Ph.D. ..... Princeton University
Nelson, David R., M.D. ..... University of Florida
Nelson, Edward L., M.D. ..... University of California, Irvine
Nemenoff, Raphael A., Ph.D. ..... University of Colorado, Denver
Nephew, Kenneth P., Ph.D. ..... Indiana University
Nes, W. David, Ph.D. ..... Texas Tech University
Ness, Scott A., Ph.D. ..... The University of New Mexico Health Science Center
Nettles, Kendall W., Ph.D. ..... The Scripps Research Institute
Neuhausen, Susan L., Ph.D. ..... City of Hope National Medical Center
Neuhouser, Marian L., Ph.D. ..... Fred Hutchinson Cancer Research Center
Neuwelt, Edward A., M.D. ..... Vanderbilt University
Ng, Andrea K., M.D. ..... Dana-Farber Cancer Institute
Ng, Hanna, Ph.D. ..... SRI International, Inc.
Nghiem, Paul, M.D., Ph.D. ..... University of Washington
Nichol, Peter F., M.D., Ph.D. ..... University of Wisconsin, Madison
Nicholson, Henry S., M.D. ..... Oregon Health & Science University
Nicosia, Santo V., M.D. ..... University of South Florida
Nieminen, Anna-Liisa, Ph.D. ..... Medical University of South Carolina
Nieva, Jorge J., M.D. ..... Billings Clinic Foundation
Nikolova-Karakashian, Mariana, Ph.D. ..... University of Kentucky
Nilsen-Hamilton, Marit, Ph.D. ..... Iowa State University
Nishimura, Michael I., Ph.D. ..... Loyola University, Chicago
Normolle, Daniel P., Ph.D. ..... The University of Pittsburgh
Norton, Jeffrey A., M.D. ..... Stanford University
Norton, Larry, M.D. ..... Memorial Sloan-Kettering Cancer Center
Novak, Julie, Ph.D. ..... Blaze Bioscience, Inc.
Novina, Carl D., M.D., Ph.D. ..... Dana-Farber Cancer Institute
Nyati, Mukesh K., Ph.D. ..... University of Michigan
Nyborg, Jennifer K., Ph.D. ..... Colorado State University

O

O'Brien, William D., Ph.D. ..... University of Illinois at Urbana-Champaign
O'Connell, Mary A., Ph.D. ..... New Mexico State University, Las Cruces
O'Connor, Kathleen L., Ph.D. ..... University of Kentucky
O'Connor, Richard J., Ph.D. ..... Roswell Park Cancer Institute
O'Dell, Walter G., Ph.D. ..... University of Florida
O'Keefe, Stephen J.D., M.D. ..... The University of Pittsburgh
O'Neill, Brian P., M.D. ..... Mayo Clinic
Obeid, Lina M., M.D. ..... Northport Virginia Medical Center
Odedina, Folakemi T., Ph.D. ..... University of Florida
O'Donnell, Joseph F., M.D. ..... Dartmouth College

Ogretmen, Besim, Ph.D. ..... Medical University of South Carolina
Oh, William K., M.D. ..... Mount Sinai School of Medicine
Ojima, Iwao, Ph.D. ..... The State University of New York at Stony Brook
Okada, Craig Y., M.D., Ph.D. ..... Oregon Health & Science University
Okcu, Mehmet F., M.D. ..... The University of Texas MD Anderson Cancer Center
Okunieff, Paul, M.D. ..... University of Florida
Oleinick, Nancy L., Ph.D. ..... Case Western Reserve University
Oliver, Janet M., Ph.D. ..... The University of New Mexico Health Science Center
Omenn, Gilbert S., M.D., Ph.D. ..... University of Michigan
Ondrey, Frank G., M.D., Ph.D. ..... University of Minnesota
Onel, Kenan, M.D., Ph.D. ..... The University of Chicago
Ong, Keat G., Ph.D. ..... Michigan Technological University
Opferman, Joseph T., Ph.D. ..... St. Jude Children's Research Hospital
Osley, Mary A., Ph.D. ..... The University of New Mexico Health Science Center
Osman, Iman, M.D. ..... New York University School of Medicine
Ostrowski, Michael C., Ph.D. ..... The Ohio State University
Oukka, Mohamed, Ph.D. ..... Seattle Children's Hospital
Overwijk, Willem W., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Owen, Jason E., Ph.D. ..... Loma Linda University
Oyajobi, Babatunde O., M.D., Ph.D. ..... The University of Texas Health Sciences Center at San Antonio
Oyana, Tonny J., Ph.D. ..... Southern Illinois University, Carbondale
Oyelere, Adegboyega, Ph.D. ..... Georgia Institute of Technology

P

Packard, Alan B., Ph.D. ..... Children's Hospital Corporation
Padilla, Geraldine V., Ph.D. ..... University of California, San Francisco
Page, Grier P., Ph.D. ..... Research Triangle Institute
Pal, Ranadip, Ph.D. ..... Texas Tech University
Paliwal, Bhudatt R., Ph.D. ..... University of Wisconsin, Madison
Palmer, J. Lynn, Ph.D. ..... American Statistical Association
Pan, Xiaochuan, Ph.D. ..... The University of Chicago
Pandita, Tej K., Ph.D. ..... The University of Texas Southwestern Medical Center
Pandit-Taskar, Neeta, M.D. ..... Memorial Sloan-Kettering Cancer Center
Pankratz, V. Shane S., Ph.D. ..... Mayo Clinic
Pannell, Lewis K., Ph.D. ..... University of South Alabama
Panyam, Jayanth, Ph.D. ..... University of Minnesota
Parangi, Sareh, M.D. ..... Massachusetts General Hospital
Parette, Mylisa, Ph.D. ..... The Pennsylvania State University
Park, Ben H., M.D., Ph.D. ..... The Johns Hopkins University
Park, Eun J., Ph.D. ..... BD Biosciences
Park, John K., M.D., Ph.D. ..... National Institute of Neurological Disorders and Stroke
Park, Julie R., M.D. ..... Seattle Children's Hospital
Parker, Alexander S., Ph.D. ..... Mayo Clinic, Jacksonville
Parker, Laurie L., Ph.D. ..... Purdue University, West Lafayette
Parsons, Barbara L., Ph.D. ..... U.S. Food and Drug Administration
Pasqualucci, Laura, M.D. ..... Columbia University

Passaniti, Antonino, Ph.D. ..... University of Maryland, Baltimore
Patel, Nilesh, Ph.D. ..... Oakland University
Patrick, Kevin, M.D. ..... University of California, San Diego
Patrick, Steve M., Ph.D. ..... University of Toledo Health Science Campus
Patterson, Michael S., Ph.D. ..... Hamilton Regional Cancer Center
Patz, Edward F., M.D. ..... Duke University
Paulos, Chrystal M., Ph.D. ..... Medical University of South Carolina
Paulsen, Keith D., Ph.D. ..... Dartmouth College
Pauly, Kim B., Ph.D. ..... Stanford University
Pauza, Charles D., Ph.D. ..... University of Maryland, Baltimore
Pavlidis, Ioannis, Ph.D. ..... The University of Houston
Pavlovic, Vladimir, Ph.D. ..... Rutgers, The State University of New Jersey
Pearman, Timothy P., Ph.D. ..... Northwestern University
Pearse, Roger N., M.D., Ph.D. ..... Weill Cornell Medical College of Cornell University
Pedrosa, Ivan, M.D. ..... The University of Texas Southwestern Medical Center
Peehl, Donna M., Ph.D. ..... Stanford University School of Medicine
Peiker, Tobias, M.D. ..... Mayo Clinic
Pence, Barbara C., Ph.D. ..... Texas Tech University Health Sciences Center
Peng, Kah-Whye, Ph.D. ..... Mayo Clinic
Penn, Linda Z., Ph.D. ..... University Health Network
Perera, Ranjan J., Ph.D. ..... Sanford-Burnham Medical Research Institute
Perez, Edith A., M.D. ..... Mayo Clinic, Jacksonville
Perkins, Susan M., Ph.D. ..... Indiana University
Person, Sharina D., Ph.D. ..... University of Massachusetts Medical School, Worcester
Perucho, Manuel, Ph.D. ..... Sanford-Burnham Medical Research Institute
Pestell, Richard G., M.D., Ph.D. ..... Thomas Jefferson University
Peter, Marcus E., Ph.D. ..... Northwestern University
Peters, Edward S., D.M.D., Sc.D. ..... Louisana State University Health Sciences Center
Petersen, Bryon E., Ph.D. ..... University of Florida
Petersen, Gloria M., Ph.D. ..... Mayo Clinic
Peterson, Douglas E., D.M.D., Ph.D. ..... University of Connecticut
Petricoin, Emanuel F., Ph.D. ..... Center for Biologics Evaluation and Research - Cytokine Biology
Petroni, Gina R., Ph.D. ..... University of Virginia
Petros, William P., Pharm.D. ..... West Virginia University
Petty, Elizabeth M., M.D. ..... University of Wisconsin, Madison
Pfefer, Josh, Ph.D. ..... U.S. Food and Drug Administration
Pfeifer, Mark P., M.D. ..... University of Louisville
Pham, Wellington, Ph.D. ..... Vanderbilt University
Phillips, Mark H., Ph.D. ..... University of Washington
Phillips, Scott T., Ph.D. ..... The Pennsylvania State University
Piazza, Gary A., Ph.D. ..... University of South Alabama
Piccirillo, Jay F., M.D. ..... Washington University in St. Louis
Pieper, Russell O., Ph.D. ..... University of California, San Francisco
Pierce, J. Michael, Ph.D. ..... The University of Georgia
Pinilla, Javier, M.D., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Pinney, Kevin G., Ph.D. ..... Baylor University
Pirisi-Creek, Lucia A., M.D. ..... University of South Carolina, Columbia
Pizer, Stephen M., Ph.D. ..... The University of North Carolina at Chapel Hill

Platanias, Leonidas C., M.D., Ph.D. ..... Northwestern University
Pleasure, David E., M.D. ..... University of California, Davis
Pledger, Warren J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Plymate, Stephen R., M.D. ..... University of Washington
Pogue, Brian W., Ph.D. ..... Dartmouth College
Pohl, Nicola L., Ph.D. ..... Indiana University Bloomington
Poisson, Laila M., Ph.D. ..... Henry Ford Health System
Pollak, Michael N., M.D. ..... McGill University
Pollock, Bradley H., M.P.H., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Polverini, Peter J., D.D.S. ..... University of Michigan
Polyak, Kornelia, M.D., Ph.D. ..... Dana-Farber Cancer Institute
Ponomarev, Vladimir, M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Porter, Peggy L., M.D. ..... Fred Hutchinson Cancer Research Center
Porteus, Matthew H., M.D., Ph.D. ..... Stanford University
Postolache, Teodor T., M.D. ..... University of Maryland, Baltimore
Pouliot, Jean, Ph.D. ..... University of California, San Francisco
Powell, Charles A., M.D. ..... Mount Sinai School of Medicine
Powell, Simon N., M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Powis, Garth, Ph.D. ..... Sanford-Burnham Medical Research Institute
Poynter, Jenny N., Ph.D. ..... University of Minnesota
Prabhakar, Bellur S., Ph.D. ..... University of Illinois at Chicago
Press, Michael F., M.D., Ph.D. ..... The University of Southern California
Price, Richard J., Ph.D. ..... University of Virginia
Prins, Robert M., Ph.D. ..... University of California, Los Angeles
Prior, Fred W., Ph.D. ..... Washington University in St. Louis
Pulsipher, Michael A., M.D. ..... The University of Utah
Puré, Ellen, Ph.D. ..... The University of Pennsylvania

Q

Qiao, Liang, M.D. ..... Loyola University, Chicago
Qin, Zhaohui S., Ph.D. ..... Emory University
Quaranta, Vito, M.D. ..... Vanderbilt University
Quarles, Christopher C., Ph.D. ..... Vanderbilt University
Quesenberry, Peter J., M.D. ..... Rhode Island Hospital
Quintiliani, Lisa, Ph.D. ..... Boston Medical Center
Quong, Andrew A., Ph.D. ..... Thomas Jefferson University

R

Raab-Traub, Nancy J., Ph.D. ..... The University of North Carolina at Chapel Hill
Rader, Janet S., M.D., F.A.C.O.G. ..... Medical College of Wisconsin
Radich, Jerald P., M.D. ..... Fred Hutchinson Cancer Research Center
Radisky, Derek C., Ph.D. ..... Mayo Clinic, Jacksonville
Radvanyi, Laszlo G., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Rae, James M., Ph.D. ..... University of Michigan
Raftery, Daniel, Ph.D. ..... University of Washington

Raghavan, Derek, M.D., Ph.D. ..... Carolinas HealthCare System
Raich, Peter C., M.D. ..... West Virginia University
Rajasekaran, Ayyappan K., Ph.D. ..... Alfred I. DuPont Hospital for Children
Ramakrishnan, Viswanathan, Ph.D. ..... Medical University of South Carolina
Ramesh, Rajagopal, Ph.D. ..... The University of Oklahoma Health Sciences Center
Rampersaud, Arfaan, Ph.D. ..... Columbus NanoWorks, Inc.
Rana, Ajay N., Ph.D. ..... Loyola University, Chicago
Rangaramanujam, Kannan, Ph.D. ..... The Johns Hopkins University
Rangnekar, Vivek M., Ph.D. ..... University of Kentucky
Rao, Chinthalapally V., Ph.D. ..... The University of Oklahoma Health Sciences Center
Rapkin, Bruce D., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Rapp, Peter R., Ph.D. ..... National Institute on Aging
Ratajczak, Mariusz Z., D.Sc., M.D., Ph.D. ..... University of Louisville
Raubitschek, Andrew A., M.D. ..... City of Hope National Medical Center
Rauscher, Frank J., Ph.D. ..... The Wistar Institute
Raveche, Elizabeth S., Ph.D. ..... Rutgers, The State University of New Jersey
Raveis, Victoria H., Ph.D. ..... New York University School of Medicine
Ray, Ranjit, Ph.D. ..... Washington University in St. Louis
Ray, Ratna B., Ph.D. ..... Saint Louis University
Raychaudhuri, Pradip, Ph.D. ..... University of Illinois at Chicago
Reczek, Peter R., Ph.D. ..... D'Youville College
Redd, William H., Ph.D. ..... Mount Sinai School of Medicine
Reddick, Wilburn E., Ph.D. ..... St. Jude Children's Research Hospital
Redinbo, Matthew R., Ph.D. ..... The University of North Carolina at Chapel Hill
Rehemtulla, Alnawaz, Ph.D. ..... University of Michigan
Reinhart-King, Cynthia A., Ph.D. ..... Cornell University
Relling, Mary V., Pharm.D. ..... St. Jude Children's Research Hospital
Remick, Scot C., M.D. ..... West Virginia University
Renne, Rolf F., Ph.D. ..... University of Florida
Ressom, Habtom W., Ph.D. ..... Georgetown University
Retterer, Scott T., Ph.D. ..... Oak Ridge National Laboratory
Reyes, Victor E., Ph.D. ..... The University of Texas Medical Branch at Galveston
Rice, Kevin G., Ph.D. ..... The University of Iowa
Rich, Jeremy N., M.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Richards, Nigel G., Ph.D. ..... Indiana University
Richardson, Adam D., Ph.D. ..... Sanford-Burnham Medical Research Institute
Richman, Carol M., M.D. ..... University of California, Davis
Richmond, Ann, Ph.D. ..... Vanderbilt University
Riethman, Harold C., Ph.D. ..... The Wistar Institute
Rifai, Nader, Ph.D. ..... Children's Hospital of Boston
Riggin, Ralph M., Ph.D. ..... Marcadia Biotech, Inc.
Riggins, Gregory J., M.D., Ph.D. ..... The Johns Hopkins University
Riley, James L., Ph.D. ..... The University of Pennsylvania
Rimm, David L., M.D., Ph.D. ..... Yale University
Ringash, Jolie, M.D. ..... Ontario Cancer Institute
Ringel, Matthew D., M.D. ..... The Ohio State University
Risch, Harvey A., M.D., Ph.D. ..... Yale University

Rishi, Arun K., Ph.D. ..... Wayne State University
Rivera, Daniel E., Ph.D. ..... Arizona State University, Tempe Campus
Roach, Nancy ..... C3: Colorectal Cancer Coalition
Roberts, John D., M.D. ..... Virginia Commonwealth University Massey Cancer Center
Robertson, Gavin P., Ph.D. ..... The Pennsylvania State University
Robertson, Keith D., Ph.D. ..... Mayo Clinic
Robertson, Michael J., M.D. ..... Indiana University
Rocco, James W., M.D., Ph.D. ..... Massachusetts General Hospital
Rodeck, Ulrich, M.D., Ph.D. ..... Thomas Jefferson University
Roden, Richard B., Ph.D. ..... The Johns Hopkins University
Rodgers, William H., M.D., Ph.D. ..... Lenox Hill Hospital
Rodland, Karin D., Ph.D. ..... Battelle Pacific Northwest Laboratories
Roe, Denise J., Dr.P.H. ..... The University of Arizona
Rogatko, Andre, Ph.D. ..... Cedars-Sinai Medical Center
Rohr, Jurgen T., Ph.D. ..... University of Kentucky
Romano, Louis J., Ph.D. ..... Wayne State University
Romkes, Marjorie, Ph.D. ..... The University of Pittsburgh
Rose, Christopher M., M.D. ..... Vantage Oncology, Inc.
Rosen, Coleman W., M.S. ..... RadAmerica II, LLC
Rosen, Eliot M., M.D., Ph.D. ..... Georgetown University
Rosen, Mark A., M.D., Ph.D. ..... The University of Pennsylvania
Rosenberg, Daniel W., Ph.D. ..... University of Connecticut Health Center
Rosenberg, Naomi, Ph.D. ..... Tufts University School of Medicine
Rosner, Gary L., Sc.D. ..... The Johns Hopkins University
Ross, Alonzo H., Ph.D. ..... University of Massachusetts Medical School, Worcester
Ross, Jeffrey S., M.D. ..... Albany Medical College
Roth, Charles M., Ph.D. ..... Rutgers, The State University of New Jersey
Roth, Kevin A., M.D., Ph.D. ..... The University of Alabama at Birmingham
Roth, Monica J., Ph.D. ..... Rutgers, The State University of New Jersey
Routes, John M., M.D. ..... Medical College of Wisconsin
Roy, Hemant K., M.D. ..... Boston Medical Center
Royce, Melanie E., M.D., Ph.D. ..... The University of New Mexico Health Science Center
Rozek, Laura, Ph.D. ..... University of Michigan
Rubin, Daniel L., M.D. ..... Stanford University
Rubin, Joshua B., M.D., Ph.D. ..... Washington University in St. Louis
Rubinsky, Boris, Ph.D. ..... University of California, Berkeley
Rubnitz, Jeffrey E., M.D., Ph.D. ..... St. Jude Children's Research Hospital
Ruczinski, Ingo, Ph.D. ..... The Johns Hopkins University
Ruddle, Nancy H., Ph.D. ..... Yale University
Ruffin IV, Mack T., M.D., M.P.H. ..... University of Michigan
Runowicz, Carolyn D., M.D. ..... Florida International University
Rushton, Gerard, Ph.D. ..... The University of Iowa
Russell, Marcia M., M.D., Ph.D. ..... VA Greater Los Angeles Healthcare System
Russo, Jose, M.D. ..... Fox Chase Cancer Center
Rutten, Lila J., Ph.D. ..... Mayo Clinic
Rutter, Carolyn M., Ph.D. ..... Group Health Cooperative
Ryazanov, Alexey G., Ph.D. ..... Rutgers, The State University of New Jersey

S

Sabbadini, Roger A., Ph.D. ..... Lpath, Inc.
Sadar, Marianne D., Ph.D. ..... British Columbia Cancer Agency
Sadelain, Michel, M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Saenger, Yvonne M., M.D. ..... Mount Sinai School of Medicine
Sakamoto, Kathleen M., M.D., Ph.D. ..... Stanford University
Saltz, Joel H., M.D., Ph.D. ..... The State University of New York at Stony Brook
Saluja, Ashok K., Ph.D. ..... University of Massachusetts Medical School, Worcester
Salvemini, Daniela, Ph.D. ..... Saint Louis University
Salz, Talya, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Samet, Jonathan M., M.D. ..... The University of Southern California
Sample, Clare E., Ph.D. ..... The Pennsylvania State University
Sampson, John H., M.D., Ph.D. ..... Duke University
Sandler, Howard M., M.D. ..... Cedars-Sinai Medical Center
Santana, Victor M., M.D. ..... St. Jude Children's Research Hospital
Sarkar, Devanand, Ph.D. ..... Virginia Commonwealth University
Sarkar, Fazlul H., Ph.D. ..... Wayne State University
Sartor, A. Oliver, M.D. ..... Tulane University
Savaraj, Niramol, M.D. ..... University of Miami Miller School of Medicine
Savitz, David A., Ph.D. ..... Brown University
Savran, Cagri, Ph.D. ..... Purdue University, West Lafayette
Scadeng, Miriam, M.D. ..... University of California, San Diego
Scarinci, Isabel C., Ph.D., M.P.H. ..... The University of Alabama at Birmingham
Scarpinato, Karin D., Ph.D. ..... Georgia Southern University
Schabath, Matthew B., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Schad, Peter A., Ph.D. ..... Digital Infuzion, Inc.
Schechter, Clyde, M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Schell, Todd D., Ph.D. ..... The Pennsylvania State University
Scheurer, Michael E., Ph.D., M.P.H. ..... Baylor College of Medicine
Schiff, Rachel, Ph.D. ..... Baylor College of Medicine
Schildkraut, Joellen M., Ph.D., M.P.H. ..... Duke University
Schmainda, Kathleen M., Ph.D. ..... Medical College of Wisconsin
Schmidt, Eric W., Ph.D. ..... The University of Utah
Schneider, Stefan, Ph.D. ..... The State University of New York at Stony Brook
Schnitzer, Jan E., M.D. ..... Proteogenomics Research Institute for Systems Medicine
Schnoll, Robert A., Ph.D. ..... The University of Pennsylvania
Schoenlein, Patricia V., Ph.D. ..... Georgia Regents University
Schootman, Mario, Ph.D. ..... Saint Louis University
Schwabe, Robert F., M.D. ..... Columbia University Health Sciences
Schwartz, Cindy L., M.D. ..... Brown University
Schwartz, David A., Ph.D. ..... Solulink Biosciences
Schwartz, David C., Ph.D. ..... University of Wisconsin, Madison
Schwartz, Gary G., Ph.D., M.P.H. ..... Wake Forest University Health Sciences
Schwartz, Gary K., M.D . ..... Memorial Sloan-Kettering Cancer Center
Schwartz, Jeffrey L., Ph.D. ..... University of Washington
Schwartz, Joel L., D.M.D., D.Med.Sc. ..... University of Illinois at Chicago
Schwartz, Jon A., Ph.D. ..... Nanospectra Biosciences, Inc.

Schwartz, Marc D., Ph.D. ..... Georgetown University
Schwartz, Russell S., Ph.D. ..... Carnegie-Mellon University
Schwertfeger, Kathryn L., Ph.D. ..... University of Minnesota
Searson, Peter C., Ph.D. ..... The Johns Hopkins University
Seeger, Robert C., M.D. ..... The University of Southern California
Seewaldt, Victoria L., M.D. ..... Duke University
Seiden, Michael V., M.D., Ph.D. ..... Fox Chase Cancer Center
Selassie, Cynthia R., Ph.D. ..... Pomona College
Seley-Radtke, Katherine L., Ph.D. ..... University of Maryland, Baltimore
Semmes, Oliver J., Ph.D. ..... Eastern Virginia Medical School
Sens, Donald A., Ph.D. ..... University of North Dakota
Serkova, Natalie J., Ph.D. ..... University of Colorado, Denver
Serody, Jonathan S., M.D. ..... The University of North Carolina at Chapel Hill
Servoss, Shannon L., Ph.D. ..... University of Arkansas, Fayetteville
Setaluri, Vijayasaradhi, Ph.D. ..... University of Wisconsin, Madison
Seth, Pankaj K., Ph.D. ..... Beth Israel Deaconess Medical Center
Seyfried, Thomas N., Ph.D. ..... Boston College
Shah, Khalid A., Ph.D. ..... Massachusetts General Hospital
Shah, Priti R., Ph.D. ..... University of Michigan
Shankar, Sharmila, Ph.D. ..... University of Kansas
Shannon, Kevin M., M.D. ..... University of California, San Francisco
Shapiro, Erik, Ph.D. ..... Michigan State University
Shapiro, Paul S., Ph.D. ..... University of Maryland, Baltimore
Sharlow, Elizabeth R., Ph.D. ..... University of Virginia
Sharma, Dipali, Ph.D. ..... The Johns Hopkins University
Shaw, Leslie M., Ph.D. ..... University of Massachusetts Medical School, Worcester
Sheffield-Moore, Melinda, Ph.D. ..... The University of Texas Medical Branch at Galveston
Sheikh, M. Saeed, M.D., Ph.D. ..... Upstate Medical University
Shen, Zhiyuan, M.D., Ph.D. ..... Rutgers, The State University of New Jersey
Sheng, Shijie, Ph.D. ..... Wayne State University
Shenoy, Sudha K., Ph.D. ..... Duke University
Sherman, Michael Y., Ph.D. ..... University of Massachusetts, Dartmouth
Sherman, Steven I., M.D., F.A.C.E. ..... The University of Texas MD Anderson Cancer Center
Sherry, Dean, Ph.D. ..... The University of Texas at Dallas
Shi, Hua, M.D., Ph.D. ..... The State University of New York at Albany
Shi, Huidong, M.D., Ph.D. ..... Georgia Regents University
Shibata, Darryl K., M.D. ..... The University of Southern California
Shih, Ie-Ming, M.D., Ph.D. ..... The Johns Hopkins University
Shilatifard, Ali, Ph.D. ..... Stowers Institute for Medical Research
Shillitoe, Edward J., Ph.D. ..... Upstate Medical University
Shim, Hyunsuk, Ph.D. ..... Emory University
Shimamura, Akiko, M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Shin, Dong-Guk, Ph.D. ..... University of Connecticut, Storrs
Shin, Dong M., M.D. ..... Emory University
Shively, John E., Ph.D. ..... City of Hope National Medical Center
Shroff, Hari, Ph.D. ..... National Institute of Biomedical Imaging and Bioengineering
Shroyer, Kenneth R., M.D., Ph.D. ..... The State University of New York at Stony Brook

Shukla, Arti, Ph.D. ..... The University of Vermont and State Agricultural College
Shull, James D., Ph.D. ..... University of Wisconsin, Madison
Shuman, Marc A., M.D. ..... University of California, San Francisco
Shuman, Ruth, Ph.D. ..... National Science Foundation
Shureiqi, Imad, M.D. ..... The University of Texas MD Anderson Cancer Center
Shurin, Michael R., M.D., Ph.D. ..... The University of Pittsburgh
Siegfried, Jill M., Ph.D. ..... The University of Pittsburgh
Siemann, Dietmar W., Ph.D. ..... University of Florida
Silva, Jose M., Ph.D. ..... Columbia University Health Sciences
Silver, Robert B., Ph.D. ..... Syracuse University
Simberg, Dimitri, Ph.D. ..... University of Colorado, Denver
Simone, Joseph V., M.D. ..... The University of Utah
Singh, Anup K., Ph.D. ..... Sandia National Laboratories
Singh, Karan P., Ph.D. ..... The University of Alabama at Birmingham
Siu, Lillian L., M.D. ..... Princess Margaret Hospital
Skapek, Stephen X., M.D. ..... The University of Texas Southwestern Medical Center
Skibola, Christine F., Ph.D. ..... The University of Alabama at Birmingham
Sklar, Charles A., M.D. ..... Memorial Sloan-Kettering Cancer Center
Slack-Davis, Jill, Ph.D. ..... University of Virginia
Slager, Susan L., Ph.D. ..... Mayo Clinic
Slominski, Andrzej T., M.D., Ph.D. ..... The University of Tennessee Health Sciences Center
Slovin, Susan F., M.D., Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Smith, Allan H., M.D., Ph.D. ..... University of California, Berkeley
Smith, Eva D., Ph.D., R.N., F.A.A.N. ..... University of Illinois at Chicago
Smithgall, Thomas E., Ph.D. ..... The University of Pittsburgh
Sohn, Lydia L., Ph.D. ..... University of California, Berkeley
Soliman, Amr, M.D., Ph.D., M.P.H. ..... University of Nebraska Medical Center
Solomon, William B., M.D. ..... The State University of New York, Downstate Medical Center
Sondak, Vernon K., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Soper, Steven A., Ph.D. ..... The University of North Carolina at Chapel Hill
Sorkin, Alexander D., Ph.D. ..... The University of Pittsburgh
Sosman, Jeffrey A., M.D. ..... Vanderbilt-Ingram Cancer Center
Soteropoulos, Patricia, Ph.D. ..... Public Health Research Institute
Sousa, Rui J., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Southwick, Frederick, M.D. ..... University of Florida
Sowers, Lawrence C., Ph.D. ..... The University of Texas Medical Branch at Galveston
Sparreboom, Alexander, Ph.D. ..... St. Jude Children's Research Hospital
Spellman, Paul T., Ph.D. ..... Oregon Health & Science University
Spiegelman, Vladimir S., M.D., Ph.D. ..... University of Wisconsin, Madison
Srivastava, Pramod K., M.D., Ph.D. ..... University of Connecticut Health Center
Srivastava, Rakesh K., Ph.D. ..... University of Kansas
Srivastava, Sanjay K., Ph.D. ..... Texas Tech University Health Sciences Center
Stadler, Walter M., M.D. ..... The University of Chicago
Stampfer, Meir J., M.D., Dr.P.H. ..... Harvard School of Public Health
Stanton, Annette L., Ph.D. ..... University of California, Los Angeles
Stauffacher, Cynthia V., Ph.D. ..... Purdue University, West Lafayette
Stauffer, Paul R., M.S. ..... Duke University
Staveley-O'Carroll, Kevin F., M.D., Ph.D. ..... The Pennsylvania State University

Stein, Gary S., Ph.D. ..... The University of Vermont and State Agricultural College
Steinle, Nanette I., M.D. ..... University of Maryland, Baltimore
Stevens, Victoria L., Ph.D. ..... American Cancer Society, Inc.
Stewart, Clinton F., Pharm.D. ..... St. Jude Children's Research Hospital
Stick, Roberta S., J.D. ..... The Leukemia & Lymphoma Society
Stone, Michael P., Ph.D. ..... Vanderbilt University
Stoner, Gary, Ph.D. ..... Medical College of Wisconsin
Storer, Barry E., Ph.D. ..... Fred Hutchinson Cancer Research Center
Stork, Linda C., M.D. ..... Oregon Health & Science University
Storkus, Walter J., Ph.D. ..... The University of Pittsburgh
Strasser, Andrew, Ph.D. ..... The University of Pennsylvania
Strome, Scott E., M.D. ..... University of Maryland, Baltimore
Strongin, Robert M., Ph.D. ..... Portland State University
Stupack, Dwayne G., Ph.D. ..... University of California, San Diego
Su, Gloria H., Ph.D. ..... Columbia University Health Sciences
Su, Lishan, Ph.D. ..... The University of North Carolina at Chapel Hill
Su, Min-Ying L., Ph.D. ..... University of California, Irvine
Su, Ying-Hsiu, Ph.D. ..... Drexel University College of Medicine
Sullivan, Christopher S., Ph.D. ..... The University of Texas at Austin
Sullivan, Mark A., Ph.D. ..... University of Michigan
Sun, Zijie, Ph.D. ..... Stanford University
Sun, Zuoming, Ph.D. ..... City of Hope National Medical Center
Sung, Hak-Joon, Ph.D. ..... Vanderbilt University
Sutphen, Rebecca, M.D. ..... University of South Florida
Swaminathan, Sankar, M.D. ..... The University of Utah
Swamy, Manjunath N., M.D. ..... Texas Tech University Health Sciences Center
Swanson, Basil I., M.D., Ph.D. ..... Los Alamos National Laboratory
Swartz, Harold M., M.D., Ph.D. ..... Dartmouth College
Swede, Helen, Ph.D. ..... University of Connecticut Health Center
Synold, Timothy W., Pharm.D. ..... City of Hope National Medical Center
Szmacinski, Henryk, Ph.D. ..... University of Maryland, Baltimore
Szoka, Francis C., Ph.D. ..... University of California, San Francisco

T

Tabar, Viviane, M.D. ..... Memorial Sloan-Kettering Cancer Center
Tabb, David L., Ph.D. ..... Vanderbilt University
Taguchi, Katsuyuki, Ph.D. ..... The Johns Hopkins University
Taichman, Russell S., D.M.D., D.M.Sc. ..... University of Michigan
Taioli, Emanuela, M.D., Ph.D. ..... Mount Sinai School of Medicine
Tajbakhsh, Jian, Ph.D. ..... Cedars-Sinai Medical Center
Talcott, James A., M.D. ..... Mount Sinai Beth Israel
Talmadge, James E., Ph.D. ..... University of Nebraska Medical Center
Tan, Ming T., Ph.D. ..... Georgetown University
Tang, Li, M.D., Ph.D. ..... Roswell Park Cancer Institute
Tang, Liping, Ph.D. ..... The University of Texas at Arlington
Tanjasiri, Sora P., Dr.P.H., M.P.H. ..... California State University, Fullerton
Tannenbaum, Charles S., Ph.D. ..... Cleveland Clinic Lerner College of Medicine

of Case Western Reserve University
Taouli, Bachir, M.D. ..... Mount Sinai School of Medicine
Tarler, Matthew D., Ph.D. ..... Cleveland Medical Devices, Inc.
Tautz, Lutz, Ph.D. ..... Sanford-Burnham Medical Research Institute
Tay, Peter C., Ph.D. ..... Western Carolina University
Taylor, Kathryn L., Ph.D. ..... Georgetown University
Taylor, Matthew H., M.D. ..... Oregon Health & Science University
Tekmal, Rajeshwar R., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Telleria, Carlos M., Ph.D. ..... University of South Dakota
Tempero, Margaret A., M.D. ..... University of California, San Francisco
Tepper, Joel E., M.D. ..... The University of North Carolina at Chapel Hill
Terrazas, Alejandro, Ph.D. ..... MediaBalance, Inc.
Tessema, Mathewos, D.V.M., Ph.D. ..... Lovelace Biomedical & Environmental Research
Tew, Kenneth D., Ph.D., D.Sc. ..... Medical University of South Carolina
Thangaraju, Muthusamy, Ph.D. ..... Georgia Regents University
Thiagalingam, Sam, Ph.D. ..... Boston University Medical Campus
Thirumalai, Devarajan, Ph.D. ..... University of Maryland, College Park
Thomas, Nancy E., M.D., Ph.D. ..... The University of North Carolina at Chapel Hill
Thomas-Tikhonenko, Andrei, Ph.D. ..... The Children's Hospital of Philadelphia
Thompson, Cheryl L., Ph.D. ..... Case Western Reserve University
Thompson, E. Aubrey, Ph.D. ..... Mayo Clinic, Jacksonville
Thompson, Patricia A., Ph.D. ..... The University of Arizona
Thompson, Todd A., Ph.D. ..... The University of New Mexico
Thomson, Cynthia A., Ph.D. ..... The University of Arizona
Thor, Ann D., M.D. ..... University of Colorado, Denver
Thorne, Stephen H., Ph.D. ..... The University of Pittsburgh
Thornquist, Mark, Ph.D. ..... Fred Hutchinson Cancer Research Center
Threadgill, David W., Ph.D. ..... Texas A&M University Health Science Center
Thulborn, Keith R., M.D., Ph.D. ..... University of Illinois at Chicago
Tiwari, Hemant K., Ph.D. ..... The University of Alabama at Birmingham
Tochtrop, Gregory P., Ph.D. ..... Case Western Reserve University
Tollefsbol, Trygve O., Ph.D. ..... The University of Alabama at Birmingham
Tolley, Luke, Ph.D. ..... Southern Illinois University, Carbondale
Tomlinson, Gail E., M.D., Ph.D. ..... The University of Texas Health Science Center at San Antonio
Toner, Mehmet, Ph.D. ..... Massachusetts General Hospital
Tooze, Janet A., Ph.D., M.P.H. ..... Wake Forest University Health Sciences
Torok, Natalie J., M.D. ..... University of California, Davis
Torres-Roca, Javier F., M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Tosteson, Tor D., Sc.D. ..... Dartmouth College
Towner, Rheal A., Ph.D. ..... Oklahoma Medical Research Foundation
Tran, Nhan L., Ph.D. ..... Translational Genomics Research Institute
Travis, Lois B., Sc.D., M.D. ..... University of Rochester
Trentham-Dietz, Amy, Ph.D. ..... University of Wisconsin, Madison
Triche, Timothy J., M.D., Ph.D. ..... Children's Hospital of Los Angeles
Tricot, Guido J., M.D., Ph.D. ..... The University of Iowa
Triglia, Dennis, M.A. ..... AgonOx, Inc.
Trobridge, Grant D., Ph.D. ..... Washington State University

Troester, Melissa A., Ph.D., M.P.H. ..... The University of North Carolina at Chapel Hill
Tropsha, Alexander, Ph.D. ..... The University of North Carolina at Chapel Hill
True, Lawrence D., M.D. ..... University of Washington
Trump, Donald L., M.D. ..... Roswell Park Cancer Institute
Tsourkas, Andrew, Ph.D. ..... The University of Pennsylvania
Tsui, Benjamin M. W., Ph.D. ..... The Johns Hopkins University
Turley, Shannon J., Ph.D. ..... Dana-Farber Cancer Institute
Turner, Jessica, Ph.D. ..... Georgia State University
Turner, Stephen W., Ph.D. ..... Pacific Biosciences of California, Inc.
Tuschl, Thomas, Ph.D. ..... The Rockefeller University
Tweedle, Michael F., Ph.D. ..... The Ohio State University
Tyler, Jessica K., Ph.D. ..... The University of Texas MD Anderson Cancer Center

U

Ueno, Naoto T., M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Ullrich, Stephen E., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Unger, Elizabeth R., M.D., Ph.D. ..... U.S. Centers for Disease Control and Prevention
Unger, Evan C., M.D. ..... NuvOx Pharma, LLC.
Urtasun, Raul C., M.D. ..... University of Alberta
Usherwood, Edward J., Ph.D. ..... Dartmouth College

V

Van Besien, Koen W., M.D., Ph.D. ..... Weill Cornell Medical College of Cornell University
Van Meir, Erwin G., Ph.D. ..... Emory University
Vannier, Michael W., M.D. ..... The University of Chicago
Van Waes, Carter, M.D., Ph.D. ..... National Institute on Deafness and Other Communication Disorders
Varki, Nissi M., M.D. ..... University of California, San Diego
Vaughan, Andrew T., Ph.D. ..... Loyola University, Chicago
Vaziri, Cyrus, Ph.D. ..... The University of North Carolina at Chapel Hill
Vazquez, Alexei, Ph.D. ..... Rutgers, The State University of New Jersey
Vega-Vazquez, Francisco, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Verbridge, Scott S., Ph.D. ..... Virginia Polytechnic Institute and State University
Verma, Amit, M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Verschraegen, Claire F., M.D. ..... The University of Vermont and State Agricultural College
Vessella, Robert L., Ph.D. ..... University of Washington
Viator, John A., Ph.D. ..... Duquesne University
Vidrine, Jennifer I., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Vieweg, Johannes W., M.D. ..... University of Florida
Visovsky, Constance G., Ph.D., R.N., A.C.N.P.-B.C. ..... University of South Florida
Visuri, Steven R., Ph.D. ..... Prodesse, Inc.
Vogel, Carl-Wilhelm E., M.D., Ph.D. ..... The University of Hawaii at Manoa
Von Gunten, Charles F., Ph.D. ..... The Institute for Palliative Medicine at San Diego Hospice
Vose, Julie M., M.D. ..... University of Nebraska Medical Center

W

Wachsman, William, M.D., Ph.D. ..... University of California, San Diego
Wagner, David H., Ph.D. ..... University of Colorado, Denver
Wagner, John E., M.D. ..... University of Minnesota
Wagner, Kay-Uwe, Ph.D. ..... University of Nebraska Medical Center
Walker, Joan L., M.D. ..... The University of Oklahoma Health Sciences Center
Walkosz, Barbara, Ph.D. ..... Klein Buendel, Inc.
Waller, Edmund K., M.D., Ph.D. ..... Emory University
Waller, Lance A., Ph.D. ..... Emory University
Wallington, Sherrie L., Ph.D. ..... Georgetown University
Walter, Roland B., M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Walton, Stephen P., Sc.D. ..... Michigan State University
Wands, Jack R., M.D. ..... Rhode Island Hospital
Wang, Binghe, Ph.D. ..... Georgia State University
Wang, Denong, Ph.D. ..... SRI International, Inc.
Wang, Edwin, Ph.D. ..... National Research Council, Canada
Wang, Henry Y., Ph.D. ..... University of Michigan
Wang, Hong-Gang, Ph.D. ..... The Pennsylvania State University
Wang, Jiwu, Ph.D. ..... Allele Biotechnology and Pharmaceuticals
Wang, Judy H., Ph.D. ..... Georgetown University
Wang, Kenneth K., M.D. ..... Mayo Clinic
Wang, Liang, Ph.D. ..... Medical College of Wisconsin
Wang, Lisa L., M.D. ..... Baylor College of Medicine
Wang, Peng G., Ph.D. ..... Georgia State University
Wang, Qiming J., Ph.D. ..... The University of Pittsburgh
Wang, Rongfu, Ph.D. ..... The Methodist Hospital Research Institute
Wang, Shan X., Ph.D. ..... Stanford University
Wang, Shaomeng, Ph.D. ..... University of Michigan
Wang, Tian-Li, Ph.D. ..... The Johns Hopkins University
Wang, Xiang-Yang, Ph.D. ..... Virginia Commonwealth University
Wang, Xiao-Fan, Ph.D. ..... Duke University
Wang, Yinsheng, Ph.D. ..... University of California, Riverside
Wang, Zaijie J., Ph.D. ..... University of Illinois at Chicago
Wang, Zhou, Ph.D. ..... The University of Pittsburgh
Wang-Rodriguez, Jessica, M.D. ..... University of California, San Diego
Ward, Dianne S., Ed.D. ..... The University of North Carolina at Chapel Hill
Ware, Carl F., Ph.D. ..... Sanford-Burnham Medical Research Institute
Wargovich, Michael, Ph.D. ..... The University of Texas Health Science Center at San Antonio
Warnecke, Richard, Ph.D. ..... University of Illinois at Chicago
Washington, Mary Kay, M.D., Ph.D. ..... Vanderbilt University
Watabe, Kounosuke, Ph.D. ..... University of Mississippi Medical Center
Wattenberg, Brian W., Ph.D. ..... University of Louisville
Watts, David C., Ph.D. ..... NNE Pharmaplan
Weaver, Alissa M., M.D., Ph.D. ..... Vanderbilt University
Weber, Michael J., Ph.D. ..... University of Virginia
Weber, Wolfgang, Ph.D. ..... University of California, Los Angeles
Webster, Thomas J., Ph.D. ..... Northeastern University

Weekes, Colin, M.D., Ph.D. ..... University of Colorado, Denver
Wei, Alexander, Ph.D. ..... Purdue University, West Lafayette
Wei, Qingyi, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Wei, Wenyi, Ph.D. ..... Beth Israel Deaconess Medical Center
Weichert, Jamey P., Ph.D. ..... University of Wisconsin, Madison
Weier, Heinz-Ulrich G., Ph.D. ..... Lawrence Berkeley National Laboratory
Weihs, Karen L., M.D. ..... The University of Arizona
Weilbaecher, Katherine N., M.D. ..... Washington University in St. Louis
Weinberg, Armin D., Ph.D. ..... Life Beyond Cancer Foundation
Weiner, Louis M., M.D. ..... Georgetown University
Weiner, Roy S., M.D. ..... Tulane University
Weinmann, Sheila A., Ph.D., M.P.H. ..... Kaiser Foundation Research Institute
Weintraub, Bruce D., M.D. ..... Trophogen, Inc.
Weiss, Geoffrey R., M.D. ..... University of Virginia
Weiss, Robert H., M.D. ..... University of California, Davis
Welch, Danny R., Ph.D. ..... University of Kansas
Weller, Edie A., Ph.D. ..... Harvard Medical School
Wells, Alan, M.D. ..... The University of Pittsburgh
Wernli, Karen J., Ph.D. ..... Group Health Cooperative
West, Dee W., Ph.D. ..... Cancer Prevention Institute of California
Westbrook, Thomas, Ph.D. ..... Baylor College of Medicine
Westphall, Michael S., Ph.D. ..... University of Wisconsin, Madison
Wethington, Elaine, Ph.D. ..... Cornell University
Wetzler, Meir, M.D. ..... Roswell Park Cancer Institute
Whitcomb, David C., M.D., Ph.D. ..... The University of Pittsburgh
White, Forest M., Ph.D. ..... Massachusetts Institute Of Technology
White, Lisa D., Ph.D. ..... Baylor College of Medicine
Whiteside, Theresa L., Ph.D. ..... The University of Pittsburgh
Wiener, Erik C., Ph.D. ..... The University of Pittsburgh
Wigdahl, Brian, Ph.D. ..... Drexel University College of Medicine
Wilburn, Louella S., M.S. ..... People Living With Cancer
Wilding, George, M.D. ..... University of Wisconsin, Madison
Wiley, Patti, M.B.A. ..... On the Wings of Angels Pediatric Cancer Foundation
Willett, Christopher G., M.D. ..... Duke University
Willey, James C., M.D. ..... The University of Toledo Health Sciences Center
Williams, Bart O., Ph.D. ..... Van Andel Research Institute
Williams, David A., M.D. ..... Children's Hospital Corporation
Williams, David M., Ph.D. ..... Brown University
Williams, Donna L., Dr.P.H., M.P.H. ..... Louisiana State University Health Sciences Center
Williams, John C., Ph.D. ..... City of Hope National Medical Center
Williams, Paul M., Ph.D. ..... SAIC-Frederick, Inc.
Williamson, Stephen K., M.D. ..... University of Kansas
Wilson, Mark A., Ph.D. ..... University of Nebraska, Lincoln
Wilwerding, Mary B., R.N. ..... Missouri Valley Cancer Consortium
Windle, Jolene J., Ph.D. ..... Virginia Commonwealth University
Wingard, John R., M.D. ..... University of Florida
Winoto, Astar, Ph.D. ..... University of California, Berkeley
Winter, Stuart S., M.D. ..... The University of New Mexico

Witt, Whitney P., Ph.D., M.P.H. ..... University of Wisconsin, Madison
Witzig, Thomas E., M.D. ..... Mayo Clinic
Wolf, Wendy A., Ph.D. ..... Children's Hospital Corporation
Woloschak, Gayle E., Ph.D. ..... Northwestern University
Wondrak, Georg T., Ph.D. ..... The University of Arizona
Wong, Melissa H., Ph.D. ..... Oregon Health & Science University
Wong, Season S.-S., Ph.D. ..... AI Biosciences, Inc.
Wong, Stephen T.C. Ph.D. ..... Houston Methodist
Wood, Charles, Ph.D. ..... University of Nebraska Lincoln
Woodall, W. Gill, Ph.D. ..... The University of New Mexico
Woodgett, James R., Ph.D. ..... Lunenfeld-Tannenbaum Research Institute
Woods, William G., M.D. ..... Children's Healthcare of Atlanta, Inc.
Woolf, Tod M., Ph.D. ..... Sequitur, Inc.
Wooster, Richard, Ph.D. ..... GlaxoSmithKline
Worsham, Maria J., Ph.D. ..... Henry Ford Health System
Woster, Patrick M., Ph.D. ..... Medical University of South Carolina
Wright, Michael E., Ph.D. ..... The University of Iowa
Wroblewski, Dariusz, Ph.D. ..... BioFormatix, Inc.
Wu, Cathy H., Ph.D. ..... University of Delaware
Wu, Mingming, Ph.D. ..... Cornell University
Wu, Tong, M.D., Ph.D. ..... Tulane University
Wu, Tzyy-Choou, M.D., Ph.D. ..... The Johns Hopkins University
Wu, Xifeng, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Wu, Zhaohui, M.D., Ph.D. ..... The University of Tennessee Health Sciences Center
Wulf, Gerburg M., M.D., Ph.D. ..... Beth Israel Deaconess Medical Center

X

Xiao, Gutian, Ph.D. ..... The University of Pittsburgh
Xiao, Hua, M.D., Ph.D. ..... Michigan State University
Xie, Keping, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Xie, Wen, M.D., Ph.D. ..... The University of Pittsburgh
Xing, Michael M., M.D., Ph.D. ..... The Johns Hopkins University
Xu, Xiangxi M., Ph.D. ..... University of Miami Miller School of Medicine
Xu, Xiaochun, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Xu, Yan, Ph.D. ..... Indiana University

Y

Yamashiro, Darrell J., M.D., Ph.D. ..... Columbia University Health Sciences
Yang, Chung S., Ph.D. ..... Rutgers, The State University of New Jersey
Yang, Hu, Ph.D. ..... Virginia Commonwealth University
Yang, James J., Ph.D. ..... Henry Ford Health System
Yang, Ping, M.D., Ph.D. ..... Mayo Clinic
Yang, Vincent W., M.D., Ph.D. ..... The State University of New York at Stony Brook
Yang, Wancai, M.D. ..... University of Illinois at Chicago
Yankeelov, Thomas E., Ph.D. ..... Vanderbilt University
Yannelli, John R., Ph.D. ..... University of Kentucky
Yee, Cassian, M.D. ..... The University of Texas MD Anderson Cancer Center

Yeo, Yoon, Ph.D. ..... Purdue University, West Lafayette
Yi, Qing, M.D., Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Ying, Shao-Yao, Ph.D. ..... The University of Southern California
Yoon, Byung-Jun, Ph.D. ..... Texas Engineering Experiment Station
Yost, David A., Ph.D. ..... Innovative Biosensors, Inc.
Young, Damian W., Ph.D. ..... Harvard University
Young, James W., M.D. ..... Memorial Sloan-Kettering Cancer Center
Young, Jeanne P., B.A. ..... Childhood Brain Tumor Foundation
Yu, Dihua, M.D., Ph.D. ..... The University of Texas MD Anderson Cancer Center
Yu, Han-Gang, Ph.D. ..... West Virginia University
Yu, Jian, Ph.D. ..... The University of Pittsburgh
Yu, Xiaochun, M.D., Ph.D. ..... University of Michigan

Z

Zahrbock, Cary A.C., M.S.W, L.I.C.S.W. ..... National Coalition/Cancer Survivorship
Zaia, Joseph, Ph.D. ..... Boston University Medical Campus
Zarbl, Helmut, Ph.D. ..... Rutgers, The State University of New Jersey
Zehnder, James L., M.D. ..... Stanford University
Zeiger, Martha A., M.D. ..... The Johns Hopkins University
Zeleznik-Le, Nancy J., Ph.D. ..... Loyola University, Chicago
Zeng, Mingtao, Ph.D. ..... Texas Tech University Health Sciences Center
Zhang, Huang-Ge, D.V.M., M.D., Ph.D. ..... The University of Alabama at Birmingham
Zhang, Jian, Ph.D. ..... University of Maryland, Baltimore
Zhang, Jinghui, Ph.D. ..... St. Jude Children's Research Hospital
Zhang, Kun, Ph.D. ..... University of California, San Diego
Zhang, Lin, Ph.D. ..... The University of Pittsburgh
Zhang, Rugang, Ph.D. ..... The Wistar Institute
Zhang, Wei, Ph.D. ..... The University of Texas MD Anderson Cancer Center
Zhao, Hongyu, Ph.D. ..... Yale University
Zhao, Zhizhuang J., Ph.D. ..... Vanderbilt University
Zheng, Bin, Ph.D. ..... The University of Oklahoma, Norman
Zheng, Tongzhang, D.Sc., M.D. ..... Yale University
Zhou, Jiangbing, Ph.D. ..... Yale University
Zhou, Jin-Rong, Ph.D. ..... Beth Israel Deaconess Medical Center
Zhu, Fanxiu, Ph.D. ..... Florida State University
Zhu, Liang, M.D., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Zhu, Wenge, Ph.D. ..... George Washington University
Zhu, Yong, Ph.D. ..... Yale University
Zimmers, Teresa A., Ph.D. ..... Indiana University
Zinkel, Sandra S., M.D., Ph.D. ..... Vanderbilt University
Zlotnik, Albert, Ph.D. ..... University of California, Irvine
Zondlo, Neal J., Ph.D. ..... University of Delaware
Zu, Youli, M.D., Ph.D. ..... Houston Methodist
Zuiderweg, Erik R., Ph.D. ..... University of Michigan

Total Number of Reviewers: 1,917

Appendix E: NCI Grant Mechanisms and Descriptions

Below is a brief description of NIH funding mechanisms. Additional information on grants, contracts, and extramural policy notices may be found by viewing the NCI DEA Web page on Grants Guidelines and Descriptions at **http://deainfo.nci.nih.gov/flash/awards.htm**.

C Series: Research Construction Programs	
C06	**Research Facilities Construction Grants** To provide matching Federal funds, up to 75 percent, for construction or major remodeling to create new research facilities, which in addition to basic research laboratories may include, under certain circumstances, animal facilities and/or limited clinical facilities where they are an integral part of an overall research effort.
D Series: Training Projects	
D43	**International Training Grants in Epidemiology** To improve and expand epidemiologic research and the utilization of epidemiology in clinical trials and prevention research in Foreign countries through support of training programs for Foreign health professionals, technicians, and other health care workers.
F Series: Fellowship Programs	
F31	**Predoctoral Individual National Research Service Award (NRSA)** To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	**Predoctoral Fellowship—Minority Students** A fellowship award that provides predoctoral minority students with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	**National Research Service Award for Individual Postdoctoral Fellows** To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F32	**National Research Service Award for Individual Postdoctoral Fellows** To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F33	**National Research Service Award for Senior Fellows** To provide opportunities for experienced scientists to make major changes in the direction of research careers, broaden scientific backgrounds, acquire new research capabilities, enlarge command of an allied research field, or take time from regular professional responsibilities to increase capabilities to engage in health-related research.

K Series: Career Development Programs	
K01	**The Howard Temin Award (no longer supported through use of the K01 by the NCI; see the K99/R00)** A previously used NCI-specific variant of the NIH Mentored Research Scientist Development Award that was designed to provide research scientists with an additional period of sponsored research experience as a way to gain expertise in a research area new to the applicant or in an area that would demonstrably enhance the applicant's scientific career.
K01	**Mentored Career Development Award for Underrepresented Minorities** To support scientists committed to research who are in need of both advanced research training and additional experience.
K05	**Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population Research** To support scientists qualified to pursue independent research that would extend the research program of the sponsoring institution, or to direct an essential part of this program.
K07	**Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award** To support the postdoctoral career development of investigators who are committed to academic research careers in cancer prevention, control, behavioral, epidemiological, and/or the population sciences. It supports up to 5 years of combined didactic and supervised (i.e., mentored) research experiences to acquire the methodological and theoretical research skills needed to become an independent scientist. The very broad nature of the prevention, control, and population sciences makes it applicable to those individuals doctorally trained in the basic sciences, medicine, behavioral sciences, and/or public health. The K07 award has been expanded from a scope limited to "preventive oncology" to include the entire spectrum of fields that are of vital importance to cancer prevention and control such as nutrition, epidemiology, and behavioral sciences.
K08	**Mentored Clinical Scientists Development Award** To provide the opportunity for promising medical scientists with demonstrated aptitude to develop into independent investigators, or for faculty members to pursue research in categorical areas applicable to the awarding unit, and to aid in filling the academic faculty gap in specific shortage areas within U.S. health professions institutions.
K08	**Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology** A specialized type of Mentored Clinical Scientist Developmental Award (K08) that supports the development of outstanding clinical research scientists, with this type being reserved for qualified individuals from underrepresented minority groups. Both types of K08 awards support periods of specialized study for clinically trained professionals who are committed to careers in research and who have the potential to develop into independent investigators. The K08 awards for Minorities in Clinical Oncology are distinct and important because they provide opportunities for promising medical scientists with demonstrated aptitudes who belong to underrepresented minority groups to develop into independent investigators, or for faculty members who belong to underrepresented minority groups to pursue research aspects of categorical areas applicable to the awarding unit(s), and aid in filling the academic faculty gaps in these shortage areas within U.S. health professions institutions.

K12	**Institutional Clinical Oncology Research Career Development Award** To support a newly trained clinician appointed by an institution for development of independent research skills and experience in a fundamental science within the framework of an interdisciplinary research and development program.
K22	**The NCI Transition Career Development Award for Underrepresented Minorities** To provide support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.
K22	**The NCI Scholars Program** To provide an opportunity for outstanding new investigators to begin their independent research careers, first within the special environment of the NCI and then at an institution of their choice. Specifically, this Program provides necessary resources to initiate an independent research program of 3 to 4 years at the NCI, followed by an extramural funding mechanism (K22) to support their research program for 2 years at the extramural institution to which they are recruited.
K23	**Mentored Patient-Oriented Research Career Development Award** To provide support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.
K23	**Mentored Patient-Oriented Research Career Development Award for Underrepresented Minorities** To support the career development of investigators who have made a commitment to focus their research on patient-oriented research. This mechanism provides support for a period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators in patient-oriented research.
K24	**Mid-Career Investigator Award in Patient-Oriented Research** To provide support for clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators. The target candidates are outstanding clinical scientists engaged in patient-oriented research who are within 15 years of their specialty training, who can demonstrate the need for a period of intensive research focus as a means of enhancing their clinical research careers, and who are committed to mentoring the next generation of clinical investigators in patient-oriented research.
K25	**Mentored Quantitative Research Career Development Award** This award allows an independent scientist in a highly technical field of research to identify an appropriate mentor with extensive experience in cancer research and to receive the necessary training and career development required to become involved in multidisciplinary cancer research.

K99/ R00	**NIH Pathway to Independence (PI) Award** The Pathway to Independence Award, which is part of the NIH Roadmap Initiative but is known as the Howard Temin Award within the NCI, will provide up to 5 years of support consisting of two phases. The initial phase will provide 1 to 2 years of mentored support for highly promising postdoctoral research scientists. This phase will be followed by up to 3 years of independent support contingent on securing an independent research position. Award recipients will be expected to compete successfully for independent R01 support from the NIH during the career transition award period. The PI Award is limited to postdoctoral trainees within 5 years of completion of their training who propose research relevant to the mission of one or more of the participating NIH Institutes and Centers.
P Series: Research Program Projects and Centers	
P01	**Research Program Projects** To support multidisciplinary or multifaceted research programs that have a focused theme. Each component project should be directly related to and contribute to the common theme.
P20	**Exploratory Grants** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.
P30	**Center Core Grants** To support shared use of resources and facilities for categorical research by investigators from different disciplines who provide a multidisciplinary approach to a joint research effort, or by investigators from the same discipline who focus on a common research problem. The core grant is integrated with the Center's component projects or Program Projects, though funded independently from them. By providing more accessible resources, this support is expected to ensure greater productivity than that provided through the separate projects and Program Projects.
P50	**Specialized Center Grants** To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. This spectrum of activities comprises a multidisciplinary attack on a specific disease or biomedical problem area. These grants differ from Program Project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division, and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.

R Series: Research Projects	
R01	**Research Project** Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific focus or objective in his or her area of interest and competence. Institutional sponsorship assures the NIH that the institution will provide facilities necessary to conduct the research and will be accountable for the grant funds. Applications are accepted for health-related research and development in all areas within the scope of the NIH's mission.
R03	**Small Research Grants** Small grants provide research support, specifically limited in time and amount, for activities such as pilot projects, testing of new techniques, or feasibility studies of innovative, high-risk research, which would provide a basis for more extended research.
R13	**Conferences** The NIH provides funding for conferences to coordinate, exchange, and disseminate information related to its program interests. Generally, such awards are limited to participation with other organizations in supporting conferences rather than provision of sole support. Costs eligible for support include salaries, consultant services, equipment rental, travel, supplies, conference services, and publications. Prospective applicants are encouraged to inquire in advance concerning possible interest on the part of an awarding Institute/Center (IC), and to obtain more information on application procedures and costs.
R15	**The NIH Academic Research Enhancement Awards (AREA)** To enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds, this award provides limited funds to those institutions' faculty members to develop new research projects or expand ongoing research activities in health sciences and to encourage students to participate in the research activity. As funds are anticipated to continue to be available each year, the NIH is now inviting applications for AREA grants through a standing, ongoing Program Announcement.
R21	**Exploratory/Developmental Grants** To encourage the development of new research activities in categorical program areas. (Support generally is restricted in the level of support and duration.)
R24	**Resource-Related Research Projects** To support research projects that will enhance the capability of resources to serve biomedical research.

R25E	**Cancer Education Grant Program (CEGP)** A flexible, curriculum-driven program aimed at developing and sustaining innovative educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality of life of cancer patients. The CEGP accepts investigator-initiated grant applications that pursue a wide spectrum of objectives ranging from short courses; to the development of new curricula in academic institutions; to national forums and seminar series; to hands-on workshop experiences for the continuing education of health care professionals, biomedical researchers, and the lay community; to structured short-term research experiences designed to motivate high school, college, medical, dental, and other health professional students to pursue careers in cancer research. Education grants can focus on education activities before, during, and after the completion of a doctoral-level degree, as long as they address a need that is not fulfilled adequately by any other grant mechanism available at the NIH, and are dedicated to areas of particular concern to the National Cancer Program.
R25T	**Cancer Education and Career Development Program** To support the development and implementation of curriculum-dependent, team-oriented programs to train predoctoral and postdoctoral candidates in cancer research team settings that are highly interdisciplinary and collaborative. This specialized program is particularly applicable to the behavioral, prevention, control, nutrition, and population sciences but also should be considered by other areas of research (e.g., imaging, pathology) that will require sustained leadership, dedicated faculty time, specialized curriculum development and implementation, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives.
R33	**Exploratory/Developmental Grants, Phase II** To provide a second phase for support of innovative exploratory and developmental research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants who demonstrate program competency equivalent to that expected under R33.
R37	**Method to Extend Research in Time (MERIT) Award** To provide long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT Award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT Award during the course of review of competing research grant applications prepared and submitted in accordance with regular Public Health Service (PHS) requirements.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs

The NIH welcomes grant applications from small businesses in any biomedical or behavioral research area as described in the solicitations below.

Support under the SBIR program is normally provided for 6 months/$100,000 for Phase I, and 2 years/$500,000 for Phase II. However, applicants may propose longer periods of time and greater amounts of funds necessary for completion of the project.

R41	**STTR Grants, Phase I** To support cooperative research and development (R&D) projects between small business concerns and research institutions, limited in time and amount; to establish the technical merit and feasibility of ideas that have potential for commercialization.
R42	**STTR Grants, Phase II** To support in-depth development of cooperative R&D projects between small business concerns and research institutions, limited in time and amount, whose feasibility has been established in Phase I and that have potential for commercial products or services.
R43	**SBIR Grants, Phase I** To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas that may ultimately lead to commercial products or services.
R44	**SBIR Grants, Phase II** To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.
R55	**James A. Shannon Director's Award** To provide a limited award to investigators to further develop, test, and refine research techniques; perform secondary analysis of available data sets; test the feasibility of innovative and creative approaches; and conduct other discrete projects that can demonstrate their research capabilities and lend additional weight to their already meritorious applications.
R56	**High-Priority, Short-Term Project Award** Begun in FY2005, this grant provides funds for 1- or 2-year high-priority new or competing renewal R01 applications that fall just outside the limits of funding of the participating NIH Institutes and Centers (ICs); recipients of R56 awards will be selected by IC staff from R01 applications that fall at or near the payline margins.

S Series: Research-Related Programs	
SC1	**Research Enhancement Award** Individual investigator-initiated research projects aimed at developing researchers at minority-serving institutions (MSIs) to a stage where they can transition successfully to other extramural support (R01 or equivalent).
SC2	**Pilot Research Project** Individual investigator-initiated pilot research projects for faculty at MSIs to generate preliminary data for a more ambitious research project.
S06	**Minority Biomedical Research Support (MBRS)** To strengthen the biomedical research and research training capability of ethnic minority institutions, and thus establish a more favorable milieu for increasing the involvement of minority faculty and students in biomedical research.
S07	**Biomedical Research Support Grants (NCRR BRSG)** As an example of this funding mechanism, the NIH issued a Request for Applications (RFA) in FY2004 to provide short-term interim support for institutional activities that will strengthen oversight of human subjects research at institutions that receive significant NIH support for clinical research. Although there is considerable flexibility in the types of activities that could be supported under the BRSG program, that RFA emphasized the importance of efforts to enhance the protection of research subjects by means that would be sustained by the recipient institution after the award period ends. Awardees also are required to collaborate with other institutions conducting human subjects research and are not currently funded under this program, and to share educational resources, computer technologies, best practices, etc. Although all NIH components supporting clinical research (including the NCI) are providing support for this program, it is administered by the National Center for Research Resources (NCRR).
S10	**Biomedical Research Support Shared Instrumentation Grants (NCRR SIG)** The National Center for Research Resources (NCRR) initiated its competitive Shared Instrumentation Grant (SIG) Program in FY1982. Shared Instrumentation Grants provide support for expensive state-of-the-art instruments utilized in both basic and clinical research. This program is designed to meet the special problems of acquisition and updating of expensive shared-use instruments that are not generally available through other NIH funding mechanisms, such as the regular research project, program project, or center grant programs. Applications for funds to design or to advance the design of new instruments are not accepted. The objective of the program is to make available to institutions with a high concentration of NIH-supported biomedical investigators expensive research instruments that can only be justified on a shared-use basis and for which meritorious research projects are described.
S21	**Research and Institutional Resources Health Disparities Endowment Grants—Capacity Building** To strengthen the research and training infrastructure of the institution, while addressing current and emerging needs in minority health and other health disparities research.

T Series: Training Programs	
T15	**Continuing Education Training Grants** To assist professional schools and other public and nonprofit institutions in the establishment, expansion, or improvement of programs of continuing professional education, especially for programs of extensive continuation, extension, or refresher education dealing with new developments in the science and technology of the profession.
T32	**NIH National Research Service Award—Institutional Research Training Grants** To enable institutions to make National Research Service Awards to individuals selected by them for predoctoral and postdoctoral research training in specified shortage areas.
U Series: Cooperative Agreements	
U01	**Research Projects—Cooperative Agreements** To support a discrete, specified, circumscribed project to be performed by the named investigators in an area representing their specific interests and competencies.
U10	**Cooperative Clinical Research—Cooperative Agreements** To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between participating institutions and Principal Investigators, and are usually conducted under established protocols.
U13	**Conference—Cooperative Agreements** To coordinate, exchange, and disseminate information related to its program interests, an NIH Institute or Center can use this type of award to provide funding and direction for appropriate scientific conferences. These cooperative agreements allow the NCI to partner with one or more outside organizations to support international, national, or regional meetings, conferences, and workshops that are of value in promoting the goals of the National Cancer Program.
U19	**Research Program—Cooperative Agreements** To support a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach.
U24	**Resource-Related Research Projects—Cooperative Agreements** To support research projects contributing to improvement of the capability of resources to serve biomedical research.
U54	**Specialized Center—Cooperative Agreements** To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program projects in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continual attention from its staff. Centers also may serve as regional or national resources for special research purposes, with assistance from staff of the funding component in identifying appropriate priority needs.

U56	**Exploratory Grants—Cooperative Agreements** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award.

Appendix F: Glossary of Acronyms

ABTC	Adult Brain Tumor Consortium
ACF	Administration for Children and Families
ACSR	AIDS and Cancer Specimen Resource
ADAMHA	Alcohol, Drug Abuse, and Mental Health Administration
AHRQ	Agency for Healthcare Research and Quality
AIDS	Acquired Immune Deficiency Syndrome
AISB	Applied Information Systems Branch
ARA	Awaiting Receipt of Application
AREA	Academic Research Enhancement Award
BAD	Basic and Applied (Coding Module)
BRG	Bioengineering Research Grants
BRSG	Biomedical Research Support Grant
BSA	Board of Scientific Advisors
BSC	Board of Scientific Counselors
C&A	Certification and Accreditation
CAM	Complementary and Alternative Medicine
CAMACS	Coordination, Analysis, and Management of the MACS
CATS	Concept to Awards Tracking System
CBIIT	NCI Center for Biomedical Informatics and Information Technology
CCR	Center for Cancer Research
CCSG	Cancer Center Support Grant
CCT	Center for Cancer Training
CD	Career Development
CDC	Centers for Disease Control and Prevention
CECTR	Center for Evaluation and Coordination of Training and Research
CEGP	Cancer Education Grant Program
CFAR	Center for AIDS Research
CGH	Center for Global Health
CHTN	Collaborative Human Tissue Network
CIT	Center for Information Technology
CMO	Committee Management Office
CoC	Council of Councils
COPD	Chronic Obstructive Pulmonary Disease
CPACHE	Comprehensive Partnerships to Advance Cancer Health Equity
CRAN	Collaborative Research on Addiction at NIH
CRCHD	Center to Reduce Cancer Health Disparities
CRP	Collaborative Research Partnership
CSO	Common Scientific Outline
CSR	Center for Scientific Review
CSSI	Center for Strategic Scientific Initiatives
CTAC	Clinical Trials and Translational Research Advisory Committee
CTDD	Cancer Target Discovery and Development
CTROC	Clinical Trials and Translational Research Operations Committee
DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCEG	Division of Cancer Epidemiology and Genetics
DCLG	Director's Consumer Liaison Group
DCP	Division of Cancer Prevention
DCTD	Division of Cancer Treatment and Diagnosis
DEA	Division of Extramural Activities
DHHS	U.S. Department of Health and Human Services (now HHS)
DOC	Division/Office/Center
DPIC	Detection of Pathogen-Induced Cancer
ECB	Electronic Council Book
EPMC	Extramural Program Management Committee
eRA	Electronic Research Administration
ESA	Extramural Support Assistant
ET-CTN	Experimental Therapeutics-Clinical Trials Network
eTUG	eRA Technical Users Group
FACA	Federal Advisory Committee Act
FDA	Food and Drug Administration
FFRDC	Federally Funded Research and Development Center
FIC	Fogarty International Center
FLARE	Fiscal Linked Analysis of Research Emphasis
FNLCR	Frederick National Laboratory for Cancer Research
FOA	Funding Opportunity Announcements
FOIA	Freedom of Information Act
FT	Fast Track
FY	Fiscal Year
GSS	General Support System
HHS	Department of Health and Human Services (replaces DHHS)
HHV8	Human herpesvirus-8
HIV	Human Immunodeficiency Virus
HTLV	Human T-cell Lymphotropic Virus
I2E	IMPAC II Extensions
IC	Institute/Center
ICRP	International Cancer Research Portfolio

IMAT	Innovative Molecular Analysis Technologies Program
IMPAC	Information for Management, Planning, Analysis, and Coordination
IRG	Initial Review Group
IRM	Information Resources Management
IT	Information Technology
LINCS	Library of Integrated Network-based Cellular Signatures
LOI	Letter of Intent
LRP	Loan Repayment Program
MACS	Multicenter AIDS Cohort Study
MBRS	Minority Biomedical Research Support
MERIT	Method to Extend Research in Time
MSI	Minority-Serving Institution
NCAB	National Cancer Advisory Board
NCCAM	National Center for Complementary and Alternative Medicine
NCI	National Cancer Institute
NCORP	Community Oncology Research Program
NCRR	National Center for Research Resources
NCTN	National Clinical Trials Network
NDPA	NIH Director Pioneer Award
NFAC	NCI Frederick Advisory Committee
NFRP	NCI Funded Research Portfolio
NGRAD	NCI Grant-related Activities Directory
NHGRI	National Human Genome Research Institute
NHLBI	National Heart, Lung, and Blood Institute
NIA	National Institute on Aging
NIAAA	National Institute on Alcohol Abuse and Alcoholism
NIBIB	National Institute of Biomedical Imaging and Bioengineering
NICHD	*Eunice Kennedy Shriver* National Institute of Child Health and Human Development
NIDA	National Institute on Drug Abuse
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIGMS	National Institute of General Medical Sciences
NIH	National Institutes of Health
NIMH	National Institute of Mental Health
NINR	National Institute of Nursing Research
NLM	National Library of Medicine
NLST	National Lung Screening Trial
NRSA	National Research Service Award
OAR	Office of AIDS Research
OBBR	Office of Biorepositories and Biospecimen Research
OBF	Office of Budget and Finance
OBSSR	Office of Behavioral and Social Sciences Research
OCAM	Office of Complementary and Alternative Medicine
OCG	Office of Cancer Genomics
OCNA	Ovarian Cancer National Alliance
OCTR	Office of Centers, Training, and Resources
OD	Office of the Director
OEA	Office of Extramural Applications
OEFIA	Office of Extramural Finance Information & Analysis
OER	Office of Extramural Research
OEWG	Operational Efficiency Working Groups
OFACP	Office of Federal Advisory Committee Policy
OGC	Office of General Counsel
OHAM	Office of HIV and AIDS Malignancies
OPERA	Office of Policy for Extramural Research Administration
ORRPC	Office of Referral, Review, and Program Coordination
ORWH	Office of Research on Women's Health
OSFM	Office of Space and Facilities Management
OSPA	Office of Strategic Planning for Administration
PA	Program Announcement
PAR	Reviewed Program Announcement
PAT	Process Analytic Technologies
PBTC	Pediatric Brain Tumor Consortium
PCP	President's Cancer Panel
PCRB	Program Coordination and Referral Branch
PHS	Public Health Service (HHS)
PI	Principal Investigator
PLCO	Prostate, Lung, Colorectal, and Ovarian (Cancer Screening Trial)
PRESTO	Program Review and Extramural Staff Training Office
PROSPR	Population-Based Research Optimizing Screening through Personalized Regimens
QVR	Query View Reporting
RAEB	Research Analysis and Evaluation Branch
R&D	Research and Development
RDCRC	Rare Diseases Clinical Research Consortia
RFA	Request for Applications
RFP	Request for Proposals
RIO	Research Integrity Officer
RNAi	RNA Interference
RO	Referral Officer
RPDU	Review Processing and Distribution Unit
RPRB	Research Programs Review Branch
RTRB	Resources and Training Review Branch
RUG	Review Users Group

SA&A	Security Assessment and Authorization
SBIR	Small Business Innovation Research
SBIRDC	SBIR Development Center
SEER	Surveillance, Epidemiology, and End Results
SEP	Special Emphasis Panel
SGE	Special Government Employee
SIC	Special Interest Category
SIG	Shared Instrumentation Grant
SITE	Organ Site Codes
SMW	Science Management Workspace
SPECS	Strategic Partnering to Evaluate Cancer Signatures
SPL	Scientific Program Leadership
SPORE	Specialized Program of Research Excellence
SPRS	Secure Payee Reimbursement System
SREA	Scientific Review and Evaluation Activities
SRLB	Special Review and Logistics Branch
SRO	Scientific Review Officer (formerly Scientific Review Administrator)
STTR	Small Business Technology Transfer Research
SV40	Simian Virus 40
TCGA	The Cancer Genome Atlas Research Network
T&E	Training and Education
TRACI	Translational Research at the Aging/Cancer Interface
UDN	Undiagnosed Diseases Network
UV	Ultraviolet

Appendix G: Cancer Information Sources on the Internet

NCI Website

The NCI maintains a number of websites containing information about the Institute and its programs. All NCI websites, including those designed to provide cancer-related information to the general public and physicians, can be reached from the NCI home page at http://www.cancer.gov/.

DEA Websites

The following websites are maintained by the DEA to provide detailed information to researchers and the public about NCI funding opportunities and the Advisory Boards and groups supported by the DEA.

http://deainfo.nci.nih.gov/index.htm
DEA home page links to the individual DEA Web pages listed below; mission of the Division; contact information for DEA staff.

Advisory Boards and Groups

http://deainfo.nci.nih.gov/advisory/boards.htm
Links to the home page of each NCI Advisory Board, Committee, and Group.

http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm
President's Cancer Panel (PCP) Charter; meeting agendas, meeting minutes, and annual reports.

http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm
National Cancer Advisory Board (NCAB) Charter; members of subcommittees, meeting agendas, and meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
Board of Scientific Advisors (BSA) Charter; members of subcommittees, meeting agendas, and meeting summaries.

http://deainfo.nci.nih.gov/advisory/fac/fac.htm
Charter, minutes, members, and agendas of the NCI Frederick Advisory Committee (NFAC) Charter; members of subcommittees, meeting agendas, and meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsc/bs/bs.htm
Board of Scientific Counselors (BSC) – Basic Sciences Charter and members.

http://deainfo.nci.nih.gov/advisory/bsc/cse/cse.htm
Board of Scientific Counselors (BSC) – Clinical Sciences and Epidemiology Charter and members.

http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm
Clinical Trials and Translational Research Advisory Committee (CTAC) Charter; members of subcommittees, meeting agendas, and meeting summaries.

http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm
NCI Director's Consumer Liaison Group (DCLG) Charter; meeting schedules, agendas, minutes, and meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
Program Review Group reports.

http://deainfo.nci.nih.gov/advisory/irg/irg.htm
Initial Review Group (IRG) Charter; subcommittee members.

http://deainfo.nci.nih.gov/advisory/sep/sep.htm
Special Emphasis Panel (SEP) Charter; rosters of recent meetings.

Funding Opportunities/Policies

http://deainfo.nci.nih.gov/funding.htm
Comprehensive information about funding for cancer research; lists of active PAs and RFAs; recently cleared concepts; grant policies and guidelines; downloadable application forms.

http://deais.nci.nih.gov/foastatus/RFA-PA.jsp?nt=P
Active PAs, with links to detailed descriptions.

http://deais.nci.nih.gov/foastatus/
Active RFAs, with links to detailed descriptions.

http://deainfo.nci.nih.gov/grantspolicies/
Links to full-text NCI and NIH policies related to grants and grant review (e.g., Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research and Instructions to Reviewers for Evaluating Research Involving Human Subjects in Grant and Cooperative Agreement Applications).

http://deainfo.nci.nih.gov/flash/awards.htm
Grant Guidelines and Descriptions (descriptions of NCI funding mechanisms, with links to PAs, RFAs, guidelines, and supplemental materials).

http://fundedresearch.cancer.gov
NCI Funded Research Portfolio: A visitor can search the database for information about research grant and contract awards made by the NCI. It includes awards for the current and past 5 fiscal years for both intramural and extramural projects. The website provides the ability to search the database in various ways, including a text search of the project abstract, and a search of the Special Interest Category (SIC), and anatomic site codes assigned to the project.

http://grants.nih.gov/grants/new_investigators/index.htm
New and Early Stage Investigator Policies.

http://www.cancer.gov/researchandfunding/cancertraining
The Center for Cancer Training (CCT).

http://report.nih.gov/index.aspx
Research Portfolio Online Reporting Tools (RePORT). Reports, Data, and Analyses of NIH Research Activities.

Other NIH Websites

http://www.nih.gov
http://grants.nih.gov/grants/ElectronicReceipt/
http://grants.nih.gov/grants/policy/policy.htm
http://grants.nih.gov/grants/guide/index.html
http://grants.nih.gov/training/extramural.htm
http://report.nih.gov

November 2014